<SEC-DOCUMENT>0001193125-21-153237.txt : 20210506
<SEC-HEADER>0001193125-21-153237.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506160125
ACCESSION NUMBER:		0001193125-21-153237
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		21897576

	BUSINESS ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-369-7100

	MAIL ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d138219d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-Q</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended March&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">000-50484</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>DELAWARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">51-0407811</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11455 El Camino Real, San Diego, CA 92130 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">369-7100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title&nbsp;of&nbsp;each&nbsp;class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name&nbsp;of&nbsp;each&nbsp;exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which&nbsp;registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common&nbsp;Stock,&nbsp;$0.00000002&nbsp;par&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MEIP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The&nbsp;NASDAQ&nbsp;Stock&nbsp;Market&nbsp;LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company, or an emerging growth company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of May&nbsp;4, 2021, the number of shares outstanding
of the issuer&#146;s common stock, $0.00000002 par value, was 112,591,778. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;I</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><A HREF="#tx138219_1">FINANCIAL INFORMATION</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_2">Financial Statements (Unaudited)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_3">Condensed Balance Sheets as of March&nbsp;31, 2021 and June&nbsp;30, 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_4">Condensed Statements of Operations for the three and nine months ended March&nbsp;31, 2021 and 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_5">Condensed Statements of Stockholders&#146; Equity for the three and nine months ended March&nbsp;31, 2021 and 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_6">Condensed Statements of Cash Flows for the nine months ended March&nbsp;31, 2021 and 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_7">Notes to Condensed Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_8">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_9">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_10">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;II</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><A HREF="#tx138219_11">OTHER INFORMATION</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_12">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1A:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_13">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_14">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_15">Defaults upon Senior Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_16">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_17">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#tx138219_18">Exhibits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx138219_19">SIGNATURES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_1"></A>PART I FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_2"></A>Item&nbsp;1: Condensed Financial Statements &#150; Unaudited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx138219_3">
</A>CONDENSED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except per share amounts) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable for foreign tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 186,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 209,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.01 par value; 100 shares authorized; none outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00000002 par value; 226,000 shares authorized; 112,592 and 111,514 shares issued
and outstanding at March&nbsp;31, 2021 and June&nbsp;30, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">367,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(322,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(277,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 186,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 209,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx138219_4"></A>CONDENSED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and dividend income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx138219_5"></A>CONDENSED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(277,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(290,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">367,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(322,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(234,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(254,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(258,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx138219_6"></A>CONDENSED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable for foreign tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(325,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from maturity of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collection of common stock proceeds receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued pursuant to cashless exercise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx138219_7"></A>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. The Company and Summary
of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new
therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage assets, including zandelisib (formerly known as <FONT STYLE="white-space:nowrap">ME-401),</FONT> currently in an
ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#147;FDA&#148;) to support accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol
&#147;MEIP&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization
and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zandelisib (formerly known as <FONT STYLE="white-space:nowrap">ME-401),</FONT> an oral phosphatidylinositol <FONT
STYLE="white-space:nowrap">3-kinase</FONT> (&#147;PI3K&#148;) delta inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voruciclib, an oral cyclin-dependent kinase (&#147;CDK&#148;) inhibitor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-344,</FONT> a mitochondrial inhibitor targeting the oxidative phosphorylation
(&#147;OXPHOS&#148;) complex; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pracinostat, an oral histone deacetylase (&#147;HDAC&#148;) inhibitor. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not necessarily predictive of
future results, and our current drug candidates may not have favorable results in later studies or trials. The commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side
effects or are less expensive than our drug candidates. We will need substantial additional funds to progress the clinical trial programs for the drug candidates zandelisib, voruciclib and <FONT STYLE="white-space:nowrap">ME-344,</FONT> and to
develop new compounds. The actual amount of funds that will be needed will depend upon a number of factors, some of which are beyond our control. Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies
on funding from the financial markets or collaborators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have accumulated losses of $322.1&nbsp;million since inception and expect to incur operating losses and generate negative cash flows from
operations for the foreseeable future. As of March&nbsp;31, 2021, we had $164.6&nbsp;million in cash and cash equivalents and short-term investments. We believe that these resources will be sufficient to meet our obligations and fund our liquidity
and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements. Our current business operations are focused on continuing the clinical development of our drug candidates. Changes to our research
and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. Our research and development expenses are expected to increase in the foreseeable future. We cannot determine with
certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including
uncertainties associated with the results of our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have obtained cash and funded our operations primarily
through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt
financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying
unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;) for interim financial information and in accordance with the instructions to Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete
financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations
and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&nbsp;30, 2020, included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> (&#147;2020 Annual Report&#148;) filed with the Securities and Exchange Commission on September&nbsp;9, 2020. Interim results are not necessarily indicative of results for a full year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including
assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>ASC Topic 606, Revenue from Contracts with Customers (&#147;Topic 606&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the
consideration we expect to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identify the distinct performance obligations &#150; or accounting units &#150; within the contract.
Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments received under
commercial arrangements, such as licensing technology rights, may include <FONT STYLE="white-space:nowrap">non-refundable</FONT> fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements,
and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price
using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&#146;s control, such as
regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achievement of development milestones
and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in
the period of adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop estimates of the stand-alone selling price for each distinct performance obligation. Variable
consideration that relates specifically to our efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone
selling price, over which management has applied significant judgment. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues,
development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by
forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a license that is a
distinct performance obligation, we recognize revenue allocated to the license from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees at the point in time when the license is transferred to
the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we use judgment to assess the nature of the performance obligation to determine whether the performance
obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress
each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selection of the method
to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at
completion of the performance obligation (an &#147;input method&#148; under Topic 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&#146; costs,
labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&nbsp;when the related sales occur
or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based or usage-based royalty revenue from license agreements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognized revenue associated with the following license agreements (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KKC License Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,321</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 812</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,979</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,282</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Helsinn License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,127</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,418</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,419</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timing of Revenue Recognition:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services performed over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,418</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,419</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,418</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,419</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The KKC Commercialization Agreement and KKC Japan License Agreement (Note 3) include other distinct
performance obligations that will be satisfied over time, and accordingly we recognized $2.3&nbsp;million and $0.8&nbsp;million related to our progress toward satisfying those obligations during the three months ended March&nbsp;31, 2021 and 2020,
respectively, and $15.0&nbsp;million and $2.3&nbsp;million during the nine months ended March&nbsp;31, 2021 and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based
on the characteristics of the Helsinn License Agreement (Note 3), control of the remaining deliverables occurs over time and therefore we recognize revenue based on the extent of progress towards completion of the performance obligations.
Accordingly, we recognized $0.1&nbsp;million and $0.4&nbsp;million related to our progress toward satisfying those obligations during the three months ended March&nbsp;31, 2021 and 2020, respectively, and $0.4&nbsp;million and $1.1&nbsp;million
during the nine months ended March&nbsp;31, 2021 and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contract Balances </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Receivables and contract assets are included in our balance sheet in &#147;Prepaid expenses and other current assets&#148;, and contract
liabilities are included in &#147;Deferred revenue&#148; and &#147;Deferred revenue, long-term&#148;. The following table presents changes in contract assets and contract liabilities during the nine months ended March&nbsp;31, 2021 and 2020 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March 31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,605</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts billed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,744</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,349</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,014</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Billable amounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,841</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">930</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts billed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,744</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,432</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,497</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,771</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,380</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,479</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,877</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and
unbilled receivables (contract assets), which are classified as &#147;prepaid expenses and other current assets&#148; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with
agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers
before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC Agreements and Helsinn License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&nbsp;March 31, 2021, we had $7.4&nbsp;million&nbsp;of contract assets related to our
remaining performance obligations under the KKC Commercialization Agreement and no contract assets related to the Helsinn License Agreement as the remaining performance obligations have been completed. During the nine months ended March&nbsp;31,
2021, contract assets increased by $22.8&nbsp;million, primarily due the recognition of revenue related to the satisfaction or partial satisfaction of performance obligations for which we had not yet billed KKC or Helsinn, partially offset by
billings of $15.7&nbsp;million to KKC and Helsinn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&nbsp;March 31, 2021, we had $89.9&nbsp;million&nbsp;of deferred revenue
associated with our remaining performance obligations under the KKC&nbsp;Commercialization&nbsp;Agreement, of which $64.5&nbsp;million relates to the U.S. License which is a unit of account under the scope of Topic 808 and is not a deliverable under
Topic 606, and $25.4&nbsp;million relates to the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> license and development services performance obligations which are under the scope of Topic 606. For the three and nine months ended March&nbsp;31,
2021, we recognized revenue of $2.4&nbsp;million and $15.4&nbsp;million, respectively, that was included in the contract liabilities balance at June&nbsp;30, 2020 related to performance obligations under ASC 606. In addition, as a result of a change
in estimated cost of completion related to our remaining performance obligations, we decreased deferred revenue by $2.1&nbsp;million. To date we have not recognized any amounts related to units of account under Topic 808. For the three and nine
months ended March&nbsp;31, 2020, we recognized revenue of $0.8&nbsp;million and $2.6&nbsp;million, respectively, that was included in the contract liabilities balance at June&nbsp;30, 2019 related to performance obligations under ASC 606 under the
KKC Japan License Agreement and Helsinn License Agreement which are described in Note 3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Revenues from Collaborators </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We earn revenue in connection with collaboration agreements, which are described in Note 3, License Agreements, and Note 4, BeiGene
Collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, we assess whether the collaboration arrangements are within the scope of ASC Topic 808,
<I>Collaborative Arrangements</I> (&#147;Topic 808&#148;), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and
rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of
account, we first determine which units of account within the arrangement are within the scope of Topic 808 and which elements are within the scope of Topic 606. For units of account within collaboration arrangements that are accounted for pursuant
to Topic 808, an appropriate recognition method is determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that are accounted for pursuant to Topic 606, we recognize revenue
as discussed above. Consideration received that does not meet the requirements to satisfy Topic 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term or
long-term deferred revenue based on our best estimate of when such amounts will be recognized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and
manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations associated with the Helsinn License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research
and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with
third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based
on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development for
early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share-based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based
compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date
fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based
on the stock&#146;s historical price volatility. The stock&#146;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&#147;RSU&#148;) equity awards, we estimate the grant date fair value using
our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense
recognized during the period. We recognize the value of the awards over the awards&#146; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of
income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. As of March&nbsp;31, 2021 and 2020, we have established a valuation allowance to fully reserve our net deferred tax assets. Tax rate changes are reflected in income during the period such changes are
enacted. Changes in our ownership may limit the amount of net operating loss carryforwards that can be utilized in the future to offset taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material changes in our unrecognized tax benefits since June&nbsp;30, 2020, and, as such, the disclosures included in our
2020 Annual Report continue to be relevant for the nine months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective July&nbsp;1, 2019, we adopted FASB ASC Topic 842, <I>Leases</I> (&#147;ASC 842&#148;), using a modified retrospective basis method
under which prior comparative periods are not restated. This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) asset representing our right to use the underlying asset for the lease term. At the inception of an arrangement, we determine whether the
arrangement is or contains a lease based on the unique facts and circumstances within the arrangement. A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time
in exchange for consideration. Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on our Condensed Balance Sheet as ROU assets and lease liabilities. Operating lease liabilities and
their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. Certain
adjustments to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset may be required for items such as initial direct costs paid or incentives received. The present value of lease payments is
determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined based on the rate of interest that we would pay to
borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The interest rate implicit in lease contracts to calculate the present value is typically not readily determinable. As
such, significant management judgment is required to estimate the incremental borrowing rate.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rent expense for
operating leases is recognized on a straight-line basis over the lease term based on the total lease payments. We have elected the practical expedient to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for our
real estate leases. Our <FONT STYLE="white-space:nowrap">non-lease</FONT> components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair
value is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Observable inputs such as quoted prices in active markets for identical assets or liabilities.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2 &#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted prices for similar
assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3 &#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of
the assets or liabilities.</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure the following financial instruments at fair value on a recurring basis. The fair values of
these financial instruments were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:12pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:12pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:12pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:12pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:12pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:12pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:12pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:12pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:12pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:12pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:12pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:12pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2020</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,442</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,483</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,442</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,483</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts
payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities.
Cash equivalents, where applicable, and short-term investments are classified as Level&nbsp;1 as defined by the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
May 2018, we issued warrants in connection with our private placement of shares of common stock. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a
result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet.&nbsp;We recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and are required to
revalue the warrants at each reporting date with any changes in fair value recorded on our Condensed Statement of Operations. The valuation of the warrants is considered under Level&nbsp;3 of the fair value hierarchy due to the need to use
assumptions in the valuation that are both significant to the fair value measurement and unobservable.&nbsp;Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the
valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities
were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change
in the fair value of the&nbsp;Level 3 warrant liability is reflected in the Condensed Statement of Operations for the three and nine months ended March&nbsp;31, 2021 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To calculate the fair value of the warrant liability, the following assumptions were used: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD style="width:14pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:14pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82.4</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77.4</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Black-Scholes Fair Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.83</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of changes in the estimated fair value of our
Level&nbsp;3 warrant liability for the nine months ended March&nbsp;31, 2021 and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:20pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:20pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:20pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:20pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;of&nbsp;Warrants&nbsp;Using&nbsp;Significant<BR>Unobservable&nbsp;Inputs&nbsp;(Level&nbsp;3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at July&nbsp;1,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,483</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,613</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of derivative liability to equity upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in estimated fair value of liability classified warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,035</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">830</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,442</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,783</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>KKC License, Development and Commercialization Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, we entered into the License, Development and Commercialization Agreement (the &#147;KKC Commercialization Agreement&#148;) with
Kyowa Kirin Company (&#147;KKC&#148;). Under the agreement, we granted to KKC a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, payment-bearing license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT>
controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the &#147;U.S. License&#148;), and an exclusive (subject to certain retained rights to perform
obligations under the KKC Commercialization Agreement), sublicensable, payment-bearing, license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by us to develop and commercialize zandelisib and any
pharmaceutical product containing zandelisib for all human indications in countries outside of the United States (the <FONT STYLE="white-space:nowrap">&#147;Ex-U.S.&#148;)</FONT> (the <FONT STYLE="white-space:nowrap">&#147;Ex-U.S.</FONT>
license&#148;). KKC granted to us a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by KKC to develop and commercialize zandelisib for
all human indications in the U.S., and a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, royalty-free, fully paid license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by KKC to perform
our obligations in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> under the KKC Commercialization Agreement. KKC paid us an initial payment of $100&nbsp;million in May 2020. Of the $100&nbsp;million paid by KKC, $20.4&nbsp;million was remitted
by KKC to the Japanese taxing authorities as a result of the U.S. Internal Revenue Service being closed due to the COVID pandemic, and therefore being unable to provide necessary documentation to support an exemption from the required foreign
withholding. We received the amount remitted to the Japanese taxing authorities in October 2020. Additionally, we may earn up to approximately $582.5&nbsp;million in potential development, regulatory and commercialization milestone payments, plus
royalties on net sales of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.,</FONT> which are tiered beginning in the teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KKC
will be responsible for the development and commercialization of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> and, subject to certain exceptions, will be solely responsible for all costs related thereto. We will <FONT
STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> zandelisib with KKC in the U.S., with the Company recording all revenue from U.S. sales. We will share U.S. profits and costs (including development
costs) on a <FONT STYLE="white-space:nowrap">50-50</FONT> basis with KKC. We will also provide to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.,</FONT>
with the understanding that KKC will assume responsibility for manufacturing for the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assessed the KKC Commercialization Agreement in accordance with Topic 808 and Topic 606 and determined that our obligations comprise the
U.S. License, the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> License, and development services (the &#147;Development Services&#148;). We determined that the KKC Commercialization Agreement is a collaborative arrangement in accordance with
Topic 808 that contains multiple units of account, as we and KKC are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the
activities of the arrangement. The U.S. License is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, while the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> License and Development Services performance
obligations are under the scope of Topic 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined, at the time of our initial assessment, that the total transaction price of
$191.5&nbsp;million is comprised of the upfront payment of $100.0&nbsp;million, expected milestone payments of $20.0&nbsp;million, estimated development cost-sharing of $66.3&nbsp;million, and deferred revenue of $5.2&nbsp;million from the KKC Japan
License Agreement (as defined below). During the nine months ended March&nbsp;31, 2021, we updated our initial assessment to reflect estimated development cost-sharing of $94.9&nbsp;million. We included the amount of estimated variable consideration
that is not constrained for development cost-sharing in the transaction price. Any variable consideration related to sales-based royalties and commercial milestones related to licenses of intellectual property will be determined when the sale or
usage occurs, and is therefore excluded from the transaction price. In addition, we are eligible to receive future development and regulatory milestones upon the achievement of certain criteria; however, these amounts are excluded from variable
consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the estimated variable
consideration included in the transaction price and any related constraints at the end of each reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We allocated the
transaction price to each unit of account. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations are allocated entirely to those performance obligations. Other components of the transaction price
are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed the estimated stand-alone selling price for the licenses using the risk-adjusted net present values of estimated cash
flows, and the estimated stand-alone selling price of the development services performance obligations by estimating costs to be incurred, and an appropriate margin, using an income approach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined that control of the U.S. License and
<FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> License were transferred to KKC during the year ended June&nbsp;30, 2020, and recognized revenue of $21.0&nbsp;million related to the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> License. The
$64.5&nbsp;million transaction price allocated to the U.S. License obligation accounted for under Topic 808 is recorded as <FONT STYLE="white-space:nowrap">non-current</FONT> deferred revenue and will begin to be recognized upon future
commercialization as <FONT STYLE="white-space:nowrap">non-ASC</FONT> 606 revenue. As of March&nbsp;31, 2021 and June&nbsp;30, 2020, we recorded deferred revenue of $25.4&nbsp;million and $18.1&nbsp;million, respectively, for the transaction price
allocated to the Development Services performance obligations and are recognizing this revenue based on the proportional performance of these development activities, which we expect to recognize through fiscal year 2026. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>KKC Japan License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we, as licensor, entered into a license agreement with KKC for zandelisib (&#147;the KKC Japan License Agreement&#148;). Under
the terms of the KKC Japan License Agreement, KKC was granted the exclusive right to develop and commercialize zandelisib in Japan. We also granted KKC the right to purchase supply of zandelisib for commercial requirements at cost plus a <FONT
STYLE="white-space:nowrap">pre-negotiated</FONT> percentage, as well as manufacturing rights in Japan. In return, we received an upfront payment of $10.0&nbsp;million and were eligible to receive additional development and commercialization
milestones, as well as royalties on net sales of zandelisib in Japan. In April 2020, we and KKC agreed to terminate the KKC Japan License Agreement. The KKC Japan License Agreement was replaced with the KKC Commercialization Agreement. Pursuant to
the terms of the KKC Commercialization Agreement, we agreed to collaborate with KKC on the development, manufacturing and commercialization of zandelisib in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assessed the KKC Japan License Agreement in accordance with ASC 606 and determined that our performance obligations comprised the license,
research and development obligations, and our obligation to provide clinical trial materials to KKC. We determined that the transaction price amounted to the upfront payment of $10.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined that control of the license was transferred to KKC during the year ended June&nbsp;30, 2019. Revenue allocated to the research
and development obligations was recognized based on the proportional performance of these research and development activities. Revenue allocated to providing clinical trial materials was recognized upon delivery. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Helsinn License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn
Healthcare SA, a Swiss pharmaceutical corporation (&#147;Helsinn&#148;) for pracinostat in acute myeloid leukemia (&#147;AML&#148;), myelodysplastic syndrome (&#147;MDS&#148;) and other potential indications (the &#147;Helsinn License
Agreement&#148;). Under the terms of the agreement, Helsinn was granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. As
compensation for such grant of rights, we received payments of $20.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We determined that the agreement contains multiple performance
obligations for purposes of revenue recognition. Revenue related to the research and development elements of the arrangement is recognized based on the extent of progress toward completion of each performance obligation. Revenue is recognized on a
gross basis as we are the primary obligor and have discretion in supplier selection. During the nine months ended March&nbsp;31, 2021, our only remaining performance obligation under the agreement was the conduct of a Phase 2 dose-optimization study
of pracinostat in combination with azacitidine in patients with high and very high risk MDS who are previously untreated with hypomethylating agents (the &#147;POC study&#148;), for which Helsinn has agreed to share third-party expenses. As of
March&nbsp;31, 2021, our performance obligations related to the Helsinn License Agreement have been met, and no future revenue or costs of revenue will be recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Presage License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2017, we entered into a license agreement with Presage Biosciences, Inc. (&#147;Presage&#148;). Under the terms of such license
agreement (the &#147;Presage License Agreement&#148;), Presage granted to us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we
paid $2.9&nbsp;million. With respect to the first indication, an incremental $2.0&nbsp;million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9&nbsp;million prior to
receipt of marketing approval of the first indication in the U.S., E.U. or Japan. Additional potential payments of up to $179&nbsp;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also
pay <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we
will pay to Presage a tiered percent (which decreases as product development progresses) of amounts received from such sublicensees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CyDex License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a license agreement with CyDex Pharmaceuticals, Inc. (&#147;CyDex&#148;). Under the license agreement, CyDex granted to us an
exclusive, nontransferable license to intellectual property rights relating to Captisol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for use with our isoflavone-based drug compounds (currently
<FONT STYLE="white-space:nowrap">ME-344).</FONT> We agreed to pay to CyDex a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales
of our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may
terminate both the license agreement and the supply agreement at any time upon 90 days&#146; prior written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. BeiGene Collaboration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (&#147;BeiGene&#148;) to evaluate the safety and efficacy of
zandelisib in combination with BeiGene&#146;s zanubrutinib (marketed as Brukinsa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), an inhibitor of Bruton&#146;s tyrosine kinase, for the treatment of patients with <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of zandelisib in combination with zanubrutinib in patients with <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies. Study costs are being shared equally by the parties, and we agreed to supply zandelisib and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our
research and development expenses. We retained full commercial rights for zandelisib and BeiGene retained full commercial rights for zanubrutinib. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Net Loss Per Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and
diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or
forfeiture for the three and nine months ended March&nbsp;31, 2021 and 2020. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the calculation of net loss used to calculate basic loss and diluted loss per share (in
thousands):&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss &#150; basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,859</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,540</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,307</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss &#150; diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,313</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,329</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65,166</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,540</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share used in calculating net loss per share was determined as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used in calculating basic net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,557</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,999</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,505</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,995</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of potentially dilutive common shares from equity awards and liability-classified
warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used in calculating diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,557</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,999</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,991</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,995</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and
warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents weighted-average potentially dilutive shares that have been excluded from the calculation of net loss per share
because of their anti-dilutive effect (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,618</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,060</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,062</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,354</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,062</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total anti-dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,651</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,126</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,402</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,036</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have contracted with various consultants and third parties to assist us in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and
development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. We also have employment
agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances. &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Presage License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 3, we are party to a license agreement with Presage under which we may be required to make future payments upon the
achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of March&nbsp;31, 2021, we have not accrued any amounts for potential future payments as achievement of the
milestones has not been met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>S*Bio Purchase Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual
property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout
payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&nbsp;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U.
and Japan. As of March&nbsp;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CyDex License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 3, we are party to a license agreement with CyDex under which we may be required to make future payments upon the
achievement of certain milestones, as well as potential future royalties based upon net sales. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of
our requirements for Captisol from CyDex. As of March&nbsp;31, 2021, we have not accrued any amounts for potential future payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">COVID-19</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the World Health Organization (&#147;WHO&#148;) announced a global health
emergency because of a new strain of coronavirus originating in Wuhan, China (the <FONT STYLE="white-space:nowrap">&#147;COVID-19</FONT> outbreak&#148;) and the risks to the international community. In March 2020, the WHO classified the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak as a pandemic, based on the rapid increase in exposure globally. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which continues to rapidly evolve, &#147;shelter in
place&#148; orders and other public health guidance measures have been implemented across much of the United States, Europe and Asia, including in the locations of our offices, clinical trial sites, key vendors and partners. Despite the relaxation
of many governmental orders in <FONT STYLE="white-space:nowrap">mid-2020,</FONT> the &#147;second wave&#148; of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has resulted in the <FONT STYLE="white-space:nowrap">re-imposition</FONT>
of many of these measures. In addition, although the FDA has authorized vaccines for the treatment of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the effectiveness and timing of distribution of the vaccines remains highly uncertain. The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus has also mutated into different strains, which could be more contagious or severe or for which treatments are unavailable. While we continue to enroll and dose patients in our clinical trials, our
clinical development program timelines continue to be subject to potential negative impacts from the ongoing pandemic. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the effectiveness and timing of distribution of treatments for
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other
countries to contain and treat the disease and to minimize its economic impact. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CARES Act </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the Coronavirus Aid, Relief, and Economic Security (&#147;CARES&#148;) Act was signed into law. The CARES Act, among
other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest
deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. Regulatory guidance has indicated that public companies are ineligible to
participate in certain of the loan programs provided by the CARES Act. There is substantial uncertainty with respect to the scope, content or timing of any further economic stimulus programs to address the economic downturn related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak. We do not expect that the CARES Act will have a material impact on our financial condition, results of operation, or liquidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Proceedings &nbsp;&nbsp;&nbsp;&nbsp; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2020, Guy Bahat, an individual who allegedly purchased 50 shares of our common stock filed a putative securities class
action lawsuit (the &#147;Securities Class&nbsp;Action&#148;) in the United States District Court for the Southern District of California against the Company, Dr.&nbsp;Daniel&nbsp;P. Gold, and Mr.&nbsp;Brian&nbsp;G. Drazba, asserting claims under
Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) and Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> thereunder. Mr.&nbsp;Bahat did not seek appointment as lead plaintiff, and the court appointed
another </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual, Ramesh Mahalingham, as lead plaintiff. The plaintiff seeks to sue on behalf of all purchasers of our securities from August&nbsp;2, 2017 through July&nbsp;1, 2020 and alleges, among
other things, that we made false and misleading statements relating to pracinostat during the proposed class period. On February&nbsp;16, 2021, the lead plaintiff filed a notice of voluntary dismissal without prejudice, thereby concluding the class
action litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;21, 2020, Peter D&#146;Arcy, an individual who alleges that he is a Company stockholder, filed a
putative stockholder derivative action nominally on behalf of the Company in the United States District Court for the District of Delaware (the &#147;Derivative Action&#148;) against Dr.&nbsp;Gold, Mr.&nbsp;Drazba, Mr.&nbsp;Charles&nbsp;V. Baltic,
III, Dr.&nbsp;Kevan&nbsp;E. Clemens, Mr.&nbsp;Frederick&nbsp;W. Driscoll, Dr.&nbsp;Nicholas&nbsp;R. Glover, Ms.&nbsp;Tamar&nbsp;D. Howson, Dr.&nbsp;Thomas&nbsp;C. Reynolds, Mr.&nbsp;William&nbsp;D. Rueckert, and Dr.&nbsp;Christine&nbsp;A. White, and
naming the Company as a nominal defendant. Additional putative stockholder derivative suits were filed in the same court naming the same defendants plus Dr.&nbsp;Robert&nbsp;D. Mass on December&nbsp;2, 2020 and December&nbsp;15, 2020 by Gerald
Wright and William Trablicy, respectively, who also allege that they are Company stockholders, and these additional suits were consolidated into the Derivative Action by court order. The Derivative Action is based upon the pracinostat-related
allegations in the Securities Class&nbsp;Action described above, and alleges claims under Section&nbsp;14(a) of the Exchange Act and claims for breach of fiduciary duty, unjust enrichment, corporate waste, and contribution. On February&nbsp;24,
2021, following the resolution of the class action litigation, the parties stipulated request for voluntary dismissal without prejudice, which the court granted on February&nbsp;25, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we
entered into a lease agreement for approximately 32,800 square feet of office space in San Diego, California.&nbsp;We have accounted for the lease as an operating lease. The contractual lease term began in July 2020 and is scheduled to expire in
March 2028. The lease contains an option to renew and extend the lease terms. We have not included the lease extension within the ROU asset and lease liability on the balance sheet as it is not reasonably certain to be exercised. The lease includes
variable <FONT STYLE="white-space:nowrap">non-lease</FONT> components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset and lease liability and are reflected as an expense in the period incurred. We do not
have any other operating or finance leases.&nbsp;Upon commencement of the lease, we recognized an operating lease ROU asset of $8.7&nbsp;million and a corresponding operating lease liability of $8.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total operating lease costs were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,130</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental cash flow information related to our operating leases were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 615</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease obligations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a schedule of the future minimum rental payments for our operating lease,
reconciled to the lease liability as of March&nbsp;31, 2021 (in thousands):&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2021</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of fiscal year ending June 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 368</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Years ending June&nbsp;30,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,519</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,565</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,612</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,064</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Present value discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,556</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,508</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Classification &#150; Operating Lease</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 900</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,608</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,508</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Balance Sheet Information &#150; Operating Lease</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Short-Term Investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021 and June&nbsp;30, 2020, our short-term investments consisted of $154.9&nbsp;million and $170.3&nbsp;million,
respectively, in U.S. government securities. The short-term investments held as of March&nbsp;31, 2021 and June&nbsp;30, 2020 had maturity dates of less than one year, are considered to be &#147;held to maturity&#148; and are carried at amortized
cost. As of March&nbsp;31, 2021 and June&nbsp;30, 2020, the gross holding gains and losses were immaterial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Transactions &nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-The-Market</FONT></FONT> Equity Offering </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2020, we entered into an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-The-Market</FONT></FONT>
Equity Offering Sales Agreement (the &#147;2020 ATM Sales Agreement&#148;), pursuant to which we may sell an aggregate of up to $60.0&nbsp;million of our common stock pursuant to the shelf registration statement. We had previously entered into an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-The-Market</FONT></FONT> Equity Offering Sales Agreement in November 2017 (the &#147;2017 ATM Sales Agreement&#148;), pursuant to which we could sell an aggregate of up to
$30.0&nbsp;million of our common stock pursuant to the shelf registration statement. The 2017 ATM Sales Agreement expired on November&nbsp;8, 2020. During the nine months ended March&nbsp;31, 2021, we sold 958,083 shares under the 2017 ATM Sales
Agreement for net proceeds of $3.1&nbsp;million, after costs of $0.1&nbsp;million. As of March&nbsp;31, 2021, there is $60.0&nbsp;million remaining available under the 2020 ATM Sales Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Shelf Registration Statement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a shelf registration statement that permits us to sell, from time to time, up to $200.0&nbsp;million of common stock, preferred stock
and warrants. The shelf registration was filed and declared effective in May 2020, replacing our prior shelf registration statement that was filed and declared effective in May 2017, and carrying forward approximately $107.5&nbsp;million of unsold
securities registered under the prior shelf registration statement. As of March&nbsp;31, 2021, there is $175.7&nbsp;million aggregate value of securities available under the shelf registration statement, including up to $60.0&nbsp;million remaining
available under the 2020 ATM Sales Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, we have outstanding warrants to purchase 16,058,985 shares of our common stock. The warrants are fully vested,
exercisable at a price of $2.54 per share and expire in May 2023. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to
be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measured at fair value and reported as a liability in the Condensed Balance Sheet. Therefore, we are required to account for the warrants as liabilities and record them at fair value. The
warrants were revalued as of March&nbsp;31, 2021 at $29.4&nbsp;million and as of June&nbsp;30, 2020 at $40.5&nbsp;million; the changes in fair value were recorded in our Condensed Statement of Operations. During the nine months ended March&nbsp;31,
2021, a warrant holder completed a cashless exercise of 2,617 warrants for 964 shares of common stock. No warrants were exercised during the nine months ended March&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Share-based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use
equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation
Plan (&#147;2008 Plan&#148;), as amended and restated in 2011, 2013, 2014, 2015, 2016, 2018 and 2020, under which 29,014,794 shares of common stock are authorized for issuance. The 2008 Plan provides for the grant of options and/or other stock-based
or stock-denominated awards to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, officers, employees and advisors. As of March&nbsp;31, 2021, there were 10,284,365 shares available for future grant under the 2008 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense for all stock awards consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,496</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,438</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,700</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,214</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,645</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,196</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,434</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock option activity for the nine months ended March&nbsp;31, 2021 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:36pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:36pt"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:73pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:73pt"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:108pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:108pt"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:52pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:52pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining&nbsp;Contractual<BR>Term (in years)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,252,976</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.81</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,763,300</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,042</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.22</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited / Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,828</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,673,406</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.01</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,775,096</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,802,361</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.74</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,006,856</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option granted during the nine months ended March&nbsp;31, 2021 is estimated on
the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the nine months ended March&nbsp;31, 2021 vest 25% one year from the date of grant and ratably each month thereafter for a
period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the nine months ended March&nbsp;31, 2021 vest ratably each month for a period of 12 months from the date of grant and expire ten years from
the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average assumptions were used to determine the fair value of options granted during the period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81.1</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.6</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, there was $10.2&nbsp;million of unrecognized compensation expense related to the
unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.7 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, we granted 442,650 RSUs to employees. Each RSU represented the contingent right to receive one share of our common stock. The
RSUs will vest in periods of either one year or two years from the date of grant. The fair value of the RSUs was measured at $3.49 per unit. Under the terms of the 2008 Plan, each of the RSUs is calculated as 1.25 shares of common stock for purposes
of determining the number of shares available for future grant. There were forfeitures of 12,000 RSUs during the nine months ended March&nbsp;31, 2021, and 430,650 unvested RSUs were outstanding as of March&nbsp;31, 2021. As of March&nbsp;31, 2021,
unrecognized compensation expense related to the unvested portion of our RSUs was approximately $0.8&nbsp;million and is expected to be recognized over approximately 1.1 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_8"></A>Item&nbsp;2: Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> includes forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other
than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The
words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in &#147;Risk Factors&#148; in our 2020
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as filed with the Securities and Exchange Commission on September&nbsp;9, 2020, and elsewhere in this report, including, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outbreak of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or other
pandemic, epidemic or outbreak of an infectious disease, and government responses thereto including but not limited to the ability of FDA to conduct necessary audit functions, may materially and adversely impact our business, including our
preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in our clinical development programs and/or receipt of FDA or other required foreign and
domestic governmental or regulatory approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, whether as a result of weaknesses in the capital markets or otherwise, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">KKC, Helsinn and other parties with which we have entered into collaboration, license, development and/or
commercialization agreements may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations under the Presage License Agreement and the S*Bio Purchase Agreement, which may reduce
our cash available for other development efforts, and other obligations and risks related to the Presage License Agreement and the S*Bio Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies by their nature typically have a high level of risk and may not produce successful results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from preclinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing regulations, third-party reimbursement practices and healthcare reform initiatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials and manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from litigation, including securities class action and stockholder derivative litigation, our
defense against third party intellectual property infringement claims, or other litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our exposure to potential product liability claims and other claims may exceed our insurance limits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or the third parties upon whom we depend may be adversely affected by natural disasters and our business
continuity and disaster recovery plans may not adequately protect us from a serious disaster; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anti-takeover provisions contained in our amended and restated certificate of incorporation and third amended and
restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally, including changes to government regulation as a result of a new U.S. President
and congressional majorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">one-time</FONT> events. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this report and our other filings with the
SEC include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. There is substantial uncertainty regarding the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> on our business, industry, global economic conditions and government policy. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact
of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. Past performance may not be an indicator of future results. The following discussion is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the
notes thereto appearing elsewhere in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and the audited financial statements and notes thereto included in our 2020 Annual Report, as filed with the SEC. Operating results are
not necessarily indicative of results that may occur in future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview and Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new
therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage assets, including our lead drug candidate, zandelisib (formerly known as (&#147;f/k/a&#148;) <FONT
STYLE="white-space:nowrap">ME-401),</FONT> currently in an ongoing Phase 2 clinical trial that, subject to the results upon completion of the trial, we intend to submit to the U.S. Food and Drug Administration (&#147;FDA&#148;) as part of a
marketing application to support accelerated approval. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization
and strategic partnerships, as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the World Health Organization (&#147;WHO&#148;) announced a global health
emergency because of a new strain of coronavirus (the <FONT STYLE="white-space:nowrap">&#147;COVID-19</FONT> outbreak&#148;) and the risks to the international community. In March 2020, the WHO classified the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak as a pandemic based on the rapid increase in exposure globally. As a result of the ongoing and rapidly evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, various public
health orders and guidance measures have been implemented across much of the United States, and across the globe, including in the locations of our office, clinical trial sites, key vendors and partners. Despite the relaxation of many governmental
orders in <FONT STYLE="white-space:nowrap">mid-2020,</FONT> the &#147;second wave&#148; of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has resulted in the <FONT STYLE="white-space:nowrap">re-imposition</FONT> of many of these
measures. In addition, although the FDA has authorized vaccines for the treatment of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the effectiveness and timing of distribution of the vaccines remains highly uncertain. The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus has also mutated into different strains, which could be more contagious or severe or for which treatments are unavailable. While we continue to enroll and dose patients in our clinical trials, our
clinical development program timelines continue to be subject to potential negative impacts from the ongoing pandemic. The extent to which the ongoing pandemic continues to impact our business, including our preclinical studies, chemistry,
manufacturing and controls (&#147;CMC&#148;) studies, manufacturing, and clinical trials, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the ultimate geographic spread of the
disease, the duration of the pandemic, the effectiveness and timing of distribution of treatments for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> travel restrictions and social distancing in the United States and other countries, business
closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and to minimize its economic impact, including vaccination rates and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By example, we may experience enrollment delays and suspensions, patient withdrawals, postponement of planned clinical or preclinical studies,
redirection of site resources from studies, and study deviations or noncompliance. We may also need to implement study modifications, suspensions, or terminations, the introduction of remote study procedures and modified informed consent procedures,
study site changes, direct delivery of investigational products to patient homes or alternative sites, which may require state licensing, and changes or delays in site monitoring. The foregoing may require that we consult with relevant review and
ethics committees, IRBs, and the FDA. The foregoing may also impact the integrity of our study data. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak may further increase the need for clinical trial patient monitoring and regulatory
reporting of adverse effects, and may delay regulatory authority meetings, inspections, or the regulatory review of marketing or investigational applications or submissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not only might the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak impact the conduct of our clinical trials, but it may also impact
our ability to procure the necessary supply of our investigational drug products, as well as any ancillary supplies necessary for the conduct of our studies. This could happen for a variety of reasons, including manufacturing shortages or shutdowns,
or a manufacturer need to prioritize other products or customers over us, including under the Defense Production Act. Third party manufacturers may also need to implement measures and changes, or deviate from typical manufacturing requirements that
may otherwise adversely impact our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, the FDA
issued a number of new guidance documents. Specifically, as a result of the potential effect of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on many clinical trial programs in the US and globally, the FDA issued guidance concerning
potential impacts on clinical trial programs, which guidance FDA has continually updated. In addition, the European Medicines Agency (&#147;EMA&#148;) as well as various country regulatory authorities have issued similar guidance. We have adapted
the FDA and EMA guidance for study procedures, data collection, and oversight resulting from the pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the &#147;Coronavirus Aid, Relief, and Economic Security
(&#147;CARES&#148;) Act&#148; was signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods,
alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.
Regulatory guidance has indicated that public companies are ineligible to participate in certain of the loan programs provided by the CARES Act. There is substantial uncertainty with respect to the scope, content or timing of any further economic
stimulus programs to address the economic downturn related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. We do not expect that the CARES Act will have a material impact on our financial condition, results of operations, or
liquidity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization
and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zandelisib (f/k/a <FONT STYLE="white-space:nowrap">ME-401),</FONT> an oral phosphatidylinositol <FONT
STYLE="white-space:nowrap">3-kinase</FONT> (&#147;PI3K&#148;) delta inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voruciclib, an oral cyclin-dependent kinase (&#147;CDK&#148;) inhibitor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-344,</FONT> a mitochondrial inhibitor targeting the oxidative phosphorylation
(&#147;OXPHOS&#148;) complex; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pracinostat, an oral histone deacetylase (&#147;HDAC&#148;) inhibitor. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g138219g0504025156354.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Phase 2 study intended to support a marketing application for FDA accelerated approval. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Study arm conducted under clinical collaboration with BeiGene, Ltd. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Initiation of clinical studies in combination with venetoclax is subject to FDA approval.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Investigator-initiated trial; completed. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><I>Zandelisib (f/k/a <FONT STYLE="white-space:nowrap">ME-401):</FONT> PI3K</I><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><I> Inhibitor in a Phase 2
Trial Intended to Support Accelerated Approvals in Relapsed or Refractory Follicular and Marginal Zone Lymphomas</I></U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zandelisib is an
oral, once-daily, selective PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitor in clinical development for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. In&nbsp;March 2020,&nbsp;the FDA granted zandelisib
Fast Track designation for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. In April 2020, we entered into a global license, development and commercialization
agreement to further develop and commercialize zandelisib with Kyowa Kirin Co., Ltd. (&#147;KKC&#148;). MEI and KKC will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> zandelisib in the
U.S., with MEI recording all revenue from U.S. sales. KKC has exclusive commercialization rights outside of the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting
multiple ongoing studies evaluating zandelisib including&nbsp;TIDAL (<B>T</B>rials of P<B>I</B>3K<B>&nbsp;D</B>elt<B>A</B>&nbsp;in <FONT STYLE="white-space:nowrap">Non-Hodgkin&#146;s</FONT><B>&nbsp;L</B>ymphoma),&nbsp;a Phase 2 clinical trial
evaluating zandelisib as a monotherapy for the treatment of adults with relapsed or refractory (&#147;r/r&#148;) follicular lymphoma (&#147;FL&#148;) and r/r marginal zone lymphoma (&#147;MZL&#148;) after failure of at least two prior systemic
therapies including chemotherapy and an anti-CD20 antibody. Subject to the results, upon completion of each study arm in TIDAL, we are planning marketing application submissions with the FDA to support accelerated approval under 21 CFR Part 314.500,
Subpart H. We are also conducting a <FONT STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase 1b dose finding and expansion trial evaluating zandelisib as a monotherapy and in combination with other therapies in patients with relapsed or
refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Other initiated studies include Phase 1 and Phase 2 studies being conducted by KKC evaluating zandelisib as a monotherapy in patients in Japan with indolent <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancy pursuant to our agreement with KKC (as described below). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Zandelisib: Potentially Highly
Differentiated Pharmaceutical Properties within a Clinically Validated Class&nbsp;of Treatments </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While PI3K<FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors as a group are a clinically validated class for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies, the FDA approved orally administered products, idelalisib (marketed as
Zydelig<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) duvelisib (marketed as COPIKTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), and umbralisib (marketed as
UKONIQ<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>), and the intravenously administered PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>/&#945; inhibitor copanlisib (marketed as
Aliqopa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), are challenged by dose-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limiting toxicities, modest efficacy and/or inconvenience of administration route. We believe this provides an opportunity for the development of a next-generation candidate with pharmaceutical
properties that may better maximize the therapeutic potential of PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibition by limiting toxicities and improving upon modest efficacy, which together hinder clinical utility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The molecular structure and pharmacodynamic characteristics of zandelisib are distinct from the FDA approved PI3K<FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors. Zandelisib&#146;s distinct characteristics include prolonged target binding, preferential cellular accumulation, high volume of distribution throughout the body tissues, and an approximately <FONT
STYLE="white-space:nowrap">28-hour</FONT> half-life suitable for once daily oral administration. The properties of zandelisib support exploration of flexible dosing regimens such as an intermittent dosing schedule, which has clinically demonstrated
to date the potential to maintain clinical benefit while minimizing immune-related toxicities common to other PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> agents, either as a monotherapy or in combination with other therapies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>KKC License, Development and Commercialization Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2020, we entered into a License, Development and Commercialization Agreement with KKC (the &#147;KKC Commercialization
Agreement&#148;). We granted to KKC a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, payment-bearing license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by us to develop and
commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S., and an exclusive (subject to certain retained rights to perform obligations under the agreement), sublicensable, payment-bearing,
license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the
United States (the <FONT STYLE="white-space:nowrap">&#147;Ex-U.S&#148;).</FONT> KKC grants to us a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, license under certain patents and
<FONT STYLE="white-space:nowrap">know-how</FONT> controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, royalty-free, fully paid
license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by KKC to perform our obligations in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> under the KKC Commercialization Agreement. The KKC
Commercialization Agreement substantially retains and consolidates the terms of the 2018 license agreement with KKC to develop and commercialize zandelisib in&nbsp;Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KKC will be responsible for the development and commercialization of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> and,
subject to certain exceptions, will be solely responsible for all costs related thereto. We will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> zandelisib with KKC in the U.S., with the
Company recording all revenue from U.S. sales. We will share U.S. profits and costs (including development costs) on a <FONT STYLE="white-space:nowrap">50-50</FONT> basis with KKC. We will also provide to KKC certain drug supplies necessary for the
development and commercialization of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> pursuant to supply agreements to be entered into on customary terms, with the understanding that KKC will assume responsibility for manufacturing
for the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> as soon as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the KKC Commercialization Agreement,
KKC paid us an initial payment of $100&nbsp;million. We may also earn up to approximately $582.5&nbsp;million in potential development, regulatory and commercialization milestone payments, plus royalties on net sales of zandelisib in the <FONT
STYLE="white-space:nowrap">Ex-U.S.,</FONT> which are tiered beginning in the teens. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Zandelisib Scientific Overview: at the Crossroads
of <FONT STYLE="white-space:nowrap">B-cell</FONT> Signaling Pathways </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PI3K/AKT/mTOR pathway is an important signaling pathway for
many cellular functions such as cell survival, cell cycle progression and cellular growth. PI3Ks are a family of enzymes within this pathway that have been shown to play a critical role in the proliferation and survival of certain cancer cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several isoforms of PI3K that are expressed in different types of cells. The PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>
isoform is at the crossroads of <FONT STYLE="white-space:nowrap">B-cell</FONT> receptor signaling pathways that are major drivers of survival and proliferation of many <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Because the <FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> isoform is often overexpressed in cancer cells of the <FONT STYLE="white-space:nowrap">B-lymphocyte</FONT> lineage, such as <FONT STYLE="white-space:nowrap">B-cell</FONT> leukemias and lymphomas, it is
understood to be important for survival of these cells. Zandelisib displays high selectivity for the PI3K delta isoform and functions to inhibit its activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
conducting multiple ongoing studies evaluating zandelisib including TIDAL, the global Phase 2 trial evaluating patients with r/r FL and MZL intended to support FDA marketing applications for accelerated approval, and a
<FONT STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase 1b dose escalation and expansion trial as a monotherapy and in combination with other therapies in patients with FL and other <FONT STYLE="white-space:nowrap">B-cell</FONT>
malignancies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1b trial includes an arm exploring zandelisib in combination with zanubrutinib (marketed as BRUKINSA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), an inhibitor of Bruton&#146;s tyrosine kinase developed by BeiGene, Ltd. (&#147;BeiGene&#148;). This study arm completed the safety evaluation stage in patients with <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies and has expanded into disease specific <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancy cohorts. The evaluation of zandelisib in combination with zanubrutinib is conducted under a
collaboration established with BeiGene in October 2018, pursuant to which the cost of the combination trial is being equally shared, and each company is supplying its own investigational agent. We retain all commercial rights to zandelisib (subject
to the KKC Commercialization Agreement) and BeiGene retains all commercial rights to zanubrutinib. Additionally, ongoing studies include Phase 1 and Phase 2 studies initiated by KKC evaluating zandelisib as a monotherapy in patients in Japan with
indolent <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies; the Phase 2 study is intended to support marketing authorization in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also in the process of expanding the zandelisib clinical development program pursuant to the KKC Commercialization Agreement. Expansion
plans include initiating, around <FONT STYLE="white-space:nowrap">mid-calendar</FONT> year 2021, COASTAL, (<B>CO</B>mbination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rituximab and <FONT STYLE="white-space:nowrap">PI3-Kina</FONT><B>S</B>e Del<B>TA</B> Inhibitor in iNH <B>L</B>ymphoma) a Phase 3 study of zandelisib in combination with rituximab evaluating
follicular lymphoma and marginal zone lymphoma patients who received one or more prior lines of treatment; this study is intended to support FDA approval for additional indications and act as the required confirmatory study for the potential
accelerated approval of zandelisib in patients with relapsed follicular lymphoma or marginal zone lymphoma who received at least two prior systemic therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to other planned clinical studies sponsored by us, we also plan to support select investigator-initiated studies, including one
being conducted at the Cleveland Clinic evaluating zandelisib combined with standard of care in patients with newly diagnosed diffuse large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma (&#147;DLBCL&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1b <FONT STYLE="white-space:nowrap">Multi-arm</FONT> Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2020, we reported updated data from the ongoing Phase 1b clinical trial evaluating zandelisib as a monotherapy and in combination with
rituximab in patients with r/r <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies as&nbsp;featured in a poster discussion at the American Society of Clinical Oncology 2020 Virtual Scientific Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data were reported from a total of 57 patients treated with zandelisib, including 36 patients with r/r FL, 10 patients with&nbsp;r/r chronic
lymphocytic leukemia (&#147;CLL&#148;), and 11 patients with <FONT STYLE="white-space:nowrap">other&nbsp;B-cell</FONT> malignancies. Zandelisib was administered once daily at 60 mg for two <FONT STYLE="white-space:nowrap">28-day</FONT> cycles and
then on an intermittent schedule (&#147;IS&#148;) of once daily dosing for the first seven days of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle. The objective of this portion of the study was to evaluate the safety,
tolerability and efficacy of zandelisib given at 60 mg on IS as monotherapy or in combination with rituximab. A previous cohort of 39 patients in the trial was treated with zandelisib at 60 to 180 mg administered continuously once daily
(&#147;CS&#148;) or were switched to the IS in later cycles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall response rate in the 36 patients with r/r FL was 83%, with 22%
achieving a complete response. The overall response rate was 76% in 17 patients administered zandelisib as a monotherapy and 89% in 19 patients administered zandelisib in combination with rituximab. The overall response rate in nine evaluable
patients with CLL was 89%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overall Response Rates (&#147;ORR&#148;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Evaluable&nbsp;Subjects</B><br><B>N</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ORR</B><br><B>N (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FL </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30&nbsp;(83%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>By treatment group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">zandelisib monotherapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13&nbsp;(76%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">zandelisib + rituximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17&nbsp;(89%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By prior lines of therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1 prior</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13&nbsp;(81%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2 prior</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17&nbsp;(85%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CLL SLL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By treatment group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8&nbsp;(89%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">zandelisib monotherapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">zandelisib + rituximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5 (83%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Median duration of response in patients with FL has not yet been reached and median <FONT
STYLE="white-space:nowrap">follow-up</FONT> was 13.2 months (range: <FONT STYLE="white-space:nowrap">3.0-27.6).</FONT> Responses appeared durable across patient subsets analyzed (prior lines of therapy (1 vs
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2), treatment group (i.e., monotherapy or in combination with rituximab) or tumor bulk (&lt; 5 cm vs <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 cm)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Duration of Response: Follicular Lymphoma Patients (N=30) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g138219g0504025156572.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zandelisib was generally well-tolerated. The rate of drug related grade 3 Adverse Events of Special
Interest (&#147;AESI&#148;) was: diarrhea 3.5% (2/57); colitis 3.5% (2/57); rash 1.8% (1/57); alanine aminotransferase (&#147;ALT&#148;)/ aspartate aminotransferase (&#147;AST&#148;) elevation 1.8% (1/57);
<FONT STYLE="white-space:nowrap">non-infectious</FONT> pneumonitis 1.8% (1/57). No grade <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3 AESI was reported after Cycle 3, when patients are treated with the IS, and the discontinuation rate due to
adverse events was 7% (4/57).</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:7%" ALIGN="center">


<IMG SRC="g138219g0504025156728.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Trial Intended to Support Accelerated Approval of Marketing Applications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are recruiting patients in TIDAL, the global Phase&nbsp;2 trial evaluating zandelisib as a monotherapy across two study arms: the first
study arm for the treatment of adults with r/r FL and the second study arm for r/r MZL, in both cases after failure of at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody. Subject to the results and discussions
with FDA, data from each study arm are intended to be submitted to FDA to support marketing applications for accelerated approval under 21&nbsp;CFR Part&nbsp;314.500, Subpart&nbsp;H. The study is evaluating zandelisib&nbsp;administered once daily at
60 mg for two <FONT STYLE="white-space:nowrap">28-day</FONT> cycles and then on an intermittent schedule of once daily dosing for the first seven days of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle (i.e., IS). The primary
efficacy endpoint will be the rate of objective responses to therapy and other endpoints will include duration of response and tolerability of&nbsp;zandelisib. The primary efficacy population sample size for r/r FL is 91 patients and the primary
efficacy population sample size for r/r MZL is 64 patients. Complete enrollment of the FL primary efficacy population was announced in April 2021. MEI will maintain the total study enrollment in the FL arm to 120 patients to provide additional
safety data for the registration application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the Phase 2 TIDAL Study
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will impact the completion of the TIDAL study
is subject to future developments, which are highly uncertain and cannot be predicted with confidence, currently the integrity of the study remains intact and patient enrollment continues, although at a reduced rate. Topline data from the Phase 2
TIDAL study is expected in the fourth calendar quarter of 2021. We will continue to closely monitor for potential negative impacts on the study related to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We will also continue
efforts to be proactive in managing the impact from the pandemic, including various actions to communicate with sites and investigators, and making accommodations to patients consistent with FDA guidance and guidance from other regulatory
authorities, as we may deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Voruciclib: CDK Inhibitor with CDK9 Inhibition in Phase 1 Studies </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Voruciclib is an orally administered CDK inhibitor differentiated by its potent in vitro inhibition of CDK9 in addition to CDK6, 4 and 1.
Voruciclib is being evaluated in a Phase 1b trial evaluating dose and schedule in patients with acute myeloid leukemia (&#147;AML&#148;) and <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Voruciclib is also being evaluated in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies to explore the potential synergistic activity in various solid tumor cancers of voruciclib in combination with drug-candidates that directly inhibit KRAS as well as other targets in the RAS
signaling pathway. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voruciclib Scientific Overview: Cell Cycle Signaling </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CDK9 has important functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CDK9 is a transcriptional regulator of the myeloid leukemia cell differentiation protein (&#147;MCL1&#148;), a
member of the family of anti-apoptotic proteins which, when elevated, may prevent the cell from undergoing cell death. Inhibition of CDK9 blocks the production of MCL1, which is an established resistance mechanism to the <FONT
STYLE="white-space:nowrap">B-cell</FONT> lymphoma (&#147;BCL2&#148;) inhibitor venetoclax (marketed as Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CDK9 is a transcriptional regulator of the MYC proto-oncogene protein (&#147;MYC&#148;) which regulates cell
proliferation and growth. Upregulation of MYC is implicated in many human cancers and is frequently associated with poor prognosis and unfavorable patient survival. CDK9, in addition to being a transcription factor for MYC, also decreases
phosphorylation of MYC protein that is implicated in stabilizing MYC in KRAS mutant cancers. Targeting MYC directly has historically been difficult, but CDK9 is a promising approach to target this oncogene. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Voruciclib: Inhibition of MCL1 </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies voruciclib shows dose-dependent suppression of MCL1; in December 2017 a study of voruciclib published in the journal <I>Nature Scientific Reports</I> reported that the combination of
voruciclib plus the <FONT STYLE="white-space:nowrap">BCL-2</FONT> inhibitor venetoclax was capable of inhibiting two master regulators of cell survival, <FONT STYLE="white-space:nowrap">MCL-1</FONT> and <FONT STYLE="white-space:nowrap">BCL-2,</FONT>
and achieved synergistic antitumor effect in an aggressive subset of DLBCL <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models. (Scientific Reports. (2017) 7:18007. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">DOI:10.1038/s41598-017-18368-w).</FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a peer reviewed manuscript published in
2020 by Luedtke et al, concluded that the inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the <FONT STYLE="white-space:nowrap">Bcl-2</FONT> selective inhibitor venetoclax in preclinical models of acute myeloid
leukemia. (Sig Transduct Target Ther&nbsp;5,&nbsp;17 (2020). <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1038/s41392-020-0112-3</FONT></FONT></FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research presented suggests that voruciclib could be an attractive therapeutic target for treating cancers in combination with venetoclax
or other <FONT STYLE="white-space:nowrap">BCL-2</FONT> inhibitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Voruciclib: Inhibition of MYC </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KRAS mutated cancers are frequently associated with overexpression of MYC, a transcription factor regulating cell proliferation and growth.
CDK9 is a known regulator of&nbsp;MYC&nbsp;transcription and a modulator of MYC protein phosphorylation. Data reported at the American Association for Cancer Research (AACR) Annual Meeting 2021 in preclinical models demonstrates that voruciclib:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results in a rapid decrease in the phosphorylation of proteins that promote MYC transcription
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly decreases phosphorylation of MYC protein on Ser62, a site implicated in stabilizing MYC in KRAS mutant
cancers </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Possesses single agent activity against multiple KRAS mutant cancer cell lines both<I>&nbsp;in
vitro</I><I></I>&nbsp;and<I>&nbsp;in vivo</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Synergistically inhibits KRAS G12C mutant cancer cell lines in combination with KRAS G12C inhibitors,
both<I>&nbsp;in vitro</I>&nbsp;and<I>&nbsp;in vivo</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research presented suggests that voruciclib could be an
attractive therapeutic target for cancers driven by KRAS mutations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are evaluating patients with hematological malignancies in a Phase 1b clinical trial evaluating the dose and schedule of voruciclib. The
trial is initially intended to evaluate the dose and schedule of voruciclib as a monotherapy in patients with relapsed and/or refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies or AML after failure of prior standard therapies to
determine the safety, preliminary efficacy and maximum tolerated dose. Once initial safe dose levels and schedules have been established, we plan in parallel, subject to FDA agreement, to evaluate the dose and schedule of voruciclib in combination
with a BCL2 inhibitor such as venetoclax to assess synergies and the opportunity for combination treatments, initially in patients with AML and subsequently across multiple indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary data to date from the Phase 1b study evaluating voruciclib as a monotherapy at
the doses studied demonstrates that voruciclib has not been associated with drug related gastrointestinal toxicity or neutropenia. Also, favorable pharmacokinetics have been observed, including a half-life supporting
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day</FONT></FONT> oral dosing, dose proportional <FONT STYLE="white-space:nowrap">C-max</FONT> and a high volume of distribution suggesting broad entry into tissues. Our
projections suggest that doses of <FONT STYLE="white-space:nowrap">150-200</FONT> mg may be sufficient to achieve plasma concentrations sufficient to inhibit the molecular target. Early signs of biological activity have also been observed in
patients with AML. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Voruciclib was also previously evaluated in more than 70 patients with solid tumors in multiple Phase 1 studies. The
totality of the clinical data, along with data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, suggests voruciclib&#146;s ability to inhibit its molecular target at a projected dose as low as 150 mg daily. In one clinical study,
voruciclib was evaluated in combination with vemurafenib (marketed as Zelboraf<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in 9 patients with BRAF mutated advanced/inoperable malignant melanoma. Three of three BRAF/MEK naive patients
achieved a response: two partial responses and one complete response. In this study voruciclib was dosed at 150 mg daily plus vemurafenib 720 mg or 960 mg twice daily in <FONT STYLE="white-space:nowrap">28-day</FONT> cycles. The most common adverse
events were fatigue, constipation, diarrhea, arthralgia and headache. One instance of grade 3 fatigue was dose limiting and no serious adverse events related to voruciclib were reported. Other clinical studies evaluated voruciclib at doses up to 850
mg in patients with solid tumors, demonstrating additional evidence of potential biologic activity and an adverse event profile generally consistent with other drugs in its class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the Voruciclib Clinical Development Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will impact the progress of the voruciclib clinical
development program, including the ongoing Phase 1b study, is subject to future developments, which are highly uncertain and cannot be predicted with confidence, the study remains ongoing and is continuing to enroll patients, although at a reduced
rate. We will continue efforts to be proactive in managing the impact from the pandemic, including various actions to communicate with sites and investigators, and making accommodations to patients consistent with FDA guidance as we may deem
appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U><FONT STYLE="white-space:nowrap">ME-344:</FONT> Clinical Stage Mitochondrial Inhibitor with Combinatorial Potential </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT> is our novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate. It
directly targets the OXPHOS complex 1, a pathway involved in ATP production in the mitochondria. <FONT STYLE="white-space:nowrap">ME-344</FONT> was studied in an investigator-initiated, multi-center, randomized clinical trial in combination with the
vascular endothelial growth factor (&#147;VEGF&#148;) inhibitor bevacizumab (marketed as Avastin<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in a total of 42 patients with human
epidermal growth factor receptor 2 (&#147;HER2&#148;) negative breast cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ME-344</FONT>
Scientific Overview: Cancer Metabolism </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumor cells often display a high metabolic rate to support cell division and growth. This
heightened metabolism requires a continual supply of energy in the form of adenosine triphosphate (&#147;ATP&#148;). The two major sources of ATP are the specialized cellular organelles termed mitochondria and through the metabolism of
carbohydrates, proteins and lipids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT> was identified through a screen of more than 400 new
chemical structures originally created based on the central design of naturally occurring plant isoflavones. We believe that some of these synthetic compounds, including our drug candidate <FONT STYLE="white-space:nowrap">ME-344,</FONT> interact
with specific mitochondrial enzyme targets, resulting in the inhibition of ATP generation. When these compounds interact with their target, a rapid reduction in ATP occurs, which leads to a cascade of biochemical events within the cell and
ultimately to cell death. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT> demonstrated evidence of single agent activity against refractory solid tumors in a Phase 1
trial, and in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies tumor cells treated with <FONT STYLE="white-space:nowrap">ME-344</FONT> resulted in a rapid loss of ATP and cancer cell death. In addition to single agent activity, <FONT
STYLE="white-space:nowrap">ME-344</FONT> may also have significant potential in combination with anti-angiogenic therapeutics. In <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, it was shown that one outcome of anti-angiogenics was to
reduce the rate of glycolysis in tumors as a mechanism to slow tumor growth. However, tumor metabolism was able to shift to mitochondrial metabolism for energy production to support continued tumor proliferation. In such cases of tumor plasticity in
the presence of treatment with anti-angiogenics, targeting the alternative metabolic source with <FONT STYLE="white-space:nowrap">ME-344</FONT> may open an important therapeutic opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Support for this combinatorial use of <FONT STYLE="white-space:nowrap">ME-344</FONT> was first published in the June 2016 edition of <I>Cell
Reports</I>; <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data from a collaboration with the Spanish National Cancer Research Centre in Madrid demonstrated mitochondria-specific effects of ME-344 in cancer cells, including substantially
enhanced anti-tumor activity when combined with agents that inhibit the activity of VEGF. These data demonstrating the potential anti-cancer effects of combining <FONT STYLE="white-space:nowrap">ME-344</FONT> with a VEGF inhibitor due to an
inhibition of both mitochondrial and glycolytic metabolism provided a basis for commencement of an investigator-initiated trial of <FONT STYLE="white-space:nowrap">ME-344</FONT> in combination with bevacizumab in HER2 negative breast cancer
patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results published in the November 2019 issue of Clinical Cancer Research from a multicenter,
investigator-initiated, randomized, open-label, clinical trial that evaluated the combination of <FONT STYLE="white-space:nowrap">ME-344</FONT> and bevacizumab in 42 women with early <FONT STYLE="white-space:nowrap">HER2-negative</FONT> breast
cancer further support for the combinatorial use of <FONT STYLE="white-space:nowrap">ME-344</FONT> with anti-angiogenic therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
primary objective of the trial was to show proof of <FONT STYLE="white-space:nowrap">ME-344</FONT> biologic activity as measured by Ki67 reductions in the presence of the nuclear protein Ki67 (expression of which is strongly associated with tumor
cell proliferation and growth) from days 0 to 28 compared to the control group who received bevacizumab alone. Secondary objectives included determining whether <FONT STYLE="white-space:nowrap">ME-344</FONT> biologic activity correlates with
vascular normalization. The data demonstrate significant biologic activity in the <FONT STYLE="white-space:nowrap">ME-344</FONT> treatment group: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In <FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients, mean absolute Ki67 decreases were 13.3
compared to an increase of 1.1 in the bevacizumab monotherapy group (P=0.01). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In <FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients, mean relative Ki67 decreases were 23%
compared to an increase of 186% in the bevacizumab monotherapy group (P &lt; 0.01). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mean relative Ki67 reduction in patients experiencing vascular normalization in the <FONT
STYLE="white-space:nowrap">ME-344</FONT> treated patients was 33%, compared to an increase of 11.8% in normalized patients from the bevacizumab monotherapy group (P=0.09). Approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of patients
in each arm had vascular normalization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment was generally well tolerated; three grade 3 adverse events of high
blood pressure were reported, two in the <FONT STYLE="white-space:nowrap">ME-344</FONT> arm and one in the bevacizumab monotherapy arm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from our earlier, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> single-agent Phase 1
clinical trial of <FONT STYLE="white-space:nowrap">ME-344</FONT> in patients with refractory solid tumors were published in the April&nbsp;1, 2015 issue of<I> Cancer</I>. The results indicated that eight of 21 evaluable patients (38%) treated with <FONT
STYLE="white-space:nowrap">ME-344</FONT> achieved stable disease or better, including five who experienced progression-free survival that was at least twice the duration of their last prior treatment before entry into the trial. In addition, one of
these patients, a heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> patient with small cell lung cancer, achieved a confirmed partial response and remained on study for two years. <FONT STYLE="white-space:nowrap">ME-344</FONT> was
generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Treatment-related adverse events included nausea, dizziness and fatigue. Dose-limiting toxicities were observed at both the 15
mg/kg and 20 mg/kg dose levels, consisting primarily of grade 3 peripheral neuropathy. We are planning to advance <FONT STYLE="white-space:nowrap">ME-344</FONT> in combination with anti-angiogenic therapies in a Phase 2 study evaluating patients
with solid tumors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Pracinostat: HDAC Inhibitor Candidate in a Phase 2 Clinical Trial </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pracinostat is an&nbsp;oral HDAC inhibitor being evaluated in a Phase 2 trial in patients with high or very high-risk myelodysplastic
syndrome<I> </I>(&#147;MDS&#148;) who are previously untreated with hypomethylating agents (the &#147;POC study&#148;). All patients in the study have completed therapy and analyses are ongoing in preparation of a final study report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn
Healthcare SA, a Swiss pharmaceutical corporation (&#147;Helsinn&#148;) for pracinostat (the &#147;Helsinn License Agreement&#148;) as a treatment for patients with MDS or AML. Under the agreement, Helsinn is primarily responsible for funding global
development and commercialization costs for pracinostat. We are responsible for conducting the POC study, the cost of which is being shared equally with Helsinn. Any future development and commercialization costs after the completion of the POC
study will be the responsibility of Helsinn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pracinostat Scientific Overview; Epigenetics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HDACs play a key role in epigenetic regulation of gene expression by regulating chromatin structure. Acetylation of positively charged lysine
residues present in histone proteins by the histone acetyltransferase (&#147;HATs&#148;) reduces the affinity between histones and negatively charged DNA, resulting in the opening of the chromatin structure. This makes it easier for the
transcriptional machinery to access the DNA, enhancing RNA transcription. Conversely, deacetylation by the HDACs closes the chromatin structure leading to a repression of gene transcription. In normal cells, HDACs and HATs together control histone
acetylation levels to maintain a balance. In diseases such as cancer, this regulation can be disturbed. HDAC inhibitors cause accumulation of acetylated histones, enhance transcription and result in changes to a variety of cellular responses
including differentiation, proliferation, migration, survival and response to metabolic and hypoxic stress. In general, tumor cells are more susceptible than normal cells to the anti-proliferative and
<FONT STYLE="white-space:nowrap">pro-apoptotic</FONT> effects of HDAC inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are currently three HDAC inhibitors, one oral and
two injectable, approved by the FDA for the treatment of <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma and a fourth orally administered HDAC inhibitor approved for multiple myeloma. Other HDAC inhibitors are being evaluated in clinical
trials as monotherapies and in combination for the treatment of various hematologic diseases and solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pracinostat is an orally
available, potent HDAC inhibitor that we believe has potentially improved physicochemical, pharmaceutical and pharmacokinetic properties when compared to other compounds of this class, including increased bioavailability and increased half-life.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pracinostat is being investigated in the POC study, which is a Phase 2 dose optimization trial evaluating patients with high and very high-risk
MDS who are previously untreated with hypomethylating agents. All patients in the study have completed therapy and analyses are ongoing in preparation of a final study report. This patient group represents the highest unmet need in MDS, with median
survival estimates of 1.6 years and 0.8 years, respectively (Greenberg et al, <I>Blood 2012</I>). The POC Study is an open-label trial evaluating a 45 mg dose of pracinostat in combination with the standard dose of azacitidine. The trial is designed
to evaluate tolerability of the combination, with the intent of maintaining patient enrollment longer than in an earlier Phase 2 trial evaluating a 60&nbsp;mg dose. A prolonged treatment may result in a systemic exposure to pracinostat and
azacitidine sufficient to achieve the desired treatment effect; data from the earlier Phase 2 trial suggested that insufficient exposure to treatment may have limited the treatment effect of the combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">pre-planned</FONT> interim analysis of the POC study demonstrated a 10% discontinuation rate among the
first 20 evaluable patients treated, meeting the predefined threshold in the first 3 treatment cycles. The 10% rate is consistent with the discontinuation rate for azacitidine given as a monotherapy in earlier studies with pracinostat. Having met
this threshold, the trial expanded open-label enrollment to a total of 60 patients in the study. An interim analysis presented at the 2018 ASH meeting demonstrated a discontinuation rate due to adverse events in the first three cycles of 4%,
substantially lower than the rate of 26% reported in our prior Phase 2 trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The POC study completed enrollment and patients were
followed for at least two years to evaluate safety and efficacy. The primary endpoints of the trial are 1) safety and tolerability and 2) overall response rate, defined as complete remission (&#147;CR&#148;), partial remission (&#147;PR&#148;) and
marrow CR. Secondary endpoints include CR rate, overall hematologic improvement (&#147;HI&#148;) response rate, clinical benefit rate (defined as rate of CR + PR + HI + Marrow CR), rate of cytogenetic complete response/remission, duration of
response, rate of leukemic transformation, event-free survival, progression-free survival and overall survival. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from the POC study
(n=64) presented as part of the American Society of Clinical Oncology 2020 Virtual Scientific Program in June 2020 demonstrated an estimated median overall survival (&#147;OS&#148;) rate of 23.5 months with a
<FONT STYLE="white-space:nowrap">one-year</FONT> OS rate of 77%. The median <FONT STYLE="white-space:nowrap">follow-up</FONT> was 17.6 months (range, 15.7&#150;18.8) and the overall response rate (&#147;ORR&#148;) was 33% (21/64), all of which are
complete responses (&#147;CR&#148;). The clinical benefit rate (CR, mCR plus hematologic improvement (&#147;HI&#148;), mCR with no HI, or HI with no mCR) was 77% (49/64). Twenty-seven percent of patients (17/64) proceeded to a stem cell transplant
while on study. Eleven percent of patients discontinued treatment because of adverse events. The most common grade <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3 treatment emergent adverse events were hematologic, and included decreased neutrophil
count (50%), anemia (39%), febrile neutropenia (34%), decreased platelet count (33%), thrombocytopenia (27%), and decreased white blood cell count (20%). The POC study results have reached maturity leading to closing the study; as of the end of
December 2020 no patients are being treated or followed in the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 study evaluating pracinostat&nbsp;in combination with
azacitidine in patients with AML who are unfit to receive standard intensive chemotherapy was discontinued by Helsinn, the study sponsor, in July 2020 after an interim futility analysis undertaken by the study Independent Data Monitoring Committee
demonstrated it was unlikely to meet the primary endpoint of overall survival compared to the control group. In connection with the discontinuation of the Phase 3 study, Helsinn has withdrawn the breakthrough therapy designation FDA granted for
pracinostat in combination with azacitidine for the treatment of patients with AML. Following the discontinuation of the Phase 3 AML study, Helsinn communicated to us their plan to continue therapy and observation of the patients currently in the
Phase 2 MDS study and that further development of pracinostat, including for the treatment of MDS, is under review. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Three Months Ended March&nbsp;31, 2021 and 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had a loss from operations of $22.1&nbsp;million for the three months ended March&nbsp;31, 2021 compared to a loss from operations of
$12.4&nbsp;million for the three months ended March&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue: </I></B>We recognized revenue of $2.4&nbsp;million for the three months
ended March&nbsp;31, 2021 compared to $1.2&nbsp;million for the three months ended March&nbsp;31, 2020. Revenue increased primarily due to amounts recognized under our license agreement with KKC and resulted from the partial satisfaction of our
research and development obligations. Revenue related to the license agreement with KKC was $2.3&nbsp;million for the three months ended March&nbsp;31, 2021 compared to $0.8&nbsp;million for the three months ended March&nbsp;31, 2020. Revenue also
includes recognition of fees allocated to performance obligations in accordance with the Helsinn License Agreement. Revenue related to the Helsinn License Agreement was $0.1&nbsp;million for the three months ended March&nbsp;31, 2021 compared to
$0.4&nbsp;million for the three months ended March&nbsp;31, 2020 due to decreased costs associated with the POC study. As of March&nbsp;31, 2021, our performance obligations related to the Helsinn License Agreement have been met, and no future
revenue or costs of revenue will be recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue:</I></B> We recognized cost of revenue of $0.4&nbsp;million for the three months
ended March&nbsp;31, 2021 compared to $0.9&nbsp;million for the three months ended March&nbsp;31, 2020. The cost of revenue includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and
manufacture drug materials, and internal compensation and related personnel expenses associated with pracinostat. Costs of revenue relate to expenses for pracinostat incurred in connection with our development activities in accordance with the
Helsinn License Agreement, including both Helsinn&#146;s share and our share of costs related to the POC study, which we are responsible for conducting. Cost of revenue decreased due to decreased costs associated with the POC study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development</I></B><B>:</B> The following is a summary of our research and development
expenses to supplement the more detailed discussion below. The dollar values in the following table are in thousands. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Research and development expenses</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zandelisib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,460</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,572</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voruciclib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">524</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,518</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,849</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,884</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,963</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of clinical trial costs (including payments to contract
research organizations &#147;CROs&#148;), <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study costs, and costs to manufacture our drug candidates for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies. Other research
and development expenses consist primarily of salaries and personnel costs, share-based compensation, legal costs, and other costs not allocated to specific drug programs. Research and development expenses were $17.9&nbsp;million for the three
months ended March&nbsp;31, 2021 compared to $9.0&nbsp;million for the three months ended March&nbsp;31, 2020. Costs related to zandelisib for the three months ended March&nbsp;31, 2021 reflected an increase in clinical trial costs ($5.3 million)
primarily as a result of increased activity in the Phase 2 study and <FONT STYLE="white-space:nowrap">start-up</FONT> costs related to the Phase 3 study, an increase in drug manufacturing costs ($1.0 million), and increased consulting fees ($0.6
million). Costs related to voruciclib increased for the three months ended March&nbsp;31, 2021 compared with the three months ended March&nbsp;31, 2020, due to increased drug manufacturing costs. Other research and development costs increased for
the three months ended March&nbsp;31, 2021 due to higher levels of personnel costs ($1.2 million) and share-based compensation ($0.5 million) associated with increased headcount to support our clinical activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative</I></B><B>: </B>General and administrative expenses increased by $2.3&nbsp;million to $6.2&nbsp;million for the three months
ended March&nbsp;31, 2021 compared to $3.9&nbsp;million for the three months ended March&nbsp;31, 2020. The increase is primarily due to increased external professional services and legal costs ($0.9 million), as well as share-based compensation
($0.6 million) and personnel costs ($0.5 million) associated with increased headcount to support our activities, including preparation for commercial launch of zandelisib, and corporate overhead costs ($0.3 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income or expense: </I></B>We recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> loss of $9.3&nbsp;million during the three months ended
March&nbsp;31, 2021 due to a change in the fair value of our warrant liability. The change in the warrant liability is primarily due to changes in our stock price. Additionally, we received interest and dividend income of $58,000 for the three
months ended March&nbsp;31, 2021 compared to $0.4&nbsp;million for the three months ended March&nbsp;31, 2020. The decrease was due to lower yields during the three months ended March&nbsp;31, 2021 compared to the three months ended March&nbsp;31,
2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Nine Months Ended March&nbsp;31, 2021 and 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had a loss from operations of $56.9&nbsp;million for the nine months ended March&nbsp;31, 2021 compared to a loss from operations of
$37.2&nbsp;million for the nine months ended March&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue: </I></B>We recognized revenue of $15.4&nbsp;million for the nine months
ended March&nbsp;31, 2021 compared to $3.4&nbsp;million for the nine months ended March&nbsp;31, 2020. Revenue increased primarily due to amounts recognized under our license agreement with KKC and resulted from the partial satisfaction of our
research and development obligations. Revenue related to the license agreement with KKC was $15.0&nbsp;million for the nine months ended March&nbsp;31, 2021 compared to $2.3&nbsp;million for the nine months ended March&nbsp;31, 2020. Revenue also
includes recognition of fees allocated to performance obligations in accordance with the Helsinn License Agreement. Revenue related to the Helsinn License Agreement was $0.4&nbsp;million for the nine months ended March&nbsp;31, 2021 compared to
$1.1&nbsp;million for the nine months ended March&nbsp;31, 2020 due to decreased costs associated with the POC study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue:</I></B> We
recognized cost of revenue of $1.4&nbsp;million for the nine months ended March&nbsp;31, 2021 compared to $2.2&nbsp;million for the nine months ended March&nbsp;31, 2020. The cost of revenue includes external costs paid to third-party contractors to
perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses associated with pracinostat. Costs of revenue relate to expenses for pracinostat incurred in connection
with our development activities in accordance with the Helsinn License Agreement, including both Helsinn&#146;s share and our share of costs related to the POC study, which we are responsible for conducting. Cost of revenue decreased due to
decreased costs associated with the POC study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development</I></B><B>:</B> The following is a summary of our research and development
expenses to supplement the more detailed discussion below. The dollar values in the following table are in thousands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>March&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Research and development expenses</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zandelisib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,350</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,741</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voruciclib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,215</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,524</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,106</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,914</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,104</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,206</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of clinical trial costs (including payments to CROs), <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> study costs, and costs to manufacture our drug candidates for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies. Other research and development expenses consist primarily of
salaries and personnel costs, share-based compensation, legal costs, and other costs not allocated to specific drug programs. Research and development expenses were $53.1&nbsp;million for the nine months ended March&nbsp;31, 2021 compared to
$26.2&nbsp;million for the nine months ended March&nbsp;31, 2020. Costs related to zandelisib for the nine months ended March&nbsp;31, 2021 reflected an increase in clinical trial costs ($19.9 million) primarily as a result of increased activity in
the Phase 2 study and <FONT STYLE="white-space:nowrap">start-up</FONT> costs related to the Phase 3 study, an increase in drug manufacturing costs ($1.5 million), and increased consulting fees ($1.2 million). Costs related to voruciclib increased
for the nine months ended March&nbsp;31, 2021 compared with the nine months ended March&nbsp;31, 2020, due to increased drug manufacturing costs. Other research and development costs increased for the nine months ended March&nbsp;31, 2021 due to
higher levels of personnel costs ($2.3 million) and share-based compensation ($1.3 million) associated with increased headcount to support our clinical activities, offset by decreased legal, consulting, and administrative costs ($0.4 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative</I></B><B>: </B>General and administrative expenses increased by $5.6&nbsp;million to $17.8&nbsp;million for the nine months
ended March&nbsp;31, 2021 compared to $12.2&nbsp;million for the nine months ended March&nbsp;31, 2020. The increase is primarily due to increased external professional services and legal costs ($1.8 million), as well as share-based compensation
($1.5 million) and personnel costs ($1.1 million) associated with increased headcount to support our activities, including preparation for commercial launch of zandelisib, and corporate overhead costs ($1.2 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income or expense: </I></B>We recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> gain of $11.0&nbsp;million during the nine months ended
March&nbsp;31, 2021 due to a change in the fair value of our warrant liability. The change in the warrant liability is primarily due to changes in our stock price. Additionally, we received interest and dividend income of $0.5&nbsp;million for the
nine months ended March&nbsp;31, 2021 compared to $1.1&nbsp;million for the nine months ended March&nbsp;31, 2020. The decrease was due to lower yields during the nine months ended March&nbsp;31, 2021 compared to the nine months ended March&nbsp;31,
2020. We also recognized a $0.5&nbsp;million gain related to foreign currency exchange rate changes on a tax receivable from the Japanese government for tax withholdings related to the KKC Commercialization Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
accumulated losses of $322.1&nbsp;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of March&nbsp;31, 2021, we had $164.6&nbsp;million in cash and cash
equivalents, and short-term investments. We believe that these resources will be sufficient to fund our operations into fiscal year 2022 and beyond. Our current business operations are focused on continuing the clinical development of our drug
candidates. Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. Our research and development expenses are expected to increase in the foreseeable
future. We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety
of factors, including uncertainties associated with the results of our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have obtained cash and funded our
operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity
securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sources and Uses of Our Cash </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the nine months ended March&nbsp;31, 2021 was $20.7&nbsp;million. Net cash used in operating
activities for the nine months ended March&nbsp;31, 2020 was $34.9&nbsp;million. The decrease in cash used in operating activities year over year reflects the receipt in October 2020 of our $20.4&nbsp;million receivable from the Japanese government
for tax withholdings related to the KKC Commercialization Agreement, as well as other changes in working capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by
investing activities for the nine months ended March&nbsp;31, 2021 was $14.7&nbsp;million compared to $21.2&nbsp;million used in investing activities for the nine months ended March&nbsp;31, 2020. The change was primarily due to decreased purchases
of short-term investments in 2021, net of maturities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities during the nine months ended March&nbsp;31, 2021
was $3.4&nbsp;million compared with $53.9&nbsp;million provided by financing activities during the nine months ended March&nbsp;31, 2020. Cash raised during the nine months ended March&nbsp;31, 2021 reflected $3.1&nbsp;million of net proceeds from
the issuance of common stock. Cash raised during the nine months ended March&nbsp;31, 2020 reflected $48.6&nbsp;million from the issuance of common stock and $5.3&nbsp;million of proceeds from the collection of common stock proceeds receivable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
contracted with various consultants and third parties to assist us in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and development and clinical trial work for our leading drug compounds. The contracts are terminable at any time, but
obligate us to reimburse the providers for any time or costs incurred through the date of termination. Additionally, we have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting for
share-based awards if their employment is terminated under specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have leased approximately 32,800 square feet of
office space in San Diego, California.&nbsp;The contractual lease term is from July 2020 through March 2028.&nbsp;The average annual lease payment over the remaining term of the lease is $1.6&nbsp;million, plus a pro rata share of certain building
expenses.&nbsp;Our total contractual obligation over the remaining term of the lease is $11.1&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Presage License Agreement
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2017, we entered into the Presage License Agreement. Under the terms of the Presage License Agreement, Presage granted to
us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid Presage $2.9&nbsp;million. With respect to the first indication, an
incremental $2.0&nbsp;million payment, due upon dosing the first subject in the first registration trial will be owed to Presage, for total payments of $4.9&nbsp;million prior to receipt of marketing approval of the first indication in the U.S.,
E.U. or Japan. Additional potential payments of up to $179&nbsp;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> tiered
royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product
development progresses) of amounts received from such sublicensees. As of March&nbsp;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>S*Bio Purchase Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual
property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout
payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&nbsp;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U.
and Japan. As of March&nbsp;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CyDex License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a license agreement with CyDex. Under the license agreement, CyDex granted to us an exclusive,
<FONT STYLE="white-space:nowrap">non-transferable</FONT> license to intellectual property rights relating to Captisol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for use with our two isoflavone-based drug compounds (currently <FONT
STYLE="white-space:nowrap">ME-344).</FONT> We agreed to pay to CyDex a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of
our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may terminate
both the license agreement and the supply agreement for convenience at any time upon 90 days&#146; prior written notice. As of March&nbsp;31, 2021, we have not accrued any amounts for potential future payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Management Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We describe our significant accounting policies in Note 1, The Company and Summary of Significant Accounting Policies, of the notes to the
financial statements included in our 2020 Annual Report. We discuss our critical accounting estimates in Item 7, Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, in our 2020 Annual Report. There have been
no changes in our significant accounting policies or critical accounting estimates since June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no recent accounting pronouncements that we anticipate adopting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_9"></A>Item&nbsp;3: Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest Rate Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to market
interest rates relates primarily to the investments of cash balances and short-term investments. We have cash reserves held in U.S. dollars and we place funds on deposit with financial institutions, which are readily available. Our short-term
investments consist solely of U.S. government securities with a maturity of three to twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We place our cash deposits with high
credit quality financial institutions and by policy limit the amount of credit exposure to any one corporation or bank. These deposits are in excess of the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) insurance limits. We are adverse to
principal loss and we ensure the safety and preservation of our invested funds by limiting default risk, market risk and reinvestment risk. We seek to mitigate default risk by depositing funds with high credit quality financial institutions, by
limiting the amount of credit exposure to any one corporation or bank, by purchasing short-term investments consisting of U.S. government securities, and by positioning our portfolio to respond appropriately to a significant reduction in a credit
rating of any such financial institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not consider the effects of interest rate movements to be a material risk to our
financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_10"></A>Item&nbsp;4: Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the end of the period covered by this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> our management, with the
participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#146;s management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s
rules and forms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes in our internal control over financial reporting during the period covered by this Quarterly
Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_11">
</A>PART II OTHER INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_12"></A>Item&nbsp;1: Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See our financial statements, Note 6 &#150; Commitments and Contingencies &#150; Legal Proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_13"></A>Item&nbsp;1A: Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material changes in our risk factors from those included in our 2020 Annual Report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_14"></A>Item&nbsp;2: Unregistered Sales of Equity Securities and Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_15"></A>Item&nbsp;3:
Defaults upon Senior Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_16"></A>Item&nbsp;4: Mine Safety Disclosures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_17"></A>Item&nbsp;5: Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_18"></A>Item&nbsp;6: Exhibits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Exhibits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d138219dex311.htm">Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> Certification of Principal Executive Officer </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d138219dex312.htm">Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> Certification of Principal Financial Officer </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d138219dex321.htm">Certification of Principal Executive Officer and Principal Financial Officer required by Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(b)</FONT> and Section&nbsp;1350
 of Chapter 63 of Title 18 of the United States Code (18 U.S.C 1350). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx138219_19"></A>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the
undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MEI Pharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel P. Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;6, 2021</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d138219dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Daniel P. Gold, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEI Pharma, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this Quarterly
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly
Report is being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in the
Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this Quarterly Report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;6, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel&nbsp;P.&nbsp;Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel P. Gold</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d138219dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Brian G. Drazba,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEI Pharma, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this Quarterly
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly
Report is being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in the
Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this Quarterly Report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;6, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d138219dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirement set forth in Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(b)</FONT> of the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of Chapter 63 of Title 18 of the
United States Code (18 U.S.C. &#167; 1350), Daniel P. Gold, the Chief Executive Officer of MEI Pharma, Inc. (the &#147;Registrant&#148;), and Brian G. Drazba, the Chief Financial Officer of the Registrant, each hereby certifies that, to his
knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Registrant&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period
ended March&nbsp;31, 2021, (the &#147;Form <FONT STYLE="white-space:nowrap">10-Q&#148;)</FONT> to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the
Securities Exchange Act of 1934, as amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> fairly presents, in all
material respects, the financial condition of the Registrant at the end of the period covered by the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and results of operations of the registrant for the period covered by the Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These certifications accompanying the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> to
which they relate, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,
as amended (whether made before or after the date of the Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> irrespective of any general incorporation language contained in such filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;6, 2021 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel P. Gold</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brian G. Drazba</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal
Financial Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>meip-20210331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-May-2021 [03:53:02] {AM}-->
<xbrli:xbrl xmlns:meip="http://www.meipharma.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31">
<link:schemaRef xlink:type="simple" xlink:href="meip-20210331.xsd" />
<xbrli:context id="PAsOn06_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2020To12_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2019To12_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-10-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn05_04_2021">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-05-04</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_TwoThousandAndEightOmnibusPlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">meip:TwoThousandAndEightOmnibusPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_TwoThousandAndTwentyAtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:TwoThousandAndTwentyAtTheMarketSaleAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_SbioPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:SbioPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_CydexLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:CydexLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_UsLicenseMemberusgaapDeferredRevenueArrangementTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">meip:UsLicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_ExUsLicenseMemberusgaapDeferredRevenueArrangementTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">meip:ExUsLicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_WarrantMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_TwoThousandAndTwentyAtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:TwoThousandAndTwentyAtTheMarketSaleAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis_UpdationOfInitialAssessmentMemberMEIPEventAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:EventAxis">meip:UpdationOfInitialAssessmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_DevelopmentServicesMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">meip:DevelopmentServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_KyowaKirinCoMemberdeiLegalEntityAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_DevelopmentServicesMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">meip:DevelopmentServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:KkcAgreementsandHelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2021To03_31_2021_HelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_KkcAgreementsMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:KkcAgreementsandHelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To03_31_2020_HelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_DirectorMembersrtTitleOfIndividualAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:AtTheMarketSaleAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:KkcAgreementsandHelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To03_31_2021_HelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2021-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_KkcAgreementsMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:KkcAgreementsandHelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To03_31_2020_HelsinnLicenseAgreementMemberMEIPAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="meip:AgreementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-10-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-10-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-10-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn05_31_2020_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-05-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ExUsLicenseMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KkcAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">meip:ExUsLicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-01</xbrli:startDate>
<xbrli:endDate>2018-10-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_30_2016To08_31_2016_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-30</xbrli:startDate>
<xbrli:endDate>2016-08-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_01_2017To09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_IncrementalPaymentMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:IncrementalPaymentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_MaximumMembersrtRangeAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_SanDiegoCaliforniaMembersrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">meip:SanDiegoCaliforniaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_08_2017_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:AtTheMarketSaleAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-11-08</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_10_2020_MaximumMembersrtRangeAxis_TwoThousandAndTwentyAtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:TwoThousandAndTwentyAtTheMarketSaleAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-11-10</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To07_31_2020_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-07-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P12_01_2019To12_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_SanDiegoCaliforniaMembersrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">meip:SanDiegoCaliforniaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-12-01</xbrli:startDate>
<xbrli:endDate>2019-12-01</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_21218711" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">1569000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_21218712" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1084000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Factid_21218715" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">186122000</us-gaap:Assets>
<us-gaap:Assets id="Factid_21218716" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">209728000</us-gaap:Assets>
<us-gaap:ShortTermInvestments id="Factid_21218717" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">154879000</us-gaap:ShortTermInvestments>
<us-gaap:ShortTermInvestments id="Factid_21218718" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">170299000</us-gaap:ShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments id="Factid_21218719" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">164624000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments id="Factid_21218720" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">182630000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_21218721" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">11937000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_21218722" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">5594000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_21218723" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">176561000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_21218724" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">208644000</us-gaap:AssetsCurrent>
<us-gaap:AccountsPayableCurrent id="Factid_21218725" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">5571000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent id="Factid_21218726" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">2437000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_21218727" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">7762000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_21218728" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">6090000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DeferredRevenueCurrent id="Factid_21218729" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">19143000</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent id="Factid_21218730" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">14777000</us-gaap:DeferredRevenueCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_21218731" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">33376000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_21218732" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">23304000</us-gaap:LiabilitiesCurrent>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_21218733" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">29442000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_21218734" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">40483000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:Liabilities id="Factid_21218735" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">141160000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_21218736" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">131510000</us-gaap:Liabilities>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_21218737" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">186122000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_21218738" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">209728000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommitmentsAndContingencies id="Factid_21218739" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_21218740" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:PreferredStockValue id="Factid_21218741" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:PreferredStockValue id="Factid_21218742" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommonStockValue id="Factid_21218743" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommonStockValue id="Factid_21218744" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_21218745" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">367055000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_21218746" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">355452000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_21218747" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">-322093000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_21218748" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">-277234000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Factid_21218749" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">44962000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21218750" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">78218000</us-gaap:StockholdersEquity>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_21218751" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">405000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_21218752" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">860000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_21218753" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">1408000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_21218754" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">2189000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_21218755" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">17884000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_21218756" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">8963000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_21218757" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">53104000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_21218758" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">26206000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_21218759" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized id="Factid_21218760" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="-3">100000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding id="Factid_21218761" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="-3">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_21218762" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">0.00000002</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_21218763" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="-3">226000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Factid_21218764" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="-3">112592000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued id="Factid_21218765" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="-3">111514000</us-gaap:CommonStockSharesIssued>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_21218766" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized id="Factid_21218767" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="-3">100000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding id="Factid_21218768" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="-3">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_21218769" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.00000002</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_21218770" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="-3">226000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesOutstanding id="Factid_21218771" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="-3">112592000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding id="Factid_21218772" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="-3">111514000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_21218773" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">6215000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_21218774" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">3864000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_21218775" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">17780000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_21218776" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">12189000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses id="Factid_21218777" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">24504000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses id="Factid_21218778" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">13687000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses id="Factid_21218779" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">72292000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses id="Factid_21218780" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">40584000</us-gaap:CostsAndExpenses>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_21218785" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">-31313000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_21218786" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-4329000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_21218787" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-65166000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="Factid_21218788" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-27540000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:Revenues id="Factid_21218789" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">2418000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21218790" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">1244000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21218791" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">15419000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21218792" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">3409000</us-gaap:Revenues>
<us-gaap:OperatingIncomeLoss id="Factid_21218793" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">-22086000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_21218794" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-12443000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_21218795" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-56873000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_21218796" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-37175000</us-gaap:OperatingIncomeLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218797" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">-9272000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218798" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">7732000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218799" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">11035000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218800" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">8562000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:InvestmentIncomeInterestAndDividend id="Factid_21218801" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">58000</us-gaap:InvestmentIncomeInterestAndDividend>
<us-gaap:InvestmentIncomeInterestAndDividend id="Factid_21218802" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">382000</us-gaap:InvestmentIncomeInterestAndDividend>
<us-gaap:InvestmentIncomeInterestAndDividend id="Factid_21218803" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">497000</us-gaap:InvestmentIncomeInterestAndDividend>
<us-gaap:InvestmentIncomeInterestAndDividend id="Factid_21218804" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">1074000</us-gaap:InvestmentIncomeInterestAndDividend>
<us-gaap:NetIncomeLoss id="Factid_21218807" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-44859000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21218808" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-27540000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic id="Factid_21218809" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">-0.28</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic id="Factid_21218810" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">-0.04</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic id="Factid_21218811" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">-0.40</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic id="Factid_21218812" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">-0.32</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted id="Factid_21218813" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">-0.28</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted id="Factid_21218814" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">-0.04</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted id="Factid_21218815" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">-0.57</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted id="Factid_21218816" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">-0.32</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_21218817" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="-3">112557000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_21218818" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3">105999000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_21218819" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="-3">112505000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Factid_21218820" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_shares" decimals="-3">85995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_21218821" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="-3">112557000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_21218822" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3">105999000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_21218823" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="-3">113991000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Factid_21218824" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_shares" decimals="-3">85995000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218825" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">11035000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218826" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">8562000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_21218829" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">215000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_21218830" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">90000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_21218831" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">6343000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_21218832" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">169000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade id="Factid_21218833" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">3134000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade id="Factid_21218834" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-2295000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="Factid_21218835" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">1672000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="Factid_21218836" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">667000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:ProfitLoss id="Factid_21218837" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-44859000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss id="Factid_21218838" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-27540000</us-gaap:ProfitLoss>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_21218839" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">7377000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_21218840" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-2479000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_21218841" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_21218842" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">785000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquireShortTermInvestments id="Factid_21218843" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">325162000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:PaymentsToAcquireShortTermInvestments id="Factid_21218844" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">90324000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments id="Factid_21218845" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">340582000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments id="Factid_21218846" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">69863000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_21218847" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">14720000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_21218848" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-21246000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromStockOptionsExercised id="Factid_21218849" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">265000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised id="Factid_21218850" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">72000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_21218851" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">3401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_21218852" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">53948000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_21218853" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-20707000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_21218854" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-34854000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_21218855" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-2586000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_21218856" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-2152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_21218857" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">12331000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_21218858" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">9590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_21218859" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">9745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_21218860" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3">7438000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<meip:AccountsReceivableNetBeginningBalance id="Factid_21218861" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">2605000</meip:AccountsReceivableNetBeginningBalance>
<meip:AccountsReceivableNetBeginningBalance id="Factid_21218862" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<meip:AccountsReceivableNetEndingBalance id="Factid_21218863" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">0</meip:AccountsReceivableNetEndingBalance>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_21218865" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">335000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_21218866" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">511000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_21218867" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">7432000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_21218868" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3">353000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerLiability id="Factid_21218869" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">82497000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability id="Factid_21218870" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">7771000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability id="Factid_21218871" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">89877000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability id="Factid_21218872" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3">5292000</us-gaap:ContractWithCustomerLiability>
<us-gaap:RevenueRemainingPerformanceObligation id="Factid_21218873" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5">89900000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:RevenueRemainingPerformanceObligation id="Factid_21218874" contextRef="PAsOn03_31_2021_UsLicenseMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5">64500000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:RevenueRemainingPerformanceObligation id="Factid_21218875" contextRef="PAsOn03_31_2021_ExUsLicenseMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5">25400000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218884" contextRef="P07_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">830000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_21218885" contextRef="P07_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">11035000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<meip:PotentialMilestonePaymentsReceivable id="Factid_21218886" contextRef="PAsOn03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5">582500000</meip:PotentialMilestonePaymentsReceivable>
<meip:UpFrontPayment id="Factid_21218887" contextRef="P07_01_2020To03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">100000000</meip:UpFrontPayment>
<meip:UpFrontPayment id="Factid_21218888" contextRef="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">10000000</meip:UpFrontPayment>
<us-gaap:ProceedsFromLicenseFeesReceived id="Factid_21218889" contextRef="P08_30_2016To08_31_2016_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">20000000</us-gaap:ProceedsFromLicenseFeesReceived>
<meip:PotentialMilestonePaymentsPayable id="Factid_21218890" contextRef="PAsOn09_30_2017_MaximumMembersrtRangeAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF">179000000</meip:PotentialMilestonePaymentsPayable>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="Factid_21218891" contextRef="PAsOn09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">4900000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="Factid_21218892" contextRef="PAsOn09_30_2017_IncrementalPaymentMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">2000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<meip:PaymentForLicenseAgreement id="Factid_21218893" contextRef="P09_01_2017To09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">2900000</meip:PaymentForLicenseAgreement>
<meip:PercentageOfPurchasesFromMajorSuppliers id="Factid_21218894" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_pure" decimals="INF">1.00</meip:PercentageOfPurchasesFromMajorSuppliers>
<meip:AgreementTerminationNoticePeriod id="Factid_21218895" contextRef="P07_01_2020To03_31_2021">P90D</meip:AgreementTerminationNoticePeriod>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_21218900" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-27540000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_21218901" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-44859000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_21218902" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-4329000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_21218903" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">-31313000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<meip:MilestonePaymentsMaximumAmount id="Factid_21218904" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="INF">74500000</meip:MilestonePaymentsMaximumAmount>
<meip:NumberOfSharesAgreedToBeSoldUnderAgreement id="Factid_21218908" contextRef="PAsOn11_10_2020_MaximumMembersrtRangeAxis_TwoThousandAndTwentyAtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">60000000</meip:NumberOfSharesAgreedToBeSoldUnderAgreement>
<meip:NumberOfSharesAgreedToBeSoldUnderAgreement id="Factid_21218909" contextRef="PAsOn11_08_2017_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF">30000000</meip:NumberOfSharesAgreedToBeSoldUnderAgreement>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_21218910" contextRef="P07_01_2020To03_31_2021_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">958083</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<meip:ShelfRegistrationStatementValue id="Factid_21218911" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5">100000</meip:ShelfRegistrationStatementValue>
<meip:NumberOfSharesAgreedToBeSoldUnderAgreement id="Factid_21218912" contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_TwoThousandAndTwentyAtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">60000000</meip:NumberOfSharesAgreedToBeSoldUnderAgreement>
<meip:SaleOfSharesAndWarrantsUnderAgreement id="Factid_21218913" contextRef="P07_01_2020To03_31_2021_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF">200000000</meip:SaleOfSharesAndWarrantsUnderAgreement>
<meip:ShelfRegistrationStatementValue id="Factid_21218914" contextRef="PAsOn03_31_2021_TwoThousandAndTwentyAtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">60000000</meip:ShelfRegistrationStatementValue>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Factid_21218915" contextRef="PAsOn03_31_2021_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">16058985</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_21218916" contextRef="PAsOn03_31_2021_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2">2.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_21218919" contextRef="PAsOn03_31_2021_TwoThousandAndEightOmnibusPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">29014794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Factid_21218920" contextRef="PAsOn03_31_2021_TwoThousandAndEightOmnibusPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">10284365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="Factid_21218921" contextRef="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_21218922" contextRef="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_21218923" contextRef="P07_01_2020To03_31_2021_DirectorMembersrtTitleOfIndividualAxis_MinimumMembersrtRangeAxis">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Factid_21218924" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5">10200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Factid_21218925" contextRef="P07_01_2020To03_31_2021">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Factid_21218926" contextRef="P07_01_2020To07_31_2020_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">442650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Factid_21218927" contextRef="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF">3.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Factid_21218928" contextRef="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Factid_21218929" contextRef="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Factid_21218930" contextRef="P07_01_2020To03_31_2021_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<meip:NumberOfSharesToBeReceived id="Factid_21218931" contextRef="PAsOn03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">1</meip:NumberOfSharesToBeReceived>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_21218932" contextRef="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_21218933" contextRef="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<meip:AccruedMilestonePayments id="Factid_21218934" contextRef="PAsOn03_31_2021_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6">0</meip:AccruedMilestonePayments>
<meip:AccruedMilestonePayments id="Factid_21218935" contextRef="PAsOn03_31_2021_SbioPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6">0</meip:AccruedMilestonePayments>
<meip:AccruedMilestonePayments id="Factid_21218936" contextRef="PAsOn03_31_2021_CydexLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6">0</meip:AccruedMilestonePayments>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="Factid_21218937" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="INF">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="Factid_21218938" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="Factid_21218939" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="INF">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="Factid_21218940" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="Factid_21218941" contextRef="P07_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">-6000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
<us-gaap:UnrecognizedTaxBenefits id="Factid_21218943" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
<us-gaap:UnrecognizedTaxBenefits id="Factid_21218944" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
<meip:AccountsReceivableNetEndingBalance id="Factid_21218945" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3">74000</meip:AccountsReceivableNetEndingBalance>
<meip:NumberOfClinicalStageCandidates id="Factid_21218946" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_ClinicalTrials" decimals="0">4</meip:NumberOfClinicalStageCandidates>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_21218955" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">29442000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:LiabilitiesFairValueDisclosure id="Factid_21218957" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">29442000</us-gaap:LiabilitiesFairValueDisclosure>
<us-gaap:LiabilitiesFairValueDisclosure id="Factid_21218958" contextRef="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">40483000</us-gaap:LiabilitiesFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_21218959" contextRef="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">40483000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_21218960" contextRef="PAsOn06_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17613000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_21218962" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">16783000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:DeferredRevenueNoncurrent id="Factid_21218965" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">70734000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:DeferredRevenueNoncurrent id="Factid_21218966" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">67723000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:ShareBasedCompensation id="Factid_21218977" contextRef="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">1207000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218978" contextRef="P01_01_2020To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">696000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218979" contextRef="P07_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">3496000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218980" contextRef="P07_01_2019To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">2220000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218981" contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">1438000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218982" contextRef="P01_01_2020To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">854000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218983" contextRef="P07_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">4700000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218984" contextRef="P07_01_2019To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">3214000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218985" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">2645000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218986" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">1550000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218987" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">8196000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_21218988" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">5434000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_21218989" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">11252976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_21218990" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_21218991" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="INF">5763300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_21218992" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2">3.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Factid_21218993" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="INF">119042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Factid_21218994" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2">2.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_21218995" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="INF">223828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_21218996" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2">3.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_21218997" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF">16673406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_21218998" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="2">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_21218999" contextRef="P07_01_2020To03_31_2021">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Factid_21219001" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF">7802361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Factid_21219002" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="2">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Factid_21219003" contextRef="P07_01_2020To03_31_2021">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Factid_21219005" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2">2.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Factid_21219006" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_21219011" contextRef="P07_01_2019To03_31_2020">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_21219012" contextRef="P07_01_2020To03_31_2021">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_21219166" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="0">9775096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Factid_21219167" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="0">7006856</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_21219190" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_pure" decimals="3">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_21219191" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_pure" decimals="3">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_21219192" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_pure" decimals="3">0.811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_21219193" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_pure" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_21219194" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_pure" decimals="3">0.736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_21219195" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_pure" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<meip:ClinicalDevelopmentProgramsPolicyTextBlock id="Factid_21219197" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Clinical Development Programs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;Zandelisib (formerly known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401),&lt;/div&gt; an oral phosphatidylinositol &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-kinase&lt;/div&gt; (&amp;#8220;PI3K&amp;#8221;) delta inhibitor; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Voruciclib, an oral cyclin-dependent kinase (&amp;#8220;CDK&amp;#8221;) inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344,&lt;/div&gt; a mitochondrial inhibitor targeting the oxidative phosphorylation (&amp;#8220;OXPHOS&amp;#8221;) complex; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pracinostat, an oral histone deacetylase (&amp;#8220;HDAC&amp;#8221;) inhibitor. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The results of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials. The commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side effects or are less expensive than our drug candidates. We will need substantial additional funds to progress the clinical trial programs for the drug candidates zandelisib, voruciclib and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344,&lt;/div&gt; and to develop new compounds. The actual amount of funds that will be needed will depend upon a number of factors, some of which are beyond our control. Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:ClinicalDevelopmentProgramsPolicyTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_21219198" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 10 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&amp;#160;30, 2020, included in our Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (&amp;#8220;2020 Annual Report&amp;#8221;) filed with the Securities and Exchange Commission on September&amp;#160;9, 2020. Interim results are not necessarily indicative of results for a full year. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates id="Factid_21219199" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
<us-gaap:ResearchAndDevelopmentExpensePolicy id="Factid_21219201" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock id="Factid_21219202" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&amp;#8217;s historical price volatility. The stock&amp;#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&amp;#8220;RSU&amp;#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&amp;#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock id="Factid_21219203" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of March&amp;#160;31, 2021 and 2020, we have established a valuation allowance to fully reserve our net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in our ownership may limit the amount of net operating loss carryforwards that can be utilized in the future to offset taxable income. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no material changes in our unrecognized tax benefits since June&amp;#160;30, 2020, and, as such, the disclosures included in our 2020 Annual Report continue to be relevant for the nine months ended March&amp;#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:FairValueDisclosuresTextBlock id="Factid_21219205" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 2. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:96%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:14%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:85%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1&amp;#160;&amp;#8211;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs such as quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2 &amp;#8211;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs other than Level&amp;#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3 &amp;#8211;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:56%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(29,442&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(40,483&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(29,442&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(40,483&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash equivalents, where applicable, and short-term investments are classified as Level&amp;#160;1 as defined by the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2018, we issued warrants in connection with our private placement of shares of common stock. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet.&amp;#160;We recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and are required to revalue the warrants at each reporting date with any changes in fair value recorded on our Condensed Statement of Operations. The valuation of the warrants is considered under Level&amp;#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable.&amp;#160;Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in the fair value of the&amp;#160;Level 3 warrant liability is reflected in the Condensed Statement of Operations for the three and nine months ended March&amp;#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To calculate the fair value of the warrant liability, the following assumptions were used: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:75%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="width: 14pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 14pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.1&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.2&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2.1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2.9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;82.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;77.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Black-Scholes Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.83&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of changes in the estimated fair value of our Level&amp;#160;3 warrant liability for the nine months ended March&amp;#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:92%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;of&amp;#160;Warrants&amp;#160;Using&amp;#160;Significant&lt;br/&gt;Unobservable&amp;#160;Inputs&amp;#160;(Level&amp;#160;3)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2021&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2020&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at July&amp;#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(40,483&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,613&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification of derivative liability to equity upon exercise of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in estimated fair value of liability classified warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,035&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;830&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at March&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(29,442&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(16,783&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="Factid_21219206" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:56%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 12pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(29,442&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(40,483&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(29,442&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(40,483&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<meip:FairValueOfWarrantLiabilityAssumptionsTableTextBlock id="Factid_21219207" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To calculate the fair value of the warrant liability, the following assumptions were used: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:75%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="width: 14pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 14pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.1&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.2&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2.1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2.9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;82.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;77.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Black-Scholes Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.83&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:FairValueOfWarrantLiabilityAssumptionsTableTextBlock>
<meip:ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock id="Factid_21219208" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of changes in the estimated fair value of our Level&amp;#160;3 warrant liability for the nine months ended March&amp;#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:92%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 20pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;of&amp;#160;Warrants&amp;#160;Using&amp;#160;Significant&lt;br/&gt;Unobservable&amp;#160;Inputs&amp;#160;(Level&amp;#160;3)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2021&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2020&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at July&amp;#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(40,483&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,613&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification of derivative liability to equity upon exercise of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in estimated fair value of liability classified warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,035&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;830&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at March&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(29,442&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(16,783&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Factid_21219209" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 3. License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;KKC License, Development and Commercialization Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In April 2020, we entered into the License, Development and Commercialization Agreement (the &amp;#8220;KKC Commercialization Agreement&amp;#8221;) with Kyowa Kirin Company (&amp;#8220;KKC&amp;#8221;). Under the agreement, we granted to KKC a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-exclusive,&lt;/div&gt; sublicensable, payment-bearing license under certain patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the &amp;#8220;U.S. License&amp;#8221;), and an exclusive (subject to certain retained rights to perform obligations under the KKC Commercialization Agreement), sublicensable, payment-bearing, license under certain patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the United States (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8220;Ex-U.S.&amp;#8221;)&lt;/div&gt; (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8220;Ex-U.S.&lt;/div&gt; license&amp;#8221;). KKC granted to us a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-exclusive,&lt;/div&gt; sublicensable, license under certain patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-exclusive,&lt;/div&gt; sublicensable, royalty-free, fully paid license under certain patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; controlled by KKC to perform our obligations in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; under the KKC Commercialization Agreement. KKC paid us an initial payment of $100&amp;#160;million in May 2020. Of the $100&amp;#160;million paid by KKC, $20.4&amp;#160;million was remitted by KKC to the Japanese taxing authorities as a result of the U.S. Internal Revenue Service being closed due to the COVID pandemic, and therefore being unable to provide necessary documentation to support an exemption from the required foreign withholding. We received the amount remitted to the Japanese taxing authorities in October 2020. Additionally, we may earn up to approximately $582.5&amp;#160;million in potential development, regulatory and commercialization milestone payments, plus royalties on net sales of zandelisib in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.,&lt;/div&gt; which are tiered beginning in the teens. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;KKC will be responsible for the development and commercialization of zandelisib in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; and, subject to certain exceptions, will be solely responsible for all costs related thereto. We will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-develop&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-promote&lt;/div&gt; zandelisib with KKC in the U.S., with the Company recording all revenue from U.S. sales. We will share U.S. profits and costs (including development costs) on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50-50&lt;/div&gt; basis with KKC. We will also provide to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.,&lt;/div&gt; with the understanding that KKC will assume responsibility for manufacturing for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; as soon as practicable. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We assessed the KKC Commercialization Agreement in accordance with Topic 808 and Topic 606 and determined that our obligations comprise the U.S. License, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; License, and development services (the &amp;#8220;Development Services&amp;#8221;). We determined that the KKC Commercialization Agreement is a collaborative arrangement in accordance with Topic 808 that contains multiple units of account, as we and KKC are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The U.S. License is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, while the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; License and Development Services performance obligations are under the scope of Topic 606. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We determined, at the time of our initial assessment, that the total transaction price of $191.5&amp;#160;million is comprised of the upfront payment of $100.0&amp;#160;million, expected milestone payments of $20.0&amp;#160;million, estimated development cost-sharing of $66.3&amp;#160;million, and deferred revenue of $5.2&amp;#160;million from the KKC Japan License Agreement (as defined below). During the nine months ended March&amp;#160;31, 2021, we updated our initial assessment to reflect estimated development cost-sharing of $94.9&amp;#160;million. We included the amount of estimated variable consideration that is not constrained for development cost-sharing in the transaction price. Any variable consideration related to sales-based royalties and commercial milestones related to licenses of intellectual property will be determined when the sale or usage occurs, and is therefore excluded from the transaction price. In addition, we are eligible to receive future development and regulatory milestones upon the achievement of certain criteria; however, these amounts are excluded from variable consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraints at the end of each reporting period. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We allocated the transaction price to each unit of account. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations are allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed the estimated stand-alone selling price for the licenses using the risk-adjusted net present values of estimated cash flows, and the estimated stand-alone selling price of the development services performance obligations by estimating costs to be incurred, and an appropriate margin, using an income approach. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;We determined that control of the U.S. License and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; License were transferred to KKC during the year ended June&amp;#160;30, 2020, and recognized revenue of $21.0&amp;#160;million related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; License. The $64.5&amp;#160;million transaction price allocated to the U.S. License obligation accounted for under Topic 808 is recorded as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; deferred revenue and will begin to be recognized upon future commercialization as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-ASC&lt;/div&gt; 606 revenue. As of March&amp;#160;31, 2021 and June&amp;#160;30, 2020, we recorded deferred revenue of $25.4&amp;#160;million and $18.1&amp;#160;million, respectively, for the transaction price allocated to the Development Services performance obligations and are recognizing this revenue based on the proportional performance of these development activities, which we expect to recognize through fiscal year 2026. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;KKC Japan License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In October 2018, we, as licensor, entered into a license agreement with KKC for zandelisib (&amp;#8220;the KKC Japan License Agreement&amp;#8221;). Under the terms of the KKC Japan License Agreement, KKC was granted the exclusive right to develop and commercialize zandelisib in Japan. We also granted KKC the right to purchase supply of zandelisib for commercial requirements at cost plus a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-negotiated&lt;/div&gt; percentage, as well as manufacturing rights in Japan. In return, we received an upfront payment of $10.0&amp;#160;million and were eligible to receive additional development and commercialization milestones, as well as royalties on net sales of zandelisib in Japan. In April 2020, we and KKC agreed to terminate the KKC Japan License Agreement. The KKC Japan License Agreement was replaced with the KKC Commercialization Agreement. Pursuant to the terms of the KKC Commercialization Agreement, we agreed to collaborate with KKC on the development, manufacturing and commercialization of zandelisib in Japan. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We assessed the KKC Japan License Agreement in accordance with ASC 606 and determined that our performance obligations comprised the license, research and development obligations, and our obligation to provide clinical trial materials to KKC. We determined that the transaction price amounted to the upfront payment of $10.0&amp;#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We determined that control of the license was transferred to KKC during the year ended June&amp;#160;30, 2019. Revenue allocated to the research and development obligations was recognized based on the proportional performance of these research and development activities. Revenue allocated to providing clinical trial materials was recognized upon delivery. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Helsinn License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation (&amp;#8220;Helsinn&amp;#8221;) for pracinostat in acute myeloid leukemia (&amp;#8220;AML&amp;#8221;), myelodysplastic syndrome (&amp;#8220;MDS&amp;#8221;) and other potential indications (the &amp;#8220;Helsinn License Agreement&amp;#8221;). Under the terms of the agreement, Helsinn was granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. As compensation for such grant of rights, we received payments of $20.0&amp;#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We determined that the agreement contains multiple performance obligations for purposes of revenue recognition. Revenue related to the research and development elements of the arrangement is recognized based on the extent of progress toward completion of each performance obligation. Revenue is recognized on a gross basis as we are the primary obligor and have discretion in supplier selection. During the nine months ended March&amp;#160;31, 2021, our only remaining performance obligation under the agreement was the conduct of a Phase 2 dose-optimization study of pracinostat in combination with azacitidine in patients with high and very high risk MDS who are previously untreated with hypomethylating agents (the &amp;#8220;POC study&amp;#8221;), for which Helsinn has agreed to share third-party expenses. As of March&amp;#160;31, 2021, our performance obligations related to the Helsinn License Agreement have been met, and no future revenue or costs of revenue will be recognized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Presage License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In September 2017, we entered into a license agreement with Presage Biosciences, Inc. (&amp;#8220;Presage&amp;#8221;). Under the terms of such license agreement (the &amp;#8220;Presage License Agreement&amp;#8221;), Presage granted to us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid $2.9&amp;#160;million. With respect to the first indication, an incremental $2.0&amp;#160;million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9&amp;#160;million prior to receipt of marketing approval of the first indication in the U.S., E.U. or Japan. Additional potential payments of up to $179&amp;#160;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single-digit&lt;/div&gt; tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product development progresses) of amounts received from such sublicensees. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;CyDex License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We are party to a license agreement with CyDex Pharmaceuticals, Inc. (&amp;#8220;CyDex&amp;#8221;). Under the license agreement, CyDex granted to us an exclusive, nontransferable license to intellectual property rights relating to Captisol&lt;div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt; for use with our isoflavone-based drug compounds (currently &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344).&lt;/div&gt; We agreed to pay to CyDex a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may terminate both the license agreement and the supply agreement at any time upon 90 days&amp;#8217; prior written notice. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:CollaborativeArrangementDisclosureTextBlock id="Factid_21219210" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 4. BeiGene Collaboration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (&amp;#8220;BeiGene&amp;#8221;) to evaluate the safety and efficacy of zandelisib in combination with BeiGene&amp;#8217;s zanubrutinib (marketed as Brukinsa&lt;div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt;), an inhibitor of Bruton&amp;#8217;s tyrosine kinase, for the treatment of patients with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-cell&lt;/div&gt; malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of zandelisib in combination with zanubrutinib in patients with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-cell&lt;/div&gt; malignancies. Study costs are being shared equally by the parties, and we agreed to supply zandelisib and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for zandelisib and BeiGene retained full commercial rights for zanubrutinib. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Factid_21219211" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the calculation of net loss used to calculate basic loss and diluted loss per share (in thousands):&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:57%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss &amp;#8211; basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(31,313&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4,329&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(44,859&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(27,540&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(20,307&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss &amp;#8211; diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(31,313&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4,329&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(65,166&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(27,540&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock id="Factid_21219212" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share used in calculating net loss per share was determined as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average shares used in calculating basic net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;112,557&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;105,999&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;112,505&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;85,995&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of potentially dilutive common shares from equity awards and liability-classified warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,486&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average shares used in calculating diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;112,557&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;105,999&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;113,991&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;85,995&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
<us-gaap:EarningsPerShareTextBlock id="Factid_21219213" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 5. Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and nine months ended March&amp;#160;31, 2021 and 2020. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the calculation of net loss used to calculate basic loss and diluted loss per share (in thousands):&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:57%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss &amp;#8211; basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(31,313&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4,329&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(44,859&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(27,540&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(20,307&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss &amp;#8211; diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(31,313&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4,329&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(65,166&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(27,540&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share used in calculating net loss per share was determined as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average shares used in calculating basic net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;112,557&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;105,999&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;112,505&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;85,995&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of potentially dilutive common shares from equity awards and liability-classified warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,486&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average shares used in calculating diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;112,557&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;105,999&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;113,991&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;85,995&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents weighted-average potentially dilutive shares that have been excluded from the calculation of net loss per share because of their anti-dilutive effect (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:64%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,161&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,064&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,618&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,974&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;430&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;430&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,060&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,062&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,354&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,062&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total anti-dilutive shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;32,651&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;27,126&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;21,402&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;27,036&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Factid_21219214" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 6. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We have contracted with various consultants and third parties to assist us in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; research and development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. We also have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances. &amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Presage License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note 3, we are party to a license agreement with Presage under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of March&amp;#160;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;S*Bio Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&amp;#160;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U. and Japan. As of March&amp;#160;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;CyDex License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note 3, we are party to a license agreement with CyDex under which we may be required to make future payments upon the achievement of certain milestones, as well as potential future royalties based upon net sales. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. As of March&amp;#160;31, 2021, we have not accrued any amounts for potential future payments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In January 2020, the World Health Organization (&amp;#8220;WHO&amp;#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8220;COVID-19&lt;/div&gt; outbreak&amp;#8221;) and the risks to the international community. In March 2020, the WHO classified the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; outbreak as a pandemic, based on the rapid increase in exposure globally. As a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, which continues to rapidly evolve, &amp;#8220;shelter in place&amp;#8221; orders and other public health guidance measures have been implemented across much of the United States, Europe and Asia, including in the locations of our offices, clinical trial sites, key vendors and partners. Despite the relaxation of many governmental orders in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-2020,&lt;/div&gt; the &amp;#8220;second wave&amp;#8221; of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; outbreak has resulted in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-imposition&lt;/div&gt; of many of these measures. In addition, although the FDA has authorized vaccines for the treatment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; the effectiveness and timing of distribution of the vaccines remains highly uncertain. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; virus has also mutated into different strains, which could be more contagious or severe or for which treatments are unavailable. While we continue to enroll and dose patients in our clinical trials, our clinical development program timelines continue to be subject to potential negative impacts from the ongoing pandemic. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the effectiveness and timing of distribution of treatments for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and to minimize its economic impact. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;CARES Act &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&amp;#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security (&amp;#8220;CARES&amp;#8221;) Act was signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. Regulatory guidance has indicated that public companies are ineligible to participate in certain of the loan programs provided by the CARES Act. There is substantial uncertainty with respect to the scope, content or timing of any further economic stimulus programs to address the economic downturn related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; outbreak. We do not expect that the CARES Act will have a material impact on our financial condition, results of operation, or liquidity. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Legal Proceedings &amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On August&amp;#160;10, 2020, Guy Bahat, an individual who allegedly purchased 50 shares of our common stock filed a putative securities class action lawsuit (the &amp;#8220;Securities Class&amp;#160;Action&amp;#8221;) in the United States District Court for the Southern District of California against the Company, Dr.&amp;#160;Daniel&amp;#160;P. Gold, and Mr.&amp;#160;Brian&amp;#160;G. Drazba, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the &amp;#8220;Exchange Act&amp;#8221;) and Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10b-5&lt;/div&gt; thereunder. Mr.&amp;#160;Bahat did not seek appointment as lead plaintiff, and the court appointed another individual, Ramesh Mahalingham, as lead plaintiff. The plaintiff seeks to sue on behalf of all purchasers of our securities from August&amp;#160;2, 2017 through July&amp;#160;1, 2020 and alleges, among other things, that we made false and misleading statements relating to pracinostat during the proposed class period. On February&amp;#160;16, 2021, the lead plaintiff filed a notice of voluntary dismissal without prejudice, thereby concluding the class action litigation. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&amp;#160;21, 2020, Peter D&amp;#8217;Arcy, an individual who alleges that he is a Company stockholder, filed a putative stockholder derivative action nominally on behalf of the Company in the United States District Court for the District of Delaware (the &amp;#8220;Derivative Action&amp;#8221;) against Dr.&amp;#160;Gold, Mr.&amp;#160;Drazba, Mr.&amp;#160;Charles&amp;#160;V. Baltic, III, Dr.&amp;#160;Kevan&amp;#160;E. Clemens, Mr.&amp;#160;Frederick&amp;#160;W. Driscoll, Dr.&amp;#160;Nicholas&amp;#160;R. Glover, Ms.&amp;#160;Tamar&amp;#160;D. Howson, Dr.&amp;#160;Thomas&amp;#160;C. Reynolds, Mr.&amp;#160;William&amp;#160;D. Rueckert, and Dr.&amp;#160;Christine&amp;#160;A. White, and naming the Company as a nominal defendant. Additional putative stockholder derivative suits were filed in the same court naming the same defendants plus Dr.&amp;#160;Robert&amp;#160;D. Mass on December&amp;#160;2, 2020 and December&amp;#160;15, 2020 by Gerald Wright and William Trablicy, respectively, who also allege that they are Company stockholders, and these additional suits were consolidated into the Derivative Action by court order. The Derivative Action is based upon the pracinostat-related allegations in the Securities Class&amp;#160;Action described above, and alleges claims under Section&amp;#160;14(a) of the Exchange Act and claims for breach of fiduciary duty, unjust enrichment, corporate waste, and contribution. On February&amp;#160;24, 2021, following the resolution of the class action litigation, the parties stipulated request for voluntary dismissal without prejudice, which the court granted on February&amp;#160;25, 2021. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="Factid_21219215" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 8. Short-Term Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&amp;#160;31, 2021 and June&amp;#160;30, 2020, our short-term investments consisted of $154.9&amp;#160;million and $170.3&amp;#160;million, respectively, in U.S. government securities. The short-term investments held as of March&amp;#160;31, 2021 and June&amp;#160;30, 2020 had maturity dates of less than one year, are considered to be &amp;#8220;held to maturity&amp;#8221; and are carried at amortized cost. As of March&amp;#160;31, 2021 and June&amp;#160;30, 2020, the gross holding gains and losses were immaterial. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_21219216" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 9. Stockholders&amp;#8217; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity Transactions &amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-The-Market&lt;/div&gt;&lt;/div&gt; Equity Offering &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On November&amp;#160;10, 2020, we entered into an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-The-Market&lt;/div&gt;&lt;/div&gt; Equity Offering Sales Agreement (the &amp;#8220;2020 ATM Sales Agreement&amp;#8221;), pursuant to which we may sell an aggregate of up to $60.0&amp;#160;million of our common stock pursuant to the shelf registration statement. We had previously entered into an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-The-Market&lt;/div&gt;&lt;/div&gt; Equity Offering Sales Agreement in November 2017 (the &amp;#8220;2017 ATM Sales Agreement&amp;#8221;), pursuant to which we could sell an aggregate of up to $30.0&amp;#160;million of our common stock pursuant to the shelf registration statement. The 2017 ATM Sales Agreement expired on November&amp;#160;8, 2020. During the nine months ended March&amp;#160;31, 2021, we sold 958,083 shares under the 2017 ATM Sales Agreement for net proceeds of $3.1&amp;#160;million, after costs of $0.1&amp;#160;million. As of March&amp;#160;31, 2021, there is $60.0&amp;#160;million remaining available under the 2020 ATM Sales Agreement. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Shelf Registration Statement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have a shelf registration statement that permits us to sell, from time to time, up to $200.0&amp;#160;million of common stock, preferred stock and warrants. The shelf registration was filed and declared effective in May 2020, replacing our prior shelf registration statement that was filed and declared effective in May 2017, and carrying forward approximately $107.5&amp;#160;million of unsold securities registered under the prior shelf registration statement. As of March&amp;#160;31, 2021, there is $175.7&amp;#160;million aggregate value of securities available under the shelf registration statement, including up to $60.0&amp;#160;million remaining available under the 2020 ATM Sales Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&amp;#160;31, 2021, we have outstanding warrants to purchase 16,058,985 shares of our common stock. The warrants are fully vested, exercisable at a price of $2.54 per share and expire in May 2023. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet. Therefore, we are required to account for the warrants as liabilities and record them at fair value. The warrants were revalued as of March&amp;#160;31, 2021 at $29.4&amp;#160;million and as of June&amp;#160;30, 2020 at $40.5&amp;#160;million; the changes in fair value were recorded in our Condensed Statement of Operations. During the nine months ended March&amp;#160;31, 2021, a warrant holder completed a cashless exercise of 2,617 warrants for 964 shares of common stock. No warrants were exercised during the nine months ended March&amp;#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Factid_21219217" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 10. Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (&amp;#8220;2008 Plan&amp;#8221;), as amended and restated in 2011, 2013, 2014, 2015, 2016, 2018 and 2020, under which 29,014,794 shares of common stock are authorized for issuance. The 2008 Plan provides for the grant of options and/or other stock-based or stock-denominated awards to our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors, officers, employees and advisors. As of March&amp;#160;31, 2021, there were 10,284,365 shares available for future grant under the 2008 Plan. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expense for all stock awards consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:72%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,207&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;696&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,496&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,220&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,438&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;854&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,700&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,214&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,645&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,550&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,196&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,434&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity for the nine months ended March&amp;#160;31, 2021 was as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:55%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 73pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 73pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 108pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 108pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 52pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 52pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&amp;#160;Price&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-Average&lt;/div&gt;&lt;br/&gt;Remaining&amp;#160;Contractual&lt;br/&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,252,976&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.81&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5,763,300&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3.40&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(119,042&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.22&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited / Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(223,828&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3.65&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at March&amp;#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,673,406&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3.01&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,775,096&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested and exercisable at March&amp;#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,802,361&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2.74&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.7&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,006,856&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of each stock option granted during the nine months ended March&amp;#160;31, 2021 is estimated on the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the nine months ended March&amp;#160;31, 2021 vest 25% one year from the date of grant and ratably each month thereafter for a period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the nine months ended March&amp;#160;31, 2021 vest ratably each month for a period of 12 months from the date of grant and expire ten years from the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following weighted-average assumptions were used to determine the fair value of options granted during the period: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:85%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.5&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.8&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;81.1&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;73.6&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.32&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.60&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&amp;#160;31, 2021, there was $10.2&amp;#160;million of unrecognized compensation expense related to the unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.7 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2020, we granted 442,650 RSUs to employees. Each RSU represented the contingent right to receive one share of our common stock. The RSUs will vest in periods of either one year or two years from the date of grant. The fair value of the RSUs was measured at $3.49 per unit. Under the terms of the 2008 Plan, each of the RSUs is calculated as 1.25 shares of common stock for purposes of determining the number of shares available for future grant. There were forfeitures of 12,000 RSUs during the nine months ended March&amp;#160;31, 2021, and 430,650 unvested RSUs were outstanding as of March&amp;#160;31, 2021. As of March&amp;#160;31, 2021, unrecognized compensation expense related to the unvested portion of our RSUs was approximately $0.8&amp;#160;million and is expected to be recognized over approximately 1.1 years. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Factid_21219218" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expense for all stock awards consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:72%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,207&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;696&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,496&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,220&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,438&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;854&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,700&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,214&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,645&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,550&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,196&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,434&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock id="Factid_21219219" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity for the nine months ended March&amp;#160;31, 2021 was as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:55%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 73pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 73pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 108pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 108pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 52pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 52pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&amp;#160;Price&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-Average&lt;/div&gt;&lt;br/&gt;Remaining&amp;#160;Contractual&lt;br/&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,252,976&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.81&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5,763,300&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3.40&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(119,042&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.22&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited / Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(223,828&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3.65&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at March&amp;#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,673,406&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3.01&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,775,096&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested and exercisable at March&amp;#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,802,361&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2.74&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.7&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,006,856&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Factid_21219220" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following weighted-average assumptions were used to determine the fair value of options granted during the period: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:85%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.5&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.8&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;81.1&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;73.6&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.32&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.60&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:StockholdersEquity id="Factid_21219221" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">111514000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219222" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">355452000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219223" contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-277234000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_21219225" contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-2092000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21219226" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-2092000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219227" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219228" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">3136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219229" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">3136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219230" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219231" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219232" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219233" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2942000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219234" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">2942000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_21219235" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">112522000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219236" contextRef="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">361654000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219237" contextRef="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-279326000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219238" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">82328000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_21219239" contextRef="P10_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-11454000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21219240" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-11454000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219241" contextRef="P10_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219242" contextRef="P10_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219243" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219244" contextRef="P10_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219245" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">2609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_21219246" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">112528000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219247" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">364278000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219248" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-290780000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219249" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">73498000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_21219250" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-31313000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21219251" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">-31313000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219252" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">63000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219253" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">126000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219254" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">126000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<meip:Stockissuedduringperiodvaluestockwarrantsexercised id="Factid_21219255" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</meip:Stockissuedduringperiodvaluestockwarrantsexercised>
<meip:Stockissuedduringperiodvaluestockwarrantsexercised id="Factid_21219256" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">6000</meip:Stockissuedduringperiodvaluestockwarrantsexercised>
<meip:Stockissuedduringperiodvaluestockwarrantsexercised id="Factid_21219257" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">6000</meip:Stockissuedduringperiodvaluestockwarrantsexercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219258" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219259" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">2645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_21219260" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">112592000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219261" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">367055000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219262" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-322093000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219264" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">73545000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219265" contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">279148000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219266" contextRef="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-231218000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219267" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">47930000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_21219268" contextRef="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-2994000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21219269" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-2994000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219270" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">64000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219271" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219272" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219273" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">46000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219274" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_21219275" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219276" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219277" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">2113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_21219278" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">73655000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219279" contextRef="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">281492000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219280" contextRef="PAsOn09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-234212000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219281" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">47280000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_21219282" contextRef="P10_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-20217000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21219283" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-20217000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219284" contextRef="P10_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">32344000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219285" contextRef="P10_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">48451000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219286" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">48451000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219287" contextRef="P10_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1771000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219288" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">1771000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_21219289" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">105999000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219290" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">331714000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219291" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-254429000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219292" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">77285000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_21219293" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-4329000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_21219294" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-4329000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219295" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219296" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219297" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219298" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1550000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_21219299" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">1550000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_21219300" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">105999000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219301" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">333256000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_21219302" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-258758000</us-gaap:StockholdersEquity>
<meip:RevenuePerformanceObligationAmount id="Factid_21219308" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-5">2300000</meip:RevenuePerformanceObligationAmount>
<meip:RevenuePerformanceObligationAmount id="Factid_21219309" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-5">15000000</meip:RevenuePerformanceObligationAmount>
<meip:RevenuePerformanceObligationAmount id="Factid_21219310" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-5">800000</meip:RevenuePerformanceObligationAmount>
<meip:RevenuePerformanceObligationAmount id="Factid_21219311" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-5">2300000</meip:RevenuePerformanceObligationAmount>
<meip:ReceivableForForeignTaxWithholding id="Factid_21219332" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">20420000</meip:ReceivableForForeignTaxWithholding>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_21219333" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">7992000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiabilityCurrent id="Factid_21219334" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">900000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent id="Factid_21219335" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">7608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_21219336" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">-13000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_21219337" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">0</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_21219338" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">482000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_21219339" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:StockholdersEquity id="Factid_21219340" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3">74498000</us-gaap:StockholdersEquity>
<meip:NonCashLeaseExpense id="Factid_21219341" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">697000</meip:NonCashLeaseExpense>
<meip:IncreaseOrDecreaseInReceivableForForeignTaxWithholding id="Factid_21219342" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">20420000</meip:IncreaseOrDecreaseInReceivableForForeignTaxWithholding>
<meip:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent id="Factid_21219343" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-181000</meip:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="Factid_21219344" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">8689000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<meip:ProceedsFromPreviouslyIssuedCommonStock id="Factid_21219345" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">5274000</meip:ProceedsFromPreviouslyIssuedCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock id="Factid_21219346" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">48602000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock id="Factid_21219347" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">3136000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:IncomeTaxesPaidNet id="Factid_21219348" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet id="Factid_21219349" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-8000</us-gaap:IncomeTaxesPaidNet>
<meip:CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable id="Factid_21219350" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5">164600000</meip:CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable>
<us-gaap:DeferredRevenueRevenueRecognized1 id="Factid_21219352" contextRef="P07_01_2019To03_31_2020_HelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">1100000</us-gaap:DeferredRevenueRevenueRecognized1>
<us-gaap:DeferredRevenueRevenueRecognized1 id="Factid_21219353" contextRef="P07_01_2020To03_31_2021_HelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">400000</us-gaap:DeferredRevenueRevenueRecognized1>
<us-gaap:DeferredRevenueRevenueRecognized1 id="Factid_21219354" contextRef="P01_01_2020To03_31_2020_HelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">400000</us-gaap:DeferredRevenueRevenueRecognized1>
<us-gaap:DeferredRevenueRevenueRecognized1 id="Factid_21219355" contextRef="P01_01_2021To03_31_2021_HelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:DeferredRevenueRevenueRecognized1>
<us-gaap:IncreaseDecreaseInContractWithCustomerAsset id="Factid_21219356" contextRef="P07_01_2020To03_31_2021_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">22800000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_21219357" contextRef="PAsOn03_31_2021_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">7400000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_21219358" contextRef="P07_01_2019To03_31_2020_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">2600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_21219359" contextRef="P01_01_2020To03_31_2020_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_21219360" contextRef="P07_01_2020To03_31_2021_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">15400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_21219361" contextRef="P01_01_2021To03_31_2021_KkcAgreementsandHelsinnLicenseAgreementMemberMEIPAgreementAxis" unitRef="Unit_USD" decimals="-5">2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219362" contextRef="PAsOn06_30_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="2">2.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219363" contextRef="PAsOn03_31_2021_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="2">1.83</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219364" contextRef="PAsOn06_30_2020_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219365" contextRef="PAsOn03_31_2021_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219366" contextRef="PAsOn06_30_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">77.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219367" contextRef="PAsOn03_31_2021_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">82.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219368" contextRef="PAsOn06_30_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">2.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219369" contextRef="PAsOn03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">2.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219370" contextRef="PAsOn06_30_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">0.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_21219371" contextRef="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">0.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<meip:IncreaseOrDecreaseInReceivableForForeignTaxWithholding id="Factid_21219372" contextRef="P07_01_2020To03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="INF">20400000</meip:IncreaseOrDecreaseInReceivableForForeignTaxWithholding>
<meip:TotalUpfrontPaymentReceivableForGrantOfRights id="Factid_21219373" contextRef="PAsOn03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6">100000000</meip:TotalUpfrontPaymentReceivableForGrantOfRights>
<meip:TotalUpfrontPaymentReceivableForGrantOfRights id="Factid_21219374" contextRef="PAsOn05_31_2020_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6">100000000</meip:TotalUpfrontPaymentReceivableForGrantOfRights>
<meip:TotalTransactionPriceInRespectOfColloborationRevenue id="Factid_21219375" contextRef="PAsOn03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">191500000</meip:TotalTransactionPriceInRespectOfColloborationRevenue>
<meip:ExpectedMilestonePaymentReceivable id="Factid_21219376" contextRef="PAsOn03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">20000000</meip:ExpectedMilestonePaymentReceivable>
<meip:EstimatedDevelopmentCostSharingRecoverableThroughEarnings id="Factid_21219377" contextRef="PAsOn03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">66300000</meip:EstimatedDevelopmentCostSharingRecoverableThroughEarnings>
<us-gaap:DeferredRevenue id="Factid_21219378" contextRef="PAsOn03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">5200000</us-gaap:DeferredRevenue>
<meip:EstimatedDevelopmentCostSharingRecoverableThroughEarnings id="Factid_21219379" contextRef="PAsOn03_31_2021_KyowaKirinCoMemberdeiLegalEntityAxis_UpdationOfInitialAssessmentMemberMEIPEventAxis" unitRef="Unit_USD" decimals="-5">94900000</meip:EstimatedDevelopmentCostSharingRecoverableThroughEarnings>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_21219380" contextRef="P07_01_2019To06_30_2020_ExUsLicenseMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">21000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<meip:LicenseObligationAccountTransactionPriceAllocated id="Factid_21219381" contextRef="P07_01_2019To06_30_2020_ExUsLicenseMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">64500000</meip:LicenseObligationAccountTransactionPriceAllocated>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_21219382" contextRef="PAsOn03_31_2021_DevelopmentServicesMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">25400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_21219383" contextRef="PAsOn06_30_2020_DevelopmentServicesMembersrtProductOrServiceAxis_KkcAgreementsMemberusgaapTypeOfArrangementAxis_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">18100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<meip:TotalUpfrontPaymentReceivableForGrantOfRights id="Factid_21219384" contextRef="PAsOn06_30_2020_KyowaKirinCoMemberdeiLegalEntityAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5">10000000</meip:TotalUpfrontPaymentReceivableForGrantOfRights>
<meip:DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability id="Factid_21219386" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-20307000</meip:DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219387" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_shares" decimals="-3">27036000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219388" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="-3">21402000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219389" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3">27126000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219390" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="-3">32651000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219391" contextRef="P07_01_2019To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">16062000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219392" contextRef="P01_01_2020To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">16062000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219393" contextRef="P07_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">430000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219394" contextRef="P01_01_2021To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">430000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219395" contextRef="P07_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">10974000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219396" contextRef="P07_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">15618000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219397" contextRef="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">11064000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219398" contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">16161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<meip:InitialRecognitionOfOperatingLeaseRightOfUseAsset id="Factid_21219400" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5">8700000</meip:InitialRecognitionOfOperatingLeaseRightOfUseAsset>
<meip:NumberOfSquareFeetUnderLease id="Factid_21219401" contextRef="PAsOn12_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_SanDiegoCaliforniaMembersrtStatementGeographicalAxis" unitRef="Unit_sqft" decimals="0">32800</meip:NumberOfSquareFeetUnderLease>
<us-gaap:OperatingLeaseCost id="Factid_21219402" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">603000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost id="Factid_21219403" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">1130000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost id="Factid_21219404" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">201000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost id="Factid_21219405" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">377000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeasePayments id="Factid_21219407" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">603000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments id="Factid_21219408" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">615000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments id="Factid_21219409" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">201000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments id="Factid_21219410" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3">369000</us-gaap:OperatingLeasePayments>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="Factid_21219411" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">1710000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="Factid_21219415" contextRef="PAsOn03_31_2021" unitRef="Unit_pure" decimals="4">0.0750</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="Factid_21219416" contextRef="PAsOn03_31_2021">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseLiability id="Factid_21219417" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">8508000</us-gaap:OperatingLeaseLiability>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="Factid_21219418" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">2556000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="Factid_21219419" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">11064000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<meip:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour id="Factid_21219420" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">3122000</meip:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="Factid_21219421" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">1168000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="Factid_21219422" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">1612000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="Factid_21219423" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">1565000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="Factid_21219424" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">1519000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear id="Factid_21219425" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3">368000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_21219426" contextRef="P07_01_2020To03_31_2021_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">3100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<meip:AggregateValueOfSecuritiesAvailableUnderAgreement id="Factid_21219427" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5">175700000</meip:AggregateValueOfSecuritiesAvailableUnderAgreement>
<meip:UnsoldSecuritiesSharesAndWarrantsUnderAgreement id="Factid_21219428" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-5">107500000</meip:UnsoldSecuritiesSharesAndWarrantsUnderAgreement>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="Factid_21219429" contextRef="PAsOn03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Factid_21219430" contextRef="PAsOn03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">430650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited id="Factid_21219431" contextRef="P07_01_2020To03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">12000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
<meip:NumberOfSharesForEachUnitOfRestrictedStock id="Factid_21219432" contextRef="PAsOn03_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2">1.25</meip:NumberOfSharesForEachUnitOfRestrictedStock>
<dei:DocumentType id="Factid_21219433" contextRef="P07_01_2020To03_31_2021">10-Q</dei:DocumentType>
<dei:AmendmentFlag id="Factid_21219434" contextRef="P07_01_2020To03_31_2021">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate id="Factid_21219435" contextRef="P07_01_2020To03_31_2021">2021-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_21219436" contextRef="P07_01_2020To03_31_2021">2021</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_21219437" contextRef="P07_01_2020To03_31_2021">Q3</dei:DocumentFiscalPeriodFocus>
<dei:TradingSymbol id="Factid_21219438" contextRef="P07_01_2020To03_31_2021">MEIP</dei:TradingSymbol>
<dei:EntityRegistrantName id="Factid_21219439" contextRef="P07_01_2020To03_31_2021">MEI Pharma, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_21219440" contextRef="P07_01_2020To03_31_2021">0001262104</dei:EntityCentralIndexKey>
<dei:EntityFilerCategory id="Factid_21219442" contextRef="P07_01_2020To03_31_2021">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:EntityCurrentReportingStatus id="Factid_21219443" contextRef="P07_01_2020To03_31_2021">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent id="Factid_21219444" contextRef="P07_01_2020To03_31_2021">Yes</dei:EntityInteractiveDataCurrent>
<dei:EntityEmergingGrowthCompany id="Factid_21219445" contextRef="P07_01_2020To03_31_2021">false</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany id="Factid_21219446" contextRef="P07_01_2020To03_31_2021">false</dei:EntityShellCompany>
<dei:EntitySmallBusiness id="Factid_21219447" contextRef="P07_01_2020To03_31_2021">true</dei:EntitySmallBusiness>
<dei:Security12bTitle id="Factid_21219448" contextRef="P07_01_2020To03_31_2021">Common Stock</dei:Security12bTitle>
<dei:SecurityExchangeName id="Factid_21219449" contextRef="P07_01_2020To03_31_2021">NASDAQ</dei:SecurityExchangeName>
<dei:EntityCommonStockSharesOutstanding id="Factid_21219451" contextRef="PAsOn05_04_2021" unitRef="Unit_shares" decimals="INF">112591778</dei:EntityCommonStockSharesOutstanding>
<meip:NumberOfWarrantsExercised id="Factid_21219463" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="INF">2617</meip:NumberOfWarrantsExercised>
<meip:NumberOfSharesIssuedOnWarrantExercise id="Factid_21219464" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="INF">964</meip:NumberOfSharesIssuedOnWarrantExercise>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219470" contextRef="P01_01_2021To03_31_2021_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">16060000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_21219471" contextRef="P07_01_2020To03_31_2021_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3">5354000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<meip:ProfitsAndCostsSharingRatio id="Factid_21219505" contextRef="PAsOn03_31_2021" unitRef="Unit_pure" decimals="1">0.5</meip:ProfitsAndCostsSharingRatio>
<meip:ReceivablesAmountsBilled id="Factid_21219506" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">15744000</meip:ReceivablesAmountsBilled>
<meip:ReceivablesAmountsBilled id="Factid_21219507" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">1088000</meip:ReceivablesAmountsBilled>
<meip:ReceivablesPaymentsReceived id="Factid_21219508" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-18349000</meip:ReceivablesPaymentsReceived>
<meip:ReceivablesPaymentsReceived id="Factid_21219509" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-1014000</meip:ReceivablesPaymentsReceived>
<meip:ContractAssetsBillableAmounts id="Factid_21219510" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">22841000</meip:ContractAssetsBillableAmounts>
<meip:ContractAssetsBillableAmounts id="Factid_21219511" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">930000</meip:ContractAssetsBillableAmounts>
<meip:ContractAssetsAmountsBilled id="Factid_21219512" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">-15744000</meip:ContractAssetsAmountsBilled>
<meip:ContractAssetsAmountsBilled id="Factid_21219513" contextRef="P07_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3">-1088000</meip:ContractAssetsAmountsBilled>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_21219520" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-5">-2100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<dei:CurrentFiscalYearEndDate id="Factid_21219521" contextRef="P07_01_2020To03_31_2021">--06-30</dei:CurrentFiscalYearEndDate>
<meip:WarrantsIssuedPursuantToCashlessExercise id="Factid_21219522" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3">6000</meip:WarrantsIssuedPursuantToCashlessExercise>
<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="Factid_21219527" contextRef="P07_01_2020To03_31_2021" unitRef="Unit_shares" decimals="-3">1486000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
<us-gaap:Revenues id="Factid_21219532" contextRef="P01_01_2021To03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">2321000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219533" contextRef="P01_01_2020To03_31_2020_KkcAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">812000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219534" contextRef="P07_01_2020To03_31_2021_KkcAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">14979000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219535" contextRef="P07_01_2019To03_31_2020_KkcAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">2282000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219536" contextRef="P01_01_2021To03_31_2021_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">97000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219537" contextRef="P01_01_2020To03_31_2020_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">432000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219538" contextRef="P07_01_2020To03_31_2021_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">440000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219539" contextRef="P07_01_2019To03_31_2020_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">1127000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219540" contextRef="P01_01_2021To03_31_2021_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">2418000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219541" contextRef="P01_01_2020To03_31_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">1244000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219542" contextRef="P07_01_2020To03_31_2021_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">15419000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_21219543" contextRef="P07_01_2019To03_31_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">3409000</us-gaap:Revenues>
<us-gaap:LeaseExpirationDate1 id="Factid_21219552" contextRef="P12_01_2019To12_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_SanDiegoCaliforniaMembersrtStatementGeographicalAxis">2028-03-31</us-gaap:LeaseExpirationDate1>
<dei:DocumentQuarterlyReport id="Factid_21219553" contextRef="P07_01_2020To03_31_2021">true</dei:DocumentQuarterlyReport>
<dei:DocumentTransitionReport id="Factid_21219554" contextRef="P07_01_2020To03_31_2021">false</dei:DocumentTransitionReport>
<meip:LiquidityPolicyTextBlock id="Factid_21219555" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have accumulated losses of $322.1&amp;#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of March&amp;#160;31, 2021, we had $164.6&amp;#160;million in cash and cash equivalents and short-term investments. We believe that these resources will be sufficient to meet our obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements. Our current business operations are focused on continuing the clinical development of our drug candidates. Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. Our research and development expenses are expected to increase in the foreseeable future. We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:LiquidityPolicyTextBlock>
<us-gaap:LesseeLeasesPolicyTextBlock id="Factid_21219556" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Effective July&amp;#160;1, 2019, we adopted FASB ASC Topic 842, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases&lt;/div&gt; (&amp;#8220;ASC 842&amp;#8221;), using a modified retrospective basis method under which prior comparative periods are not restated. This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&amp;#8220;ROU&amp;#8221;) asset representing our right to use the underlying asset for the lease term. At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement. A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration. Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on our Condensed Balance Sheet as ROU assets and lease liabilities. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. Certain adjustments to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset may be required for items such as initial direct costs paid or incentives received. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined based on the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The interest rate implicit in lease contracts to calculate the present value is typically not readily determinable. As such, significant management judgment is required to estimate the incremental borrowing rate.&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Rent expense for operating leases is recognized on a straight-line basis over the lease term based on the total lease payments. We have elected the practical expedient to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for our real estate leases. Our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
<meip:ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock id="Factid_21219557" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognized revenue associated with the following license agreements (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:71%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KKC License Agreements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,321&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;812&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,979&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,282&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Helsinn License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;97&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;432&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;440&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;1,127&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Timing of Revenue Recognition:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services performed over tim&lt;div style="display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Factid_21219558" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents weighted-average potentially dilutive shares that have been excluded from the calculation of net loss per share because of their anti-dilutive effect (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:64%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,161&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,064&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,618&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,974&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;430&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;430&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,060&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,062&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,354&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,062&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total anti-dilutive shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;32,651&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;27,126&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;21,402&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;27,036&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:LesseeOperatingLeasesTextBlock id="Factid_21219559" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 7. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2019, we entered into a lease agreement for approximately 32,800 square feet of office space in San Diego, California.&amp;#160;We have accounted for the lease as an operating lease. The contractual lease term began in July 2020 and is scheduled to expire in March 2028. The lease contains an option to renew and extend the lease terms. We have not included the lease extension within the ROU asset and lease liability on the balance sheet as it is not reasonably certain to be exercised. The lease includes variable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset and lease liability and are reflected as an expense in the period incurred. We do not have any other operating or finance leases.&amp;#160;Upon commencement of the lease, we recognized an operating lease ROU asset of $8.7&amp;#160;million and a corresponding operating lease liability of $8.7&amp;#160;million. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total operating lease costs were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:66%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;377&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;201&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,130&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;603&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information related to our operating leases were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:66%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;369&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;201&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;615&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;603&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets obtained in exchange for operating lease obligations:&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,689&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a schedule of the future minimum rental payments for our operating lease, reconciled to the lease liability as of March&amp;#160;31, 2021 (in thousands):&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:88%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Remainder of fiscal year ending June 30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;368&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years ending June&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,519&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,565&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,612&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,168&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,710&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,122&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,064&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Present value discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(2,556&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,508&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet Classification &amp;#8211; Operating Lease&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liability, long-term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,608&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,508&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other Balance Sheet Information &amp;#8211; Operating Lease&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average remaining lease term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.0&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7.50&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LeaseCostTableTextBlock id="Factid_21219560" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total operating lease costs were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:66%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;377&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;201&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,130&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;603&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
<meip:DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock id="Factid_21219561" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information related to our operating leases were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:66%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br/&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;369&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;201&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;615&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;603&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets obtained in exchange for operating lease obligations:&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,689&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="Factid_21219562" contextRef="P07_01_2020To03_31_2021">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a schedule of the future minimum rental payments for our operating lease, reconciled to the lease liability as of March&amp;#160;31, 2021 (in thousands):&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:88%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 17pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Remainder of fiscal year ending June 30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;368&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years ending June&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,519&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,565&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,612&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,168&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,710&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,122&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,064&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Present value discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(2,556&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,508&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet Classification &amp;#8211; Operating Lease&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liability, long-term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,608&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,508&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other Balance Sheet Information &amp;#8211; Operating Lease&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average remaining lease term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.0&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7.50&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<dei:EntityAddressStateOrProvince id="Factid_21219563" contextRef="P07_01_2020To03_31_2021">CA</dei:EntityAddressStateOrProvince>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="Factid_21219564" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 1. The Company and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage assets, including zandelisib (formerly known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401),&lt;/div&gt; currently in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) to support accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &amp;#8220;MEIP&amp;#8221;. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Clinical Development Programs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Zandelisib (formerly known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401),&lt;/div&gt; an oral phosphatidylinositol &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-kinase&lt;/div&gt; (&amp;#8220;PI3K&amp;#8221;) delta inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Voruciclib, an oral cyclin-dependent kinase (&amp;#8220;CDK&amp;#8221;) inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344,&lt;/div&gt; a mitochondrial inhibitor targeting the oxidative phosphorylation (&amp;#8220;OXPHOS&amp;#8221;) complex; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pracinostat, an oral histone deacetylase (&amp;#8220;HDAC&amp;#8221;) inhibitor. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The results of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials. The commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side effects or are less expensive than our drug candidates. We will need substantial additional funds to progress the clinical trial programs for the drug candidates zandelisib, voruciclib and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344,&lt;/div&gt; and to develop new compounds. The actual amount of funds that will be needed will depend upon a number of factors, some of which are beyond our control. Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have accumulated losses of $322.1&amp;#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of March&amp;#160;31, 2021, we had $164.6&amp;#160;million in cash and cash equivalents and short-term investments. We believe that these resources will be sufficient to meet our obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements. Our current business operations are focused on continuing the clinical development of our drug candidates. Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. Our research and development expenses are expected to increase in the foreseeable future. We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 10 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&amp;#160;30, 2020, included in our Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (&amp;#8220;2020 Annual Report&amp;#8221;) filed with the Securities and Exchange Commission on September&amp;#160;9, 2020. Interim results are not necessarily indicative of results for a full year. &lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;ASC Topic 606, Revenue from Contracts with Customers (&amp;#8220;Topic 606&amp;#8221;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identify the distinct performance obligations &amp;#8211; or accounting units &amp;#8211; within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Payments received under commercial arrangements, such as licensing technology rights, may include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenues and earnings in the period of adjustment. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We develop estimates of the stand-alone selling price for each distinct performance obligation. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In the case of a license that is a distinct performance obligation, we recognize revenue allocated to the license from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we use judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &amp;#8220;input method&amp;#8221; under Topic 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&amp;#8217; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&amp;#160;when the related sales occur or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based or usage-based royalty revenue from license agreements&lt;div style="display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognized revenue associated with the following license agreements (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:63%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KKC License Agreements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;2,321&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;812&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;14,979&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;2,282&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Helsinn License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;97&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;432&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;440&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;1,127&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); padding: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,418&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;1,244&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,419&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,409&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Timing of Revenue Recognition:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services performed over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,418&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;1,244&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,419&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,409&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The KKC Commercialization Agreement and KKC Japan License Agreement (Note 3) include other distinct performance obligations that will be satisfied over time, and accordingly we recognized $2.3&amp;#160;million and $0.8&amp;#160;million related to our progress toward satisfying those obligations during the three months ended March&amp;#160;31, 2021 and 2020, respectively, and $15.0&amp;#160;million and $2.3&amp;#160;million during the nine months ended March&amp;#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the characteristics of the Helsinn License Agreement (Note 3), control of the remaining deliverables occurs over time and therefore we recognize revenue based on the extent of progress towards completion of the performance obligations. Accordingly, we recognized $0.1&amp;#160;million and $0.4&amp;#160;million related to our progress toward satisfying those obligations during the three months ended March&amp;#160;31, 2021 and 2020, respectively, and $0.4&amp;#160;million and $1.1&amp;#160;million during the nine months ended March&amp;#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contract Balances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables and contract assets are included in our balance sheet in &amp;#8220;Prepaid expenses and other current assets&amp;#8221;, and contract liabilities are included in &amp;#8220;Deferred revenue&amp;#8221; and &amp;#8220;Deferred revenue, long-term&amp;#8221;. The following table presents changes in contract assets and contract liabilities during the nine months ended March&amp;#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width: 87%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="width: 0.8%;"&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&lt;/td&gt;&lt;td style="width: 3.6%;"&gt;&lt;/td&gt;&lt;td style="width: 0.8%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 0.8%;"&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;2,605&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts billed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;15,744&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;1,088&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments received&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;(18,349&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;(1,014&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;74&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;511&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Billable amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;22,841&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;930&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts billed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;(15,744&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;(1,088&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;7,432&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;353&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;82,497&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;7,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 87%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Net change&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;7,380&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;(2,479&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;89,877&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;5,292&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;   &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets), which are classified as &amp;#8220;prepaid expenses and other current assets&amp;#8221; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC Agreements and Helsinn License Agreement&lt;div style="display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of&amp;#160;March 31, 2021, we had $7.4&amp;#160;million&amp;#160;of contract assets related to our remaining performance obligations under the KKC&amp;#160;Commercialization&amp;#160;Agreement and no contract assets related to the Helsinn License Agreement as the remaining performance obligations have been completed. During the nine months ended March&amp;#160;31, 2021, contract assets increased by $22.8&amp;#160;million, primarily due the recognition of revenue related to the satisfaction or partial satisfaction of performance obligations for which we had not yet billed KKC or Helsinn, partially offset by billings of $15.7&amp;#160;million to KKC and Helsinn. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As of&amp;#160;March 31, 2021, we had $89.9&amp;#160;million&amp;#160;of deferred revenue associated with our remaining performance obligations under the KKC&amp;#160;Commercialization&amp;#160;Agreement, of which $64.5&amp;#160;million relates to the U.S. License which is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, and $25.4&amp;#160;million relates to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; license and development services performance obligations which are under the scope of Topic 606. For the three and nine months ended March&amp;#160;31, 2021, we recognized revenue of $2.4&amp;#160;million and $15.4&amp;#160;million, respectively, that was included in the contract liabilities balance at June&amp;#160;30, 2020 related to performance obligations under ASC 606. In addition, as a result of a change in estimated cost of completion related to our remaining performance obligations, we &lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;decreased&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;deferred revenue by $2.1&amp;#160;million. To date we have not recognized any amounts related to units of account under Topic 808. For the three and nine months ended March&amp;#160;31, 2020, we recognized revenue of $0.8&amp;#160;million and $2.6&amp;#160;million, respectively, that was included in the contract liabilities balance at June&amp;#160;30, 2019 related to performance obligations under ASC 606 under the KKC Japan License Agreement and Helsinn License Agreement which are described in Note 3. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenues from Collaborators &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We earn revenue in connection with collaboration agreements, which are described in Note 3, License Agreements, and Note 4, BeiGene Collaboration. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At contract inception, we assess whether the collaboration arrangements are within the scope of ASC Topic 808, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Collaborative Arrangements&lt;/div&gt; (&amp;#8220;Topic 808&amp;#8221;), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determine which units of account within the arrangement are within the scope of Topic 808 and which elements are within the scope of Topic 606. For units of account within collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that are accounted for pursuant to Topic 606, we recognize revenue as discussed above. Consideration received that does not meet the requirements to satisfy Topic 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term or long-term deferred revenue based on our best estimate of when such amounts will be recognized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cost of Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations associated with the Helsinn License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&amp;#8217;s historical price volatility. The stock&amp;#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&amp;#8220;RSU&amp;#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&amp;#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of March&amp;#160;31, 2021 and 2020, we have established a valuation allowance to fully reserve our net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in our ownership may limit the amount of net operating loss carryforwards that can be utilized in the future to offset taxable income. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no material changes in our unrecognized tax benefits since June&amp;#160;30, 2020, and, as such, the disclosures included in our 2020 Annual Report continue to be relevant for the nine months ended March&amp;#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective July&amp;#160;1, 2019, we adopted FASB ASC Topic 842, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases&lt;/div&gt; (&amp;#8220;ASC 842&amp;#8221;), using a modified retrospective basis method under which prior comparative periods are not restated. This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&amp;#8220;ROU&amp;#8221;) asset representing our right to use the underlying asset for the lease term. At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement. A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration. Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on our Condensed Balance Sheet as ROU assets and lease liabilities. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. Certain adjustments to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset may be required for items such as initial direct costs paid or incentives received. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined based on the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The interest rate implicit in lease contracts to calculate the present value is typically not readily determinable. As such, significant management judgment is required to estimate the incremental borrowing rate.&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rent expense for operating leases is recognized on a straight-line basis over the lease term based on the total lease payments. We have elected the practical expedient to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for our real estate leases. Our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock id="Factid_21219578" contextRef="P07_01_2020To03_31_2021">The following table presents changes in contract assets and contract liabilities during the nine months ended March&amp;#160;31, 2021 and 2020 (in thousands):&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width: 87%;"&gt;&lt;/td&gt;&lt;td style="width: 1%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="width: 0.8%;"&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&lt;/td&gt;&lt;td style="width: 3.6%;"&gt;&lt;/td&gt;&lt;td style="width: 0.8%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&lt;/td&gt;&lt;td style="width: 0.8%;"&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;2,605&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts billed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;15,744&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;1,088&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments received&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;(18,349&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;(1,014&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;74&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;511&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Billable amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;22,841&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;930&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts billed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;"&gt;(15,744&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;"&gt;(1,088&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;7,432&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;353&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;82,497&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;7,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 87%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Net change&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;7,380&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;(2,479&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;89,877&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;5,292&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_21219610" contextRef="P07_01_2020To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;ASC Topic 606, Revenue from Contracts with Customers (&amp;#8220;Topic 606&amp;#8221;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identify the distinct performance obligations &amp;#8211; or accounting units &amp;#8211; within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Payments received under commercial arrangements, such as licensing technology rights, may include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenues and earnings in the period of adjustment. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We develop estimates of the stand-alone selling price for each distinct performance obligation. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In the case of a license that is a distinct performance obligation, we recognize revenue allocated to the license from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we use judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &amp;#8220;input method&amp;#8221; under Topic 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&amp;#8217; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&amp;#160;when the related sales occur or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based or usage-based royalty revenue from license agreements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognized revenue associated with the following license agreements (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:71%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KKC License Agreements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,321&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;812&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,979&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,282&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Helsinn License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;97&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;432&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;440&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;1,127&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Timing of Revenue Recognition:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services performed over tim&lt;div style="display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;2,418&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;1,244&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;15,419&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;"&gt;3,409&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The KKC Commercialization Agreement and KKC Japan License Agreement (Note 3) include other distinct performance obligations that will be satisfied over time, and accordingly we recognized $2.3&amp;#160;million and $0.8&amp;#160;million related to our progress toward satisfying those obligations during the three months ended March&amp;#160;31, 2021 and 2020, respectively, and $15.0&amp;#160;million and $2.3&amp;#160;million during the nine months ended March&amp;#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the characteristics of the Helsinn License Agreement (Note 3), control of the remaining deliverables occurs over time and therefore we recognize revenue based on the extent of progress towards completion of the performance obligations. Accordingly, we recognized $0.1&amp;#160;million and $0.4&amp;#160;million related to our progress toward satisfying those obligations during the three months ended March&amp;#160;31, 2021 and 2020, respectively, and $0.4&amp;#160;million and $1.1&amp;#160;million during the nine months ended March&amp;#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contract Balances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables and contract assets are included in our balance sheet in &amp;#8220;Prepaid expenses and other current assets&amp;#8221;, and contract liabilities are included in &amp;#8220;Deferred revenue&amp;#8221; and &amp;#8220;Deferred revenue, long-term&amp;#8221;. The following table presents changes in contract assets and contract liabilities during the nine months ended March&amp;#160;31, 2021 and 2020 (in thousands):&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:87%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt;March 31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2,605&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Amounts billed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,744&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,088&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments received&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(18,349&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(1,014&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Receivables, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;74&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Contract assets, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;335&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;511&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Billable amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;22,841&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;930&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Amounts billed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(15,744&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(1,088&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,432&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;353&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Contract liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;82,497&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;7,771&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,380&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,479&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities, end of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;89,877&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5,292&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:87%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 8pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets), which are classified as &amp;#8220;prepaid expenses and other current assets&amp;#8221; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC Agreements and Helsinn License Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of&amp;#160;March 31, 2021, we had $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.4&lt;/div&gt;&amp;#160;million&amp;#160;of contract assets related to our remaining performance obligations under the KKC Commercialization Agreement and no contract assets related to the Helsinn License Agreement as the remaining performance obligations have been completed. During the nine months ended March&amp;#160;31, 2021, contract assets increased by $22.8&amp;#160;million, primarily due the recognition of revenue related to the satisfaction or partial satisfaction of performance obligations for which we had not yet billed KKC or Helsinn, partially offset by billings of $15.7&amp;#160;million to KKC and Helsinn. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of&amp;#160;March 31, 2021, we had $89.9&amp;#160;million&amp;#160;of deferred revenue associated with our remaining performance obligations under the KKC&amp;#160;Commercialization&amp;#160;Agreement, of which $64.5&amp;#160;million relates to the U.S. License which is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, and $25.4&amp;#160;million relates to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ex-U.S.&lt;/div&gt; license and development services performance obligations which are under the scope of Topic 606. For the three and nine months ended March&amp;#160;31, 2021, we recognized revenue of $2.4&amp;#160;million and $15.4&amp;#160;million, respectively, that was included in the contract liabilities balance at June&amp;#160;30, 2020 related to performance obligations under ASC 606. In addition, as a result of a change in estimated cost of completion related to our remaining performance obligations, we decreased deferred revenue by $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.1&lt;/div&gt;&amp;#160;million. To date we have not recognized any amounts related to units of account under Topic 808. For the three and nine months ended March&amp;#160;31, 2020, we recognized revenue of $0.8&amp;#160;million and $2.6&amp;#160;million, respectively, that was included in the contract liabilities balance at June&amp;#160;30, 2019 related to performance obligations under ASC 606 under the KKC Japan License Agreement and Helsinn License Agreement which are described in Note 3. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenues from Collaborators &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We earn revenue in connection with collaboration agreements, which are described in Note 3, License Agreements, and Note 4, BeiGene Collaboration. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At contract inception, we assess whether the collaboration arrangements are within the scope of ASC Topic 808, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Collaborative Arrangements&lt;/div&gt; (&amp;#8220;Topic 808&amp;#8221;), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determine which units of account within the arrangement are within the scope of Topic 808 and which elements are within the scope of Topic 606. For units of account within collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that are accounted for pursuant to Topic 606, we recognize revenue as discussed above. Consideration received that does not meet the requirements to satisfy Topic 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term or long-term deferred revenue based on our best estimate of when such amounts will be recognized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cost of Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations associated with the Helsinn License Agreement. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<xbrli:unit id="Unit_ClinicalTrials">
<xbrli:measure>meip:ClinicalTrials</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_sqft">
<xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>meip-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-May-2021 [03:53:02] {AM}-->
<schema targetNamespace="http://www.meipharma.com/20210331" elementFormDefault="qualified" xmlns:meip="http://www.meipharma.com/20210331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.meipharma.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - CONDENSED BALANCE SHEETS (parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" id="CondensedStatementsOfOperations">
<link:definition>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity" id="CondensedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
<link:definition>1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies" id="TheCompanyAndSummaryOfSignificantAccountingPolicies">
<link:definition>1007 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1008 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LicenseAgreements" id="LicenseAgreements">
<link:definition>1009 - Disclosure - License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/BeigeneCollaboration" id="BeigeneCollaboration">
<link:definition>1010 - Disclosure - BeiGene Collaboration</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1011 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1012 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/Leases" id="Leases">
<link:definition>1013 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShortTermInvestments" id="ShortTermInvestments">
<link:definition>1014 - Disclosure - Short-Term Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1015 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1016 - Disclosure - Share-based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1017 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesTables" id="TheCompanyAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1018 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1019 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1020 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LeasesTables" id="LeasesTables">
<link:definition>1021 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1022 - Disclosure - Share-based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1023 - Disclosure - The Company and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" id="TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail">
<link:definition>1024 - Disclosure - The Company - Revenue Associated With The Following license agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" id="TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail">
<link:definition>1025 - Disclosure - The Company - Schedule of Changes in Contract Assets and Contract Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" id="ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<link:definition>1026 - Disclosure - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" id="ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail">
<link:definition>1027 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" id="ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail">
<link:definition>1028 - Disclosure - Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail" id="LicenseAgreementsAdditionalInformationDetail">
<link:definition>1029 - Disclosure - License Agreements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail" id="NetLossPerShareAdditionalInformationDetail">
<link:definition>1030 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail" id="ScheduleOfLossPerShareBasicAndDilutedDetail">
<link:definition>1031 - Disclosure - Schedule of (Loss) Per Share, Basic and Diluted (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail" id="CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail">
<link:definition>1032 - Disclosure - Calculation of Weighted Average Shares Used to Calculate Basic and Diluted (Loss) Earnings Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail" id="AntidilutiveSecuritiesDetail">
<link:definition>1033 - Disclosure - Antidilutive Securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1034 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1035 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfTotalOperatingCostsDetail" id="ScheduleOfTotalOperatingCostsDetail">
<link:definition>1036 - Disclosure - Schedule of Total Operating Costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" id="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail">
<link:definition>1037 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail" id="ScheduleOfFutureMinimumRentalPaymentsDetail">
<link:definition>1038 - Disclosure - Schedule of Future Minimum Rental Payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail" id="ShortTermInvestmentsAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Short-Term Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail" id="ShareBasedCompensationAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Share-based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail" id="ShareBasedCompensationExpenseForStockAwardsDetail">
<link:definition>1042 - Disclosure - Share-Based Compensation Expense for Stock Awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail" id="SummaryOfStockOptionActivityDetail">
<link:definition>1043 - Disclosure - Summary of Stock Option Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" id="FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail">
<link:definition>1044 - Disclosure - Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="ReceivableForForeignTaxWithholding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_ReceivableForForeignTaxWithholding" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Stockissuedduringperiodvaluestockwarrantsexercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_Stockissuedduringperiodvaluestockwarrantsexercised" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromPreviouslyIssuedCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ProceedsFromPreviouslyIssuedCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NonCashLeaseExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseOrDecreaseInReceivableForForeignTaxWithholding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WarrantsIssuedPursuantToCashlessExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_WarrantsIssuedPursuantToCashlessExercise" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClinicalDevelopmentProgramsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ClinicalDevelopmentProgramsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="LiquidityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_LiquidityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantLiabilityAssumptionsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" substitutionGroup="xbrli:item" />
<element name="NumberOfClinicalStageCandidates" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NumberOfClinicalStageCandidates" substitutionGroup="xbrli:item" />
<element name="RevenuePerformanceObligationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_RevenuePerformanceObligationAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UsLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_UsLicenseMember" substitutionGroup="xbrli:item" />
<element name="ExUsLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ExUsLicenseMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="KkcAgreementsandHelsinnLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_KkcAgreementsandHelsinnLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="HelsinnLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_HelsinnLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" substitutionGroup="xbrli:item" />
<element name="RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" substitutionGroup="xbrli:item" />
<element name="KkcAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_KkcAgreementsMember" substitutionGroup="xbrli:item" />
<element name="ContractWithCustomerAssetAndLiabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ContractWithCustomerAssetAndLiabilityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ContractWithCustomerAssetAndLiabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ContractWithCustomerAssetAndLiabilityLineItems" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableNetBeginningBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AccountsReceivableNetBeginningBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccountsReceivableNetEndingBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AccountsReceivableNetEndingBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReceivablesAmountsBilled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ReceivablesAmountsBilled" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReceivablesPaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ReceivablesPaymentsReceived" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractAssetsBillableAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ContractAssetsBillableAmounts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContractAssetsAmountsBilled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ContractAssetsAmountsBilled" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementsSignificantUnobservableInputsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_FairValueMeasurementsSignificantUnobservableInputsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueMeasurementsSignificantUnobservableInputsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" substitutionGroup="xbrli:item" />
<element name="KyowaKirinCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_KyowaKirinCoMember" substitutionGroup="xbrli:item" />
<element name="PresageBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PresageBiosciencesIncMember" substitutionGroup="xbrli:item" />
<element name="IncrementalPaymentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_IncrementalPaymentMember" substitutionGroup="xbrli:item" />
<element name="PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" substitutionGroup="xbrli:item" />
<element name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_AgreementTerminationNoticePeriod" substitutionGroup="xbrli:item" />
<element name="PaymentForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_PaymentForLicenseAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfPurchasesFromMajorSuppliers" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_PercentageOfPurchasesFromMajorSuppliers" substitutionGroup="xbrli:item" />
<element name="PotentialMilestonePaymentsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_PotentialMilestonePaymentsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_PotentialMilestonePaymentsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EstimatedDevelopmentCostSharingRecoverableThroughEarnings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_UpFrontPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalUpfrontPaymentReceivableForGrantOfRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_TotalUpfrontPaymentReceivableForGrantOfRights" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalTransactionPriceInRespectOfColloborationRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_TotalTransactionPriceInRespectOfColloborationRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExpectedMilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_ExpectedMilestonePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicenseObligationAccountTransactionPriceAllocated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_LicenseObligationAccountTransactionPriceAllocated" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProfitsAndCostsSharingRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_ProfitsAndCostsSharingRatio" substitutionGroup="xbrli:item" />
<element name="DevelopmentServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_DevelopmentServicesMember" substitutionGroup="xbrli:item" />
<element name="PresageLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PresageLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_EventDomain" substitutionGroup="xbrli:item" />
<element name="UpdationOfInitialAssessmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_UpdationOfInitialAssessmentMember" substitutionGroup="xbrli:item" />
<element name="PotentiallyDilutiveSecuritiesOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" substitutionGroup="xbrli:item" />
<element name="DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_MilestonePaymentsMaximumAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AccruedMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CydexLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_CydexLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="SbioPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_SbioPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSquareFeetUnderLease" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_NumberOfSquareFeetUnderLease" substitutionGroup="xbrli:item" />
<element name="InitialRecognitionOfOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SanDiegoCaliforniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_SanDiegoCaliforniaMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfSharesAgreedToBeSoldUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_NumberOfSharesAgreedToBeSoldUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SaleOfSharesAndWarrantsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_SaleOfSharesAndWarrantsUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShelfRegistrationStatementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_ShelfRegistrationStatementValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnsoldSecuritiesSharesAndWarrantsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AggregateValueOfSecuritiesAvailableUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AggregateValueOfSecuritiesAvailableUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NumberOfWarrantsExercised" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesIssuedOnWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NumberOfSharesIssuedOnWarrantExercise" substitutionGroup="xbrli:item" />
<element name="AtTheMarketSaleAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_AtTheMarketSaleAgreementMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyAtTheMarketSaleAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEightOmnibusPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_TwoThousandAndEightOmnibusPlanMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesToBeReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_NumberOfSharesToBeReceived" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesForEachUnitOfRestrictedStock" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_NumberOfSharesForEachUnitOfRestrictedStock" substitutionGroup="xbrli:item" />
<element name="EmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_EmployeesMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>meip-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-May-2021 [03:53:02] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedBalanceSheets" roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfOperations" roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfLossPerShareBasicAndDilutedDetail" roleURI="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfFutureMinimumRentalPaymentsDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_ShortTermInvestments" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivableForForeignTaxWithholding" xlink:label="loc_MEIP_ReceivableForForeignTaxWithholding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_MEIP_ReceivableForForeignTaxWithholding" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="22" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_CostsAndExpenses" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_MEIP_ProceedsFromPreviouslyIssuedCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MEIP_ProceedsFromPreviouslyIssuedCommonStock" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_MEIP_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MEIP_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NonCashLeaseExpense" xlink:label="loc_MEIP_NonCashLeaseExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MEIP_NonCashLeaseExpense" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:label="loc_MEIP_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MEIP_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="loc_MEIP_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_MEIP_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_MEIP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_MEIP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" order="1" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>meip-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-May-2021 [03:53:02] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedBalanceSheets" roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfOperations" roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfStockholdersEquity" roleURI="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#FairValueMeasurements" roleURI="http://www.meipharma.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LicenseAgreements" roleURI="http://www.meipharma.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#BeigeneCollaboration" roleURI="http://www.meipharma.com/role/BeigeneCollaboration" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#NetLossPerShare" roleURI="http://www.meipharma.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CommitmentsAndContingencies" roleURI="http://www.meipharma.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShortTermInvestments" roleURI="http://www.meipharma.com/role/ShortTermInvestments" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#StockholdersEquity" roleURI="http://www.meipharma.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensation" roleURI="http://www.meipharma.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#FairValueMeasurementsTables" roleURI="http://www.meipharma.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#NetLossPerShareTables" roleURI="http://www.meipharma.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensationTables" roleURI="http://www.meipharma.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" roleURI="http://www.meipharma.com/role/TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" roleURI="http://www.meipharma.com/role/TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#NetLossPerShareAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfLossPerShareBasicAndDilutedDetail" roleURI="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail" roleURI="http://www.meipharma.com/role/CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#AntidilutiveSecuritiesDetail" roleURI="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShortTermInvestmentsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensationExpenseForStockAwardsDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#SummaryOfStockOptionActivityDetail" roleURI="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" roleURI="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CoverPage" roleURI="http://www.meipharma.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#Leases" roleURI="http://www.meipharma.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LeasesTables" roleURI="http://www.meipharma.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfFutureMinimumRentalPaymentsDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfTotalOperatingCostsDetail" roleURI="http://www.meipharma.com/role/ScheduleOfTotalOperatingCostsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" roleURI="http://www.meipharma.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_Assets_32" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_23" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_AssetsCurrent_37" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_ShortTermInvestments_34" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivableForForeignTaxWithholding" xlink:label="loc_meip_ReceivableForForeignTaxWithholding_765429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_meip_ReceivableForForeignTaxWithholding_765429" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_765674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_765674" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommitmentsAndContingencies_41" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_43" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_44" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_DeferredRevenueCurrent_45" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_46" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_765678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_765678" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_Liabilities_40" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_765679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_765679" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_48" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_47" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_51" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_311823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_311823" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_StatementTable_28" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_28" xlink:to="loc_dei_LegalEntityAxis_24" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_24" xlink:to="loc_dei_EntityDomain_38" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_38_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_24" xlink:to="loc_dei_EntityDomain_38_default" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StatementTable_56" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56" xlink:to="loc_dei_LegalEntityAxis_54" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_54" xlink:to="loc_dei_EntityDomain_57" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_57_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_54" xlink:to="loc_dei_EntityDomain_57_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_62" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesIssued_63" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_59" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_60" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_72" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_67" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_75" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostsAndExpenses_78" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_77" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_90" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_91" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NetIncomeLossAbstract_69" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_69" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_80" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_69" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_81" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_85" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_765439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_765439" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_OperatingIncomeLoss_88" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_Revenues_86" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_StatementTable_73" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_73" xlink:to="loc_dei_LegalEntityAxis_68" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_68" xlink:to="loc_dei_EntityDomain_79" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_68" xlink:to="loc_dei_EntityDomain_79_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409054" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_409058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockholdersEquity_409058" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_409046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StatementTable_409046" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_409047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_dei_LegalEntityAxis_409047" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_409048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_409047" xlink:to="loc_dei_EntityDomain_409048" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_409048_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_409047" xlink:to="loc_dei_EntityDomain_409048_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_409049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_409049" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_409050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_409049" xlink:to="loc_us-gaap_EquityComponentDomain_409050" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_409050_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_409049" xlink:to="loc_us-gaap_EquityComponentDomain_409050_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_409051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_CommonStockMember_409051" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_409052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_409052" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_409053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_RetainedEarningsMember_409053" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_478157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" xlink:to="loc_us-gaap_LossContingencyNatureDomain_478157" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_478157_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" xlink:to="loc_us-gaap_LossContingencyNatureDomain_478157_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_409059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_NetIncomeLoss_409059" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:label="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_102" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_112" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_765455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_765455" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_765456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_765456" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_106" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_ShareBasedCompensation_105" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NonCashLeaseExpense" xlink:label="loc_meip_NonCashLeaseExpense_765686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_meip_NonCashLeaseExpense_765686" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_765685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_765685" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:label="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_810778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_810778" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_ProfitLoss_120" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_StatementTable_103" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_103" xlink:to="loc_dei_LegalEntityAxis_98" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_98" xlink:to="loc_dei_EntityDomain_111" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_111_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_98" xlink:to="loc_dei_EntityDomain_111_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_765687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_765687" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_478167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_478167" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_WarrantsIssuedPursuantToCashlessExercise" xlink:label="loc_meip_WarrantsIssuedPursuantToCashlessExercise_918392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_meip_WarrantsIssuedPursuantToCashlessExercise_918392" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_402" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_402" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_402" xlink:to="loc_us-gaap_StatementTable_403" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_403" xlink:to="loc_dei_LegalEntityAxis_401" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_401" xlink:to="loc_dei_EntityDomain_404" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_404_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_401" xlink:to="loc_dei_EntityDomain_404_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_430" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_430" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_433" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_430" xlink:to="loc_us-gaap_StatementTable_431" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_431" xlink:to="loc_dei_LegalEntityAxis_429" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_429" xlink:to="loc_dei_EntityDomain_432" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_429" xlink:to="loc_dei_EntityDomain_432_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_446" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_446" xlink:to="loc_us-gaap_StatementTable_447" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_447" xlink:to="loc_dei_LegalEntityAxis_445" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_445" xlink:to="loc_dei_EntityDomain_448" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_445" xlink:to="loc_dei_EntityDomain_448_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_446" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/BeigeneCollaboration">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_453" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_StatementTable_454" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_454" xlink:to="loc_dei_LegalEntityAxis_452" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_452" xlink:to="loc_dei_EntityDomain_455" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_455_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_452" xlink:to="loc_dei_EntityDomain_455_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_460" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_460" xlink:to="loc_us-gaap_StatementTable_461" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_461" xlink:to="loc_dei_LegalEntityAxis_459" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_459" xlink:to="loc_dei_EntityDomain_462" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_462_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_459" xlink:to="loc_dei_EntityDomain_462_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_460" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_463" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_475" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_475" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_475" xlink:to="loc_us-gaap_StatementTable_476" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_476" xlink:to="loc_dei_LegalEntityAxis_474" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_474" xlink:to="loc_dei_EntityDomain_477" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_477_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_474" xlink:to="loc_dei_EntityDomain_477_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_482" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_482" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_482" xlink:to="loc_us-gaap_StatementTable_483" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_483" xlink:to="loc_dei_LegalEntityAxis_481" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_484" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_484_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_489" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="loc_us-gaap_StatementTable_490" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_490" xlink:to="loc_dei_LegalEntityAxis_488" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_488" xlink:to="loc_dei_EntityDomain_491" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_491_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_488" xlink:to="loc_dei_EntityDomain_491_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_496" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_496" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_496" xlink:to="loc_us-gaap_StatementTable_497" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_497" xlink:to="loc_dei_LegalEntityAxis_495" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_495" xlink:to="loc_dei_EntityDomain_498" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_498_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_495" xlink:to="loc_dei_EntityDomain_498_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:label="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_418" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_StatementTable_410" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_410" xlink:to="loc_dei_LegalEntityAxis_408" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_408" xlink:to="loc_dei_EntityDomain_411" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_408" xlink:to="loc_dei_EntityDomain_411_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_UseOfEstimates_414" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_LiquidityPolicyTextBlock" xlink:label="loc_meip_LiquidityPolicyTextBlock_481048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_LiquidityPolicyTextBlock_481048" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_765461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_765461" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_423" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_426" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_423" xlink:to="loc_us-gaap_StatementTable_424" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_424" xlink:to="loc_dei_LegalEntityAxis_422" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_422" xlink:to="loc_dei_EntityDomain_425" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_425_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_422" xlink:to="loc_dei_EntityDomain_425_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:label="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_311933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423" xlink:to="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_311933" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_437" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_us-gaap_StatementTable_438" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_438" xlink:to="loc_dei_LegalEntityAxis_436" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_436" xlink:to="loc_dei_EntityDomain_439" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_439_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_436" xlink:to="loc_dei_EntityDomain_439_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:label="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_467" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_StatementTable_468" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468" xlink:to="loc_dei_LegalEntityAxis_466" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_466" xlink:to="loc_dei_EntityDomain_469" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_466" xlink:to="loc_dei_EntityDomain_469_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_765487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_765487" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_470" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_471" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_StatementTable_504" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504" xlink:to="loc_dei_LegalEntityAxis_502" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_502" xlink:to="loc_dei_EntityDomain_505" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_502" xlink:to="loc_dei_EntityDomain_505_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TargetedOrTrackingStockStockLineItems" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfClinicalStageCandidates" xlink:label="loc_meip_NumberOfClinicalStageCandidates_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_NumberOfClinicalStageCandidates_131" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_133" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TargetedOrTrackingStockStockTable" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockTable_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_dei_LegalEntityAxis_127" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_127" xlink:to="loc_dei_EntityDomain_130" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_127" xlink:to="loc_dei_EntityDomain_130_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311913" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_478189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_srt_RangeAxis_478189" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_478189" xlink:to="loc_srt_RangeMember_478190" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478190_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_478189" xlink:to="loc_srt_RangeMember_478190_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_478194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" xlink:to="loc_us-gaap_TypeOfAdoptionMember_478194" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_478194_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" xlink:to="loc_us-gaap_TypeOfAdoptionMember_478194_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UsLicenseMember" xlink:label="loc_meip_UsLicenseMember_810804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" xlink:to="loc_meip_UsLicenseMember_810804" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ExUsLicenseMember" xlink:label="loc_meip_ExUsLicenseMember_810805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" xlink:to="loc_meip_ExUsLicenseMember_810805" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementAxis" xlink:label="loc_meip_AgreementAxis_765465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_meip_AgreementAxis_765465" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementDomain" xlink:label="loc_meip_AgreementDomain_765466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_meip_AgreementAxis_765465" xlink:to="loc_meip_AgreementDomain_765466" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementDomain" xlink:label="loc_meip_AgreementDomain_765466_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_meip_AgreementAxis_765465" xlink:to="loc_meip_AgreementDomain_765466_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:label="loc_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember_810790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_AgreementDomain_765466" xlink:to="loc_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember_810790" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:label="loc_meip_KkcAgreementsandHelsinnLicenseAgreementMember_811812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_AgreementDomain_765466" xlink:to="loc_meip_KkcAgreementsandHelsinnLicenseAgreementMember_811812" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_765467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_AgreementDomain_765466" xlink:to="loc_meip_HelsinnLicenseAgreementMember_765467" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_136" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RevenuePerformanceObligationAmount" xlink:label="loc_meip_RevenuePerformanceObligationAmount_311934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_RevenuePerformanceObligationAmount_311934" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_810786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_810786" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_810792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_810792" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_810809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_810809" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_811818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_811818" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:label="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_918170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_918170" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" xlink:to="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311881" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311881" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311881" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcAgreementsMember" xlink:label="loc_meip_KkcAgreementsMember_311883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_KkcAgreementsMember_311883" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_311892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_HelsinnLicenseAgreementMember_311892" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_481084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" xlink:to="loc_us-gaap_TransferredOverTimeMember_481084" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_311885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" xlink:to="loc_us-gaap_Revenues_311885" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AccountsReceivableNetBeginningBalance" xlink:label="loc_meip_AccountsReceivableNetBeginningBalance_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetBeginningBalance_142" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AccountsReceivableNetEndingBalance" xlink:label="loc_meip_AccountsReceivableNetEndingBalance_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetEndingBalance_144" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractWithCustomerAssetAndLiabilityTable" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xlink:to="loc_dei_LegalEntityAxis_141" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_141" xlink:to="loc_dei_EntityDomain_151" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_151_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_141" xlink:to="loc_dei_EntityDomain_151_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerLiability_148" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivablesAmountsBilled" xlink:label="loc_meip_ReceivablesAmountsBilled_918157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ReceivablesAmountsBilled_918157" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivablesPaymentsReceived" xlink:label="loc_meip_ReceivablesPaymentsReceived_918158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ReceivablesPaymentsReceived_918158" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractAssetsBillableAmounts" xlink:label="loc_meip_ContractAssetsBillableAmounts_918160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ContractAssetsBillableAmounts_918160" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractAssetsAmountsBilled" xlink:label="loc_meip_ContractAssetsAmountsBilled_918164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ContractAssetsAmountsBilled_918164" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_168" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_158_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_158_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_166" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_dei_LegalEntityAxis_160" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_160" xlink:to="loc_dei_EntityDomain_169" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_169_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_160" xlink:to="loc_dei_EntityDomain_169_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_165" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_dei_LegalEntityAxis_174" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_174" xlink:to="loc_dei_EntityDomain_180" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_180_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_174" xlink:to="loc_dei_EntityDomain_180_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_175" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_175" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_176" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_175" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_176_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_182" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_478745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_478745" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_189_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_189_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_194" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_195" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_dei_LegalEntityAxis_193" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_193" xlink:to="loc_dei_EntityDomain_200" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_200_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_193" xlink:to="loc_dei_EntityDomain_200_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_211" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementTerminationNoticePeriod" xlink:label="loc_meip_AgreementTerminationNoticePeriod_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_AgreementTerminationNoticePeriod_236" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PaymentForLicenseAgreement" xlink:label="loc_meip_PaymentForLicenseAgreement_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PaymentForLicenseAgreement_234" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentialMilestonePaymentsPayable" xlink:label="loc_meip_PotentialMilestonePaymentsPayable_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsPayable_233" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentialMilestonePaymentsReceivable" xlink:label="loc_meip_PotentialMilestonePaymentsReceivable_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsReceivable_226" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_225" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:label="loc_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings_765473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings_765473" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_765474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_DeferredRevenue_765474" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_765475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_765475" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_dei_LegalEntityAxis_205" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_205" xlink:to="loc_dei_EntityDomain_204" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_204_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_205" xlink:to="loc_dei_EntityDomain_204_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KyowaKirinCoMember" xlink:label="loc_meip_KyowaKirinCoMember_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_204" xlink:to="loc_meip_KyowaKirinCoMember_218" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" xlink:to="loc_us-gaap_RelatedPartyDomain_208" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" xlink:to="loc_us-gaap_RelatedPartyDomain_208_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PresageBiosciencesIncMember" xlink:label="loc_meip_PresageBiosciencesIncMember_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_208" xlink:to="loc_meip_PresageBiosciencesIncMember_221" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_srt_RangeAxis_206" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_206" xlink:to="loc_srt_RangeMember_207" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_207_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_206" xlink:to="loc_srt_RangeMember_207_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_207" xlink:to="loc_srt_MaximumMember_219" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_209" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_209" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_210" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_210_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_209" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_210_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncrementalPaymentMember" xlink:label="loc_meip_IncrementalPaymentMember_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_IncrementalPaymentMember_223" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_765476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_srt_ProductOrServiceAxis_765476" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_765477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_765476" xlink:to="loc_srt_ProductsAndServicesDomain_765477" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_765477_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_765476" xlink:to="loc_srt_ProductsAndServicesDomain_765477_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ExUsLicenseMember" xlink:label="loc_meip_ExUsLicenseMember_765478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_765477" xlink:to="loc_meip_ExUsLicenseMember_765478" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DevelopmentServicesMember" xlink:label="loc_meip_DevelopmentServicesMember_765483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_765477" xlink:to="loc_meip_DevelopmentServicesMember_765483" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_TypeOfArrangementAxis_214" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_214" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_214" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_HelsinnLicenseAgreementMember_215" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_PresageLicenseAgreementMember_216" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcAgreementsMember" xlink:label="loc_meip_KkcAgreementsMember_765471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_KkcAgreementsMember_765471" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EventAxis" xlink:label="loc_meip_EventAxis_765700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_meip_EventAxis_765700" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EventDomain" xlink:label="loc_meip_EventDomain_765702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_meip_EventAxis_765700" xlink:to="loc_meip_EventDomain_765702" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EventDomain" xlink:label="loc_meip_EventDomain_765702_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_meip_EventAxis_765700" xlink:to="loc_meip_EventDomain_765702_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UpdationOfInitialAssessmentMember" xlink:label="loc_meip_UpdationOfInitialAssessmentMember_765704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_EventDomain_765702" xlink:to="loc_meip_UpdationOfInitialAssessmentMember_765704" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UpFrontPayment" xlink:label="loc_meip_UpFrontPayment_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_UpFrontPayment_228" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:label="loc_meip_TotalUpfrontPaymentReceivableForGrantOfRights_765468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_TotalUpfrontPaymentReceivableForGrantOfRights_765468" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:label="loc_meip_TotalTransactionPriceInRespectOfColloborationRevenue_765470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_TotalTransactionPriceInRespectOfColloborationRevenue_765470" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ExpectedMilestonePaymentReceivable" xlink:label="loc_meip_ExpectedMilestonePaymentReceivable_765472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_ExpectedMilestonePaymentReceivable_765472" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_LicenseObligationAccountTransactionPriceAllocated" xlink:label="loc_meip_LicenseObligationAccountTransactionPriceAllocated_765480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_LicenseObligationAccountTransactionPriceAllocated_765480" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_765481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_765481" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ProfitsAndCostsSharingRatio" xlink:label="loc_meip_ProfitsAndCostsSharingRatio_766229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_ProfitsAndCostsSharingRatio_766229" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:label="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_766231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_766231" use="optional" order="51" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xlink:to="loc_dei_LegalEntityAxis_239" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_242" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_242_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_247" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_252" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StatementTable_248" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_248" xlink:to="loc_dei_LegalEntityAxis_246" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_246" xlink:to="loc_dei_EntityDomain_249" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_249_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_246" xlink:to="loc_dei_EntityDomain_249_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="loc_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability_766234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability_766234" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_478208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" xlink:to="loc_dei_LegalEntityAxis_478208" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_478208" xlink:to="loc_dei_EntityDomain_478209" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478209_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_478208" xlink:to="loc_dei_EntityDomain_478209_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_478213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_478213" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_478215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_478215" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_478219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_478219" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_478230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_dei_LegalEntityAxis_478230" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_478230" xlink:to="loc_dei_EntityDomain_478231" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478231_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_478230" xlink:to="loc_dei_EntityDomain_478231_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_478234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_EmployeeStockOptionMember_478234" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_478236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_WarrantMember_478236" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_MilestonePaymentsMaximumAmount" xlink:label="loc_meip_MilestonePaymentsMaximumAmount_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_MilestonePaymentsMaximumAmount_285" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AccruedMilestonePayments" xlink:label="loc_meip_AccruedMilestonePayments_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_AccruedMilestonePayments_284" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_TypeOfArrangementAxis_273" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_273" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_273" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_PresageLicenseAgreementMember_274" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_CydexLicenseAgreementMember" xlink:label="loc_meip_CydexLicenseAgreementMember_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_CydexLicenseAgreementMember_276" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_SbioPurchaseAgreementMember" xlink:label="loc_meip_SbioPurchaseAgreementMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_SbioPurchaseAgreementMember_275" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_478582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_OtherCommitmentsAxis_478582" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_478583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_478582" xlink:to="loc_us-gaap_OtherCommitmentsDomain_478583" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_478583_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_478582" xlink:to="loc_us-gaap_OtherCommitmentsDomain_478583_default" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_765501" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_765500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_us-gaap_StatementTable_765500" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_765500" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_765503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" xlink:to="loc_us-gaap_TypeOfAdoptionMember_765503" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_765503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" xlink:to="loc_us-gaap_TypeOfAdoptionMember_765503_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_765505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_765503" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_765505" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_765506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_765500" xlink:to="loc_srt_StatementGeographicalAxis_765506" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_765507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_765506" xlink:to="loc_srt_SegmentGeographicalDomain_765507" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_765507_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_765506" xlink:to="loc_srt_SegmentGeographicalDomain_765507_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_SanDiegoCaliforniaMember" xlink:label="loc_meip_SanDiegoCaliforniaMember_765508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_765507" xlink:to="loc_meip_SanDiegoCaliforniaMember_765508" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSquareFeetUnderLease" xlink:label="loc_meip_NumberOfSquareFeetUnderLease_765509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_meip_NumberOfSquareFeetUnderLease_765509" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_765511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_us-gaap_LeaseExpirationDate1_765511" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_765708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_us-gaap_OperatingLeaseLiability_765708" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:label="loc_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset_813724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset_813724" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xlink:to="loc_dei_LegalEntityAxis_289" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_292" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_292_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" xlink:to="loc_us-gaap_ShortTermInvestments_293" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_296" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_312" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:label="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_301" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_srt_RangeAxis_298" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_298" xlink:to="loc_srt_RangeMember_299" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_299_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_298" xlink:to="loc_srt_RangeMember_299_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_299" xlink:to="loc_srt_MaximumMember_317" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_dei_LegalEntityAxis_297" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_297" xlink:to="loc_dei_EntityDomain_316" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_297" xlink:to="loc_dei_EntityDomain_316_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_302" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AtTheMarketSaleAgreementMember" xlink:label="loc_meip_AtTheMarketSaleAgreementMember_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" xlink:to="loc_meip_AtTheMarketSaleAgreementMember_318" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:label="loc_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember_810883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" xlink:to="loc_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember_810883" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_478573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" xlink:to="loc_us-gaap_RelatedPartyDomain_478573" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_478573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" xlink:to="loc_us-gaap_RelatedPartyDomain_478573_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_478574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_TypeOfArrangementAxis_478574" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_478574" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_478574" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_766237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_766237" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_766238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_766237" xlink:to="loc_us-gaap_EquityComponentDomain_766238" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_766238_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_766237" xlink:to="loc_us-gaap_EquityComponentDomain_766238_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_766239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_766238" xlink:to="loc_us-gaap_WarrantMember_766239" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ShelfRegistrationStatementValue" xlink:label="loc_meip_ShelfRegistrationStatementValue_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_ShelfRegistrationStatementValue_315" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement_765537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement_765537" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:label="loc_meip_AggregateValueOfSecuritiesAvailableUnderAgreement_766236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_AggregateValueOfSecuritiesAvailableUnderAgreement_766236" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfWarrantsExercised" xlink:label="loc_meip_NumberOfWarrantsExercised_918137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfWarrantsExercised_918137" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesIssuedOnWarrantExercise" xlink:label="loc_meip_NumberOfSharesIssuedOnWarrantExercise_918138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfSharesIssuedOnWarrantExercise_918138" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesToBeReceived" xlink:label="loc_meip_NumberOfSharesToBeReceived_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_meip_NumberOfSharesToBeReceived_341" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_AwardTypeAxis_322" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_EmployeeStockOptionMember_345" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_346" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_RangeAxis_323" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_323" xlink:to="loc_srt_RangeMember_478618" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478618_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_323" xlink:to="loc_srt_RangeMember_478618_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_478619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MaximumMember_478619" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_478620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MinimumMember_478620" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_PlanNameAxis_324" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_324" xlink:to="loc_us-gaap_PlanNameDomain_325" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_324" xlink:to="loc_us-gaap_PlanNameDomain_325_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TwoThousandAndEightOmnibusPlanMember" xlink:label="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_325" xlink:to="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_TitleOfIndividualAxis_329" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_329" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_329" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_srt_DirectorMember_347" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EmployeesMember" xlink:label="loc_meip_EmployeesMember_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_meip_EmployeesMember_348" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_765757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_VestingAxis_765757" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_765759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_765757" xlink:to="loc_us-gaap_VestingDomain_765759" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_765759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_765757" xlink:to="loc_us-gaap_VestingDomain_765759_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_765760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_765759" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_765760" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_765779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_765779" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_765780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_765780" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_765781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_765781" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:label="loc_meip_NumberOfSharesForEachUnitOfRestrictedStock_765782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_meip_NumberOfSharesForEachUnitOfRestrictedStock_765782" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_352" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_352" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_353" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_353_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_352" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_353_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_dei_LegalEntityAxis_354" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_354" xlink:to="loc_dei_EntityDomain_359" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_354" xlink:to="loc_dei_EntityDomain_359_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensation_356" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_dei_LegalEntityAxis_362" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_362" xlink:to="loc_dei_EntityDomain_369" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_362" xlink:to="loc_dei_EntityDomain_369_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_dei_LegalEntityAxis_390" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390" xlink:to="loc_dei_EntityDomain_393" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390" xlink:to="loc_dei_EntityDomain_393_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_311943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_311943" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_311944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_311943" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_311944" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_311944_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_311943" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_311944_default" use="optional" order="12" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>meip-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-May-2021 [03:53:02] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" xlink:type="locator"/>
    <label xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator"/>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator"/>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator"/>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator"/>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</label>
    <label xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <label xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" xlink:type="locator"/>
    <label xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of the period</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and short-term investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</label>
    <label xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ReceivableForForeignTaxWithholding" xlink:label="loc_meip_ReceivableForForeignTaxWithholding" xlink:type="locator"/>
    <label xlink:label="lab_meip_ReceivableForForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable For Foreign Tax Withholding</label>
    <label xlink:label="lab_meip_ReceivableForForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable for foreign tax withholding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ReceivableForForeignTaxWithholding" xlink:to="lab_meip_ReceivableForForeignTaxWithholding" xlink:type="arc"/>
    <label xlink:label="lab_meip_ReceivableForForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable for foreign tax withholding.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 6)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, long-term</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, long-term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.00000002 par value; 226,000 shares authorized; 112,528 and 111,514 shares issued and outstanding at December 31, 2020 and June 30, 2020, respectively</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value; 100 shares authorized; none outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Losses Since Inception</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</label>
    <label xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</label>
    <label xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</label>
    <label xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</label>
    <label xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, long-term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <label xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <label xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</label>
    <label xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</label>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss - basic</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</label>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss - diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)</label>
    <label xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in estimated fair value of liability classified warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest and Dividend</label>
    <label xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and dividend income</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</label>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net loss per share:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used in calculating diluted net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used in calculating basic net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock Value Issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:label="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:type="locator"/>
    <label xlink:label="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">StockIssuedDuringPeriodValueStockWarrantsExercised</label>
    <label xlink:label="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:to="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:type="arc"/>
    <label xlink:label="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued as a result of the exercise of stock warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Previously Issued Common Stock</label>
    <label xlink:label="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collection of common stock proceeds receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:to="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:type="arc"/>
    <label xlink:label="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Previously Issued Common Stock.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</label>
    <label xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of short-term investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_NonCashLeaseExpense" xlink:label="loc_meip_NonCashLeaseExpense" xlink:type="locator"/>
    <label xlink:label="lab_meip_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Lease Expense</label>
    <label xlink:label="lab_meip_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NonCashLeaseExpense" xlink:to="lab_meip_NonCashLeaseExpense" xlink:type="arc"/>
    <label xlink:label="lab_meip_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non cash lease expense.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Net change</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities Current</label>
    <label xlink:label="lab_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:to="lab_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:type="arc"/>
    <label xlink:label="lab_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in operating lease liabilities current.</label>
    <loc xlink:href="meip-20210331.xsd#meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:label="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:type="locator"/>
    <label xlink:label="lab_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Or Decrease In Receivable For Foreign Tax Withholding</label>
    <label xlink:label="lab_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable for foreign tax withholding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:to="lab_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:type="arc"/>
    <label xlink:label="lab_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase or Decrease in Receivable for foreign tax withholding.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</label>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_WarrantsIssuedPursuantToCashlessExercise" xlink:label="loc_meip_WarrantsIssuedPursuantToCashlessExercise" xlink:type="locator"/>
    <label xlink:label="lab_meip_WarrantsIssuedPursuantToCashlessExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued pursuant to cashless exercise</label>
    <label xlink:label="lab_meip_WarrantsIssuedPursuantToCashlessExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued pursuant to cashless exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_WarrantsIssuedPursuantToCashlessExercise" xlink:to="lab_meip_WarrantsIssuedPursuantToCashlessExercise" xlink:type="arc"/>
    <label xlink:label="lab_meip_WarrantsIssuedPursuantToCashlessExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants issued pursuant to cashless exercise</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company and Summary of Significant Accounting Policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BeiGene Collaboration</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FederalHomeLoanBanksAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Home Loan Banks [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract" xlink:to="lab_us-gaap_FederalHomeLoanBanksAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:label="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Development Programs [Policy Text Block]</label>
    <label xlink:label="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Development Programs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:to="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical development programs.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_LiquidityPolicyTextBlock" xlink:label="loc_meip_LiquidityPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_meip_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity [Policy Text Block]</label>
    <label xlink:label="lab_meip_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_LiquidityPolicyTextBlock" xlink:to="lab_meip_LiquidityPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_meip_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Disclosure In Its Entirety Pertaining to the Accounting Policy In Respect Of Liquid Resources Held By The Entity.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Contract Assets and Contract Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:label="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue Associated With License Agreement [Table Text Block]</label>
    <label xlink:label="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue Associated With License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:to="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue Associated With License Agreement</label>
    <loc xlink:href="meip-20210331.xsd#meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:label="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions [Table Text Block]</label>
    <label xlink:label="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:to="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions [Table Text Block]</label>
    <loc xlink:href="meip-20210331.xsd#meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]</label>
    <label xlink:label="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Estimated Fair Value of Warrant Liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:to="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income (Loss) Per Share, Basic and Diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Calculation of Weighted Average Shares Used to Calculate Basic and Diluted (Loss) Earnings Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Operating Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Table Text Block]</label>
    <label xlink:label="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Operating Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of supplemental cash flow information related to operating leases.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity and Related Data</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Expense for Stock Awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Stock Options Weighted-Average Assumptions Used</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:type="locator"/>
    <label xlink:label="lab_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Eliminated upon Consolidation [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:to="lab_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:type="arc"/>
    <label xlink:label="lab_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Eliminated upon Consolidation [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TargetedOrTrackingStockStockTable" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TargetedOrTrackingStockStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Targeted or Tracking Stock, Stock [Table]</label>
    <label xlink:label="lab_us-gaap_TargetedOrTrackingStockStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Targeted or Tracking Stock, Stock [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable" xlink:to="lab_us-gaap_TargetedOrTrackingStockStockTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TargetedOrTrackingStockStockLineItems" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TargetedOrTrackingStockStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Targeted or Tracking Stock, Stock [Line Items]</label>
    <label xlink:label="lab_us-gaap_TargetedOrTrackingStockStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Targeted or Tracking Stock, Stock [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems" xlink:to="lab_us-gaap_TargetedOrTrackingStockStockLineItems" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfClinicalStageCandidates" xlink:label="loc_meip_NumberOfClinicalStageCandidates" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfClinicalStageCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Clinical Stage Candidates</label>
    <label xlink:label="lab_meip_NumberOfClinicalStageCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of clinical stage candidates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfClinicalStageCandidates" xlink:to="lab_meip_NumberOfClinicalStageCandidates" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfClinicalStageCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of clinical stage candidates.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <label xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Associated With Remaining Performance Obligation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_RevenuePerformanceObligationAmount" xlink:label="loc_meip_RevenuePerformanceObligationAmount" xlink:type="locator"/>
    <label xlink:label="lab_meip_RevenuePerformanceObligationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation Amount</label>
    <label xlink:label="lab_meip_RevenuePerformanceObligationAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognised With Performance Obligation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RevenuePerformanceObligationAmount" xlink:to="lab_meip_RevenuePerformanceObligationAmount" xlink:type="arc"/>
    <label xlink:label="lab_meip_RevenuePerformanceObligationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in contract assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets, Current</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Contract assets, beginning of period</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Contract assets, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligation revenue recognised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <label xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:label="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:type="locator"/>
    <label xlink:label="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash EquivalentsShort Term Investments And Common Stock Proceeds Receivable</label>
    <label xlink:label="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:to="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:type="arc"/>
    <label xlink:label="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Cash And Cash Equivalents,Short Term Investments And Proceeds Receivable From The Sale Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</label>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <label xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <label xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_UsLicenseMember" xlink:label="loc_meip_UsLicenseMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_UsLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US License [Member]</label>
    <label xlink:label="lab_meip_UsLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US License</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_UsLicenseMember" xlink:to="lab_meip_UsLicenseMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_UsLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US license.</label>
    <loc xlink:href="meip-20210331.xsd#meip_ExUsLicenseMember" xlink:label="loc_meip_ExUsLicenseMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_ExUsLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ex Us License [Member]</label>
    <label xlink:label="lab_meip_ExUsLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ex US License</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ExUsLicenseMember" xlink:to="lab_meip_ExUsLicenseMember" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_AgreementAxis" xlink:label="loc_meip_AgreementAxis" xlink:type="locator"/>
    <label xlink:label="lab_meip_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AgreementAxis" xlink:to="lab_meip_AgreementAxis" xlink:type="arc"/>
    <label xlink:label="lab_meip_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement [Axis].</label>
    <loc xlink:href="meip-20210331.xsd#meip_AgreementDomain" xlink:label="loc_meip_AgreementDomain" xlink:type="locator"/>
    <label xlink:label="lab_meip_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AgreementDomain" xlink:to="lab_meip_AgreementDomain" xlink:type="arc"/>
    <label xlink:label="lab_meip_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement [Domain].</label>
    <loc xlink:href="meip-20210331.xsd#meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:label="loc_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KKC Commercialization Agreement And The Helsinn License Agreement [Member]</label>
    <label xlink:label="lab_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KKC Commercialization Agreement And The Helsinn License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:to="lab_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KKC&#xA0;commercialization&#xA0;agreement and the helsinn license agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:label="loc_meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KKC Agreements And Helsinn License Agreement [Member]</label>
    <label xlink:label="lab_meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KKC Agreements and Helsinn License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:to="lab_meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KKC agreements and helsinn license agreement [Member].</label>
    <loc xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_HelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Helsinn License Agreement [Member]</label>
    <label xlink:label="lab_meip_HelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Helsinn License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_HelsinnLicenseAgreementMember" xlink:to="lab_meip_HelsinnLicenseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_HelsinnLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Helsinn license agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognized Revenue Associated with The Following License Agreements [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:to="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:type="locator"/>
    <label xlink:label="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognized Revenue Associated with The Following License Agreements [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:to="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognized Revenue Associated with The Following License Agreements [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:to="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_KkcAgreementsMember" xlink:label="loc_meip_KkcAgreementsMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_KkcAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kkc Agreements [Member]</label>
    <label xlink:label="lab_meip_KkcAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KKC License Agreement [Member]</label>
    <label xlink:label="lab_meip_KkcAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:type="resource" xml:lang="en-US">KKC License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_KkcAgreementsMember" xlink:to="lab_meip_KkcAgreementsMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_KkcAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kkc Agreements [Member].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</label>
    <label xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services performed over time [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ContractWithCustomerAssetAndLiabilityTable" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:type="locator"/>
    <label xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer Asset and Liability [Table]</label>
    <label xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer Asset and Liability [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:to="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:type="arc"/>
    <label xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with customer asset and liability.</label>
    <loc xlink:href="meip-20210331.xsd#meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:type="locator"/>
    <label xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer Asset and Liability [Line Items]</label>
    <label xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer Asset and Liability [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:to="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:type="arc"/>
    <label xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with customer asset and liability Line items.</label>
    <loc xlink:href="meip-20210331.xsd#meip_AccountsReceivableNetBeginningBalance" xlink:label="loc_meip_AccountsReceivableNetBeginningBalance" xlink:type="locator"/>
    <label xlink:label="lab_meip_AccountsReceivableNetBeginningBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable Net Beginning Balance</label>
    <label xlink:label="lab_meip_AccountsReceivableNetBeginningBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Receivables, beginning of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AccountsReceivableNetBeginningBalance" xlink:to="lab_meip_AccountsReceivableNetBeginningBalance" xlink:type="arc"/>
    <label xlink:label="lab_meip_AccountsReceivableNetBeginningBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts receivable net beginning balance.</label>
    <loc xlink:href="meip-20210331.xsd#meip_AccountsReceivableNetEndingBalance" xlink:label="loc_meip_AccountsReceivableNetEndingBalance" xlink:type="locator"/>
    <label xlink:label="lab_meip_AccountsReceivableNetEndingBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable Net Ending Balance</label>
    <label xlink:label="lab_meip_AccountsReceivableNetEndingBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Receivables, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AccountsReceivableNetEndingBalance" xlink:to="lab_meip_AccountsReceivableNetEndingBalance" xlink:type="arc"/>
    <label xlink:label="lab_meip_AccountsReceivableNetEndingBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts receivable net ending balance.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, beginning of period</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ReceivablesAmountsBilled" xlink:label="loc_meip_ReceivablesAmountsBilled" xlink:type="locator"/>
    <label xlink:label="lab_meip_ReceivablesAmountsBilled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Amounts billed</label>
    <label xlink:label="lab_meip_ReceivablesAmountsBilled" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts billed</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ReceivablesAmountsBilled" xlink:to="lab_meip_ReceivablesAmountsBilled" xlink:type="arc"/>
    <label xlink:label="lab_meip_ReceivablesAmountsBilled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables Amounts billed</label>
    <loc xlink:href="meip-20210331.xsd#meip_ReceivablesPaymentsReceived" xlink:label="loc_meip_ReceivablesPaymentsReceived" xlink:type="locator"/>
    <label xlink:label="lab_meip_ReceivablesPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Payments received</label>
    <label xlink:label="lab_meip_ReceivablesPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments received</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ReceivablesPaymentsReceived" xlink:to="lab_meip_ReceivablesPaymentsReceived" xlink:type="arc"/>
    <label xlink:label="lab_meip_ReceivablesPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables Payments received</label>
    <loc xlink:href="meip-20210331.xsd#meip_ContractAssetsBillableAmounts" xlink:label="loc_meip_ContractAssetsBillableAmounts" xlink:type="locator"/>
    <label xlink:label="lab_meip_ContractAssetsBillableAmounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract assets Billable amounts</label>
    <label xlink:label="lab_meip_ContractAssetsBillableAmounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Billable amounts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ContractAssetsBillableAmounts" xlink:to="lab_meip_ContractAssetsBillableAmounts" xlink:type="arc"/>
    <label xlink:label="lab_meip_ContractAssetsBillableAmounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract assets Billable amounts</label>
    <loc xlink:href="meip-20210331.xsd#meip_ContractAssetsAmountsBilled" xlink:label="loc_meip_ContractAssetsAmountsBilled" xlink:type="locator"/>
    <label xlink:label="lab_meip_ContractAssetsAmountsBilled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract assets Amounts billed</label>
    <label xlink:label="lab_meip_ContractAssetsAmountsBilled" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts billed</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ContractAssetsAmountsBilled" xlink:to="lab_meip_ContractAssetsAmountsBilled" xlink:type="arc"/>
    <label xlink:label="lab_meip_ContractAssetsAmountsBilled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract assets Amounts billed</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
    <label xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <label xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <label xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend Yield</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life years</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <label xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes Fair Value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:type="locator"/>
    <label xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Significant Unobservable Inputs [Table]</label>
    <label xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements Significant unobservable inputs [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:to="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:type="arc"/>
    <label xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of fair value measurements significant unobservable inputs.</label>
    <loc xlink:href="meip-20210331.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Significant Unobservable Inputs [Line Items]</label>
    <label xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements Significant unobservable inputs [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:to="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:type="arc"/>
    <label xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Significant Unobservable Inputs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification of derivative liability to equity upon exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_KyowaKirinCoMember" xlink:label="loc_meip_KyowaKirinCoMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_KyowaKirinCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kyowa Kirin Co [Member]</label>
    <label xlink:label="lab_meip_KyowaKirinCoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Kyowa Kirin Co</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_KyowaKirinCoMember" xlink:to="lab_meip_KyowaKirinCoMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_PresageBiosciencesIncMember" xlink:label="loc_meip_PresageBiosciencesIncMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_PresageBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presage Biosciences Inc [Member]</label>
    <label xlink:label="lab_meip_PresageBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Presage Biosciences, Inc.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PresageBiosciencesIncMember" xlink:to="lab_meip_PresageBiosciencesIncMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_PresageBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Presage Biosciences Inc.</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_IncrementalPaymentMember" xlink:label="loc_meip_IncrementalPaymentMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_IncrementalPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Payment [Member]</label>
    <label xlink:label="lab_meip_IncrementalPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental Payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_IncrementalPaymentMember" xlink:to="lab_meip_IncrementalPaymentMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_IncrementalPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Payment.</label>
    <loc xlink:href="meip-20210331.xsd#meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Payments on Achievement of Development Regulatory and Commercial Milestones [Member]</label>
    <label xlink:label="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Payments on Achievement of Development Regulatory and Commercial Milestones</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential payments on achievement of development regulatory and commercial milestones.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_AgreementTerminationNoticePeriod" xlink:label="loc_meip_AgreementTerminationNoticePeriod" xlink:type="locator"/>
    <label xlink:label="lab_meip_AgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination Notice Period</label>
    <label xlink:label="lab_meip_AgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and supply agreement notice period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AgreementTerminationNoticePeriod" xlink:to="lab_meip_AgreementTerminationNoticePeriod" xlink:type="arc"/>
    <label xlink:label="lab_meip_AgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination notice period.</label>
    <loc xlink:href="meip-20210331.xsd#meip_PaymentForLicenseAgreement" xlink:label="loc_meip_PaymentForLicenseAgreement" xlink:type="locator"/>
    <label xlink:label="lab_meip_PaymentForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For License Agreement</label>
    <label xlink:label="lab_meip_PaymentForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for license</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PaymentForLicenseAgreement" xlink:to="lab_meip_PaymentForLicenseAgreement" xlink:type="arc"/>
    <label xlink:label="lab_meip_PaymentForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment for license agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:type="locator"/>
    <label xlink:label="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Purchases from Major Suppliers</label>
    <label xlink:label="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Purchase Requirement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:to="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:type="arc"/>
    <label xlink:label="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of purchases from major suppliers.</label>
    <loc xlink:href="meip-20210331.xsd#meip_PotentialMilestonePaymentsPayable" xlink:label="loc_meip_PotentialMilestonePaymentsPayable" xlink:type="locator"/>
    <label xlink:label="lab_meip_PotentialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Payable</label>
    <label xlink:label="lab_meip_PotentialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments payable amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialMilestonePaymentsPayable" xlink:to="lab_meip_PotentialMilestonePaymentsPayable" xlink:type="arc"/>
    <label xlink:label="lab_meip_PotentialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential milestone payments payable.</label>
    <loc xlink:href="meip-20210331.xsd#meip_PotentialMilestonePaymentsReceivable" xlink:label="loc_meip_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <label xlink:label="lab_meip_PotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable</label>
    <label xlink:label="lab_meip_PotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialMilestonePaymentsReceivable" xlink:to="lab_meip_PotentialMilestonePaymentsReceivable" xlink:type="arc"/>
    <label xlink:label="lab_meip_PotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential milestone payments receivable.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</label>
    <label xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation payable for grant of rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</label>
    <label xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation receivable for grant of rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:label="loc_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:type="locator"/>
    <label xlink:label="lab_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Development Cost Sharing Recoverable Through Earnings</label>
    <label xlink:label="lab_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated development cost sharing recovered through earnings</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:to="lab_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:type="arc"/>
    <label xlink:label="lab_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated development cost sharing reoverable through earnings.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</label>
    <label xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_UpFrontPayment" xlink:label="loc_meip_UpFrontPayment" xlink:type="locator"/>
    <label xlink:label="lab_meip_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Up Front Payment</label>
    <label xlink:label="lab_meip_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_UpFrontPayment" xlink:to="lab_meip_UpFrontPayment" xlink:type="arc"/>
    <label xlink:label="lab_meip_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Up Front Payment</label>
    <loc xlink:href="meip-20210331.xsd#meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:label="loc_meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:type="locator"/>
    <label xlink:label="lab_meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Upfront Payment Receivable For Grant Of Rights</label>
    <label xlink:label="lab_meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total upfront payment receivable for grant of rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:to="lab_meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:type="arc"/>
    <label xlink:label="lab_meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront payment receivable for grant of rights.</label>
    <loc xlink:href="meip-20210331.xsd#meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:label="loc_meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:type="locator"/>
    <label xlink:label="lab_meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Transaction Price In Respect Of Colloboration Revenue</label>
    <label xlink:label="lab_meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction price relating to the performance obligation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:to="lab_meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:type="arc"/>
    <label xlink:label="lab_meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total transaction price in respect of colloboration revenue.</label>
    <loc xlink:href="meip-20210331.xsd#meip_ExpectedMilestonePaymentReceivable" xlink:label="loc_meip_ExpectedMilestonePaymentReceivable" xlink:type="locator"/>
    <label xlink:label="lab_meip_ExpectedMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Milestone Payment Receivable</label>
    <label xlink:label="lab_meip_ExpectedMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected milestone payment receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ExpectedMilestonePaymentReceivable" xlink:to="lab_meip_ExpectedMilestonePaymentReceivable" xlink:type="arc"/>
    <label xlink:label="lab_meip_ExpectedMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected milestone payment receivable.</label>
    <loc xlink:href="meip-20210331.xsd#meip_LicenseObligationAccountTransactionPriceAllocated" xlink:label="loc_meip_LicenseObligationAccountTransactionPriceAllocated" xlink:type="locator"/>
    <label xlink:label="lab_meip_LicenseObligationAccountTransactionPriceAllocated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Obligation Account Transaction Price Allocated</label>
    <label xlink:label="lab_meip_LicenseObligationAccountTransactionPriceAllocated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Obligation Account Transaction Price Allocated</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_LicenseObligationAccountTransactionPriceAllocated" xlink:to="lab_meip_LicenseObligationAccountTransactionPriceAllocated" xlink:type="arc"/>
    <label xlink:label="lab_meip_LicenseObligationAccountTransactionPriceAllocated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License obligation account transaction price allocated.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer liability non current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ProfitsAndCostsSharingRatio" xlink:label="loc_meip_ProfitsAndCostsSharingRatio" xlink:type="locator"/>
    <label xlink:label="lab_meip_ProfitsAndCostsSharingRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profits And Costs Sharing Ratio</label>
    <label xlink:label="lab_meip_ProfitsAndCostsSharingRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit sharing ratio</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ProfitsAndCostsSharingRatio" xlink:to="lab_meip_ProfitsAndCostsSharingRatio" xlink:type="arc"/>
    <label xlink:label="lab_meip_ProfitsAndCostsSharingRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profits and costs sharing ratio.</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_DevelopmentServicesMember" xlink:label="loc_meip_DevelopmentServicesMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_DevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Services [Member]</label>
    <label xlink:label="lab_meip_DevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Services</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_DevelopmentServicesMember" xlink:to="lab_meip_DevelopmentServicesMember" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_PresageLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presage License Agreement [Member]</label>
    <label xlink:label="lab_meip_PresageLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Presage License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PresageLicenseAgreementMember" xlink:to="lab_meip_PresageLicenseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_PresageLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Presage License Agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_EventAxis" xlink:label="loc_meip_EventAxis" xlink:type="locator"/>
    <label xlink:label="lab_meip_EventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_EventAxis" xlink:to="lab_meip_EventAxis" xlink:type="arc"/>
    <label xlink:label="lab_meip_EventAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event</label>
    <loc xlink:href="meip-20210331.xsd#meip_EventDomain" xlink:label="loc_meip_EventDomain" xlink:type="locator"/>
    <label xlink:label="lab_meip_EventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_EventDomain" xlink:to="lab_meip_EventDomain" xlink:type="arc"/>
    <label xlink:label="lab_meip_EventDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event</label>
    <loc xlink:href="meip-20210331.xsd#meip_UpdationOfInitialAssessmentMember" xlink:label="loc_meip_UpdationOfInitialAssessmentMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_UpdationOfInitialAssessmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Updation Of Initial Assessment [Member]</label>
    <label xlink:label="lab_meip_UpdationOfInitialAssessmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Updation of Initial Assessment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_UpdationOfInitialAssessmentMember" xlink:to="lab_meip_UpdationOfInitialAssessmentMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_UpdationOfInitialAssessmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Updation Of Initial Assessment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:type="locator"/>
    <label xlink:label="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potentially Dilutive Securities Outstanding [Line Items]</label>
    <label xlink:label="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially Dilutive Securities Outstanding [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:to="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:type="arc"/>
    <label xlink:label="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potentially Dilutive Securities Outstanding [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock subject to repurchase or forfeiture</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="loc_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="locator"/>
    <label xlink:label="lab_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability</label>
    <label xlink:label="lab_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:to="lab_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="arc"/>
    <label xlink:label="lab_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dilutive securities effect on basic earnings per share change in fair value of warrant liability.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of potentially dilutive common shares from equity awards and liability-classified warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock option</label>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</label>
    <label xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total anti-dilutive shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</label>
    <label xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</label>
    <label xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_MilestonePaymentsMaximumAmount" xlink:label="loc_meip_MilestonePaymentsMaximumAmount" xlink:type="locator"/>
    <label xlink:label="lab_meip_MilestonePaymentsMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments, Maximum Amount</label>
    <label xlink:label="lab_meip_MilestonePaymentsMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future aggregate milestone payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_MilestonePaymentsMaximumAmount" xlink:to="lab_meip_MilestonePaymentsMaximumAmount" xlink:type="arc"/>
    <label xlink:label="lab_meip_MilestonePaymentsMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments, maximum amount.</label>
    <loc xlink:href="meip-20210331.xsd#meip_AccruedMilestonePayments" xlink:label="loc_meip_AccruedMilestonePayments" xlink:type="locator"/>
    <label xlink:label="lab_meip_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payments</label>
    <label xlink:label="lab_meip_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payment for potential future payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AccruedMilestonePayments" xlink:to="lab_meip_AccruedMilestonePayments" xlink:type="arc"/>
    <label xlink:label="lab_meip_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued milestone payments.</label>
    <loc xlink:href="meip-20210331.xsd#meip_CydexLicenseAgreementMember" xlink:label="loc_meip_CydexLicenseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_CydexLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CyDex License Agreement [Member]</label>
    <label xlink:label="lab_meip_CydexLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CyDex License Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_CydexLicenseAgreementMember" xlink:to="lab_meip_CydexLicenseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_CydexLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CyDex License Agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_SbioPurchaseAgreementMember" xlink:label="loc_meip_SbioPurchaseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_SbioPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SBio Purchase Agreement [Member]</label>
    <label xlink:label="lab_meip_SbioPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">S*Bio Purchase Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_SbioPurchaseAgreementMember" xlink:to="lab_meip_SbioPurchaseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_SbioPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S Bio Purchase Agreement.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfSquareFeetUnderLease" xlink:label="loc_meip_NumberOfSquareFeetUnderLease" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfSquareFeetUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Square Feet Under Lease</label>
    <label xlink:label="lab_meip_NumberOfSquareFeetUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of square feet under lease</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSquareFeetUnderLease" xlink:to="lab_meip_NumberOfSquareFeetUnderLease" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfSquareFeetUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of square feet under lease.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Expiration Date</label>
    <label xlink:label="lab_us-gaap_LeaseExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease expire date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:label="loc_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <label xlink:label="lab_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Recognition Of Operating Lease Right Of Use Asset</label>
    <label xlink:label="lab_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:to="lab_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <label xlink:label="lab_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial recognition of operating lease right of use asset.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_SanDiegoCaliforniaMember" xlink:label="loc_meip_SanDiegoCaliforniaMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego California [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_SanDiegoCaliforniaMember" xlink:to="lab_meip_SanDiegoCaliforniaMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:label="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:type="arc"/>
    <label xlink:label="lab_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of supplemental cash flow information related to operating leases.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <label xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of fiscal year ending June 30, 2021</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator"/>
    <label xlink:label="lab_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</label>
    <label xlink:label="lab_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc"/>
    <label xlink:label="lab_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease liability payments due after year four.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Present value discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:label="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Agreed to be Sold Under Agreement</label>
    <label xlink:label="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of shares under agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:to="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Agreed to be Sold Under Agreement</label>
    <loc xlink:href="meip-20210331.xsd#meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:type="locator"/>
    <label xlink:label="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Shares And Warrants Under Agreement</label>
    <label xlink:label="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of shares and warrants under agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:to="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:type="arc"/>
    <label xlink:label="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of shares and warrants under agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_ShelfRegistrationStatementValue" xlink:label="loc_meip_ShelfRegistrationStatementValue" xlink:type="locator"/>
    <label xlink:label="lab_meip_ShelfRegistrationStatementValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement Value</label>
    <label xlink:label="lab_meip_ShelfRegistrationStatementValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate value of securities available under shelf registration statement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ShelfRegistrationStatementValue" xlink:to="lab_meip_ShelfRegistrationStatementValue" xlink:type="arc"/>
    <label xlink:label="lab_meip_ShelfRegistrationStatementValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Shelf registration statement value.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock share issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:type="locator"/>
    <label xlink:label="lab_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsold Securities Shares And Warrants Under Agreement</label>
    <label xlink:label="lab_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsold Securities Shares and Warrants Under Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:to="lab_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:type="arc"/>
    <label xlink:label="lab_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unsold securities shares and warrants under agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:label="loc_meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:type="locator"/>
    <label xlink:label="lab_meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Value of Securities Available Under Agreement</label>
    <label xlink:label="lab_meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Value of Securities Available Under Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:to="lab_meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:type="arc"/>
    <label xlink:label="lab_meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate value of securities available under agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfWarrantsExercised" xlink:label="loc_meip_NumberOfWarrantsExercised" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:label="lab_meip_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfWarrantsExercised" xlink:to="lab_meip_NumberOfWarrantsExercised" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised.</label>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfSharesIssuedOnWarrantExercise" xlink:label="loc_meip_NumberOfSharesIssuedOnWarrantExercise" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfSharesIssuedOnWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued On Warrant Exercise</label>
    <label xlink:label="lab_meip_NumberOfSharesIssuedOnWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued on warrant exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSharesIssuedOnWarrantExercise" xlink:to="lab_meip_NumberOfSharesIssuedOnWarrantExercise" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfSharesIssuedOnWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued on warrant exercise.</label>
    <loc xlink:href="meip-20210331.xsd#meip_AtTheMarketSaleAgreementMember" xlink:label="loc_meip_AtTheMarketSaleAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_AtTheMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Sale Agreement [Member]</label>
    <label xlink:label="lab_meip_AtTheMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Sales Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AtTheMarketSaleAgreementMember" xlink:to="lab_meip_AtTheMarketSaleAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_AtTheMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-market equity offering sales agreement.</label>
    <loc xlink:href="meip-20210331.xsd#meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:label="loc_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Twenty At The Market Sale Agreement [Member]</label>
    <label xlink:label="lab_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand And Twenty At The Market Sale Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:to="lab_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and twenty at the market sale agreement.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_TwoThousandAndEightOmnibusPlanMember" xlink:label="loc_meip_TwoThousandAndEightOmnibusPlanMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_TwoThousandAndEightOmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eight Omnibus Plan [Member]</label>
    <label xlink:label="lab_meip_TwoThousandAndEightOmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Omnibus Plan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_TwoThousandAndEightOmnibusPlanMember" xlink:to="lab_meip_TwoThousandAndEightOmnibusPlanMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_TwoThousandAndEightOmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and eight omnibus plan.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted average period for recognition of compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfSharesToBeReceived" xlink:label="loc_meip_NumberOfSharesToBeReceived" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfSharesToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares to be Received</label>
    <label xlink:label="lab_meip_NumberOfSharesToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock to be received for each RSUs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSharesToBeReceived" xlink:to="lab_meip_NumberOfSharesToBeReceived" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfSharesToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares to be received.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option vested percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs grant date fair value per unit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, expiration period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award vesting period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grant</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units forfeiture during the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation by share based payment arrangement other than options unvested outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation by share based payment arrangement other than options unvested cost not yet recognised amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:label="loc_meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:type="locator"/>
    <label xlink:label="lab_meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares For Each Unit Of Restricted Stock</label>
    <label xlink:label="lab_meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares for each unit of restricted stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:to="lab_meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:type="arc"/>
    <label xlink:label="lab_meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares for each unit of restricted stock.</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</label>
    <label xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_EmployeesMember" xlink:label="loc_meip_EmployeesMember" xlink:type="locator"/>
    <label xlink:label="lab_meip_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees [Member]</label>
    <label xlink:label="lab_meip_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_EmployeesMember" xlink:to="lab_meip_EmployeesMember" xlink:type="arc"/>
    <label xlink:label="lab_meip_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement Tranche Two</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited / Cancelled</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited / Cancelled</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="meip-20210331.xsd#meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="locator"/>
    <label xlink:label="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:label="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc"/>
    <label xlink:label="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>meip-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-May-2021 [03:53:02] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CoverPage" roleURI="http://www.meipharma.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedBalanceSheets" roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfOperations" roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfStockholdersEquity" roleURI="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#FairValueMeasurements" roleURI="http://www.meipharma.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LicenseAgreements" roleURI="http://www.meipharma.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#BeigeneCollaboration" roleURI="http://www.meipharma.com/role/BeigeneCollaboration" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#NetLossPerShare" roleURI="http://www.meipharma.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CommitmentsAndContingencies" roleURI="http://www.meipharma.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#Leases" roleURI="http://www.meipharma.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShortTermInvestments" roleURI="http://www.meipharma.com/role/ShortTermInvestments" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#StockholdersEquity" roleURI="http://www.meipharma.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensation" roleURI="http://www.meipharma.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#FairValueMeasurementsTables" roleURI="http://www.meipharma.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#NetLossPerShareTables" roleURI="http://www.meipharma.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LeasesTables" roleURI="http://www.meipharma.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensationTables" roleURI="http://www.meipharma.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" roleURI="http://www.meipharma.com/role/TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" roleURI="http://www.meipharma.com/role/TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#NetLossPerShareAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfLossPerShareBasicAndDilutedDetail" roleURI="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail" roleURI="http://www.meipharma.com/role/CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#AntidilutiveSecuritiesDetail" roleURI="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfTotalOperatingCostsDetail" roleURI="http://www.meipharma.com/role/ScheduleOfTotalOperatingCostsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" roleURI="http://www.meipharma.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ScheduleOfFutureMinimumRentalPaymentsDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShortTermInvestmentsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#ShareBasedCompensationExpenseForStockAwardsDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#SummaryOfStockOptionActivityDetail" roleURI="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20210331.xsd#FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" roleURI="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_765513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_765513" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_765514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_765514" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_918060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentQuarterlyReport_918060" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_918061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentTransitionReport_918061" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_765515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_765515" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_765516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_765516" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_765517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_765517" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_478689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_478689" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_765518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_765518" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_765519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_765519" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_765520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_765520" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_765521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_765521" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_765522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_765522" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_765523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_765523" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_765524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_765524" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_765525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_765525" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_765526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_765526" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_765527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_765527" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_765528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_765528" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_765530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_765530" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_765529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_765529" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21" xlink:to="loc_us-gaap_StatementTable_28" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_28" xlink:to="loc_dei_LegalEntityAxis_24" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_24" xlink:to="loc_dei_EntityDomain_38" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_28" xlink:to="loc_us-gaap_StatementLineItems_27" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_23" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_ShortTermInvestments_34" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivableForForeignTaxWithholding" xlink:label="loc_meip_ReceivableForForeignTaxWithholding_765429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_meip_ReceivableForForeignTaxWithholding_765429" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_AssetsCurrent_37" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_765674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_765674" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_Assets_32" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_43" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_44" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_DeferredRevenueCurrent_45" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_765678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_765678" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_46" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_311823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_311823" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_765679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_765679" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_Liabilities_40" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommitmentsAndContingencies_41" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_47" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_48" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_51" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_53" xlink:to="loc_us-gaap_StatementTable_56" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56" xlink:to="loc_dei_LegalEntityAxis_54" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_54" xlink:to="loc_dei_EntityDomain_57" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56" xlink:to="loc_us-gaap_StatementLineItems_55" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_59" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_60" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_62" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesIssued_63" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_66" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66" xlink:to="loc_us-gaap_StatementTable_73" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73" xlink:to="loc_dei_LegalEntityAxis_68" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_68" xlink:to="loc_dei_EntityDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73" xlink:to="loc_us-gaap_StatementLineItems_72" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_Revenues_86" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_75" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_77" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostsAndExpenses_78" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_OperatingIncomeLoss_88" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_765439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_765439" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_85" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NetIncomeLossAbstract_69" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_69" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_80" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_69" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_81" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_90" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_91" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_409045" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_409046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_409045" xlink:to="loc_us-gaap_StatementTable_409046" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_409047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_dei_LegalEntityAxis_409047" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_409048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_409047" xlink:to="loc_dei_EntityDomain_409048" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_409049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_409049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_409050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_409049" xlink:to="loc_us-gaap_EquityComponentDomain_409050" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_409051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_CommonStockMember_409051" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_409052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_409052" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_409053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_RetainedEarningsMember_409053" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_478157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" xlink:to="loc_us-gaap_LossContingencyNatureDomain_478157" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_StatementLineItems_409054" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_409058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockholdersEquity_409058" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_409059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_NetIncomeLoss_409059" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:label="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_409071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockholdersEquity_409071" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95" xlink:to="loc_us-gaap_StatementTable_103" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_103" xlink:to="loc_dei_LegalEntityAxis_98" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_98" xlink:to="loc_dei_EntityDomain_111" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_103" xlink:to="loc_us-gaap_StatementLineItems_102" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_ProfitLoss_120" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_ShareBasedCompensation_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NonCashLeaseExpense" xlink:label="loc_meip_NonCashLeaseExpense_765686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_meip_NonCashLeaseExpense_765686" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:label="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_810778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_810778" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_765685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_765685" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_112" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_765455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_765455" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_765456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_765456" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_124" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_478167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_478167" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_765687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_765687" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_WarrantsIssuedPursuantToCashlessExercise" xlink:label="loc_meip_WarrantsIssuedPursuantToCashlessExercise_918392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_meip_WarrantsIssuedPursuantToCashlessExercise_918392" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400" xlink:to="loc_us-gaap_StatementTable_403" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_403" xlink:to="loc_dei_LegalEntityAxis_401" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_401" xlink:to="loc_dei_EntityDomain_404" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_403" xlink:to="loc_us-gaap_StatementLineItems_402" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_402" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_428" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_428" xlink:to="loc_us-gaap_StatementTable_431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_431" xlink:to="loc_dei_LegalEntityAxis_429" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_429" xlink:to="loc_dei_EntityDomain_432" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_431" xlink:to="loc_us-gaap_StatementLineItems_430" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_430" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_433" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_444" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_444" xlink:to="loc_us-gaap_StatementTable_447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_447" xlink:to="loc_dei_LegalEntityAxis_445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_445" xlink:to="loc_dei_EntityDomain_448" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_447" xlink:to="loc_us-gaap_StatementLineItems_446" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_446" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/BeigeneCollaboration">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_451" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_451" xlink:to="loc_us-gaap_StatementTable_454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_454" xlink:to="loc_dei_LegalEntityAxis_452" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_452" xlink:to="loc_dei_EntityDomain_455" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_454" xlink:to="loc_us-gaap_StatementLineItems_453" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_458" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_458" xlink:to="loc_us-gaap_StatementTable_461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_461" xlink:to="loc_dei_LegalEntityAxis_459" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_459" xlink:to="loc_dei_EntityDomain_462" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_461" xlink:to="loc_us-gaap_StatementLineItems_460" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_460" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_463" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" xlink:to="loc_us-gaap_StatementTable_476" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_476" xlink:to="loc_dei_LegalEntityAxis_474" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_474" xlink:to="loc_dei_EntityDomain_477" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_476" xlink:to="loc_us-gaap_StatementLineItems_475" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_475" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_765491" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_765492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765491" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_765492" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_480" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_480" xlink:to="loc_us-gaap_StatementTable_483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_483" xlink:to="loc_dei_LegalEntityAxis_481" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_484" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_483" xlink:to="loc_us-gaap_StatementLineItems_482" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_482" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract_487" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract_487" xlink:to="loc_us-gaap_StatementTable_490" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490" xlink:to="loc_dei_LegalEntityAxis_488" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_488" xlink:to="loc_dei_EntityDomain_491" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490" xlink:to="loc_us-gaap_StatementLineItems_489" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_494" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_494" xlink:to="loc_us-gaap_StatementTable_497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_497" xlink:to="loc_dei_LegalEntityAxis_495" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_495" xlink:to="loc_dei_EntityDomain_498" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_497" xlink:to="loc_us-gaap_StatementLineItems_496" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_496" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_407" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_407" xlink:to="loc_us-gaap_StatementTable_410" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410" xlink:to="loc_dei_LegalEntityAxis_408" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_408" xlink:to="loc_dei_EntityDomain_411" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410" xlink:to="loc_us-gaap_StatementLineItems_409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:label="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_LiquidityPolicyTextBlock" xlink:label="loc_meip_LiquidityPolicyTextBlock_481048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_LiquidityPolicyTextBlock_481048" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_UseOfEstimates_414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_418" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_765461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_765461" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_421" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_421" xlink:to="loc_us-gaap_StatementTable_424" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_424" xlink:to="loc_dei_LegalEntityAxis_422" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_422" xlink:to="loc_dei_EntityDomain_425" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_424" xlink:to="loc_us-gaap_StatementLineItems_423" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:label="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_311933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423" xlink:to="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_311933" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_426" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_435" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_435" xlink:to="loc_us-gaap_StatementTable_438" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_438" xlink:to="loc_dei_LegalEntityAxis_436" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_436" xlink:to="loc_dei_EntityDomain_439" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_438" xlink:to="loc_us-gaap_StatementLineItems_437" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:label="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_465" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_465" xlink:to="loc_us-gaap_StatementTable_468" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468" xlink:to="loc_dei_LegalEntityAxis_466" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_466" xlink:to="loc_dei_EntityDomain_469" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468" xlink:to="loc_us-gaap_StatementLineItems_467" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_470" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_471" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_765487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_765487" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_765721" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_810830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765721" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_810830" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_811814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765721" xlink:to="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_811814" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_765722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765721" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_765722" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_501" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_501" xlink:to="loc_us-gaap_StatementTable_504" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504" xlink:to="loc_dei_LegalEntityAxis_502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_502" xlink:to="loc_dei_EntityDomain_505" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504" xlink:to="loc_us-gaap_StatementLineItems_503" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_126" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TargetedOrTrackingStockStockTable" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockTable_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_126" xlink:to="loc_us-gaap_TargetedOrTrackingStockStockTable_129" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_dei_LegalEntityAxis_127" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_127" xlink:to="loc_dei_EntityDomain_130" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311913" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_478189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_srt_RangeAxis_478189" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_478189" xlink:to="loc_srt_RangeMember_478190" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_478194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" xlink:to="loc_us-gaap_TypeOfAdoptionMember_478194" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementAxis" xlink:label="loc_meip_AgreementAxis_765465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_meip_AgreementAxis_765465" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementDomain" xlink:label="loc_meip_AgreementDomain_765466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_AgreementAxis_765465" xlink:to="loc_meip_AgreementDomain_765466" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_765467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_AgreementDomain_765466" xlink:to="loc_meip_HelsinnLicenseAgreementMember_765467" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember" xlink:label="loc_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember_810790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_AgreementDomain_765466" xlink:to="loc_meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember_810790" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcAgreementsandHelsinnLicenseAgreementMember" xlink:label="loc_meip_KkcAgreementsandHelsinnLicenseAgreementMember_811812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_AgreementDomain_765466" xlink:to="loc_meip_KkcAgreementsandHelsinnLicenseAgreementMember_811812" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_810802" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UsLicenseMember" xlink:label="loc_meip_UsLicenseMember_810804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" xlink:to="loc_meip_UsLicenseMember_810804" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ExUsLicenseMember" xlink:label="loc_meip_ExUsLicenseMember_810805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_810803" xlink:to="loc_meip_ExUsLicenseMember_810805" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TargetedOrTrackingStockStockLineItems" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfClinicalStageCandidates" xlink:label="loc_meip_NumberOfClinicalStageCandidates_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_NumberOfClinicalStageCandidates_131" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_133" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_136" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RevenuePerformanceObligationAmount" xlink:label="loc_meip_RevenuePerformanceObligationAmount_311934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_RevenuePerformanceObligationAmount_311934" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:label="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_810792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_810792" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_810786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_810786" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_810809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_810809" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_811818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_811818" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_918170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_918170" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract_311876" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract_311876" xlink:to="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_481084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" xlink:to="loc_us-gaap_TransferredOverTimeMember_481084" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311881" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311881" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcAgreementsMember" xlink:label="loc_meip_KkcAgreementsMember_311883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_KkcAgreementsMember_311883" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_311892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_HelsinnLicenseAgreementMember_311892" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_311885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" xlink:to="loc_us-gaap_Revenues_311885" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_138" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractWithCustomerAssetAndLiabilityTable" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_138" xlink:to="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xlink:to="loc_dei_LegalEntityAxis_141" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_141" xlink:to="loc_dei_EntityDomain_151" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xlink:to="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AccountsReceivableNetBeginningBalance" xlink:label="loc_meip_AccountsReceivableNetBeginningBalance_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetBeginningBalance_142" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivablesAmountsBilled" xlink:label="loc_meip_ReceivablesAmountsBilled_918157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ReceivablesAmountsBilled_918157" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ReceivablesPaymentsReceived" xlink:label="loc_meip_ReceivablesPaymentsReceived_918158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ReceivablesPaymentsReceived_918158" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AccountsReceivableNetEndingBalance" xlink:label="loc_meip_AccountsReceivableNetEndingBalance_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetEndingBalance_144" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractAssetsBillableAmounts" xlink:label="loc_meip_ContractAssetsBillableAmounts_918160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ContractAssetsBillableAmounts_918160" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ContractAssetsAmountsBilled" xlink:label="loc_meip_ContractAssetsAmountsBilled_918164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ContractAssetsAmountsBilled_918164" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_147" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerLiability_148" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerLiability_150" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_153" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_153" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_dei_LegalEntityAxis_160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_160" xlink:to="loc_dei_EntityDomain_169" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_166" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_165" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_171" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_171" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_dei_LegalEntityAxis_174" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_174" xlink:to="loc_dei_EntityDomain_180" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_175" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_175" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_176" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_182" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_478745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_478745" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_186" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_186" xlink:to="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_dei_LegalEntityAxis_193" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_193" xlink:to="loc_dei_EntityDomain_200" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_199" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_202" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_202" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_TypeOfArrangementAxis_214" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_214" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_HelsinnLicenseAgreementMember_215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_PresageLicenseAgreementMember_216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KkcAgreementsMember" xlink:label="loc_meip_KkcAgreementsMember_765471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_KkcAgreementsMember_765471" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" xlink:to="loc_us-gaap_RelatedPartyDomain_208" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PresageBiosciencesIncMember" xlink:label="loc_meip_PresageBiosciencesIncMember_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_208" xlink:to="loc_meip_PresageBiosciencesIncMember_221" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_dei_LegalEntityAxis_205" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_205" xlink:to="loc_dei_EntityDomain_204" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_KyowaKirinCoMember" xlink:label="loc_meip_KyowaKirinCoMember_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_204" xlink:to="loc_meip_KyowaKirinCoMember_218" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_209" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_209" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_210" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncrementalPaymentMember" xlink:label="loc_meip_IncrementalPaymentMember_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_IncrementalPaymentMember_223" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_srt_RangeAxis_206" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_206" xlink:to="loc_srt_RangeMember_207" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_207" xlink:to="loc_srt_MaximumMember_219" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_765476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_srt_ProductOrServiceAxis_765476" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_765477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_765476" xlink:to="loc_srt_ProductsAndServicesDomain_765477" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ExUsLicenseMember" xlink:label="loc_meip_ExUsLicenseMember_765478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_765477" xlink:to="loc_meip_ExUsLicenseMember_765478" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DevelopmentServicesMember" xlink:label="loc_meip_DevelopmentServicesMember_765483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_765477" xlink:to="loc_meip_DevelopmentServicesMember_765483" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EventAxis" xlink:label="loc_meip_EventAxis_765700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_meip_EventAxis_765700" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EventDomain" xlink:label="loc_meip_EventDomain_765702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_EventAxis_765700" xlink:to="loc_meip_EventDomain_765702" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UpdationOfInitialAssessmentMember" xlink:label="loc_meip_UpdationOfInitialAssessmentMember_765704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_EventDomain_765702" xlink:to="loc_meip_UpdationOfInitialAssessmentMember_765704" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_211" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_225" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentialMilestonePaymentsReceivable" xlink:label="loc_meip_PotentialMilestonePaymentsReceivable_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsReceivable_226" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UpFrontPayment" xlink:label="loc_meip_UpFrontPayment_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_UpFrontPayment_228" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentialMilestonePaymentsPayable" xlink:label="loc_meip_PotentialMilestonePaymentsPayable_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsPayable_233" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PaymentForLicenseAgreement" xlink:label="loc_meip_PaymentForLicenseAgreement_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PaymentForLicenseAgreement_234" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AgreementTerminationNoticePeriod" xlink:label="loc_meip_AgreementTerminationNoticePeriod_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_AgreementTerminationNoticePeriod_236" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TotalUpfrontPaymentReceivableForGrantOfRights" xlink:label="loc_meip_TotalUpfrontPaymentReceivableForGrantOfRights_765468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_TotalUpfrontPaymentReceivableForGrantOfRights_765468" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TotalTransactionPriceInRespectOfColloborationRevenue" xlink:label="loc_meip_TotalTransactionPriceInRespectOfColloborationRevenue_765470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_TotalTransactionPriceInRespectOfColloborationRevenue_765470" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ExpectedMilestonePaymentReceivable" xlink:label="loc_meip_ExpectedMilestonePaymentReceivable_765472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_ExpectedMilestonePaymentReceivable_765472" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings" xlink:label="loc_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings_765473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings_765473" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_765474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_DeferredRevenue_765474" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_765475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_765475" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_LicenseObligationAccountTransactionPriceAllocated" xlink:label="loc_meip_LicenseObligationAccountTransactionPriceAllocated_765480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_LicenseObligationAccountTransactionPriceAllocated_765480" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_765481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_765481" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ProfitsAndCostsSharingRatio" xlink:label="loc_meip_ProfitsAndCostsSharingRatio_766229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_ProfitsAndCostsSharingRatio_766229" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding" xlink:label="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_766231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding_766231" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_238" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_238" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xlink:to="loc_dei_LegalEntityAxis_239" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xlink:to="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_245" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_245" xlink:to="loc_us-gaap_StatementTable_248" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_248" xlink:to="loc_dei_LegalEntityAxis_246" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_246" xlink:to="loc_dei_EntityDomain_249" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_248" xlink:to="loc_us-gaap_StatementLineItems_247" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="loc_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability_766234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability_766234" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_252" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_478206" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_478206" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_478208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" xlink:to="loc_dei_LegalEntityAxis_478208" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_478208" xlink:to="loc_dei_EntityDomain_478209" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478207" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_478213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_478213" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_478215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_478215" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_478219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_478210" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_478219" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_478228" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_478228" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_478230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_dei_LegalEntityAxis_478230" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_478230" xlink:to="loc_dei_EntityDomain_478231" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_478234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_EmployeeStockOptionMember_478234" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_478236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_WarrantMember_478236" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_TypeOfArrangementAxis_273" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_273" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_SbioPurchaseAgreementMember" xlink:label="loc_meip_SbioPurchaseAgreementMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_SbioPurchaseAgreementMember_275" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_CydexLicenseAgreementMember" xlink:label="loc_meip_CydexLicenseAgreementMember_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_CydexLicenseAgreementMember_276" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_PresageLicenseAgreementMember_274" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_478582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_OtherCommitmentsAxis_478582" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_478583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_478582" xlink:to="loc_us-gaap_OtherCommitmentsDomain_478583" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AccruedMilestonePayments" xlink:label="loc_meip_AccruedMilestonePayments_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_AccruedMilestonePayments_284" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_MilestonePaymentsMaximumAmount" xlink:label="loc_meip_MilestonePaymentsMaximumAmount_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_MilestonePaymentsMaximumAmount_285" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_765494" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_765500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765494" xlink:to="loc_us-gaap_StatementTable_765500" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_765500" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_765503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_765502" xlink:to="loc_us-gaap_TypeOfAdoptionMember_765503" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_765505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_765503" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_765505" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_765506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_765500" xlink:to="loc_srt_StatementGeographicalAxis_765506" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_765507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_765506" xlink:to="loc_srt_SegmentGeographicalDomain_765507" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_SanDiegoCaliforniaMember" xlink:label="loc_meip_SanDiegoCaliforniaMember_765508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_765507" xlink:to="loc_meip_SanDiegoCaliforniaMember_765508" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_765501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_765500" xlink:to="loc_us-gaap_StatementLineItems_765501" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSquareFeetUnderLease" xlink:label="loc_meip_NumberOfSquareFeetUnderLease_765509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_meip_NumberOfSquareFeetUnderLease_765509" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_765511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_us-gaap_LeaseExpirationDate1_765511" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset" xlink:label="loc_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset_813724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset_813724" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_765708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765501" xlink:to="loc_us-gaap_OperatingLeaseLiability_765708" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfTotalOperatingCostsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_810839" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_810847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_810839" xlink:to="loc_us-gaap_OperatingLeaseCost_810847" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail">
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:label="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract_810870" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_810872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract_810870" xlink:to="loc_us-gaap_LeaseCostAbstract_810872" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_810873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_810872" xlink:to="loc_us-gaap_OperatingLeasePayments_810873" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_810874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_810872" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_810874" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_765726" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_765728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_765728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_765729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_765729" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_765730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_765730" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_765731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_765731" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_765732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_765732" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_810879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_810879" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_765733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_765733" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_765734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_765734" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_765735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_765735" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_765736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_OperatingLeaseLiability_765736" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_810875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_810875" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_810876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_810876" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_810877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_OperatingLeaseLiability_810877" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_765737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_765737" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_765738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_765726" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_765738" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_288" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_288" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xlink:to="loc_dei_LegalEntityAxis_289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" xlink:to="loc_us-gaap_ShortTermInvestments_293" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_295" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_295" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_dei_LegalEntityAxis_297" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_297" xlink:to="loc_dei_EntityDomain_316" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_srt_RangeAxis_298" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_298" xlink:to="loc_srt_RangeMember_299" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_299" xlink:to="loc_srt_MaximumMember_317" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_302" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AtTheMarketSaleAgreementMember" xlink:label="loc_meip_AtTheMarketSaleAgreementMember_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" xlink:to="loc_meip_AtTheMarketSaleAgreementMember_318" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember" xlink:label="loc_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember_810883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" xlink:to="loc_meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember_810883" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_478573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" xlink:to="loc_us-gaap_RelatedPartyDomain_478573" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_478574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_TypeOfArrangementAxis_478574" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_478574" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_766237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_766237" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_766238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_766237" xlink:to="loc_us-gaap_EquityComponentDomain_766238" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_766239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_766238" xlink:to="loc_us-gaap_WarrantMember_766239" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_ClassOfStockLineItems_296" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ShelfRegistrationStatementValue" xlink:label="loc_meip_ShelfRegistrationStatementValue_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_ShelfRegistrationStatementValue_315" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_312" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:label="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement_765537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement_765537" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_AggregateValueOfSecuritiesAvailableUnderAgreement" xlink:label="loc_meip_AggregateValueOfSecuritiesAvailableUnderAgreement_766236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_AggregateValueOfSecuritiesAvailableUnderAgreement_766236" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfWarrantsExercised" xlink:label="loc_meip_NumberOfWarrantsExercised_918137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfWarrantsExercised_918137" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesIssuedOnWarrantExercise" xlink:label="loc_meip_NumberOfSharesIssuedOnWarrantExercise_918138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfSharesIssuedOnWarrantExercise_918138" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_321" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_321" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_RangeAxis_323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_323" xlink:to="loc_srt_RangeMember_478618" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_478619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MaximumMember_478619" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_478620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MinimumMember_478620" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_PlanNameAxis_324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_324" xlink:to="loc_us-gaap_PlanNameDomain_325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_TwoThousandAndEightOmnibusPlanMember" xlink:label="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_325" xlink:to="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_AwardTypeAxis_322" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_EmployeeStockOptionMember_345" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_346" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_TitleOfIndividualAxis_329" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_329" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_srt_DirectorMember_347" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_EmployeesMember" xlink:label="loc_meip_EmployeesMember_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_meip_EmployeesMember_348" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_765757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_VestingAxis_765757" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_765759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_765757" xlink:to="loc_us-gaap_VestingDomain_765759" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_765760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_765759" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_765760" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesToBeReceived" xlink:label="loc_meip_NumberOfSharesToBeReceived_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_meip_NumberOfSharesToBeReceived_341" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_765779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_765779" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_765780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_765780" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_765781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_765781" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_NumberOfSharesForEachUnitOfRestrictedStock" xlink:label="loc_meip_NumberOfSharesForEachUnitOfRestrictedStock_765782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_meip_NumberOfSharesForEachUnitOfRestrictedStock_765782" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_350" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_350" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_dei_LegalEntityAxis_354" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_354" xlink:to="loc_dei_EntityDomain_359" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_352" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_352" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_353" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensation_356" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_361" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_361" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_dei_LegalEntityAxis_362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_362" xlink:to="loc_dei_EntityDomain_369" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_378" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_384" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20210331.xsd#meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_389" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_389" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_dei_LegalEntityAxis_390" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390" xlink:to="loc_dei_EntityDomain_393" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_311943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_311943" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_311944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_311943" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_311944" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g138219g0504025156354.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g138219g0504025156354.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 G # 2(  A$! Q$!_\0
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M]FU*(2VD=Q/)(UKL)81JF"H#= &YX/J* ,'[;=?\_$O_ 'T:/MMU_P _$O\
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M7_/Q+_WT:/MMU_S\2_\ ?1J"NCD73O[0B&-,^QY;[.03N/R?)YOMNQG/?VH
MP_MMU_S\2_\ ?1H^VW7_ #\2_P#?1KIK=-"9)4O#9+.8XB[1'Y XWLP3M@@*
MIQQDTZ9=#:VO#&+)06GV<IE>!Y>.=W7IM_&@#E_MMU_S\2_]]&C[;=?\_$O_
M 'T:Z.Y30GM[I8OLRSJEP8B"-K9;"#ZC@CVS4%]_9$%Q8/8O:2B&06]PK1\2
M#C]X0>O\7S#VH P_MMU_S\2_]]&C[;=?\_$O_?1K>+Z;*)GC33EN@\X@5P%B
M(#(%W=ON[L9X)S4\:^'2\J-]F!$KLC _+Q$,KS_"7+;3ZB@#FOMMU_S\2_\
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ML;^Z?RKWC[%:_P#/M#_W[%'V*U_Y]H?^_8H \'V-_=/Y4;&_NG\J]X^Q6O\
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M+9Y_AX"\$=ZZ'=+_ ,\T_P"^_P#ZU&Z7_GFG_??_ -:@#!EO-9M%5%B$H#E
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M4KEF WC+D<)D>YW<?=-=/6+XGUN70=-CN(;99GDE$>7<(B?*3EB> /EQ]2*
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MGI\IZ\]..: -6H_^7G_@']:9:7D5[$9822@. Q'7@'C\\?4&G_\ +S_P#^M
M!Y$/VC[1Y2>=MV>9M&[;G.,]<9[5DKI6ERLK"9G$^0H\P8;!8MC\\'V4>E:7
MV-/[0^V^9+YGE>5L\P[,9SG;TS[UE76A33-<[+@*C,&A3&-H+!I 3Z,1Z?G0
M!9&AV^)-\L\CR(49V89(^7T&.-@_6H_[$LV=H?M$V]4 "[AE(SO&T<=/F;KS
MQUXJM_PCLWE<76V; 4298D+L9=OTR1^5%QH%Q/&H$L40  ,,9(0@%SC)STW@
M].H[=@"W/H5C)=K<2.PD9AC<5.[A>.1_L#ISUK/U73[.*6WA+W1<1;(^043
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M$?PF:4OC1QV?#/\ SSU3_OY'_P#$T9\,_P#//5/^_D?_ ,365]FG_P">+_\
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M_P 6#T%=K7;E]*4(N4NOZ(Z8;!3)?]4_^Z:?3)?]4_\ NFO0*/ +S_D(S_\
M70_SKW]&&Q>1TKY[O/\ D(S_ /71OYU]!)#%L7]VG3^Z*B.$]AK>]Q+$^VZ6
ML2;AZBC</44WR8O^>:?]\BCR8O\ GFG_ 'R*L8[</44;AZBF^3%_SS3_ +Y%
M'DQ?\\T_[Y% #MP]11N'J*;Y,7_/-/\ OD4>3%_SS3_OD4 .W#U%&X>HIODQ
M?\\T_P"^11Y,7_/-/^^10 [</44;AZBF^3%_SS3_ +Y%'DQ?\\T_[Y% #MP]
M11N'J*;Y,7_/-/\ OD4>3%_SS3_OD4 -!'VEN1]P?S-.=(W9&<*2C;E)['!&
M?R)J,11?:&_=I]P?PCU-2>3%_P \T_[Y% %;^S;#<#]FB& 1P/7.?YG\S4,V
MBZ;-U@126#$KQG!!Q],@&K_DQ?\ /-/^^11Y,7_/-/\ OD4 5?[+T_\ Y]8?
MN;,8XQT_R:1M*TYRA:VB8H,*2,^OY]3^9JWY,7_/-/\ OD4>3%_SS3_OD4 0
M26-G*<O#&3O+Y]SU_/ I'L+*165X(R&(8\=P20?S8_F:L>3%_P \T_[Y%'DQ
M?\\T_P"^10!5&E:<!@6L(&SR^!CY?3]!^0IR6%G$[210QQR%MVY0,@X(S^I_
M,U8\F+_GFG_?(H\F+_GFG_?(H CM+>*RM4MXC\B9Y.,DDY)_$DFG9'VGJ/N?
MUIWDQ?\ /-/^^14?E1?:<>6GW/[H]: )MP]11N'J*;Y,7_/-/^^11Y,7_/-/
M^^10 [</44;AZBF^3%_SS3_OD4>3%_SS3_OD4 .W#U%&X>HIODQ?\\T_[Y%'
MDQ?\\T_[Y% #MP]11N'J*;Y,7_/-/^^11Y,7_/-/^^10 [</44;AZBF^3%_S
MS3_OD4>3%_SS3_OD4 .W#U%&X>HIODQ?\\T_[Y%'DQ?\\T_[Y% #MP]14>X?
M:>H^YZ^].\F+_GFG_?(J%D@6X^98P-G<#UH L;AZBC</45%_HW_3']*/]&_Z
M8_I0!+N'J*-P]147^C?],?TH_P!&_P"F/Z4 2[AZBC</45%_HW_3']*/]&_Z
M8_I0!+N'J*-P]147^C?],?TH_P!&_P"F/Z4 +,1Y?4?>'\Q4FX>HJO*+<IA1
M$3N'3'J*F\F+_GFG_?(H =N'J*-P]13?)B_YYI_WR*/)B_YYI_WR* ';AZBC
M</44WR8O^>:?]\BCR8O^>:?]\B@!VX>HHW#U%-\F+_GFG_?(H\F+_GFG_?(H
M =N'J*-P]13?)B_YYI_WR*/)B_YYI_WR* &PD;#R/O-_,U)N'J*ABABV']VG
MWF_A'J:D\F+_ )YI_P!\B@!VX>HHW#U%-\F+_GFG_?(H\F+_ )YI_P!\B@!V
MX>HHW#U%-\F+_GFG_?(H\F+_ )YI_P!\B@!VX>HHW#U%-\F+_GFG_?(H\F+_
M )YI_P!\B@!VX>HJ/(^TCD?</\Z=Y,7_ #S3_OD5'Y47VD?NT^X?X1ZT 3;A
MZBC</44WR8O^>:?]\BCR8O\ GFG_ 'R* ';AZBC</44WR8O^>:?]\BCR8O\
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MFN],>]T?46:*W#!UM(UE=WP,#GH!G)]JM:?X>_L]X=NJ:C-#$NQ8)9%,97&
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MSSSZ\;F';$ZJZ[G&U"J9#8'N5.T=>:C3^V7:*61)RVS;M8+M)#YW$8&#C^5
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M"0RW-O&(Y6B)8MR5QGH#QS62EQ<RV-JB3>2JVXAVAB/-!<MS^=;@U=L3).@
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MB^DNVFF$CR&0XQ@'<A';MLQ_P(U2/A>TBL"^HW4=N?M$DA(8&-4?CR\L.0%
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M^NDO\EJZ<5*23)D[*YV/_"S_  9_T&X_^_,G_P 31_PL_P &?]!N/_OS)_\
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M-Q_]^9/_ (FC_A9_@S_H-Q_]^9/_ (FOF*BCZM'N'M9'T[_PL_P9_P!!N/\
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M 'CM&W!P*8GA34(R'COO*F_YZ+*YP2)0Q /'\4?_ 'S6AOUDSQ%S)L\X,0B
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M_P!!%;U97AJRFTWPSIMC<;?.MK=8I-IR-RC!P?PK5KSI;G2M@HHHI#"BBB@
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&@HHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g138219g0504025156572.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g138219g0504025156572.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R 58# 2(  A$! Q$!_\0
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M?"GFR3Q.,-(H*XSU.<?C77>%O$/_  DVD/??8I;-X[B2WD@D8,RLC;3R..M
M&Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !DURXOM0CDT:=TBU&""-8X#E$8L&5N?OG Q]#0![E17%_\ "?3@?\BIKO\
MX#__ %ZR_#_Q)OK_ $I9[CPUJTTADD7?!;_)@.0!UZ@#!]Z /2**\VNOB5?1
M>(["S3PUJRP2PRN\;6_[QBNW!7GH,G/U%&G?$J^N-9U6WD\-:J\5O)&(DCM_
MG0%,G?SU)Z>U 'I-%>;#XE7W_"4FR_X1K5_L_P!C$OE?9_WN[?C=U^[CCZUK
M?\)[/_T*FN_^ _\ ]>@#LZ*XS_A/9_\ H5-=_P# ?_Z]'_">S_\ 0J:[_P"
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M[;G"X9@,9.:N=*JZ9_R#H?H?YF@"W1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\OE\$ZQI_CB;7+'6-,AEEN9IXTG0[V20*I5CW V\>E>
MH=J\F^(4%C_PF=I+>7MU9QRP"!I(X_,#*<@@ '*GGKCTH ]77.!GKWK*_M^U
M\B\F*R!;9=QX^^,D9'X@BM2, 1J%)("C!/6L]-#MHQ<;'D'G=>?NC).!^))H
M ?)K%I;VD$]PQB$PRH(S_*JVF:M9?V? !*3D<?*>[8_G6C;6<-K;1VZ*"B#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5 ;.W99%,,9$ARXV_>^M3&LV#6X9Q=$1R 6Z&3IG>H)&
M1^*F@#02-(D6-%"JHP !P*KZ9_R#H?H?YFHI-8M(+2WN9F=$G4,GR%CR,\XI
M^D.LFE6[H<JRY!QVS0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J6HZI::5 LUY)L1W$:X4L68]@!5VN?\2 ?;=!_P"PDO\ Z ] #_\ A+M)
M_OW'_@,_^%'_  EVD_W[C_P&?_"H]>\0#1]1TNQ2WADDOV=5:641JNT GGU.
M>!5.Z\<Z6NU+(?:)3<1Q8*[0RM)Y9=3_ ! -Q0!H?\)=I/\ ?N/_  &?_"C_
M (2[2?[]Q_X#/_A6;I_CW1[BPM9KO,$TT(D9%0LJ$AB%)_O$*2!5V#QCX?N;
ME;>&\C:1I$CQMZ%H_,'/IMYS0!+_ ,)=I/\ ?N/_  &?_"C_ (2[2?[]Q_X#
M/_A1/XIT6WEFC>X7=%((W*KD;C&9!SW^52:GT?7=-UV.9[%BWE%=ZNA4@,H9
M3@]B#D4 0?\ "7:3_?N/_ 9_\*/^$NTG^_<?^ S_ .%5[_QGH>FZA-97#R>?
M"VUPD)8;MF_&?7;S2-XW\-I<M"U]&"L7FEMORXV;\9]=O.* +/\ PEVD_P!^
MX_\  9_\*/\ A+M)_OW'_@,_^%9.G^.K6_U":$6ICACDE4;E(D8)&CY"X_VZ
MN)XW\/R&VVSMB< J?*.%R_E_,>WS\4 6O^$NTG^_<?\ @,_^%'_"7:3_ '[C
M_P !G_PJ'5O%%GH^K2VMU&%MK>R^V7$^,[ 7V* !U).?RIK^--"B,HF>2)HX
MEF*O"0Q4L%&!UZL!^- %C_A+M)_OW'_@,_\ A1_PEVD_W[C_ ,!G_P *J_\
M";Z!YEK'YKF2Y?RU40G*-O*8;T^8$?A4$GCK2)(5FL&6YB2ZAAG.,;4E8HL@
M]1N_K0!H_P#"7:3_ '[C_P !G_PH_P"$NTG^_<?^ S_X5MA%_NC\J-B_W1^5
M &)_PEVD_P!^X_\  9_\*!XNT?<H::5-S!0SP.HR3@<D>I%;>Q?[H_*L+QBB
MCPQ<X _UD/;_ *:I0!OT444 %%%% "&J$.D6MN\[('S-D,"W '/ ]!R36A4
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MNFW4\-\[R1Q,R+Y0.2!P*DM[>_EMHI'U!PSHK,/+7@D4 :M%9_V.]_Z"+_\
M?M:/L=[_ -!%_P#OVM &AFBL*]&IV]Y811WKLD\I20^4#M 4G\.15W['>_\
M01?_ +]K0!H45G_8[W_H(O\ ]^UH^QWO_01?_OVM &A16';KJ<NIWMN]ZXBA
M$9C;RA\VX$FKGV.]_P"@B_\ W[6@#0HK/^QWO_01?_OVM!M+X G^T7Z?\\UH
M T**P]*74[S2[>XGO7CED3++Y0&#5S['>_\ 01?_ +]K0!H45G_8[W_H(O\
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MXD_Z MK_ .!?_P!C6A]CO?\ H(O_ -^UH^QWO_01?_OVM &?_:'B3_H"VO\
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M$5&2:2+"G(PK$ _I4TUI;W+Q/-"DC1'=&67)4^U2*BH"%4+DDG [F@!U%%%
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; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g138219g0504025156728.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g138219g0504025156728.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #G 4X# 2(  A$! Q$!_\0
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MI26\MY+;JTLEN<QN2/O+['K^-:U')$.5%"/2Q'(K_;KYMISM:8D'ZU#X<_Y
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MZ?<:/_:\-Y%)IYB,WVA&RFP#).?;!_*L6/XB>#I0"GB33CF18A^^'WF&1_\
MKZ5@Z5X U*V\!P:7-J5Q!>P6]W$+:VN,6LQE:0KY@*Y/WQTQ61?_  SU>XT:
M[MHDL!-+X>LM-0ER )HG#/SM^Z<=>^* /13XHT,:U_8YU.W_ +0W;/(W<[L;
MMN>F['.WKCM567QIHS6336%W'?SFWFGBMH&_>2B+.\ 'H01CG'-<G=^#?$]W
MXMM;^XEMI[2TUE;Z(BY9 (-FW8(0NW>,\N22?:H])\-:SX5UC7?%.H1Z>T6J
M6\\U_#;@[K8KN:,1G&7W#[W3+<\T >CZ9J-OJ^EVNHVC[[:ZB6:)O56&1_.K
M5<WX TRXT?P!H=A=J5N(K1/,4]5)&2I^F<?A724 %%%% !65X;_Y <7_ %TE
M_P#1C5JUE>&_^0'%_P!=)?\ T8U #O#G_(L:5_UYQ?\ H KB_%/C?Q%X?\03
M6*P:-Y3*DEHDOG^;<AF(V(%4@N,<C/<5VGAS_D6-*_Z\XO\ T 5YWX_\1:AX
M?\8A]/O[RV66VB$PQ!Y60S[<>9DEB-W"CG'&30!ZO11VKFH(=3?2+V&9;LSO
M@1DRE2'P S @Y"[B2!GH* -S4/\ D&W7_7)OY57U(W.(?L]TT'!W8C5L]/6H
MM6L[IK)S!J4L,<<!#)Y:/OP.I+#/-6+[I%]#4RV$]C-SJ7_05?\ [\)_A1G4
MO^@J_P#WX3_"IJ*RL00YU+_H*O\ ]^$_PHSJ7_05?_OPG^%3446 C"ZH1D:G
M(1_U[I_A3<ZE_P!!5_\ OPG^%<MXBT33-6\4:99-91_:9]UW=W )#^3%M 4$
M'C<Q4?0-77]Z=@(<ZE_T%7_[\)_A1G4O^@J__?A/\*FHI6 ASJ7_ $%7_P"_
M"?X49U+_ *"K_P#?A/\ "IJ*+ 0YU+_H*O\ ]^$_PHSJ7_05?_OPG^%3446
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M=CJ_^)E_T%7_ ._"?X4F=2_Z"K_]^$_PK"T+5)!X+TJ[BL+^]+1!/+CD663
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M;39V:%D(VQ,5<!]P=_; ((JRCVH=***Y7[%K!TF>'_2%D:1&;+[F? &_;\W
M9N1R/PZ4 =#J'_(-NO\ KDW\JJZK<1VXAWB0[@<;(V?T] :AU"SNYM+\QK^X
MMF2VQ)%'L96;'.2RD^W6M@=!2:NA/4YO^T8/[MQ_X#2?_$T?VC!_=N/_  &D
M_P#B:Z6BHY'W%RLYK^T8/[MQ_P" TG_Q-']HP?W;C_P&D_\ B:Z6BCD?<.5G
M+?:K+[1]H\B7S]GE^9]E?=MSG;G;TSSBI/[1@_NW'_@-)_\ $UTM%'(^X<K.
M:_M&#^[<?^ TG_Q-']HP?W;C_P !I/\ XFNEHHY'W#E9S7]HP?W;C_P&D_\
MB:/[1@_NW'_@-)_\372T4<C[ARLYK^T8/[MQ_P" TG_Q-']HP?W;C_P&D_\
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_D&W/\ UR;^56!]T?2LO6M+L[RVEN)XF:2.)MI$C*!CGH" :U!T% "T444
M%>=:]!J_C#Q!X@T?3M3O[*RL]/%N0B((IKEU9BI+*21L9,XQUKK-;\4Z1X>E
MLXM1NXXGNITA12Z@KNSAF!(PO')K(\ M!<'Q)>02K,+C6YSYJOO#!0BK@],
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M)&I!C@\G8O)Z9CS5'6?AYK=[K^D7D7BO49(K5V+R3>3YD><?<Q'@].]>CT4
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M (U4T_3)!;R?;);HR>=*5S<N?DWG9T/]W%:]9&@/?O;3#4 _FB3JP('09"Y
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M+G_P(?\ QJGH[Z@U]J(O!)Y0E_=;AQC<W3@?P[>F1[YR!L4 4_[-@_YZ7/\
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M&&VC>%X&5#9Q0!>CL8HI%=7G)'0-.[#\B:I^&_\ D!Q?]=)?_1C5JUE>&_\
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M\:/["A_Y_=2_\#9/\:** #^PH?\ G]U+_P #9/\ &C^PH?\ G]U+_P #9/\
M&BB@ _L*'_G]U+_P-D_QH_L*'_G]U+_P-D_QHHH /["A_P"?W4O_  -D_P :
M/["A_P"?W4O_  -D_P :** #^PH?^?W4O_ V3_&C^PH?^?W4O_ V3_&BB@ _
ML*'_ )_=2_\  V3_ !H_L*'_ )_=2_\  V3_ !HHH /["A_Y_=2_\#9/\:/[
M"A_Y_=2_\#9/\:** #^PH?\ G]U+_P #9/\ &C^PH?\ G]U+_P #9/\ &BB@
F _L*'_G]U+_P-D_QJ[9VD-A:I;0!A&F<;F+'DDG)/7DFBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945747970888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEIP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEI Pharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001262104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,591,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945747984680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,745<span></span>
</td>
<td class="nump">$ 12,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">154,879<span></span>
</td>
<td class="nump">170,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and short-term investments</a></td>
<td class="nump">164,624<span></span>
</td>
<td class="nump">182,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ReceivableForForeignTaxWithholding', window );">Receivable for foreign tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,937<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">176,561<span></span>
</td>
<td class="nump">208,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">7,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">186,122<span></span>
</td>
<td class="nump">209,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,762<span></span>
</td>
<td class="nump">6,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">19,143<span></span>
</td>
<td class="nump">14,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,376<span></span>
</td>
<td class="nump">23,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">70,734<span></span>
</td>
<td class="nump">67,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term</a></td>
<td class="nump">7,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">29,442<span></span>
</td>
<td class="nump">40,483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">141,160<span></span>
</td>
<td class="nump">131,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 100 shares authorized; none outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00000002 par value; 226,000 shares authorized; 112,528 and 111,514 shares issued and outstanding at December 31, 2020 and June 30, 2020, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">367,055<span></span>
</td>
<td class="nump">355,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(322,093)<span></span>
</td>
<td class="num">(277,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">44,962<span></span>
</td>
<td class="nump">78,218<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 186,122<span></span>
</td>
<td class="nump">$ 209,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ReceivableForForeignTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable for foreign tax withholding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ReceivableForForeignTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945747974648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00000002<span></span>
</td>
<td class="nump">$ 0.00000002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">226,000<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">112,592<span></span>
</td>
<td class="nump">111,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">112,592<span></span>
</td>
<td class="nump">111,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945746426792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 2,418<span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="nump">$ 3,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,884<span></span>
</td>
<td class="nump">8,963<span></span>
</td>
<td class="nump">53,104<span></span>
</td>
<td class="nump">26,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,215<span></span>
</td>
<td class="nump">3,864<span></span>
</td>
<td class="nump">17,780<span></span>
</td>
<td class="nump">12,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,504<span></span>
</td>
<td class="nump">13,687<span></span>
</td>
<td class="nump">72,292<span></span>
</td>
<td class="nump">40,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,086)<span></span>
</td>
<td class="num">(12,443)<span></span>
</td>
<td class="num">(56,873)<span></span>
</td>
<td class="num">(37,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value of warrant liability</a></td>
<td class="num">(9,272)<span></span>
</td>
<td class="nump">7,732<span></span>
</td>
<td class="nump">11,035<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividend income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,313)<span></span>
</td>
<td class="num">(4,329)<span></span>
</td>
<td class="num">(44,859)<span></span>
</td>
<td class="num">(27,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Basic</a></td>
<td class="num">(31,313)<span></span>
</td>
<td class="num">(4,329)<span></span>
</td>
<td class="num">(44,859)<span></span>
</td>
<td class="num">(27,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Diluted</a></td>
<td class="num">$ (31,313)<span></span>
</td>
<td class="num">$ (4,329)<span></span>
</td>
<td class="num">$ (65,166)<span></span>
</td>
<td class="num">$ (27,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">112,557<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">112,505<span></span>
</td>
<td class="nump">85,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">112,557<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">113,991<span></span>
</td>
<td class="nump">85,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945746176968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 47,930<span></span>
</td>
<td class="nump">$ 73,545<span></span>
</td>
<td class="nump">$ 279,148<span></span>
</td>
<td class="num">$ (231,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">47,280<span></span>
</td>
<td class="nump">73,655<span></span>
</td>
<td class="nump">281,492<span></span>
</td>
<td class="num">(234,212)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2019</a></td>
<td class="nump">47,930<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
<td class="nump">279,148<span></span>
</td>
<td class="num">(231,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">74,498<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">333,256<span></span>
</td>
<td class="num">(258,758)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Sep. 30, 2019</a></td>
<td class="nump">47,280<span></span>
</td>
<td class="nump">73,655<span></span>
</td>
<td class="nump">281,492<span></span>
</td>
<td class="num">(234,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">48,451<span></span>
</td>
<td class="nump">32,344<span></span>
</td>
<td class="nump">48,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">77,285<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">331,714<span></span>
</td>
<td class="num">(254,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">74,498<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">333,256<span></span>
</td>
<td class="num">(258,758)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">78,218<span></span>
</td>
<td class="nump">111,514<span></span>
</td>
<td class="nump">355,452<span></span>
</td>
<td class="num">(277,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">3,136<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">82,328<span></span>
</td>
<td class="nump">112,522<span></span>
</td>
<td class="nump">361,654<span></span>
</td>
<td class="num">(279,326)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">78,218<span></span>
</td>
<td class="nump">111,514<span></span>
</td>
<td class="nump">355,452<span></span>
</td>
<td class="num">(277,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">44,962<span></span>
</td>
<td class="nump">112,592<span></span>
</td>
<td class="nump">367,055<span></span>
</td>
<td class="num">(322,093)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Sep. 30, 2020</a></td>
<td class="nump">82,328<span></span>
</td>
<td class="nump">112,522<span></span>
</td>
<td class="nump">361,654<span></span>
</td>
<td class="num">(279,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">73,498<span></span>
</td>
<td class="nump">112,528<span></span>
</td>
<td class="nump">364,278<span></span>
</td>
<td class="num">(290,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_Stockissuedduringperiodvaluestockwarrantsexercised', window );">Exercise of warrants</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 44,962<span></span>
</td>
<td class="nump">$ 112,592<span></span>
</td>
<td class="nump">$ 367,055<span></span>
</td>
<td class="num">$ (322,093)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_Stockissuedduringperiodvaluestockwarrantsexercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_Stockissuedduringperiodvaluestockwarrantsexercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945747864248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (44,859)<span></span>
</td>
<td class="num">$ (27,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value of warrant liability</a></td>
<td class="num">(11,035)<span></span>
</td>
<td class="num">(8,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">8,196<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding', window );">Receivable for foreign tax withholding</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,343)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">3,134<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent', window );">Operating lease liability</a></td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,707)<span></span>
</td>
<td class="num">(34,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(325,162)<span></span>
</td>
<td class="num">(90,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">340,582<span></span>
</td>
<td class="nump">69,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">14,720<span></span>
</td>
<td class="num">(21,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">3,136<span></span>
</td>
<td class="nump">48,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ProceedsFromPreviouslyIssuedCommonStock', window );">Collection of common stock proceeds receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,401<span></span>
</td>
<td class="nump">53,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(2,586)<span></span>
</td>
<td class="num">(2,152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">12,331<span></span>
</td>
<td class="nump">9,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">9,745<span></span>
</td>
<td class="nump">7,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">8,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_WarrantsIssuedPursuantToCashlessExercise', window );">Warrants issued pursuant to cashless exercise</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase or Decrease in Receivable for foreign tax withholding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ProceedsFromPreviouslyIssuedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Previously Issued Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ProceedsFromPreviouslyIssuedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_WarrantsIssuedPursuantToCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued pursuant to cashless exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_WarrantsIssuedPursuantToCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945751940952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1. The Company and Summary of Significant Accounting Policies </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Company </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage assets, including zandelisib (formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-401),</div> currently in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) to support accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &#8220;MEIP&#8221;. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clinical Development Programs </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="text-align:left;;vertical-align:top;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Zandelisib (formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-401),</div> an oral phosphatidylinositol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-kinase</div> (&#8220;PI3K&#8221;) delta inhibitor; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="text-align:left;;vertical-align:top;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Voruciclib, an oral cyclin-dependent kinase (&#8220;CDK&#8221;) inhibitor; </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="text-align:left;;vertical-align:top;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-344,</div> a mitochondrial inhibitor targeting the oxidative phosphorylation (&#8220;OXPHOS&#8221;) complex; and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="text-align:left;;vertical-align:top;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pracinostat, an oral histone deacetylase (&#8220;HDAC&#8221;) inhibitor. </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials. The commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side effects or are less expensive than our drug candidates. We will need substantial additional funds to progress the clinical trial programs for the drug candidates zandelisib, voruciclib and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-344,</div> and to develop new compounds. The actual amount of funds that will be needed will depend upon a number of factors, some of which are beyond our control. Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have accumulated losses of $322.1&#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of March&#160;31, 2021, we had $164.6&#160;million in cash and cash equivalents and short-term investments. We believe that these resources will be sufficient to meet our obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements. Our current business operations are focused on continuing the clinical development of our drug candidates. Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. Our research and development expenses are expected to increase in the foreseeable future. We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&#160;30, 2020, included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (&#8220;2020 Annual Report&#8221;) filed with the Securities and Exchange Commission on September&#160;9, 2020. Interim results are not necessarily indicative of results for a full year. </div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">ASC Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;) </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identify the distinct performance obligations &#8211; or accounting units &#8211; within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Payments received under commercial arrangements, such as licensing technology rights, may include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop estimates of the stand-alone selling price for each distinct performance obligation. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the case of a license that is a distinct performance obligation, we recognize revenue allocated to the license from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we use judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &#8220;input method&#8221; under Topic 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&#8217; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&#160;when the related sales occur or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based or usage-based royalty revenue from license agreements<div style="display:inline;">.</div></div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognized revenue associated with the following license agreements (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:63%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">KKC License Agreements</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;2,321</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">812</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;14,979</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;2,282</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Helsinn License Agreement</div></div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">97</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">432</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">440</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,127</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); padding: 0px;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2,418</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;1,244</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">15,419</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgb(204, 238, 255); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">3,409</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Timing of Revenue Recognition:</div></div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services performed over time</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;1,244</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2,418</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;1,244</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">15,419</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;">&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td colspan="2" style="background-color: rgba(255, 255, 255, 0); text-align: right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">3,409</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The KKC Commercialization Agreement and KKC Japan License Agreement (Note 3) include other distinct performance obligations that will be satisfied over time, and accordingly we recognized $2.3&#160;million and $0.8&#160;million related to our progress toward satisfying those obligations during the three months ended March&#160;31, 2021 and 2020, respectively, and $15.0&#160;million and $2.3&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the characteristics of the Helsinn License Agreement (Note 3), control of the remaining deliverables occurs over time and therefore we recognize revenue based on the extent of progress towards completion of the performance obligations. Accordingly, we recognized $0.1&#160;million and $0.4&#160;million related to our progress toward satisfying those obligations during the three months ended March&#160;31, 2021 and 2020, respectively, and $0.4&#160;million and $1.1&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contract Balances </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables and contract assets are included in our balance sheet in &#8220;Prepaid expenses and other current assets&#8221;, and contract liabilities are included in &#8220;Deferred revenue&#8221; and &#8220;Deferred revenue, long-term&#8221;. The following table presents changes in contract assets and contract liabilities during the nine months ended March&#160;31, 2021 and 2020 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width: 87%;"></td><td style="width: 1%;;vertical-align:bottom;"></td><td style="width: 0.8%;"></td><td style="width: 0.5%;"></td><td style="width: 3.6%;"></td><td style="width: 0.8%;;vertical-align:bottom;"></td><td style="width: 1%;"></td><td style="width: 0.8%;"></td><td style="width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables, beginning of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">2,605</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts billed</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">15,744</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">1,088</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments received</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(18,349</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">)&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(1,014</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables, end of period</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">74</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, beginning of period</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">511</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Billable amounts</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">22,841</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">930</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts billed</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">(15,744</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">(1,088</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, end of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">7,432</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">353</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities, beginning of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">82,497</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">7,771</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr><td style="width: 87%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Net change<br/></div></td><td style="width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 0.5%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">7,380</div></td><td style="white-space: nowrap; width: 3.6%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 1%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">(2,479</div></td><td style="white-space: nowrap; width: 0.5%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">)</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities, end of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">89,877</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">5,292</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div>   <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets), which are classified as &#8220;prepaid expenses and other current assets&#8221; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC Agreements and Helsinn License Agreement<div style="display:inline;">.</div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of&#160;March 31, 2021, we had $7.4&#160;million&#160;of contract assets related to our remaining performance obligations under the KKC&#160;Commercialization&#160;Agreement and no contract assets related to the Helsinn License Agreement as the remaining performance obligations have been completed. During the nine months ended March&#160;31, 2021, contract assets increased by $22.8&#160;million, primarily due the recognition of revenue related to the satisfaction or partial satisfaction of performance obligations for which we had not yet billed KKC or Helsinn, partially offset by billings of $15.7&#160;million to KKC and Helsinn. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of&#160;March 31, 2021, we had $89.9&#160;million&#160;of deferred revenue associated with our remaining performance obligations under the KKC&#160;Commercialization&#160;Agreement, of which $64.5&#160;million relates to the U.S. License which is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, and $25.4&#160;million relates to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> license and development services performance obligations which are under the scope of Topic 606. For the three and nine months ended March&#160;31, 2021, we recognized revenue of $2.4&#160;million and $15.4&#160;million, respectively, that was included in the contract liabilities balance at June&#160;30, 2020 related to performance obligations under ASC 606. In addition, as a result of a change in estimated cost of completion related to our remaining performance obligations, we <div style="font-size: 10pt; font-family: &quot;times new roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">decreased<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>deferred revenue by $2.1&#160;million. To date we have not recognized any amounts related to units of account under Topic 808. For the three and nine months ended March&#160;31, 2020, we recognized revenue of $0.8&#160;million and $2.6&#160;million, respectively, that was included in the contract liabilities balance at June&#160;30, 2019 related to performance obligations under ASC 606 under the KKC Japan License Agreement and Helsinn License Agreement which are described in Note 3. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenues from Collaborators </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We earn revenue in connection with collaboration agreements, which are described in Note 3, License Agreements, and Note 4, BeiGene Collaboration. </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, we assess whether the collaboration arrangements are within the scope of ASC Topic 808, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Collaborative Arrangements</div> (&#8220;Topic 808&#8221;), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determine which units of account within the arrangement are within the scope of Topic 808 and which elements are within the scope of Topic 606. For units of account within collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that are accounted for pursuant to Topic 606, we recognize revenue as discussed above. Consideration received that does not meet the requirements to satisfy Topic 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term or long-term deferred revenue based on our best estimate of when such amounts will be recognized. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cost of Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations associated with the Helsinn License Agreement. </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-based Compensation </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&#8217;s historical price volatility. The stock&#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&#8220;RSU&#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of March&#160;31, 2021 and 2020, we have established a valuation allowance to fully reserve our net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in our ownership may limit the amount of net operating loss carryforwards that can be utilized in the future to offset taxable income. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes in our unrecognized tax benefits since June&#160;30, 2020, and, as such, the disclosures included in our 2020 Annual Report continue to be relevant for the nine months ended March&#160;31, 2021. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effective July&#160;1, 2019, we adopted FASB ASC Topic 842, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases</div> (&#8220;ASC 842&#8221;), using a modified retrospective basis method under which prior comparative periods are not restated. This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) asset representing our right to use the underlying asset for the lease term. At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement. A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration. Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on our Condensed Balance Sheet as ROU assets and lease liabilities. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. Certain adjustments to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset may be required for items such as initial direct costs paid or incentives received. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined based on the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The interest rate implicit in lease contracts to calculate the present value is typically not readily determinable. As such, significant management judgment is required to estimate the incremental borrowing rate.&#160;&#160;&#160;&#160; </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Rent expense for operating leases is recognized on a straight-line basis over the lease term based on the total lease payments. We have elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for our real estate leases. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945749795352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Fair Value Measurements </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value is as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:96%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:14%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:1%;"></td><td style="font-family: &quot;times new roman&quot;;;width:85%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&#160;&#8211;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -2em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs such as quoted prices in active markets for identical assets or liabilities.</div></div></td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;"></td><td colspan="2" style="font-family: &quot;times new roman&quot;;;height:8;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2 &#8211;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -2em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></div></td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;"></td><td colspan="2" style="font-family: &quot;times new roman&quot;;;height:8;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3 &#8211;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -2em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(29,442</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(40,483</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(29,442</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(40,483</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash equivalents, where applicable, and short-term investments are classified as Level&#160;1 as defined by the fair value hierarchy. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2018, we issued warrants in connection with our private placement of shares of common stock. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet.&#160;We recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and are required to revalue the warrants at each reporting date with any changes in fair value recorded on our Condensed Statement of Operations. The valuation of the warrants is considered under Level&#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable.&#160;Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in the fair value of the&#160;Level 3 warrant liability is reflected in the Condensed Statement of Operations for the three and nine months ended March&#160;31, 2021 and 2020, respectively. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To calculate the fair value of the warrant liability, the following assumptions were used: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:75%;"></td><td style="vertical-align:bottom;;width:10%;"></td><td style="width: 17pt;"></td><td></td><td></td><td style="width: 17pt;"></td><td style="vertical-align:bottom;;width:9%;"></td><td style="width: 14pt;"></td><td></td><td></td><td style="width: 14pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.2</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.1</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">82.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">77.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Black-Scholes Fair Value</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.83</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.52</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of changes in the estimated fair value of our Level&#160;3 warrant liability for the nine months ended March&#160;31, 2021 and 2020 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:92%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 20pt;"></td><td></td><td></td><td style="width: 20pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 20pt;"></td><td></td><td></td><td style="width: 20pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;of&#160;Warrants&#160;Using&#160;Significant<br/>Unobservable&#160;Inputs&#160;(Level&#160;3)</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance at July&#160;1,</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(40,483</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,613</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of derivative liability to equity upon exercise of warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in estimated fair value of liability classified warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,035</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">830</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at March&#160;31,</div></div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(29,442</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(16,783</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753619960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 3. License Agreements </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">KKC License, Development and Commercialization Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2020, we entered into the License, Development and Commercialization Agreement (the &#8220;KKC Commercialization Agreement&#8221;) with Kyowa Kirin Company (&#8220;KKC&#8221;). Under the agreement, we granted to KKC a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-exclusive,</div> sublicensable, payment-bearing license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the &#8220;U.S. License&#8221;), and an exclusive (subject to certain retained rights to perform obligations under the KKC Commercialization Agreement), sublicensable, payment-bearing, license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the United States (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Ex-U.S.&#8221;)</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Ex-U.S.</div> license&#8221;). KKC granted to us a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-exclusive,</div> sublicensable, license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-exclusive,</div> sublicensable, royalty-free, fully paid license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> controlled by KKC to perform our obligations in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> under the KKC Commercialization Agreement. KKC paid us an initial payment of $100&#160;million in May 2020. Of the $100&#160;million paid by KKC, $20.4&#160;million was remitted by KKC to the Japanese taxing authorities as a result of the U.S. Internal Revenue Service being closed due to the COVID pandemic, and therefore being unable to provide necessary documentation to support an exemption from the required foreign withholding. We received the amount remitted to the Japanese taxing authorities in October 2020. Additionally, we may earn up to approximately $582.5&#160;million in potential development, regulatory and commercialization milestone payments, plus royalties on net sales of zandelisib in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.,</div> which are tiered beginning in the teens. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">KKC will be responsible for the development and commercialization of zandelisib in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> and, subject to certain exceptions, will be solely responsible for all costs related thereto. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promote</div> zandelisib with KKC in the U.S., with the Company recording all revenue from U.S. sales. We will share U.S. profits and costs (including development costs) on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50-50</div> basis with KKC. We will also provide to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.,</div> with the understanding that KKC will assume responsibility for manufacturing for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> as soon as practicable. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We assessed the KKC Commercialization Agreement in accordance with Topic 808 and Topic 606 and determined that our obligations comprise the U.S. License, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> License, and development services (the &#8220;Development Services&#8221;). We determined that the KKC Commercialization Agreement is a collaborative arrangement in accordance with Topic 808 that contains multiple units of account, as we and KKC are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The U.S. License is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, while the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> License and Development Services performance obligations are under the scope of Topic 606. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We determined, at the time of our initial assessment, that the total transaction price of $191.5&#160;million is comprised of the upfront payment of $100.0&#160;million, expected milestone payments of $20.0&#160;million, estimated development cost-sharing of $66.3&#160;million, and deferred revenue of $5.2&#160;million from the KKC Japan License Agreement (as defined below). During the nine months ended March&#160;31, 2021, we updated our initial assessment to reflect estimated development cost-sharing of $94.9&#160;million. We included the amount of estimated variable consideration that is not constrained for development cost-sharing in the transaction price. Any variable consideration related to sales-based royalties and commercial milestones related to licenses of intellectual property will be determined when the sale or usage occurs, and is therefore excluded from the transaction price. In addition, we are eligible to receive future development and regulatory milestones upon the achievement of certain criteria; however, these amounts are excluded from variable consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the estimated variable consideration included in the transaction price and any related constraints at the end of each reporting period. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We allocated the transaction price to each unit of account. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations are allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed the estimated stand-alone selling price for the licenses using the risk-adjusted net present values of estimated cash flows, and the estimated stand-alone selling price of the development services performance obligations by estimating costs to be incurred, and an appropriate margin, using an income approach. </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We determined that control of the U.S. License and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> License were transferred to KKC during the year ended June&#160;30, 2020, and recognized revenue of $21.0&#160;million related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> License. The $64.5&#160;million transaction price allocated to the U.S. License obligation accounted for under Topic 808 is recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> deferred revenue and will begin to be recognized upon future commercialization as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-ASC</div> 606 revenue. As of March&#160;31, 2021 and June&#160;30, 2020, we recorded deferred revenue of $25.4&#160;million and $18.1&#160;million, respectively, for the transaction price allocated to the Development Services performance obligations and are recognizing this revenue based on the proportional performance of these development activities, which we expect to recognize through fiscal year 2026. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">KKC Japan License Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2018, we, as licensor, entered into a license agreement with KKC for zandelisib (&#8220;the KKC Japan License Agreement&#8221;). Under the terms of the KKC Japan License Agreement, KKC was granted the exclusive right to develop and commercialize zandelisib in Japan. We also granted KKC the right to purchase supply of zandelisib for commercial requirements at cost plus a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-negotiated</div> percentage, as well as manufacturing rights in Japan. In return, we received an upfront payment of $10.0&#160;million and were eligible to receive additional development and commercialization milestones, as well as royalties on net sales of zandelisib in Japan. In April 2020, we and KKC agreed to terminate the KKC Japan License Agreement. The KKC Japan License Agreement was replaced with the KKC Commercialization Agreement. Pursuant to the terms of the KKC Commercialization Agreement, we agreed to collaborate with KKC on the development, manufacturing and commercialization of zandelisib in Japan. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We assessed the KKC Japan License Agreement in accordance with ASC 606 and determined that our performance obligations comprised the license, research and development obligations, and our obligation to provide clinical trial materials to KKC. We determined that the transaction price amounted to the upfront payment of $10.0&#160;million. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We determined that control of the license was transferred to KKC during the year ended June&#160;30, 2019. Revenue allocated to the research and development obligations was recognized based on the proportional performance of these research and development activities. Revenue allocated to providing clinical trial materials was recognized upon delivery. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Helsinn License Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation (&#8220;Helsinn&#8221;) for pracinostat in acute myeloid leukemia (&#8220;AML&#8221;), myelodysplastic syndrome (&#8220;MDS&#8221;) and other potential indications (the &#8220;Helsinn License Agreement&#8221;). Under the terms of the agreement, Helsinn was granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. As compensation for such grant of rights, we received payments of $20.0&#160;million. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We determined that the agreement contains multiple performance obligations for purposes of revenue recognition. Revenue related to the research and development elements of the arrangement is recognized based on the extent of progress toward completion of each performance obligation. Revenue is recognized on a gross basis as we are the primary obligor and have discretion in supplier selection. During the nine months ended March&#160;31, 2021, our only remaining performance obligation under the agreement was the conduct of a Phase 2 dose-optimization study of pracinostat in combination with azacitidine in patients with high and very high risk MDS who are previously untreated with hypomethylating agents (the &#8220;POC study&#8221;), for which Helsinn has agreed to share third-party expenses. As of March&#160;31, 2021, our performance obligations related to the Helsinn License Agreement have been met, and no future revenue or costs of revenue will be recognized. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Presage License Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2017, we entered into a license agreement with Presage Biosciences, Inc. (&#8220;Presage&#8221;). Under the terms of such license agreement (the &#8220;Presage License Agreement&#8221;), Presage granted to us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid $2.9&#160;million. With respect to the first indication, an incremental $2.0&#160;million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9&#160;million prior to receipt of marketing approval of the first indication in the U.S., E.U. or Japan. Additional potential payments of up to $179&#160;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product development progresses) of amounts received from such sublicensees. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">CyDex License Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are party to a license agreement with CyDex Pharmaceuticals, Inc. (&#8220;CyDex&#8221;). Under the license agreement, CyDex granted to us an exclusive, nontransferable license to intellectual property rights relating to Captisol<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> for use with our isoflavone-based drug compounds (currently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-344).</div> We agreed to pay to CyDex a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may terminate both the license agreement and the supply agreement at any time upon 90 days&#8217; prior written notice. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753432776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BeiGene Collaboration<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">BeiGene Collaboration</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 4. BeiGene Collaboration </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (&#8220;BeiGene&#8221;) to evaluate the safety and efficacy of zandelisib in combination with BeiGene&#8217;s zanubrutinib (marketed as Brukinsa<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>), an inhibitor of Bruton&#8217;s tyrosine kinase, for the treatment of patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of zandelisib in combination with zanubrutinib in patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> malignancies. Study costs are being shared equally by the parties, and we agreed to supply zandelisib and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for zandelisib and BeiGene retained full commercial rights for zanubrutinib. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945749812776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 5. Net Loss Per Share </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and nine months ended March&#160;31, 2021 and 2020. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the calculation of net loss used to calculate basic loss and diluted loss per share (in thousands):&#160;&#160;&#160;&#160; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:57%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss &#8211; basic</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(31,313</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,329</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(44,859</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(27,540</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(20,307</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss &#8211; diluted</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(31,313</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,329</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(65,166</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(27,540</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share used in calculating net loss per share was determined as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:61%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average shares used in calculating basic net loss per share</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">112,557</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">105,999</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">112,505</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">85,995</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of potentially dilutive common shares from equity awards and liability-classified warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,486</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average shares used in calculating diluted net loss per share</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">112,557</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">105,999</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">113,991</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">85,995</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents weighted-average potentially dilutive shares that have been excluded from the calculation of net loss per share because of their anti-dilutive effect (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:64%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock options</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,161</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,064</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,618</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,974</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">430</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">430</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,060</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,062</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,354</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,062</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive shares</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">32,651</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27,126</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">21,402</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27,036</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945751991720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 6. Commitments and Contingencies </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have contracted with various consultants and third parties to assist us in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> research and development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. We also have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances. &#160;&#160;&#160;&#160; </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Presage License Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 3, we are party to a license agreement with Presage under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of March&#160;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">S*Bio Purchase Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&#160;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U. and Japan. As of March&#160;31, 2021, we have not accrued any amounts for potential future payments as achievement of the milestones has not been met. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">CyDex License Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 3, we are party to a license agreement with CyDex under which we may be required to make future payments upon the achievement of certain milestones, as well as potential future royalties based upon net sales. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. As of March&#160;31, 2021, we have not accrued any amounts for potential future payments. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In January 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;COVID-19</div> outbreak&#8221;) and the risks to the international community. In March 2020, the WHO classified the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak as a pandemic, based on the rapid increase in exposure globally. As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, which continues to rapidly evolve, &#8220;shelter in place&#8221; orders and other public health guidance measures have been implemented across much of the United States, Europe and Asia, including in the locations of our offices, clinical trial sites, key vendors and partners. Despite the relaxation of many governmental orders in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020,</div> the &#8220;second wave&#8221; of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak has resulted in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-imposition</div> of many of these measures. In addition, although the FDA has authorized vaccines for the treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the effectiveness and timing of distribution of the vaccines remains highly uncertain. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus has also mutated into different strains, which could be more contagious or severe or for which treatments are unavailable. While we continue to enroll and dose patients in our clinical trials, our clinical development program timelines continue to be subject to potential negative impacts from the ongoing pandemic. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the effectiveness and timing of distribution of treatments for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and to minimize its economic impact. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">CARES Act </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act was signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. Regulatory guidance has indicated that public companies are ineligible to participate in certain of the loan programs provided by the CARES Act. There is substantial uncertainty with respect to the scope, content or timing of any further economic stimulus programs to address the economic downturn related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak. We do not expect that the CARES Act will have a material impact on our financial condition, results of operation, or liquidity. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Legal Proceedings &#160;&#160;&#160;&#160; </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;10, 2020, Guy Bahat, an individual who allegedly purchased 50 shares of our common stock filed a putative securities class action lawsuit (the &#8220;Securities Class&#160;Action&#8221;) in the United States District Court for the Southern District of California against the Company, Dr.&#160;Daniel&#160;P. Gold, and Mr.&#160;Brian&#160;G. Drazba, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5</div> thereunder. Mr.&#160;Bahat did not seek appointment as lead plaintiff, and the court appointed another individual, Ramesh Mahalingham, as lead plaintiff. The plaintiff seeks to sue on behalf of all purchasers of our securities from August&#160;2, 2017 through July&#160;1, 2020 and alleges, among other things, that we made false and misleading statements relating to pracinostat during the proposed class period. On February&#160;16, 2021, the lead plaintiff filed a notice of voluntary dismissal without prejudice, thereby concluding the class action litigation. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;21, 2020, Peter D&#8217;Arcy, an individual who alleges that he is a Company stockholder, filed a putative stockholder derivative action nominally on behalf of the Company in the United States District Court for the District of Delaware (the &#8220;Derivative Action&#8221;) against Dr.&#160;Gold, Mr.&#160;Drazba, Mr.&#160;Charles&#160;V. Baltic, III, Dr.&#160;Kevan&#160;E. Clemens, Mr.&#160;Frederick&#160;W. Driscoll, Dr.&#160;Nicholas&#160;R. Glover, Ms.&#160;Tamar&#160;D. Howson, Dr.&#160;Thomas&#160;C. Reynolds, Mr.&#160;William&#160;D. Rueckert, and Dr.&#160;Christine&#160;A. White, and naming the Company as a nominal defendant. Additional putative stockholder derivative suits were filed in the same court naming the same defendants plus Dr.&#160;Robert&#160;D. Mass on December&#160;2, 2020 and December&#160;15, 2020 by Gerald Wright and William Trablicy, respectively, who also allege that they are Company stockholders, and these additional suits were consolidated into the Derivative Action by court order. The Derivative Action is based upon the pracinostat-related allegations in the Securities Class&#160;Action described above, and alleges claims under Section&#160;14(a) of the Exchange Act and claims for breach of fiduciary duty, unjust enrichment, corporate waste, and contribution. On February&#160;24, 2021, following the resolution of the class action litigation, the parties stipulated request for voluntary dismissal without prejudice, which the court granted on February&#160;25, 2021. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753500040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 7. Leases </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, we entered into a lease agreement for approximately 32,800 square feet of office space in San Diego, California.&#160;We have accounted for the lease as an operating lease. The contractual lease term began in July 2020 and is scheduled to expire in March 2028. The lease contains an option to renew and extend the lease terms. We have not included the lease extension within the ROU asset and lease liability on the balance sheet as it is not reasonably certain to be exercised. The lease includes variable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset and lease liability and are reflected as an expense in the period incurred. We do not have any other operating or finance leases.&#160;Upon commencement of the lease, we recognized an operating lease ROU asset of $8.7&#160;million and a corresponding operating lease liability of $8.7&#160;million. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total operating lease costs were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:66%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Operating lease cost</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">377</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">201</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,130</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">603</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to our operating leases were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:66%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">369</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">201</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">615</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">603</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease obligations:</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,689</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a schedule of the future minimum rental payments for our operating lease, reconciled to the lease liability as of March&#160;31, 2021 (in thousands):&#160;&#160;&#160;&#160; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:88%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 17pt;"></td><td></td><td></td><td style="width: 17pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Remainder of fiscal year ending June 30, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">368</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ending June&#160;30,</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2022</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,519</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,565</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2024</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,612</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,168</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2026</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,710</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,122</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total lease payments</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,064</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(2,556</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,508</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet Classification &#8211; Operating Lease</div></div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Operating lease liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">900</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, long-term</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,608</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,508</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other Balance Sheet Information &#8211; Operating Lease</div></div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average remaining lease term (in years)</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.0</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7.50</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945749749528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 8. Short-Term Investments </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021 and June&#160;30, 2020, our short-term investments consisted of $154.9&#160;million and $170.3&#160;million, respectively, in U.S. government securities. The short-term investments held as of March&#160;31, 2021 and June&#160;30, 2020 had maturity dates of less than one year, are considered to be &#8220;held to maturity&#8221; and are carried at amortized cost. As of March&#160;31, 2021 and June&#160;30, 2020, the gross holding gains and losses were immaterial. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753652440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 9. Stockholders&#8217; Equity </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity Transactions &#160;&#160;&#160;&#160; </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Equity Offering </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;10, 2020, we entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Equity Offering Sales Agreement (the &#8220;2020 ATM Sales Agreement&#8221;), pursuant to which we may sell an aggregate of up to $60.0&#160;million of our common stock pursuant to the shelf registration statement. We had previously entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Equity Offering Sales Agreement in November 2017 (the &#8220;2017 ATM Sales Agreement&#8221;), pursuant to which we could sell an aggregate of up to $30.0&#160;million of our common stock pursuant to the shelf registration statement. The 2017 ATM Sales Agreement expired on November&#160;8, 2020. During the nine months ended March&#160;31, 2021, we sold 958,083 shares under the 2017 ATM Sales Agreement for net proceeds of $3.1&#160;million, after costs of $0.1&#160;million. As of March&#160;31, 2021, there is $60.0&#160;million remaining available under the 2020 ATM Sales Agreement. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Shelf Registration Statement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a shelf registration statement that permits us to sell, from time to time, up to $200.0&#160;million of common stock, preferred stock and warrants. The shelf registration was filed and declared effective in May 2020, replacing our prior shelf registration statement that was filed and declared effective in May 2017, and carrying forward approximately $107.5&#160;million of unsold securities registered under the prior shelf registration statement. As of March&#160;31, 2021, there is $175.7&#160;million aggregate value of securities available under the shelf registration statement, including up to $60.0&#160;million remaining available under the 2020 ATM Sales Agreement. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrants </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, we have outstanding warrants to purchase 16,058,985 shares of our common stock. The warrants are fully vested, exercisable at a price of $2.54 per share and expire in May 2023. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet. Therefore, we are required to account for the warrants as liabilities and record them at fair value. The warrants were revalued as of March&#160;31, 2021 at $29.4&#160;million and as of June&#160;30, 2020 at $40.5&#160;million; the changes in fair value were recorded in our Condensed Statement of Operations. During the nine months ended March&#160;31, 2021, a warrant holder completed a cashless exercise of 2,617 warrants for 964 shares of common stock. No warrants were exercised during the nine months ended March&#160;31, 2020. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945749781304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 10. Share-based Compensation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (&#8220;2008 Plan&#8221;), as amended and restated in 2011, 2013, 2014, 2015, 2016, 2018 and 2020, under which 29,014,794 shares of common stock are authorized for issuance. The 2008 Plan provides for the grant of options and/or other stock-based or stock-denominated awards to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, officers, employees and advisors. As of March&#160;31, 2021, there were 10,284,365 shares available for future grant under the 2008 Plan. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense for all stock awards consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:72%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,207</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">696</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,496</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,220</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,438</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">854</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,700</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,214</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,645</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,550</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,196</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,434</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock option activity for the nine months ended March&#160;31, 2021 was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:55%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 36pt;"></td><td></td><td></td><td style="width: 36pt;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 73pt;"></td><td></td><td></td><td style="width: 73pt;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 108pt;"></td><td></td><td></td><td style="width: 108pt;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 52pt;"></td><td></td><td></td><td style="width: 52pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Number of<br/>Options</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise&#160;Price</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/>Remaining&#160;Contractual<br/>Term (in years)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,252,976</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.81</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5,763,300</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.40</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(119,042</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.22</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited / Cancelled</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(223,828</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.65</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at March&#160;31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,673,406</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.01</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,775,096</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and exercisable at March&#160;31, 2021</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,802,361</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.74</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.7</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,006,856</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of each stock option granted during the nine months ended March&#160;31, 2021 is estimated on the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the nine months ended March&#160;31, 2021 vest 25% one year from the date of grant and ratably each month thereafter for a period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the nine months ended March&#160;31, 2021 vest ratably each month for a period of 12 months from the date of grant and expire ten years from the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following weighted-average assumptions were used to determine the fair value of options granted during the period: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:85%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.5</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.8</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">81.1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">73.6</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted-average grant date fair value</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.32</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.60</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, there was $10.2&#160;million of unrecognized compensation expense related to the unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.7 years. </div></div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted Stock Units </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2020, we granted 442,650 RSUs to employees. Each RSU represented the contingent right to receive one share of our common stock. The RSUs will vest in periods of either one year or two years from the date of grant. The fair value of the RSUs was measured at $3.49 per unit. Under the terms of the 2008 Plan, each of the RSUs is calculated as 1.25 shares of common stock for purposes of determining the number of shares available for future grant. There were forfeitures of 12,000 RSUs during the nine months ended March&#160;31, 2021, and 430,650 unvested RSUs were outstanding as of March&#160;31, 2021. As of March&#160;31, 2021, unrecognized compensation expense related to the unvested portion of our RSUs was approximately $0.8&#160;million and is expected to be recognized over approximately 1.1 years. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945845048568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ClinicalDevelopmentProgramsPolicyTextBlock', window );">Clinical Development Programs</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clinical Development Programs </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;">Zandelisib (formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-401),</div> an oral phosphatidylinositol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-kinase</div> (&#8220;PI3K&#8221;) delta inhibitor; </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Voruciclib, an oral cyclin-dependent kinase (&#8220;CDK&#8221;) inhibitor; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-344,</div> a mitochondrial inhibitor targeting the oxidative phosphorylation (&#8220;OXPHOS&#8221;) complex; and </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pracinostat, an oral histone deacetylase (&#8220;HDAC&#8221;) inhibitor. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials. The commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side effects or are less expensive than our drug candidates. We will need substantial additional funds to progress the clinical trial programs for the drug candidates zandelisib, voruciclib and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ME-344,</div> and to develop new compounds. The actual amount of funds that will be needed will depend upon a number of factors, some of which are beyond our control. Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have accumulated losses of $322.1&#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of March&#160;31, 2021, we had $164.6&#160;million in cash and cash equivalents and short-term investments. We believe that these resources will be sufficient to meet our obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements. Our current business operations are focused on continuing the clinical development of our drug candidates. Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. Our research and development expenses are expected to increase in the foreseeable future. We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&#160;30, 2020, included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (&#8220;2020 Annual Report&#8221;) filed with the Securities and Exchange Commission on September&#160;9, 2020. Interim results are not necessarily indicative of results for a full year. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">ASC Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;) </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identify the distinct performance obligations &#8211; or accounting units &#8211; within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Payments received under commercial arrangements, such as licensing technology rights, may include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop estimates of the stand-alone selling price for each distinct performance obligation. Variable consideration that relates specifically to our efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. Other components of the transaction price are allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the case of a license that is a distinct performance obligation, we recognize revenue allocated to the license from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we use judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &#8220;input method&#8221; under Topic 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&#8217; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&#160;when the related sales occur or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based or usage-based royalty revenue from license agreements. </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognized revenue associated with the following license agreements (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:71%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">KKC License Agreements</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,321</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">812</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,979</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,282</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Helsinn License Agreement</div></div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">97</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">432</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">440</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,127</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,244</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Timing of Revenue Recognition:</div></div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services performed over tim<div style="display:inline;">e</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,244</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,244</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The KKC Commercialization Agreement and KKC Japan License Agreement (Note 3) include other distinct performance obligations that will be satisfied over time, and accordingly we recognized $2.3&#160;million and $0.8&#160;million related to our progress toward satisfying those obligations during the three months ended March&#160;31, 2021 and 2020, respectively, and $15.0&#160;million and $2.3&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the characteristics of the Helsinn License Agreement (Note 3), control of the remaining deliverables occurs over time and therefore we recognize revenue based on the extent of progress towards completion of the performance obligations. Accordingly, we recognized $0.1&#160;million and $0.4&#160;million related to our progress toward satisfying those obligations during the three months ended March&#160;31, 2021 and 2020, respectively, and $0.4&#160;million and $1.1&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contract Balances </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables and contract assets are included in our balance sheet in &#8220;Prepaid expenses and other current assets&#8221;, and contract liabilities are included in &#8220;Deferred revenue&#8221; and &#8220;Deferred revenue, long-term&#8221;. The following table presents changes in contract assets and contract liabilities during the nine months ended March&#160;31, 2021 and 2020 (in thousands):</div><br/></div> <div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:87%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March 31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Receivables</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables, beginning of period</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2,605</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Amounts billed</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,744</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,088</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments received</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(18,349</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(1,014</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Receivables, end of period</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">74</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets, beginning of period</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">335</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">511</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Billable amounts</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">22,841</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">930</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Amounts billed</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(15,744</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,088</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, end of period</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,432</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">353</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities, beginning of period</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">82,497</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,771</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net change</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,380</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,479</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities, end of period</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">89,877</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5,292</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:87%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets), which are classified as &#8220;prepaid expenses and other current assets&#8221; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC Agreements and Helsinn License Agreement. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of&#160;March 31, 2021, we had $<div style="letter-spacing: 0px; top: 0px;;display:inline;">7.4</div>&#160;million&#160;of contract assets related to our remaining performance obligations under the KKC Commercialization Agreement and no contract assets related to the Helsinn License Agreement as the remaining performance obligations have been completed. During the nine months ended March&#160;31, 2021, contract assets increased by $22.8&#160;million, primarily due the recognition of revenue related to the satisfaction or partial satisfaction of performance obligations for which we had not yet billed KKC or Helsinn, partially offset by billings of $15.7&#160;million to KKC and Helsinn. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of&#160;March 31, 2021, we had $89.9&#160;million&#160;of deferred revenue associated with our remaining performance obligations under the KKC&#160;Commercialization&#160;Agreement, of which $64.5&#160;million relates to the U.S. License which is a unit of account under the scope of Topic 808 and is not a deliverable under Topic 606, and $25.4&#160;million relates to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Ex-U.S.</div> license and development services performance obligations which are under the scope of Topic 606. For the three and nine months ended March&#160;31, 2021, we recognized revenue of $2.4&#160;million and $15.4&#160;million, respectively, that was included in the contract liabilities balance at June&#160;30, 2020 related to performance obligations under ASC 606. In addition, as a result of a change in estimated cost of completion related to our remaining performance obligations, we decreased deferred revenue by $<div style="letter-spacing: 0px; top: 0px;;display:inline;">2.1</div>&#160;million. To date we have not recognized any amounts related to units of account under Topic 808. For the three and nine months ended March&#160;31, 2020, we recognized revenue of $0.8&#160;million and $2.6&#160;million, respectively, that was included in the contract liabilities balance at June&#160;30, 2019 related to performance obligations under ASC 606 under the KKC Japan License Agreement and Helsinn License Agreement which are described in Note 3. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenues from Collaborators </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We earn revenue in connection with collaboration agreements, which are described in Note 3, License Agreements, and Note 4, BeiGene Collaboration. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, we assess whether the collaboration arrangements are within the scope of ASC Topic 808, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Collaborative Arrangements</div> (&#8220;Topic 808&#8221;), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determine which units of account within the arrangement are within the scope of Topic 808 and which elements are within the scope of Topic 606. For units of account within collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that are accounted for pursuant to Topic 606, we recognize revenue as discussed above. Consideration received that does not meet the requirements to satisfy Topic 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term or long-term deferred revenue based on our best estimate of when such amounts will be recognized. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cost of Revenue </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations associated with the Helsinn License Agreement. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-based Compensation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&#8217;s historical price volatility. The stock&#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&#8220;RSU&#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of March&#160;31, 2021 and 2020, we have established a valuation allowance to fully reserve our net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in our ownership may limit the amount of net operating loss carryforwards that can be utilized in the future to offset taxable income. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes in our unrecognized tax benefits since June&#160;30, 2020, and, as such, the disclosures included in our 2020 Annual Report continue to be relevant for the nine months ended March&#160;31, 2021. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective July&#160;1, 2019, we adopted FASB ASC Topic 842, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases</div> (&#8220;ASC 842&#8221;), using a modified retrospective basis method under which prior comparative periods are not restated. This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) asset representing our right to use the underlying asset for the lease term. At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement. A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration. Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on our Condensed Balance Sheet as ROU assets and lease liabilities. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. Certain adjustments to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset may be required for items such as initial direct costs paid or incentives received. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined based on the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The interest rate implicit in lease contracts to calculate the present value is typically not readily determinable. As such, significant management judgment is required to estimate the incremental borrowing rate.&#160;&#160;&#160;&#160; </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Rent expense for operating leases is recognized on a straight-line basis over the lease term based on the total lease payments. We have elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for our real estate leases. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ClinicalDevelopmentProgramsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical development programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ClinicalDevelopmentProgramsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Disclosure In Its Entirety Pertaining to the Accounting Policy In Respect Of Liquid Resources Held By The Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753505128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock', window );">Schedule Of Revenue Associated With License Agreement</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognized revenue associated with the following license agreements (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:71%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">KKC License Agreements</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,321</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">812</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,979</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,282</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Helsinn License Agreement</div></div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">97</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">432</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">440</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,127</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,244</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Timing of Revenue Recognition:</div></div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services performed over tim<div style="display:inline;">e</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,244</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">2,418</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,244</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">15,419</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">3,409</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Assets and Contract Liabilities</a></td>
<td class="text">The following table presents changes in contract assets and contract liabilities during the nine months ended March&#160;31, 2021 and 2020 (in thousands):<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width: 87%;"></td><td style="width: 1%;;vertical-align:bottom;"></td><td style="width: 0.8%;"></td><td style="width: 0.5%;"></td><td style="width: 3.6%;"></td><td style="width: 0.8%;;vertical-align:bottom;"></td><td style="width: 1%;"></td><td style="width: 0.8%;"></td><td style="width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables, beginning of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">2,605</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts billed</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">15,744</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">1,088</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments received</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(18,349</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">)&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(1,014</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables, end of period</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">74</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, beginning of period</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">511</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Billable amounts</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">22,841</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">930</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts billed</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;text-align:right;;vertical-align:bottom;">(15,744</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.8%;;text-align:right;;vertical-align:bottom;">(1,088</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, end of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">7,432</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">353</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 87%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 3.6%;;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.8%;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities, beginning of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">82,497</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">7,771</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr><td style="width: 87%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Net change<br/></div></td><td style="width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 0.5%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">7,380</div></td><td style="white-space: nowrap; width: 3.6%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 1%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="white-space: nowrap; width: 0.8%; border-bottom: 0.75pt solid black; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">(2,479</div></td><td style="white-space: nowrap; width: 0.5%; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">)</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities, end of period</div></div></td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">89,877</td><td style="white-space: nowrap; width: 3.6%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="white-space: nowrap; width: 0.8%; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">5,292</td><td style="white-space: nowrap; width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 87%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 3.6%; background-color: rgba(255, 255, 255, 0);">&#160;</td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">&#160;&#160;</td><td style="width: 1%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.8%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue Associated With License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945751995240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 12pt;"></td><td></td><td></td><td style="width: 12pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(29,442</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(40,483</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(29,442</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(40,483</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To calculate the fair value of the warrant liability, the following assumptions were used: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:75%;"></td><td style="vertical-align:bottom;;width:10%;"></td><td style="width: 17pt;"></td><td></td><td></td><td style="width: 17pt;"></td><td style="vertical-align:bottom;;width:9%;"></td><td style="width: 14pt;"></td><td></td><td></td><td style="width: 14pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.2</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.1</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">82.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">77.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Black-Scholes Fair Value</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.83</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.52</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Schedule of Changes in Estimated Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of changes in the estimated fair value of our Level&#160;3 warrant liability for the nine months ended March&#160;31, 2021 and 2020 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:92%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 20pt;"></td><td></td><td></td><td style="width: 20pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 20pt;"></td><td></td><td></td><td style="width: 20pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;of&#160;Warrants&#160;Using&#160;Significant<br/>Unobservable&#160;Inputs&#160;(Level&#160;3)</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance at July&#160;1,</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(40,483</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,613</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of derivative liability to equity upon exercise of warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in estimated fair value of liability classified warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,035</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">830</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at March&#160;31,</div></div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(29,442</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(16,783</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945765155576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Income (Loss) Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the calculation of net loss used to calculate basic loss and diluted loss per share (in thousands):&#160;&#160;&#160;&#160; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:57%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss &#8211; basic</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(31,313</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,329</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(44,859</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(27,540</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(20,307</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss &#8211; diluted</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(31,313</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,329</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(65,166</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(27,540</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Calculation of Weighted Average Shares Used to Calculate Basic and Diluted (Loss) Earnings Per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share used in calculating net loss per share was determined as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:61%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average shares used in calculating basic net loss per share</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">112,557</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">105,999</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">112,505</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">85,995</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of potentially dilutive common shares from equity awards and liability-classified warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,486</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average shares used in calculating diluted net loss per share</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">112,557</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">105,999</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">113,991</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">85,995</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents weighted-average potentially dilutive shares that have been excluded from the calculation of net loss per share because of their anti-dilutive effect (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:64%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:2%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock options</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,161</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,064</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,618</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,974</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">430</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">430</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,060</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,062</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,354</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,062</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive shares</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">32,651</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27,126</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">21,402</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27,036</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945750540488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Total Operating Costs</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total operating lease costs were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:66%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Operating lease cost</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">377</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">201</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,130</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">603</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to our operating leases were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:66%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">369</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">201</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">615</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">603</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease obligations:</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,689</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a schedule of the future minimum rental payments for our operating lease, reconciled to the lease liability as of March&#160;31, 2021 (in thousands):&#160;&#160;&#160;&#160; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:88%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 17pt;"></td><td></td><td></td><td style="width: 17pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Remainder of fiscal year ending June 30, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">368</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ending June&#160;30,</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2022</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,519</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,565</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2024</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,612</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,168</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2026</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,710</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,122</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total lease payments</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,064</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(2,556</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,508</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet Classification &#8211; Operating Lease</div></div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Operating lease liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">900</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, long-term</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,608</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease liability</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,508</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other Balance Sheet Information &#8211; Operating Lease</div></div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average remaining lease term (in years)</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.0</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7.50</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplemental cash flow information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945764432232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Compensation Expense for Stock Awards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense for all stock awards consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:72%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,207</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">696</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,496</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,220</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,438</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">854</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,700</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,214</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,645</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,550</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,196</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,434</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock Option Activity and Related Data</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock option activity for the nine months ended March&#160;31, 2021 was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:55%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 36pt;"></td><td></td><td></td><td style="width: 36pt;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 73pt;"></td><td></td><td></td><td style="width: 73pt;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 108pt;"></td><td></td><td></td><td style="width: 108pt;"></td><td style="vertical-align:bottom;;width:6%;"></td><td style="width: 52pt;"></td><td></td><td></td><td style="width: 52pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Number of<br/>Options</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise&#160;Price</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/>Remaining&#160;Contractual<br/>Term (in years)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,252,976</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.81</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5,763,300</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.40</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(119,042</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.22</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited / Cancelled</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(223,828</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.65</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at March&#160;31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,673,406</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.01</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,775,096</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and exercisable at March&#160;31, 2021</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,802,361</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.74</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.7</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7,006,856</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options Weighted-Average Assumptions Used</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following weighted-average assumptions were used to determine the fair value of options granted during the period: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:85%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td><td style="vertical-align:bottom;;width:4%;"></td><td style="width: 8pt;"></td><td></td><td></td><td style="width: 8pt;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="9" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/>March&#160;31,</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="4" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.5</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.8</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">81.1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">73.6</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap;;vertical-align:bottom;">%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted-average grant date fair value</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.32</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.60</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945746004312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ClinicalTrials</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfClinicalStageCandidates', window );">Number of clinical stage candidates | ClinicalTrials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred Revenue Associated With Remaining Performance Obligation</a></td>
<td class="nump">$ 89,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RevenuePerformanceObligationAmount', window );">Revenue Recognised With Performance Obligation</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Losses Since Inception</a></td>
<td class="num">(322,093,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322,093,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277,234,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable', window );">Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable</a></td>
<td class="nump">164,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, Current</a></td>
<td class="nump">7,432,000<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
<td class="nump">7,432,000<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="nump">$ 511,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (Decrease) in Deferred Revenue</a></td>
<td class="num">(2,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,377,000<span></span>
</td>
<td class="num">(2,479,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=meip_UsLicenseMember', window );">US License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred Revenue Associated With Remaining Performance Obligation</a></td>
<td class="nump">64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=meip_ExUsLicenseMember', window );">Ex US License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred Revenue Associated With Remaining Performance Obligation</a></td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AgreementAxis=meip_HelsinnLicenseAgreementMember', window );">Helsinn License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred Revenue, Revenue Recognized</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AgreementAxis=meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember', window );">KKC Commercialization Agreement And The Helsinn License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, Current</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Increase in contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AgreementAxis=meip_KkcAgreementsandHelsinnLicenseAgreementMember', window );">KKC Agreements and Helsinn License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Cash And Cash Equivalents,Short Term Investments And Proceeds Receivable From The Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfClinicalStageCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical stage candidates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfClinicalStageCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_RevenuePerformanceObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_RevenuePerformanceObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TargetedOrTrackingStockStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TargetedOrTrackingStockStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=meip_UsLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=meip_UsLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=meip_ExUsLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=meip_ExUsLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AgreementAxis=meip_HelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AgreementAxis=meip_HelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AgreementAxis=meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AgreementAxis=meip_KkcCommercializationAgreementAndTheHelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AgreementAxis=meip_KkcAgreementsandHelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AgreementAxis=meip_KkcAgreementsandHelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945745982136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Revenue Associated With The Following license agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,418<span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="nump">$ 3,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember', window );">KKC License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">14,979<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember', window );">Helsinn License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services performed over time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,418<span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="nump">$ 3,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945743763912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Schedule of Changes in Contract Assets and Contract Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ContractWithCustomerAssetAndLiabilityLineItems', window );"><strong>Contract with Customer Asset and Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccountsReceivableNetBeginningBalance', window );">Receivables, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,605<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ReceivablesAmountsBilled', window );">Amounts billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,744<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ReceivablesPaymentsReceived', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,349)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccountsReceivableNetEndingBalance', window );">Receivables, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ContractAssetsBillableAmounts', window );">Billable amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,841<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ContractAssetsAmountsBilled', window );">Amounts billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,744)<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, end of period</a></td>
<td class="nump">7,432<span></span>
</td>
<td class="nump">7,432<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,497<span></span>
</td>
<td class="nump">7,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Net change</a></td>
<td class="num">(2,100)<span></span>
</td>
<td class="nump">7,377<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, end of period</a></td>
<td class="nump">$ 89,877<span></span>
</td>
<td class="nump">$ 89,877<span></span>
</td>
<td class="nump">$ 5,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AccountsReceivableNetBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable net beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AccountsReceivableNetBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AccountsReceivableNetEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable net ending balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AccountsReceivableNetEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ContractAssetsAmountsBilled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract assets Amounts billed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ContractAssetsAmountsBilled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ContractAssetsBillableAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract assets Billable amounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ContractAssetsBillableAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ContractWithCustomerAssetAndLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset and liability Line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ContractWithCustomerAssetAndLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ReceivablesAmountsBilled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables Amounts billed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ReceivablesAmountsBilled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ReceivablesPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables Payments received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ReceivablesPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945747984360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant liability</a></td>
<td class="num">$ (29,442)<span></span>
</td>
<td class="num">$ (40,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant liability</a></td>
<td class="num">(29,442)<span></span>
</td>
<td class="num">(40,483)<span></span>
</td>
<td class="num">$ (16,783)<span></span>
</td>
<td class="num">$ (17,613)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liability</a></td>
<td class="num">$ (29,442)<span></span>
</td>
<td class="num">$ (40,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945746007400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail) - ClinicalTrials<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">82.4<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Black-Scholes Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">1.83<span></span>
</td>
<td class="nump">2.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945746336264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems', window );"><strong>Fair value measurements Significant unobservable inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in estimated fair value of liability classified warrants</a></td>
<td class="num">$ (9,272)<span></span>
</td>
<td class="nump">$ 7,732<span></span>
</td>
<td class="nump">11,035<span></span>
</td>
<td class="nump">$ 8,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Ending balance</a></td>
<td class="num">(29,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems', window );"><strong>Fair value measurements Significant unobservable inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,483)<span></span>
</td>
<td class="num">(17,613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Reclassification of derivative liability to equity upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in estimated fair value of liability classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,035<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Ending balance</a></td>
<td class="num">$ (29,442)<span></span>
</td>
<td class="num">$ (16,783)<span></span>
</td>
<td class="num">$ (29,442)<span></span>
</td>
<td class="num">$ (16,783)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements, Significant Unobservable Inputs [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_FairValueMeasurementsSignificantUnobservableInputsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945744992456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PercentageOfPurchasesFromMajorSuppliers', window );">Percentage of Purchase Requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AgreementTerminationNoticePeriod', window );">License and supply agreement notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ProfitsAndCostsSharingRatio', window );">Profit sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding', window );">Receivable for foreign tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember', window );">Kyowa Kirin Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_TotalUpfrontPaymentReceivableForGrantOfRights', window );">Total upfront payment receivable for grant of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding', window );">Receivable for foreign tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember', window );">Kyowa Kirin Co | Updation of Initial Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings', window );">Estimated development cost sharing recovered through earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember', window );">Kyowa Kirin Co | Potential Payments on Achievement of Development Regulatory and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_TotalUpfrontPaymentReceivableForGrantOfRights', window );">Total upfront payment receivable for grant of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember', window );">Kyowa Kirin Co | Potential Payments on Achievement of Development Regulatory and Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentialMilestonePaymentsReceivable', window );">Milestone payment receivable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember', window );">Helsinn License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Compensation receivable for grant of rights</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement | Presage Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Compensation payable for grant of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PaymentForLicenseAgreement', window );">Payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement | Presage Biosciences, Inc. | Incremental Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Compensation payable for grant of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement | Presage Biosciences, Inc. | Potential Payments on Achievement of Development Regulatory and Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentialMilestonePaymentsPayable', window );">Milestone payments payable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember', window );">KKC License Agreement | Kyowa Kirin Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_TotalTransactionPriceInRespectOfColloborationRevenue', window );">Transaction price relating to the performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ExpectedMilestonePaymentReceivable', window );">Expected milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings', window );">Estimated development cost sharing recovered through earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember', window );">KKC License Agreement | Kyowa Kirin Co | Ex US License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Performance obligation revenue recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_LicenseObligationAccountTransactionPriceAllocated', window );">License Obligation Account Transaction Price Allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember', window );">KKC License Agreement | Kyowa Kirin Co | Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with customer liability non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated development cost sharing reoverable through earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ExpectedMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ExpectedMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase or Decrease in Receivable for foreign tax withholding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_IncreaseOrDecreaseInReceivableForForeignTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_LicenseObligationAccountTransactionPriceAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License obligation account transaction price allocated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_LicenseObligationAccountTransactionPriceAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PaymentForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PaymentForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PercentageOfPurchasesFromMajorSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchases from major suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PercentageOfPurchasesFromMajorSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ProfitsAndCostsSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and costs sharing ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ProfitsAndCostsSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_TotalTransactionPriceInRespectOfColloborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total transaction price in respect of colloboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_TotalTransactionPriceInRespectOfColloborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_TotalUpfrontPaymentReceivableForGrantOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront payment receivable for grant of rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_TotalUpfrontPaymentReceivableForGrantOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=meip_KyowaKirinCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_EventAxis=meip_UpdationOfInitialAssessmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_EventAxis=meip_UpdationOfInitialAssessmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=meip_PresageBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=meip_PresageBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=meip_IncrementalPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=meip_IncrementalPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_KkcAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=meip_ExUsLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=meip_ExUsLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=meip_DevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=meip_DevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945751066552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Common stock subject to repurchase or forfeiture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potentially Dilutive Securities Outstanding [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentiallyDilutiveSecuritiesOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753562920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of (Loss) Per Share, Basic and Diluted (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss - basic</a></td>
<td class="num">$ (31,313)<span></span>
</td>
<td class="num">$ (4,329)<span></span>
</td>
<td class="num">$ (44,859)<span></span>
</td>
<td class="num">$ (27,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss - diluted</a></td>
<td class="num">$ (31,313)<span></span>
</td>
<td class="num">$ (4,329)<span></span>
</td>
<td class="num">$ (65,166)<span></span>
</td>
<td class="num">$ (27,540)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dilutive securities effect on basic earnings per share change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945747821768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Calculation of Weighted Average Shares Used to Calculate Basic and Diluted (Loss) Earnings Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating basic net loss per share</a></td>
<td class="nump">112,557<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">112,505<span></span>
</td>
<td class="nump">85,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of potentially dilutive common shares from equity awards and liability-classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating diluted net loss per share</a></td>
<td class="nump">112,557<span></span>
</td>
<td class="nump">105,999<span></span>
</td>
<td class="nump">113,991<span></span>
</td>
<td class="nump">85,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945745977928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Antidilutive Securities (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">32,651<span></span>
</td>
<td class="nump">27,126<span></span>
</td>
<td class="nump">21,402<span></span>
</td>
<td class="nump">27,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">16,161<span></span>
</td>
<td class="nump">11,064<span></span>
</td>
<td class="nump">15,618<span></span>
</td>
<td class="nump">10,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">16,060<span></span>
</td>
<td class="nump">16,062<span></span>
</td>
<td class="nump">5,354<span></span>
</td>
<td class="nump">16,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potentially Dilutive Securities Outstanding [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentiallyDilutiveSecuritiesOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945778653096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_MilestonePaymentsMaximumAmount', window );">Future aggregate milestone payments</a></td>
<td class="nump">$ 74,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PercentageOfPurchasesFromMajorSuppliers', window );">Percentage of Purchase Requirement</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_SbioPurchaseAgreementMember', window );">S*Bio Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccruedMilestonePayments', window );">Accrued payment for potential future payments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_CydexLicenseAgreementMember', window );">CyDex License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccruedMilestonePayments', window );">Accrued payment for potential future payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccruedMilestonePayments', window );">Accrued payment for potential future payments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_MilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, maximum amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_MilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PercentageOfPurchasesFromMajorSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchases from major suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PercentageOfPurchasesFromMajorSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_SbioPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_SbioPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_CydexLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_CydexLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753462776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | San Diego California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSquareFeetUnderLease', window );">Number of square feet under lease | ft&#178;</a></td>
<td class="nump">32,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expire date</a></td>
<td class="text">Mar. 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_InitialRecognitionOfOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSquareFeetUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of square feet under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSquareFeetUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=meip_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=meip_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945750603240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Total Operating Costs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 377<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945750694792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945744046840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Rental Payments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of fiscal year ending June 30, 2021</a></td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">3,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">11,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="num">(2,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">8,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="nump">7,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 8,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945753340552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 154,879<span></span>
</td>
<td class="nump">$ 170,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945745061560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Nov. 08, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ShelfRegistrationStatementValue', window );">Aggregate value of securities available under shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock Value Issued</a></td>
<td class="nump">$ 3,136,000<span></span>
</td>
<td class="num">$ (8,000)<span></span>
</td>
<td class="nump">$ 48,451,000<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement', window );">Unsold Securities Shares and Warrants Under Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AggregateValueOfSecuritiesAvailableUnderAgreement', window );">Aggregate Value of Securities Available Under Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesIssuedOnWarrantExercise', window );">Number of shares issued on warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,058,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=meip_AtTheMarketSaleAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock Value Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember', window );">Two Thousand And Twenty At The Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ShelfRegistrationStatementValue', window );">Aggregate value of securities available under shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_SaleOfSharesAndWarrantsUnderAgreement', window );">Sale of shares and warrants under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesAgreedToBeSoldUnderAgreement', window );">Sale of shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Two Thousand And Twenty At The Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesAgreedToBeSoldUnderAgreement', window );">Sale of shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AggregateValueOfSecuritiesAvailableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of securities available under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AggregateValueOfSecuritiesAvailableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSharesAgreedToBeSoldUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Agreed to be Sold Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSharesAgreedToBeSoldUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSharesIssuedOnWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued on warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSharesIssuedOnWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_SaleOfSharesAndWarrantsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of shares and warrants under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_SaleOfSharesAndWarrantsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ShelfRegistrationStatementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Shelf registration statement value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ShelfRegistrationStatementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsold securities shares and warrants under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_UnsoldSecuritiesSharesAndWarrantsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=meip_AtTheMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=meip_AtTheMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945743950488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognition of compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Share-based Payment Arrangement Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognition of compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="nump">442,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesToBeReceived', window );">Number of common stock to be received for each RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs grant date fair value per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock units forfeiture during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share based compensation by share based payment arrangement other than options unvested outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share based compensation by share based payment arrangement other than options unvested cost not yet recognised amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesForEachUnitOfRestrictedStock', window );">Number of shares for each unit of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=meip_TwoThousandAndEightOmnibusPlanMember', window );">2008 Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,014,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,284,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restricted Stock Units (RSUs) | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Restricted Stock Units (RSUs) | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSharesForEachUnitOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for each unit of restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSharesForEachUnitOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSharesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSharesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=meip_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=meip_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=meip_TwoThousandAndEightOmnibusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=meip_TwoThousandAndEightOmnibusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945744107432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Expense for Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 2,645<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
<td class="nump">$ 8,196<span></span>
</td>
<td class="nump">$ 5,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,438<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 3,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945743948360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance | shares</a></td>
<td class="nump">11,252,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">5,763,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(119,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited / Cancelled | shares</a></td>
<td class="num">(223,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance | shares</a></td>
<td class="nump">16,673,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable at end of period | shares</a></td>
<td class="nump">7,802,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance | $ / shares</a></td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">3.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">2.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited / Cancelled | $ / shares</a></td>
<td class="nump">3.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance | $ / shares</a></td>
<td class="nump">3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at end of period | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at end of period</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period | $</a></td>
<td class="nump">$ 9,775,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable at end of period | $</a></td>
<td class="nump">$ 7,006,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139945751933352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Stock Options Weighted-Average Assumptions Used (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.10%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?EV6S?--^UN TZ]+9O\"4$L#!!0    ( "J IE**ATC^6P8  !H8   8
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M9M,-80 5?.ZMJ6(3A[L4%01;AP)OK(9!T@+)0OTD<EL(W5*E(BQPF:0]VU.
MYS%GY/I)@X>&77/IH_9M?Z<)(/-/)@7TJ6E#'2V3NB/C4H2\;:S2&5P9.9]S
M%"D$T>/"T]'J//FZ>M)O[:#G5$ D0P'6=+MM*%^476"0J:3L?A\:8[RUK-;4
MKTW3%ME),-R:N^C<Y(E\HG1;PGS?+SRRII#A'V6O\(^V'5HC1I=."WJ;)D:V
M4:&EOSTBQ$+\L1LG5>(B3UV7T5A,YS&SF&M0JO4&WWZ"N<'IQE250LDLU*9#
M3\<GCS7D+S-/FK$E0KSG[H>@YE1,*H6\[C=&Q:W]THU?CKQ*OQ=GG0)I:$*%
M (D2MO>_W1$5!S#&9G--59"G\_D0-1=9A[,.[<E,4,?F:82H1$ZAY#:DF7O/
MER>QI"*.V)S 6LI =Q">8*Z('5@2Z%ED::Q=+CVMV_%2;L'28 DB[\LD&@"2
M#LAD[3'!NKJ>7N>2=6";#IKL?ZQ\%72I$.3IJXOIR[T(-K5IN&T8I4O6<UV)
MBN9<<Q(_D%WL*[OETHST+J[.KF()ATA>YO%^V)5U1R2%>7D042=XOOD\89!J
M'67L8VSPA(X*>7WKJ/#GN<!7NG:P4VR.6IVU%:NT@:/E9#AR%U5K7SFSD!!2
M,IKB2%HOX//[BT*]T^;/NM491%SVOND&?4F#2"P7I#U(%8;&N=X'+J\J$5Q9
MKR)1?6@W@?)%?CO4_"8_X9:J55E=('Z/Q!I4-<ZA<7;EN"W.=3)VT<P8X^H)
MJ<PN(4?DIWD!$=140&5K(0,:>R,B6665/T.X>U)L*O3QO$)LP@4ZLP]MPP E
M.#&TK+."=:@@IS""F@;]5GJY7QSK.=7P.5)).FF#J>B8G9]/+MXR_3Z>NGXH
M0P;(.3:*)<F OA1#_D\Y,1WF,GEO+-4//=GC$T,GP"S"L&S>ZTC-%Q'-1P:?
MI*8O7TZO%J!2W8 &U(?Z%Y?58Y\D.L'8"K7Q\"+OTS@:MO-TU+A39KND*NFR
MI/Q95RDYWD)J&*V#UL90$.'=/ZCS6@2+,"IB9/H@T3'I+L5T(F!)8O:\Z;8'
M6;AKX+*F(0XT[23,8R&V C-" ?8V5['\Q4CW(MVY!P@P[4[K.!X +\^".(H4
MXY3 $-C=Q5D  N;OPV!4(E\D<!H R(6-SEHYDAJ>HUV6QH4AWE!&&GHPL?DJ
M(;GTGQ'<5I^4W<:V5M8=.GUR[Z5]\ZXIJT^3NVIM*>.1;BH196/A\*(S2=T-
M.B],^FTH5 9/(Z/)3IMVVPO[ F8#VF$HZ]Y24Q&!\JX8D +AEYH',?TAQCPF
M&@I?)5?$Q@VPT>*#6\95-J84I^N7K[T,^3JV M(Q&[9)H#]>?G@V91_CN0J=
M89PM#"V0@1/".. +31"^,@\Y.HDS%!_O?DK3$V'R3/#_?2R623_+G^4603:0
MA#>!O'S$N!$A^,@,"\T$95PR[7$52BV;?#&G>T+13![2@M 7W2=F'"_=7Q>B
M89YO.1C]D1'4:$:3OF;UJ:@X!X@*S4:"%NJYZ7L0!5$';ZC[&M11^K[)]<HE
M/LZ$[Z\.!0^33TIU4NS0>4N=6.<SJQ6@HHEILO85M;U^+#]K^2&!D0==^3F1
M@$<40M,VU1_RBL*1/4!E :B6!G?<ACU?7,9C.2,.#,LY]AK&>1><G7,(S>*?
M)CGBG%L$D@;=$',>!92S-?$ DG/O]JQS&IH3A:4]1 BN-5#-M^R@=8N^BX.4
MO "7F)C+6[B1"E'K#B<)R=DJV2"?<LI"=P]:GYPODP/8QH:B73X=?:)R$(R?
M<5G=FL$C_D.<4G$WT4&B+3SJ*\E;R\R&4\_S04H^T,LBNBU$V6UPQ$,P@+?,
M21Z-;<PG'C19ERUG/]R2"H.V+J:R6;>U/@(7=[!HLPQ'-L2:X]EE5JZ/?59(
M.+AC_)JD_BA&X(;\\H>B)7<O%:]6=\=@F9*6L/D8!MV9:CP;)OX\"-B!I9 A
MI7R;;JF55 ^S]J$M8!_"-"^;LL9LS+YE(O#&/]/8$S.F<Y@![LEW9,%&E&8;
M,WO@QQ(LD,<)XJ$LTMH4\.9%?0*U;S-U8?D25?;AER9[PZ7@#_\ B$A1Q)&U
M-#>YWQ[A@OUX_C0?569Q:/0]>:RHJ8_5:I#*4]+LU3?R^X1[ A&\Y]>S:TE#
M:\N3IG^ZN7N79Y,7\R+NYI&RB5U.*(09??F8!>,,5<8FV3LV,3R.3Z/<? C_
MZ&DAH]718_ V"5Y&(8@$U_(V5BJGZ== .@BDC(=0>:@*OU2IX\]=2*6\#.O&
M6Z3FUD[D6_IT[">,+[+?=FZT6_$O6'E<M.WD9Y[I:?J1[(W\-G18+K^P_9ZG
M>3Q@6&+KV?3RY1,A:OS2V2W_4G1AN\YN^.-:E[5VM #OE]9V\0M=D'XZ_/9?
M4$L#!!0    ( "J IE*"5.D:&P@  ,,5   8    >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&ULI5AI<]LX$OTK*&UVRZE2=-".[?BJ&GMF=F=JLY.*D\EGB&R9
M*(,$ X"2M;]^7P.\))O.5LT7B0?0Y^O7#5YMC7UT.9$73X4NW?4D][ZZF,]=
MFE,AW<Q45.+-VMA">MS:A[FK+,DL;"KT/%DL3N>%5.7DYBH\^V1OKDSMM2KI
MDQ6N+@II=[>DS?9ZLIRT#SZKA]SS@_G-524?Z)[\U^J3Q=V\DY*I@DJG3"DL
MK:\G/RTO;H]Y?5CPIZ*M&UP+]F1ES"/?_)9=3Q9L$&E*/4N0^-O0'6G-@F#&
M]T;FI%/)&X?7K?1?@^_P924=W1G]364^OYZ<3T1&:UEK_]EL_T6-/^]97FJT
M"[]B&]<F)Q.1ULZ;HMD,"PI5QG_YU,1AL.%\,;(A:38DP>ZH*%CYL_3RYLJ:
MK;"\&M+X(K@:=L,X57)2[KW%6X5]_N97J:SX4^J:Q$>2KK:$B'MW-?<0SDOF
M:2/H-@I*1@1]$!]-Z7,G?BDSRO;WSV%49UG26G:;O"KPH[0S<;R<BF21+%^1
M=]QY>ASDG?QU3U\5Q&5RX2J9TO4$=>#(;FAR\Q_C220S,:(E/M^$Y\HQ;" T
M$]()GY.@IS27Y0.)RJJ4\$AZ@+G6F5@1D)\2@)L)5*"0P+%SJ%5<5U)EPAOA
MK2S=FO!2:"572BN_$T=824_*1Y%OA2J#)MR5J:JD9@&%<5[(;"-+C_HSM0.P
M[".$LR9>W:GJY4(.)!N;D=6[J%K&^EJ1WQ*5K8Q*6J]8%7MOHO:BCXC(I*=9
MB)0,VSVE>:F^U^1$[2@XUBP7ZSYV!2J"X:\*]5\*,K%8F+4P*TZ$7&G$MZQJ
MZ)1EQ@7S;&5=/EL[$U_R/36Y(BMMFN]"Q6?1?DLD-&U(.Q83=T[Y<INK- \J
MULK"/K\U0L+NU("[$"@6T*MDNWBMEE@Z-&8:$U_(':?]E2  0 #.VF@PJKL0
M__C;>9*<7HI_LVUB&>Z7RTOQQ[.0N!IV8NOW&FC-(C1<2&G@QB9U+N0?AI=(
M() 24."&,%"$D.VK33JUOT5=!CXRBH"6UK#@'@=FZ#.IL#!3P+D'I%AUV=Y-
M1TQF QTRJZ5]V;S+YSZVSG56E,8WCE_R[FAP$ZD73.4UJ62<(['6FI6QDC6L
M=L-%#?J!;AFMK%?.HP:4U%POC)%::Z#=%@R=KLI^%-_C+KY?G^.W-]?5565L
M8Q8D^6AW:5K#@L-<R!&&[3;U4*HULHW"9$;9KX;7[?S6U77<%V"IR@<40RE!
M-D"0*IVW=21":!R*!O:8X6IK>0NJ33VK1M<8X&A$Y!8E-J@(<13(#GP&']W;
M"_&12[EK)>+WNB1QO AWBPZ<+8S;<(\]_R:MY3#UE/@FIB:YW+LZ2CY,3TX2
M\7;L_<EB>G)^C/=?C(=#?UD*8I;"MAW'41:F#KR['@E96U:I=+F@[[5"I/D%
M"BX'?MX%?*IR0\XW:0-<9)I&L97<12JK*FO Q:B#D'M+.I3$,'<9LMQ :B :
M6VH; -0G=V!?0%54+TQMN4&2:ZQ%<D=@$&B8X<S3J4*Y@8 WA#84*P56L(">
M4PI3TJ[K>37 $MS\.KN?B0>#G67H5([AV8#][EF\MGE 7U5IE$]@-)8Q%D7N
M"B!^AV*+[;^%F>R'@M7NL "[=C0#NP+..T!W>0[=W M<C3W;B,I =/"Z;&;>
M+<@U!! TN.$L51IS2_ *87<Y[ D)2$V!8 A,F^GC3'RJK:L'5,!NM'GJ- 7M
M:3^D("8V=BRP!-/.<'$PJTE>&'@VC0D\SZ38ZE2PM]%Q9PK,#8&CIAP9I@B'
M,7NZ+S2FNE>\ZI@H.Z 93HFEAAF#P+V))NK$W%IRT[V5&N@B<<]#=4 B"(HG
MGFR$&#N#Z@H^<$;"_MIQ*?*"6T3]\=U]FAN->&^ZF:<P&9(?2NO %4M1P[Z_
M7I $=*,G+)R'J)AD#E<<(D.P!T9VQG-\ 87>T7N/[2T8_JB ,;:JX=_>RD,O
M,7X,)AN4#=IFRX[-VA='J0$3E!3=Y)$,U5 75=#<YJ+7W76H%=KS#]K4<+KD
MF YGJUD[EK1C54:,:M2;0'$&!LO&,SML>+ QU7464_/:WA 8'>@XU!6G;]\Y
MSM[T0,YP,.A+S2KW^&[- RAH#&$'+?+P@3?T5*'6L3%#6T=>&PZ+IXKFU<:
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M?XH?YOKE\?,F#'C M"HTK;%U,3M[/P&MAT^&\<:;*GRF0Z?SI@B7.>98LKP
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M,BB3 %2J76+#P4@IKJ4::&VN=/_A],Q5J&!@T6TU=WD'[< ,\.1V*]2 C*>
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MC\<O,#7]Z DF7'T"*#\':FK'# UUBYIFK:L:TZ;3_#BF;U^69%M:AQ V23B
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M6/$21NL#^/O*< _N#)^@7^NS/U!+ P04    "  J@*92(FY5G[L$   ,"P
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MWB?VD&)9$:@V^<X/HDC?@2M!B +SQ)3^"EL6=PG%1]6)#(YR$\F3) 38$(5
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MU$OT.;$1V/_AZT926=4-5T,1>B$IYI0L-'RB$JFH&."EQJ8BTP$M#L^?[_?
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M&U\/%-^9QG;%%78MYC''3Q\0V@#?;SA7IX%VT'Y,S7X 4$L#!!0    ( "J
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MU$N6EU8YT2)WI_)4:'/&N^'2W/,H;8!Y/Q="OT_L05__<QC]!%!+ P04
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M3-E%/*^%9<(D;3JLO"YU']2I:ZM3?^\0];A3U$_&ITD0:(0?Q&.>3_])%/%
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MA9Y4[6#Y*]^..?TQK B3B,)2FPIN;K7+HAT=[4;QM;T;YUSIF]8N*SUM01B
M?K_D7.TVQD _O_,_4$L#!!0    ( "J IE(/^;+-,P,  #D)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;*U66V_3,!3^*T=Y @F62YNR3FVE]8)
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M+9AET[%6&]#.FKRYA:^^1U.]N'0Z65I-MYQP=KHDX66U0% Y+.NJ$D@BL$S
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M4N(Z;=*3]I:;E5#&E? (SY;<"+5Z(G]_6AJK<?/_&4 D+2*I$:,>Q#VX![T
M[=JU1A[VYP68)B ++C?DCTH"2:*F,E]CFO19G=Z],/MYDHVGX=ZC:=1J&@UJ
M0E3L0S51Z1F*IG3B9Z4M*WV+E?A8J8>5I7Y6UK*RMU@C'ROKLC(:^UEYR\K?
M8J4^5MYET;[]&K>L\5NLS,<:=UDYC?RL2<N:#+(>MX!6O;:@?<1)AYC0N*>3
M-#H92C3,5,XU!*!5DMW1.[P>$7F:&V6C'OZ9H=%!_I]@S#59:#!()GLF*B %
MOJJJDM:K@W9T?(S3-.O1<7(C&O]&'_#SJ9EUWM!T1'"VY(+;%Z^4N"-EG$8]
MSQL]F18==JV_>C1P\&],TE$QB7H>1'IR*3IL4P,B/A"AY.8C/J6E5T_7R?*L
MMRLG*Z/#7O9_]B?MV/? _IR,C@X[W<]Z=(""L#V*V0!..^XS<Q+E.D,N\*/K
MOC7FTBMM&)$WH0.?0'KR2CILEAVYKV\7P4Z"5]QPPOPJC=[[I(5G<XV;$7%P
MV'!IL"MK3!1=Y;@?NAF[FH55NWK462J+@U-]N,51%;2[ :^OE;*O"S<]M</O
M_#]02P,$%     @ *H"F4FI&Q* C @  F@0  !D   !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&ULC53?;]HP$/Y7K*@/K;3BD$!IJQ"IA4UC6B54VNUAVH,A
M!['J'ZE]@?:_G^T$2B5 >TE\]GW?W7UW=K;1YL66 $C>I%!V&)6(U2VE=E&"
M9+:C*U#N9*F-9.A,LZ*V,L"* )*")G%\127C*LJSL#<U>:9K%%S!U!!;2\G,
M^ST(O1E&W6B[\<A7)?H-FF<56\$,\+F:&F?1'4O!)2C+M2(&EL/HKGL[2KU_
M</C%86/WUL17,M?ZQ1N38AC%/B$0L$#/P-QO#2,0PA.Y-%Y;SF@7T@/WUUOV
M;Z%V5\N<61AI\9L76 ZCZX@4L&2UP$>]^0YM/7W/M]#"AB_9M+YQ1!:U12U;
ML,M <M7\V5NKPQZ@VSL"2%I \K^ M 4$Y6B362AKS)#EF=$;8KRW8_.+H$U
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MLG2/!QCOX,Z76N/6\/.Y>X[R?U!+ P04    "  J@*92)GNP\/4$  ! %0
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MTN(7OY1"U "P"X!* 'H/<#H =@FP^P*<$N#T!;@EP.T[!Z\$>'U'&)6 45^
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M'<:QXKBNN!%TGY_E/%$A:))?[@B6<J@.\OF&4G&Z40-4AZ:3_P!02P,$%
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M)&T"]9F7OGB;\&Q/'N@4R.&^C_JD3<-)N\67W^74^OQ.CR2_4Y_?Z8%_-?U
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M8T-]N=$'-1#F _U^Q;DZWAB"YN@W_0]02P,$%     @ *H"F4H>!L [W @
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MUS">I*'VXQY3^D! 90-H/9'2' ;V!?4GQ^0W4$L#!!0    ( "J IE+POWV
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M=VE?QQM4_$&9STN['=G,H5?8C68%7S7S5=$)P-@CG)U6E5A_$GPN2^8V_^*
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MS3EX<!Z%FW,JW/[Z,_X-4$L#!!0    ( "J IE*7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ *H"F4@BD;G1<!
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  J@*92F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M "J IE+V3HXR-@0  &D0   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  J@*921O(MOK8%   Y%@  &
M            @(%Y#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ *H"F4H@Q$,*8 @  )P@  !@              ("!91(  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "J IE)N*@P;, 4  /L5
M   8              " @3,5  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  J@*92U,%E27D&  !I(@  &               @(&9&@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ *H"F4HJ'2/Y;
M!@  &A@  !@              ("!2"$  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( "J IE)<B#=^EA0  $8\   8              "
M@=DG  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  J@*92
M@E3I&AL(  ##%0  &               @(&E/   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ *H"F4L^K<+K4"@  81X  !@
M     ("!]D0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M "J IE)5C?$:5@(  /@$   9              " @0!0  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ *H"F4G,.?42E!   *@P  !D
M             ("!C5(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  J@*92P$<_K*()  !=%P  &0              @(%I5P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "J IE+F5><SV 0
M "H+   9              " @4)A  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ *H"F4EKORL"I @  X@4  !D              ("!
M468  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  J@*92
M(FY5G[L$   ,"P  &0              @($Q:0  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( "J IE+J_+]F+0<  '<1   9
M      " @2-N  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ *H"F4I+@SD%-%   _3P  !D              ("!AW4  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  J@*92A&)(NN(#  !,"0
M&0              @($+B@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( "J IE(W0P3X#@0  $ *   9              " @22.  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ *H"F4A')IF,D
M!   T0H  !D              ("!:9(  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  J@*929E;R]C$$  "?"@  &0
M@('$E@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "J
MIE*_IAK5/ 0  )()   9              " @2R;  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ *H"F4HY45#EN!0  A1<  !D
M         ("!GY\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  J@*92[F:YVDH#  !V#   &0              @(%$I0  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "J IE*<<W0%PP,  %@-
M   9              " @<6H  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ *H"F4I\W-43* @  10@  !D              ("!OZP
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  J@*921EXO
M(!\#  # "P  &0              @(' KP  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( "J IE*J#*NHH0,  #X,   9
M  " @1:S  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M*H"F4E9-"V0W!@  [1T  !D              ("![K8  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  J@*92O? +S84"  "\!@  &0
M            @(%<O0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( "J IE+4Y>['K@(  ,L'   9              " @1C   !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ *H"F4@_YLLTS P
M.0D  !D              ("!_<(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  J@*92[_RL;RX#  #'"P  &0              @(%G
MQ@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "J IE(0
MEA4A\P(  )P)   9              " @<S)  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ *H"F4G%;(]Z: @  .@8  !D
M     ("!]LP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "J IE(F>[#P]00  $ 5   9              "
M@7/;  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ *H"F
M4EVUMA^9!0  L!H  !D              ("!G^   'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  J@*92Q2K=I"T#  #&"@  &0
M        @(%OY@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( "J IE+.UW[BX@,   8.   9              " @=/I  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ *H"F4H>!L [W @  ?@@
M !D              ("![.T  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  J@*92\+]]@" #   *$@  #0              @ $:\0
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "J IE*7BKL<P    !,"   +
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4!08     -  T ",.  "2_0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>156</ContextCount>
  <ElementCount>308</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED BALANCE SHEETS (parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - BeiGene Collaboration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/BeigeneCollaboration</Role>
      <ShortName>BeiGene Collaboration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/NetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/ShareBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - The Company and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - The Company - Revenue Associated With The Following license agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyRevenueAssociatedWithTheFollowingLicenseAgreementsDetail</Role>
      <ShortName>The Company - Revenue Associated With The Following license agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - The Company - Schedule of Changes in Contract Assets and Contract Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail</Role>
      <ShortName>The Company - Schedule of Changes in Contract Assets and Contract Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Schedule of (Loss) Per Share, Basic and Diluted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfLossPerShareBasicAndDilutedDetail</Role>
      <ShortName>Schedule of (Loss) Per Share, Basic and Diluted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Calculation of Weighted Average Shares Used to Calculate Basic and Diluted (Loss) Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CalculationOfWeightedAverageSharesUsedToCalculateBasicAndDilutedLossEarningsPerShareDetail</Role>
      <ShortName>Calculation of Weighted Average Shares Used to Calculate Basic and Diluted (Loss) Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Antidilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/AntidilutiveSecuritiesDetail</Role>
      <ShortName>Antidilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Schedule of Total Operating Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfTotalOperatingCostsDetail</Role>
      <ShortName>Schedule of Total Operating Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Schedule of Future Minimum Rental Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfFutureMinimumRentalPaymentsDetail</Role>
      <ShortName>Schedule of Future Minimum Rental Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Short-Term Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Short-Term Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Share-based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Share-Based Compensation Expense for Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail</Role>
      <ShortName>Share-Based Compensation Expense for Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail</Role>
      <ShortName>Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="meip-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail</Role>
      <ShortName>Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>meip-20210331.xml</File>
    <File>meip-20210331.xsd</File>
    <File>meip-20210331_cal.xml</File>
    <File>meip-20210331_def.xml</File>
    <File>meip-20210331_lab.xml</File>
    <File>meip-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001193125-21-153237-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-153237-xbrl.zip
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MO('?_Q 3*E?]3A<^PE_=4?N+MFKWNCU5^;^[_;?#_MMN[_]1_M^S+_]?NXT
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M9F'X\Q)T^NK&U6RNZ1@,QSF/0ZC J&!W"'KXA0%3/BXM4S<] :QBF/"[R ,
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M]@ [&X@%,]=?^-0#%4PVC,$6@+VW=&[W039/TQIW,R1[P[VWB&[WQN!>#_:
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M\[VYXYK_9@5"9%2HYTJ!YS1@/AF:%LSK@=@$[H7O8:K: /.B -[M')MB>#>
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M%=,9/'MK,9#N[]F=:=N46@*G7"^"N_!D_59=3$=!E41U,/8&>MT!^Q(6+^I
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MC[B_:]C:&R%\,CQ4C'P\&1[JL0L_@[PT;6[JQ=M*+2XPV*(P=CH>#[O3P_@
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MAI@CF4P^1_U3N#0@"Z;85N32NYB!@[U@ X<4 -5!>4+*7!%YP!!]E%87UG;
M:3F]#<8GZ,3D:\S6=$IG?PB^#'*ESD/07H$,"RPNS-H)"%Z0.(<Y"OB-$*X#
M]@%Y/EIT"5<@9&L'1IKA5H#U$2L+R->KYB=)AS="1-Y@5CQ1YF,[43 QHFI
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MXB(?5ECZI*?VML/Y8? A&4HRE&0HR5!)"%[WIJW!H'?D=?_XI+24_"(%D!1
MDJ$D0SU'AGH]Z+8&D_X3:[3-594U'6'9A9GK8M-:ZP;7!&0J10N"<)"HJUH^
MBDA0)IA4'C\HK\=Y)J#70!3)&I(U)&M(UC@F225#- MT*2LD:TC6D*Q1(VLT
MYE26U<C$9[]1B<_B/E'8.CW' /OP\?$$05$XH+X QQ/&PEY2*$$241*Q5B+N
MDA;;+>'UE*Y3DS NMXTDHB1B$XBX2P)%ID9.Q3OM@XMG.#X>+#XY]_1@L,O0
MA60.R1R2.62"I"%H/678I;R0S"&90S+'X=(DS[3AULMMLH4=L8HNORENB!5V
MM-0U/J>[YNXUB]&EA7SNN%Z;6D.:-EXZ%E]I'ES)SJ/;A+3ETG4>XUOIPDMG
MDYVY#'&O!EW.%P\-K_BNN'TG:MV5@(]N:Q/3TZ4=[!&ODA70FG99DR_J R]N
MEM$,P#YV@*<]++KB 10X0-S.<P%LM(J:[@-GB65^[5QWE#N\D<VF5OD<FX^)
MQG;*AQR^'NB"$\"$!:*"FHGB&&58Q+;TEL:Y.3/%_0.Y_J1:?#W![2K;=2]J
MC"^OFREK *M\T59*KZM.Z#8CDW,?[Z 6!R:#:PQMFXD[$^AJ:N2OI0L$!2:&
M\?3HED^ZA$]<XN4L@%<4NDRQHUSZ+O<371&1RB$;1S/1['I\B01=KTDW"G!&
M'1B3#Q-8 6_3A13W 0AXWX0N+A(,+X"F6TD72\U>11??8'\\[EM>*SVHV GQ
MQ+=1&SXCTV-/W)L<-(FD 5,W3J1O0GVO670#U/6<,:\3LVYPOZ*+]^,4-XN,
M(/.7L!@D#0TD;JW$!]9>52I$4&9-+A,SI!?N*4RC2TWIWBP8G.Z\)&HCWA+W
M#B6 C(!WQ$5!&^]^%5T(8RBSJS1Y\@H*$"_,S6[W?OA2X>47"=%I,[%>O$0#
MQ(>_$'?!AM2)@8C:=Z(:W=##,WD?""(W>1M&@K!!4^7P1HSPIO34W9YEM$[=
MLQ;>8)^^/37_+J'*6L7WEP:WJL:K1'JV,N,DNQG'N] U^??V#.\.,?$,/RH4
MNE4T<3DM""WL_VX47$V;N-FU!+;@#MD$G@LN.!&X"R\2*R; &KQ1]TI"0 P.
MW:86P;L6"1WEE_#"4;J3&+0CAU%?&RSX\\<"T$I) 5-FIA-7Y0@11/WU@S[:
M0"CJ-QWVR#9!:ND;^%"@,[B.IPRJF#5I.RG]'-:"NPD3]\M5N\TYO'E'W#:#
M:ZU\]U?B%KWX%D%+*NK2>A_0>);N6Z'MN%F$K%J9]K%)04A[!+>9;.;:B'MX
MJG=S'>]Z5T_P>LE]-9O<^*B7;-4.D>,#=(@L'[,2\-.JL \. 'O9F++=7O'@
MSZMW45X+XBBW[AO\\6G;7#X+_.:Z7*;1>[A^E[)7U//J%755[ "M,S/DZ?7&
M3KQ5%5:WHQYY\7][4H(VG':GPC3'[N2391IYF.>$-%.ASOD8QL\L<\:4URNF
MN?S'K35.,Q+8VY:J[CKD5INTMZUD;U+EZXNBT[0Y=))^P;.3OGOX!1_S.0[I
M$SQ_\V[2ZPRD4] <XIT&UXS'3\XUTBLX(;U4J''.@SR[LC*994AWH#XSL]OI
MU@9PN;26UOT1T2Z-]6<G%/<PUM.%<9^P5.(/+)60%ONS[4&K=K9M0+L] Y]&
MKV/)7?5S5Z\SW#+,__3<]:).KV2:&63+^QX+M-]CN5I+#'2PXK0#U3)N78GW
M)"=OXJ)$4:/'F4?5I%AQKG!_ 0N@$N)$Z?FZ*FBL/\^5BN>+7,-RU>V+5)77
M!('C<_B&_RB+)D^L:'(RV*MH<KKQ7NRU=8=5;]7NI:A?3]WAFC%/%W99,[FA
MIF_Z'&KZT&^+5RL<N.BC,TL<I0I.;L3??,4S4O''Z_B\"0(2U 5^39P\R1[?
MB3^_SBJ6?&9>,N;+*N8M7'/%OZC6=X_W*X4M)!$/3L3N@8@H YDRD)E@TAT8
M.SQPK'G*/WUK%7.=.'-0&O^4L=#G$JUJQGU<DG-.D'/4<6ND/C7GR-J%4[^>
MX(J%;5OTJ-D#V'K8-<2\9XF0G.=0>QCXBYI<L$?FZB:GH%YX'G]K124K'THG
M&1TXB7'"#8 ;22\QR0ET]Y9NR[,3['NX+1^BAB1E&9M8 R3Z>^TL\:6!V82)
MMZO74%O=_O#  NQ$*C8DRQVGEK^_7?UA _A-7MRPU]MIC=F8N_E.&/0:B")9
MXP6RA@SIG%#"XA"IB.(&2#LG(YHA8!IUAU3#[L][4;A71ZVQO+_KF>IZ>7&"
M- 0E<U2'O?3@0:ZT.%7NJ7:[?WLGZL';8$@XOO=V9CXR,.]R)<>9DN18-F;X
MLP)<?W_C\_:=IBW?8KDA%1F>FURW'&RQS&] "[RW'/W[S__Y'W\/'[S6Y\SP
M+78QBUXYXUC!?F8;O\5]J+\$S>,O["N\$<$%8-]KW.0W.'4TL&(:/[WZI.F>
M:7SKJ3UUVNN.7F$C=%1 5VSVTZO+[OA;5_V&-4<W3K?_K4]_JZ]^7F?+/O^.
MR']&C; S;8Z+;[M(=_!W;+H%(""+<HMT$;VTDW=Q1%=ME%R@03=9\&!J+L\(
M'/:,P.2P1P1(_.QQ1F X.LH9 :)LS77V:\:4L$O8)>RG +L\>K"A:EU]%F7K
M)2<5*[D2!VD?_CS0FNL?KART:_@+V&[/@BVRU\T=>IN]5,3V)&(/@]C^TRF&
MYXA.*0"D #@MQ*X3 +)H]]FE[O<HVOTSVR]E7010UD2>]#FO6L\5R");R5"2
MH21#U7L2=8=RIE,YPRSY10H@*8 D0TF&>DD,U8RN'+*45!X;:13H-1!%LH9D
M#<D:DC6.25+)$,T"7<H*R1J2-21KR#/+QTI\-JM;4?%5$XZG63D&D&>+GVT;
M,DE$2<1G3<2FG?)__AB7VT8241*Q"43<)8$B4R.GXIW*1@HR="&90S)'@Q!\
MRK ?Q4Z7+'%*L$MY(9E#,H=DCL.E24ZIW5>M7;RP/=B"F8DF8A>SX#Q5.-8*
M1O<72[P-9W,+L+%L 58IO:/ 1M)]2_.")F"I.R;PF]PEX*U,MS MIHIHZ.5S
M9LC>72=VO_=XM%?OKO%PK]Y=:K=J0Z#Q 1H"E8]9"?AI5=@'!X"];$S97>4E
M'%4O[@D>W,[]M%V-G@5^<TV-TN@]7'LCV1K@>;4&N#+Y]_;,97BE%\S N*>X
M8'.M,S/D8:7&3KQ5TJW;48^\^+\]*4$;3KM389IC']S.,HVLW3PAS52H<SX^
M+IF.%T=:YHPIKU=,<_F/6VN<9L0K&WFW;&];R=ZD0H<71:=I<^@D_8)G)WWW
M\ LB&7WO6)HGFX:]$/-NTNL,I%/0'.*=!M>,QT_.-=(K."&]5*AQSLU[0+EM
M*"N3689T!^HS,[N=[6['WDU:2^O^B&B7QOJS$XI[&.OO+7BU?:W/'0N P4(5
MA2I5I,7^;%N.J9UM^XUMS\"GT=I.<E?]W-7K#+<,\S\]=YU8L>+.-85106)<
MYOAAKMEWC'^VUXRWL3!Q\O2%B5N7U1V_+C%582@X"RM+X4O7FRN: D2#!:RP
M2%$75%'H[E"F, ZP:1A22]<R.KZK9&]VR!<WX@0TC VP* M8RIPKX"W!<"7W
MABD:^%)(/GE[Z6E70$X&>U5 3C?>:;BVB+#JC8B]%/7K*2)<,^;IPBX+(#<4
MZ$V?0X$>:N)XM<(;BSXZL_CO0$_S^)NO') ;?[P&<,P9@&9["$A0Y/?5=FXY
M<^_)H(B>_6PO_>10K[.*)9]FEXSYLBIS"]=<\2\JW-WC_4HQ"$G$@Q.Q>R B
MRJBDC$HFF'0'QGZO69JM,T7SE'_ZUBKF.G& H#28*0.;SR7TU(R[%"3GG"#G
MJ./62'UJSI&%"*?>6O:*Z9;&.?E<&'_%(!W8>N8]?+IGB9"<YRCL7S[^Y2_A
M,?;(7-WD%-1["+VZ;165+&,HG61TX(S$"3=O:R2]Q"0GT)E1NBW/3K#OX;:(
M9!IF;<HR-K$&"!4%/+*SQ)<&9A,FWJ[X0FUU^\,#"[ 3*;^0+'><POS^=L6$
M#> WV71WK[>M_3J&R2MA<J#70!3)&B^0-61(YX02%H=(111W,]HY&=$, =.H
M_O\-N_OD1>%>';7&\NZ%9ZKK9=-;:0A*YJ@.^RF>(MCG( ">)@C[)E\Q;+=K
M7&HN/ 7O<#P?X-C\W.2ZY6"OY'7G!Z:[G1_8IX_QI/'G!78Q/']W/*;T.\IO
MILYLSI2S.Y>Q!5CY?&WE_KHJ_MWP.ZID_B>+K!N);U&<9WH@@_3L2^\V/D'#
M_OKKAY <+>4<:VJ=)5*$SEA\<!8+S/S"V_\6">.(8KL0K,X#-644I$5]!D"7
MKFG1(9&6\L 4*E9D!K:"=.BPR4YK?HUOALF_7I>0M^;YZ$GUW8_*@^G-E5]7
MSH.F_&JZIHTO+C5[I;Q.#YA\J:-\!6R)TS%:."JMYPX%'ZP'5H- :$H&U86!
MTQVX3G?:[%&W?&[>LY1KJ'!04(1#%+HM9:FM$+CV+=.PW;QB!5O<IP7HH"TU
M6/,2I##N=D3T@2#^#N^VY\Y#"E@4WZYC68"QVY7B<\2;(0A/L.@)(C+EW_ 5
MLTQNWM*/2*3E7 -UJS.?E+ZR=!W#UST:%]:%"TZ\A >:-,M2YC[P,;"<$91;
M1 >FOG:N.SEFHB\#MDPR02L 0HD(H;P&Y/_%8'Y81HA:E^&_8('D%]$*E\P%
M4!:* Y2Z"R#P(X;:P+PP[WH2MR2-RVBL.S[ 8H(X W,)0V)A9_^OMHF[]MH#
M'/&  PZ#H@1C?7QL(V\E>2J%N".#D9S:RK-[AQ@S(=^ DD\OWIK,ZHBOJKQ>
M230%$N?)D>XZ*\WR5M3$N:7,?,N"3:J9QBE0(Y*]OIN2OP&:#P1?T1ZK+/'%
MSB,$XYY#]C ]$R6A$/PHQ'X =S#V-L%PLW (6-07;4765D>Y$**N^$D:76"I
MI?P CP_RSSQH'+39PO2\%$9QT']J8#(QH+RG/=)%*+XW=URZ\T;14$ZXC/N6
M%XE;5*F?T?2S81E7L$%LGRG7S+T'!E)N&0Z!_A_,8\ /P20?+O[X? Z0 MX6
MIBXV WSO,B!H^)9OD].,A'8=[.X$AJO..,<#TH:C^X@O@5YXA/O+I>-Z0H<S
M<?1=F8&52].Y6&F)MBD.;][99"G.P86">3K*G_B SF"K&,(,7*!NB?%3 3%
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M/&)W$D,)X%.*%J4^VFJ8:TL/.0LL[Y25&P5F6H'F?6"!:QRX!((CX%77\>]
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M;2*AJ"ZK7(F[]KJ'/89<,SC()Y!(]D^OII$8# 25&"MYXU]\E4+ZD0#U:D(
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MQ7#2?(.*#6,V"OMTV#SL&\9L%'9EL(?.()L&;13ZL=H\\*5CRO8(YW!N^DO
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MO8WR<P#E,FF];OELDY\#ZQE5R: 'BS*J!Q^-U-YD/"#?;G[S4J<W^N0C'DF
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M?^_2>W$5LJ#U9V  FB,])L,_"F]6D-4_)WSF:X?JG^MD9UF?_!S8"?4]'+!
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M\YH6$>/*,FV\M>76!97M)>FB EGZ8S6F21W,&J3(YGV% U-$Z<^&1Z?(IF8
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MT3;H>E&O2\1H<\N@*J>\9M/T[GY-D.)SUP%R[GIQ\^\ ,/U$J?^;;5"7O5,
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MY-+/53I(O]@"HHJ.'ZKI$L<0QHIP5[P)OG&X9YGM@YI@5PO^F@=;&<VG\UT
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MB3F0Q)22V4IB;I),N>5R<INV#9X/P#Q'[?RFW%;I2L'3<#H],,Y2:#HO-.I
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MM\+4.?PFW%KNZ*->S$&$K4?0ZX='=)Y7U],BE('O$:V$Z_EQ\Q@6B;$H$^"
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MX&:[;H<=7Z@O;I%&\,7%H8UX]-O2\V493HEL3JX;D\^7?;+D-8TA/F+-W%E
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MI<DW,YQ'L';>TEPS@V^9*S-KOQ&\>/NU0-[X[B%0'X@7H*>5<-%#L7;"FE_
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MQEQ5&Z&?YHH]>S)3KB^L,A%D(]2?:+*Y6QJ'Q1C(U[%!H":MEE1.\#T60(G
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M/%,'/Y$I5M@>M: #&/D(V?"2#J:EFYR$?O&V:$NQY]U9ZRP_AG:K!4,0SUR
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MQ')Z<!*$.CQWM9.R4[\PF271D52*V-&Y6_ATN<,E<<Z9\IN\=/E$DCD1H>J
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M?5QI70@%#EYWQ;]1]7[X-W#WLBC;U:QV7X'(:-4F9;&ALDKRN@U@Y\7;[WP
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M<!5(0SZ-)'P UIET^2YE[(S*TZFP[:?'ZPN](INT#7M!&4;##S&7CBEAPEY
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M;BS5M\$8+6@]-[/2/,3E3)V?0X+OLBA _TACK $0QY*V()GC,6;0BHEF9"F
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MGHIN@U6'>D,CQ7YW;",1>5%">87%CWEZA[(HY=:5E8WSAB/0D HU]C%NVM2
MV;LVK2H^7Z?9X<+FB8(_ M,*ZC-M+ 09)'MMG["0\0L+?XGFB[L-M@_]'.77
M&-D7_Y]I]K!Y?HZQX<@-XU <CE& FL;-!:.#S\#-(D]**3XGBLB/OT0QRHLT
M0=M"Z?B_HB@"Z4!,.6AH;G/)J"&SUT>>3\!;/7M]L;R-]8;#?IXHZN"<N<^[
MW*#'M 8X0GG58:<,/0RD;8D49\"+$C2KH8E0&T%TYE;O+DL#A$*Z:5>'ZS5"
MHJX;BB/Q$N[=F:8%S< U'6?KW(6N7A+7<OI,:[RD>?& 31ULBA,+_05E9)]X
M7&7I9KFZ\C/2K)2KAC2>T#L?GYU:JE!A>Y]M#]J9*[E+5+;5KMHTB_;9_2=+
M*+U3^F5HG+DD$_:MJJA^Z]\MD)O>1"4C>KN]-@3K3A;96[H!APWYI]>]OT@J
M##6:#W,8H'10&[FW@&FRIH^K17V&)PZ4R&@CHZ/+*R;"'ET46CHX&UW$4MY)
M[P?ES:V<XJ^+%[&*C)9>Q)IPHOS]-?WF_SW"^NI%RHV]X3R)/TJ05"?VJF0H
MZ#R2)5=(\/<U!UN@).Q5?1(,WX[W ^8$:,H COP!G"-U^J3QCL</XY4/W2-"
ME_=R"=:A<20%$*IL0%+09U$7(I,>6EK.#9[G/T.YOT2?HC0/(I0$)!L[$)]>
M@B'>< A:0H.W]EF>?1D*#M/;.R[RK*A]*_A?A]\)_I5W3U)_.8?5WM\Q0 <Z
M"AH[AQC8.!?&[5T)ZH+@?A '3V""+46C20\1!N,XG*V3RN%M^YH$=G@+O>TW
M8;)L&Q^VS\M68O87_WNTWO#+F1T]@S]/2RFWXLV<N5"/V<R@E<-@@"A;SB[8
MS/JH%IL=83AI;KPAYH@4(%:50ZJ6 GLT#O,&.H%.*@(MR=5A<63GCF^@O>R@
M#R3;0I0>7EJ&/L<&P8IW&0;MQU5TC=@ X3V/]787;[_KGP3#$!&CX;#=1.3"
M+K9I&](T3V;!*D(OE)KYHG85?X^6I&U+FKW.DO B7:])/;I:4%0NL1B-OPDS
MQ\6+<HFH;?&!LTC:!S\H*99W61IN@F*>/:#L)0I$5BOKT?+*^*]FPPJ1<N35
MD6NA(HU4#:R(R[D'H?#Y$@^DP2OD,E<H B2<L.>.? VF)0.MG5@0D4PA&9G(
MX[CZ_C6O0@G%!]O1@R65(%=Y:@N<<2KQ07!8;")7HW;4;2D5LYH[@%(+4Y.[
M,<OE8#BL!W!ED)+%\\6,9!<NJ9XB<6(PG\?'I --L(R[+P18.0($<%S4R,O+
MZ';_[3=U\-*"(9HS8<O3TF>I[-P0"(@MT480.;(&<'2 RAI:W>A2Z%(]Q(1C
MY&\HSJ,D.<RC%!^4PD&8"Z"1R(T^+\8!J@"2(Q<CGI/R[EA/+L)!F&30!#E3
M<E$ R9&+B6"&O_\>O)42D(3@'3]:*FR@\0NFQ"!"Q^&_EO.!9S>]\-7#_0<(
M->>6:B?!J(0<?)R<72V'@HC;7/_ X2,E1982-J7Z&(<[/!8>D,QAHA%3OPD3
MH16=-MR4MBXU8=U_?0YI\8WYXH8PQH])<Y0\EQ^2TH$E"A#?/W=Y,OBNCH,C
M!1.5%KX^7V=I4E27#7R6UY_RAD,0[U7K#%(6# YO303[/Z:%'W]]7M3>^581
MX#K-?B7%F/"A0MOR\%BO-0D]P,?]%$XSH!SQ:9G5(O'5(-#.6C?)/<I)C\/Y
MXB*-X_0IS:JZ:KQ,WL9SE=J8I="/+H39%"]'IB:LY6U_RL-2'?(2)O*1)?V]
M*W>ABXXC'1,V<V42SI_B:$E7QBP(TLV>54,7TBRFLS(3L)M-5/K4^_FM-0?+
M$25 001A!KE201K%&4KLSB0@&,VT9Z#D2-B$(7^7I8N(NB!($8Y\6X6#K$"^
M>XL[!%,\'@Y!8HG;%X!2@,4I_63"QJ?!83[> +)+5/Y$#MJ:YH3_AZ)E\NA_
M)\MFE<:D]Z,P<$Y[-HISU+O/R@1BCF2WO+!?(/46%:3?WQW*R,I#1LJCRL(!
MX]?+*-X4T0MZ( 6%:8O"6F/1S[)VF-H3>4,]?YCINB S3&UX1.G5]R#>8'&1
MNE(7Z?IY4U06_;;TT%8HZ@5#3+P(,\O.I\AOBMA0H.Q3S@8W3!8<<;7>R,BI
M] ^#LMM;)5SHAEI:VJ^3<0KE8N>R[IC#QQ0;:B39!7NAG>\M^"SUO0-4X$?$
MYX;"&2FOMT2W&Z*(S1?T*\U)W'F:/!1I\/O#YNF?*"A(T<SGJG;P/+OPDP#%
M,?W(!0>@L7=@'H+$^9D_!0VS1%Q\MLN6[G5ME;2A"+#E1-E%2CM"E/%_P&<0
MU0=$>BO_8<Q?@ H96.W'EDNZ1H2=LQ?,-EKZ,JVM#&*JH"RG/!8@TIS)&YZ!
M.LIX F!_18W &=+[NA1R]0$9$7,U%^8%J#?;EJ#WX#G3!WV'5FHK[CV(66+G
MOD]8-5)/-"R*#=IC]E70AO;8J0L9:RS>R^VI4VX4GK8"VH'"#]7VG<LZJ9[/
M=PF[R%XG[2DU/LOL*1.WRL>Z_M5B0>ZY$ZI3''HV+E8D7/,FV?7<FB^JSER[
MJQR>W]3\FTH_-FBBM-IA8AN_N/R_??OHPH^#35PYPPYLO]+F^XI/0JS/5,\=
MFDY$[3G$#V-.M73\J1AAIE[AG9Y/AK 5Q_MULT#X9:E^F5#A-"[P3FX>MMSZ
M 2X?*%0[E@CD_<-.@E*5><N OMQ"4'I=4IRW#)3H=%NZ^W(=4=+KH@:MQ?"^
MW4O4O.TR_Z?6/.4! EI#JJ.SL!E;G.EQ5ZN95;D *>&SHLBB)\P<ZAS<WD&0
MN"$:\%K/KA,LF?:3EPR#3;3M9AT9Y)4S7?8XWT9EBAU](OJ;#V^FDA6@<9*P
MVX^4,=!V/)L]_0_ (_S5RXS_EZ5L*:#99!C>5JR=V<.$)S^(/3QR*GG=K 25
M[.$1O\*ODW::K0CVQO;PZ.AXY-+=)WMX-'#5'E9FN(/V<,L/_-,K>P))+3>+
M;RU9[50++8N;:)<,=<9*9]-ZZZ^1M/"Z;&@)%KJZ7!?2U%E'#/XX8U7;7PS0
MQTYO5H7L> ,P!*_6SW'ZBA -Y9M3@J05"KEC2IB@80_*WR=;D')HSK2[OT=Y
MD46DO@ E]BMF=7[_\%4J/>&X$J:##E1E":K!8TNQ?1UX?9]G&3DCE=K><R4,
MV+J%[:3$AN-.[_J61\EL36I%V-/OR_E+OH$4)K+B%S/+%$E?^PYBS]+U.BJV
M)25)D0E,+4H"HE*82"<WL]+OJNRF-VI+AA.YI<FR0-GZ[4\B#WB[";WAN8FJ
M@H>E=O*J61WW@U08Y0TGH =B&X;N?VC*8 UXA7EW+2@+R*WE$IO]6V Y^;2_
M^/],LX?-\W,<H8Q_PZ(V'*, /1T-BTP+M0'7,$=VLR#(-L?EK+C"XCV/Z02U
M$0Q+1PS3D >YXXU>=JVG/QEFGQV?HS#"U9RHVR(W>#L'X 4WU(ODW([C4,OM
MW%B S.4@ .J..QBN-\48JDF9@GPX1D@3B.XX>R%%[8H?N N9&W7E=MCMXAS6
M.]ODXV(IQ'*0!ORT'+%<O(;HNYY0!$,PM?UJ0,(1B12B 9<K1R /3U&Z/=45
M!2(8@JGM5Z<>CD"D$-WQMLZ+%<KJ[C*Q<LEZG+C]SB8.1#6852^%4"4>3D !
M2F^6V0-*9-#!!4*>JXGI  Y'4 #U4,P*RA6%S[3$9,K=+E/)_B7"9U(ZUZ7[
M@K9EO<['9V<G %M4TTI E%X[(<>ZQ8"VK&.O: [=D%'A!NS9\)^;O/Q"K]/L
M%GVKRO#CT_0N2Q/\8X!45 :M>4K>.:!+\$3*-F(;072F4E=EM(>I6@P2Z_$2
M%+3ZT$P.0N\B&Z4S-POF1.>*0M&1#%T,=]\!?2#1&WX6YK2E&AJ>#,8G0[G;
M4&5\"1_4RA9^69P-5@N:+>]_GA4U:>)_'4H2_^KMX/@5I<O,?UY%@1]SCDCA
M\R4<]RKNL8]"-2BVG/5JDBGUKCIQ7!M,^'P)!^IZ18W3#.E(X=B*C :1#O1Y
M9DM,LH/+A)O]P4\N([0DI=DB;/,FD2]QZ7*>+TD&B9)46_$LWZT,BSUG^JXB
MR1\;/T/7"!5?$SPY]4/P6"\:4Y(,6EM!V916!^..[YS2=?7].2K;/EYBJ .!
M?L9ZG*(:@/:9TO9V"'$XY!C'*HY/5$9*KZ@2J61$V;88M FMMHQD4$RXQ;GM
MVR(2F'Z/@G19,FJ^V">'MKR=+[[FB'2(YH8&:T_D30:C\Z%KI5\%^UUSA.#.
M\8=5FA6/*%O?)"^HLM==<I7O$IRO_MC@A?\%%:LTK-&JY$)7GL0;3D%KKG+H
M4Z\0(YH @^NP^UI3YG,\\QH(?X B+L.)4QW5%&2R)U4NI+[49!E.G>J4-E'H
MX#7M4Z>TJ9N=TM3X[*!+FG7*B\X3QN,8&6AQ44/G"!<9>!NR6B.@$J%#:MA%
M[.<YMN<)C2H:%_-YS&> <.Z*E"I;>IY13?SJ.S[FHAS1_O.[/^;57W.1]=]H
M/F]DR\VL]O$(Y,'^3EJ@=";P@8EAYYK:)4=?8/45A9]>K_Q@M?^L[BK0F=L;
M#2RI$%VN"'W$]E(K]^M TW#=\#']A![PGDK=C[L(7JD/5CH#Q@+JGE"67B-<
M!M1$[H4$.< K.I)PNX.HB4=I,$8 JJ;H248#DCNZY$X1HR _O5+(ZBZ*HU'X
MV #P2VAO@%($!OT.'<4XW).<"$%,P^[OF"].M5#A26!/< P$H'$+E!;N!>S!
M$YA>J!XH#+YQ&%LG%33H0)NUT.Z%)CPV&C'0G-=5K1,AM_>>P><7B/'#7*;'
M7&;0:JBT65?.X*D=]MK<F[DX3$4%6/=1C@:6<DZ;N8"GS%Y@QQ2;NM?O@K_0
MFW0+1DO3GP#2 QXV3WD41G[V6ID=Y$.5)'UPQ^"/VH7L#KU=1Q&5Y%*^2Y&]
MD4?J0LX7M>1E:=ZA?#"&:R<M2SW50R(*COP4D7$$"6$TVQ<D]&[9@42ENZJ6
MW<PKT58\KM 7/_L=%80JQ6H(XE'X2("-.U/\8!@N*A5@'&F8:&'^^"U]7*6;
MW$_"61(^?L-O?FTF(?V9O,G@9&(KE]ZZX%K@Y<@3H+;Z/2(=Q<,[/RM>ZX4[
M/KW6_R)18M0GH<GKEHKL=:'8-$#*D35(-?8W$J5GXO'#)2+HU-4&$I"+\@ @
M1V0 I=?-B,P5S<6^[&0*S! @^M1,74J*S\Z=:!<;IQ@41U@0Q1S BA-27D"Y
MO-3$Q!9M4Z <H0,X;J"%[LK^W)WTI?LTA"]HFY)21@>2/@YIHE"W13C..Q^/
MW[KG]F_?5@/'$2* '^B 3*G.Q'R^Q&7)H:#NN5-B/5ML8E@<<0&4?38I+E=V
M45MRD^Z9 ,&_S5I#43R@Z=;B[X,M&S8&CBQ,U%9^6*%X<8^645Z4&<2[E?4/
M/]YP,]TEP[S1 +2JC68 GPH8C@P 7"P4U4V>;U!XN<E(*2:416E8!B#>HF_T
M3V)E0F4"?&+W(SRV"2R.-.$:W^6W:?& BB)&1%NZ22[\?'7M1QE=@9=13@(.
M-YDH.%-O(LP&T,U16[I-X'%BH"&R@]EKDU+=XI/='T_MGE/0.RI3'RT'&$>@
M)AIR?4WR- [?<B :QK=K3D,+$E@RW:R<E4WQ<21G(F=DML1O6^(3FRZ:>A[+
M[,6/8K)/J,E.>Z)200-M6Z GO>8(.?(SD4^RS6S9KJ!MAEK(DQ-W@#<=D)H<
M_9&'' F'[UI>#Z5<JW(/GB<5*5M*9#(0#BY1].- :H"*(YL.TXUINW8?KQ=B
M9:(DI]:+0RG'' +?G+>?7M\>J?H%SK[Y6?A9I2),Z\F]D9X-;<@?M>VMCK*7
M*$!L&+<IS6U'(:4X?TP+/Z[__2+-"ZP*_V]45 6+_L08J>ITG6:U&D:B+.AN
M"?%&L.X84\N%XU0#X*4S2=K6P--M>TX1BG:"3MZ/>0X;_M?/]7O,PJZRQTEV
M-*8#12]R5?)XA#<ZA:T$:47<2J"=*:A?NT^4<2/GL4,CI[G=.S"[[5B"XLIL
M5G<%P\SI=^_?$@U^BZS'2OTY#-RM2%0C<F0N%@9N9UK_-H?]ABH)[V(_(1'<
M\F0/"Z_#'(6.%F!(F+-O6,/O3(?AO\B*<B6@ 7QI&6UD;-BL>E.AI4$0W#%8
MM0.]DK>W)4@,&C8C;%5?:!!]GQ=9%!25I?05"R:_?_@J%;1P',8(>BO1M; 5
MF&&H'(3M&CVCH9WD%W?4109>:UTD+-2=.3V?C&WE@6I6]:&\XS#W@%IKG2"L
M<1A:,6G(Z@YJ1E@J\$/I!_'0\Q;M,;_9%%LK]:#&:<PH*:?KSU"ZAY9J-ACC
M-)-B=VHQ;'4#B2^F_AC^B-W*;;/GBCF&;:+6@EG)24W>(_7/DOVB[/XXYJJ8
M^W7"3517 .<_])G<7A#2X]E$3/U^T88KVC5HG41/FYP0I%/@@CW6&XWL^)05
MK3O6^F9<,ZE#L5:^0.D ?XP*LAW?)&'T$H4;88-8YK.8 TYU<K%DM FP6RMF
MT$R OT7%BJ;ODTOG5?3\F$H*US68!:]<J+);$F$H2$X%FK7B!F[+%/J,ZT*X
MTBR_COP"EU&& CR?T';:?\@;G8+5H6WT&1T+C 7(1)T"CC:R=83S"PNP'L-D
M@;4*-L!G/B1W:@'\ ^6DM:3$@JT]11N&GKF5YV_/AF4!=Z<&0$6=U(C:>Z[$
M 5427L18H0@.B'<GL[^-$*#/>3/2<#%?G[,GT(\>[PMX[\"6H?1^4V,6RHLQ
MB$-5_*6PY=@$F8D*  :E^R0/.'QBWNQ6?"I[C=WA$P?_U5\*XS-MO ^K#&X'
M0[2+VK3',H>J(#1E85F6XR;)BVQ#-91YL4+9X\I/JBCU7VDJWDU29EZTB<DR
M1 )67$$WMPY6:V=<=*?P0U>X?T/D2T;A[ 5E^#NF?[ST"[2KFN# "I?2B(4'
MZO+^:WP"BFQVJ&Q&TY/LZOMS5-;R4=O%3;P#GY"@J>>.*A5L-IFHY &\#Q]T
MY-P4JS0C&6\V]E/>NS S84O;N[DOBMEEHA8)\-JK:^KE9R5*]#;Y&LQ"MT.+
M858<EU,F"J>XM=%M*\5<IQG5(#K8[PY?B5D+6IO.T46HQ#43%64Z*&1X$-)/
M\6$@"Q05XB.V\:34V7;^%ZY188 UDI(W?=C-I#;3KLI!^3F!F,<'-%#^3_[E
M!#+(2<Y*!K@OL5=Z8S=3.>B0-8*5#493*9^_8.4-=SC+6?DF(E_W%1!\?%SY
MP8IDX\T7!^<++PQ%?882SU_0*]B4#QRY;N]FH,K177TG/Q(E]$VQR&'*T2E]
M>[.84H!_(JS>+\-%OKO\LT)M.L-O\D9G$)ZQ79B/&3CJI7@,O@^SSLY5K[ L
MCQ7Y<U0G>UPS6*\'8/G>)'AG0KM:_I\KV))X.\$HS!2G:OF8ES=S@4DY8J"@
MFU6)2^/#A.,P1NA^E%(): FN#LN94F_61.=*G)\M&<HB  '\>K^B!&5^/$O"
M6;C&W"[;JKR@2A.4AOXIC<?80<MQ*GQ<;(EJH'.F?!HV.1#FSPH3?8E>4)P^
M$\RJ\E08C?&"WITWEJ8R-D.%R_(MV!P%/RW3%VS51:4<\0^'XL._\CZCI1^7
MZ1(<S8?Q%";9J51YRYH.EP.&2H%I"TV2VG;X""86*JF R[IC#A]3;*@(5Q?L
MA58C6O!9IB$X$_NH?=."T8'&(G1IY0L8("F?U8'C;[->^]EKU6:C]#?/ JS4
MD'7XK\83++?O&.+*M%_EM,=VS&[KY;3'7$^*8>9 NN>ZTD/'3GG<S(A-KGN.
MS7G5["M'8Z=TS_&1*X5-L2'/5Q?L=5+W5..S@]ZIQEM\=8\^WQ1YX2<AR9%+
MX_@ZS<@?;:@+PA=B[O8^#E=P4EKDF3->-8,@[86J\=[EC<[[F7F@L$*LK\DZ
M"]WI:" *#ZVW<1(UZ&P^&>9&/W.RFR^HACQRID%!6Y95\<4;TFO38KHU_VV8
MG_T\1,$V,2X3G6FHT!;A?LKLKUF:6_$%\=^&^=G/Y!:P1<EEHN,.[T8\/4CB
MWIX-=UD4(,+O19<&B2(Q6/B]3XWNQ%C1XJ>UMAFN+F_X-8VWE7XFB+5<:J +
MOV2ZM18FYE<[UPM\H,_S"G,86_1&"?%&/<W+@5G[%GAOK:5,]Y\ PXZ ^@@T
M2<&BZ&?2D9N?02/N6^OXT_V'(*S0U-DWH$X%%D _\Y#=7/ZZC'>G U-;053@
MR+TXD,ZO2 %F_%_%,>V SJ_%=!-=JSBIRFUQ'!!_CX@L,8LOTJ3(_*#8^/$C
MRM:SIYS^D[&,(<C D@7-FK#CB('CI#MMO2BV)SG\)^U=@L>)H6QK[I8:O&.
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MM@T/!-=V'\E;B;/T/_X_4$L#!!0    ( "J IE($V-BZEV$  )*'!0 5
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MU19U>#$&H7L1X0X&E[8/1"ILT0J;*(7U#$=#O1O )$1S X2$S2#H'&QA8>4
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MPQL<%?@NV3R5R_5GNC"S!5F!#*UV(&AH]>P>&PU9Q.DN$*=\0M8GE+;P(HW
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MW$?:U<O;'M*^ &7M<;)Y*O'JE$YWM,&?]NPUKN6Z=\E>XUP%VA6LM#V0F'M
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M?GLTXWYV1OO'(EDE4?YZ'Z6XRD@8._,?:P/;Z8SUZL&J4$)-;@GHG-\%SX!
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MQ67RS#: +/I1&_:+J(RFJUKI$A&**I;.@1?TJ&2[2\DKQO<X?TYB+)$EY;:
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MBU_U_;RQUK9.WEC_[H'1H8@:DI:NG0LI , P%"6,0S>J,7)O3D_9IG'E&H9
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M=#]\H;7I\V[%22W7UUG";D">%@4NBG&?0;LA)&%5LVL?.:R"-$MEJ8BCECK
M@7 J"RC;==4\6=H7*&CRJZZ^$,CPF:;(.IP5:-:L2M-"'/BT3S*>9F6R2M(]
M>\WVGKW#FK +FY<O<;I?X16[?\;NUNW+:LSJJR2W.&?10:S_\*E+0J#C(S^L
MN+=#W9="NYRBEE54\RIN;W:X98UJ?EGY01Z#QY:OJ(8>+\OG5?T/FL>3+D^
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MGL.N$*K*;J,V0S@)\$17E6W% MQ)R8+6@F&6>$JR#7OROOW3V,T3>&>PA[S
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M.M\UK\X)HT!JH_"E5O.H4O.\4?.XH^840-L@=<ZY;(_CD_5H?(XIF[</8WN
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M:N*-N_2)D**P5?87]BNQ#5'U+> ^[TV 5WPI47K<O@/I0TW?;73J!5S0PIL
M+],6J"U#L5;@%[*@)R(7-:'@&"\=_@Q=+Q>/*+UYVHG=U5BG3;ORH*^V,EJ_
M*Z'K1QU@7>BJ]=ZH'V\"[.BM1'@]W7D'WHM:P7S4Q0IJDAYAV),W 7;Z-J\Z
M4NBVR@:[E&+!J88$5P>G8C54C?;>_MYD;WVI20=2,>AX78EPU9(L?YX)8%E*
MTH@<SL^@4%T);-V4_B95LL%;RM5HAR?3- T*$B@X1B;T77JXP[:4LE&)&XL+
M(UM.3I/%<Q*3;Y)@BFFU8[)QQ7TEFW1F<"RE=@!1O05-.$&ESU-9P%=.U6%+
MX/&0HK*4$P+$<,F__@T12UH:;;KU+),!M M+R@Z?43&2'J2!".H]*^F5MF,"
M G9 5*%:#U4O$D,VRSPK^>8W8"(!=A=4(5H!IP?)(/?+QRP,0C]]N_<C5&SM
M5$:7J(VW?S0>0/-L9G IH5A*_H"RJ]]17?L+_.-#ZL<9WJAC.$K+2]V820GZ
M@$')H8![?7BV4D> M(#$/VS<F73R=NWGRQ1C?O^UR)MAW@D3FRON*IUEH (V
M6RDH3JA$@5:Y(DA:,<$ >[@J\*BC$'R@MO)1H%TN5]4*9% C"'KIK^1<V<5@
M*\\#C,IZ5Y10,;B7%[AB1T2G$(>M5(UGE(8).2!+<Q<"/K6C]:D<7/%[ZO+)
MAV KY<*!BQU9$<:S)4D^NZ6:1;/4KM$/^A?Y\JO1GLK,P0JD&M-8&YJMS(VJ
MZD .T@G)@[U103'Y#0,14A !!<%6CA<"(B-_^U%<2XQ>43H-,VY<7\6>B&P&
M8U>.%E6TUP79CTP/F=+3O]U0A-FY1%TJ]\4FDRN6FXUU0@[35N(']#64_URR
M--7L(1$XH&F@TJ./P1,W)XHSRNH=PM91%N:H*%W$!'>'ILDLIKVHKBAM^M6,
MJ:[9GZU)Q59"B@-+7LT]RI%[A?0K[5&.Q&'MQBY%]ND\CP-'0@A/_6Q^$24_
M6B_27(I/6X_!+&!PIYDWZ5",(#9)'9D=(DDJW#(E&!^E:O/$E8]>2?:;+(E&
MW?^RS8,!T-=&)/)=8G;'^[-P,U9B5UP@PDFE&GT/:C=?HYQ\!&[3A)30"4[>
MOF,[X3)>%W0[GN;A"[ME6*MVA6%G6([NV8J46Z'SLQ+"7ERLESR%N<*__?Z0
M-QC"%ZNHQ!6?^6UDEH(%'7)6D(UM/ TCM.'A?TCLK0]-O,Z;  <PV%6SQD1D
M*<H15E^[4I9QL ?LMFU,C?A::U-L=8,U)TQ18VR9YRB ,HZ+PA>;#D69@<QM
M@"4"7-"M9462B:$'Y;W/$![K-*2@\,\1HFS&P?$B2?/P7RHET6F.907\06Q9
M9?2% GNEHN!(^CJ)B2RN\&HIJ>\I>I24O#R$OE.G)<*5,FCL,L465P@LLI1@
M.T/LOR4A%6=5>K<::G;B38 #$NQ:SX; 82N5"Q:$%8:;]!T%GE0H?"%NJHLD
MQ?]#X2Q^\%]_#_,Y.;7BUPNIT9LW'NP=0=\G84@F9[&H"=Y6M*E;Z\EMBI[]
M,#@K$*SJ\\8!+:Y\G&4HE^V0JG6()RWP0E-+FVR KQWLZL3&9E<"Q]-ILL2?
M_EO_C9;M3/U =AJJUP$669=7GRI@^U"TG(LW7>*1O_L%3'5CJSD6%G#$='.:
MP85JK0BZ4WI!DG:(B,AW]Q3O'O ^(5U!ET4<&?;D#0; IQ -:8L&:ELAN(U8
MMQQQT#U=2?U/ERD1L,JRU>^);12!'6KVK-H*P'M26UUSQVCEI-H;#.'+J5O<
M(ILBMU9F'?8.#AYF=J.0I2 '26>8#E<J(-4)<E BM!4J"QKEX+^M0L6G?R[#
M%&$IX*F1O]U&?DSNFB+AP?2V65D4A'8G^$OMYO&UDFQ!E(0A\MH5X9W8%.^@
MOI\G:?Z TL7[I672J!F=]EA@;OIJ;:F*&'3MTO)N:$F:3!$*L@LLV&^D4 $5
M%74@,4G@Z7'J1Q&I[TM$D>OK3[V>L9"!G2V6-<N&.&P5JW?05.:(U8J]@P4'
M?;>@53TR16ZM3+U[IO)%&/OQU)*I+.G,F[A7#L'<4E8!;*PD/=#7S#056MD6
MSR?HBXVK,:O^($GP"M2B4Y[>,E22!8ZE18LZK6NN:JH%MRV]X/4 ^HK3IC1#
M#EF@'+#>W/+PL7WU$B;++'ICV?]RSDV:,QFXN4\VH[T2:@'S?7#:<J1GQ9S
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MW7P0XW<EYU"+5=[H^>R-N\3>'?ZVQ$MTAZ8)WOD3)/K35]D62\D5;[P6QYJ
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ML :2?B>N1$_I$ZG0"!%*T(,N:TX@V4%$W2ZQG" O$+'X.;$CB3Z<AX&E9$V
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MQQ9D@5YT*OP&&P-3A(+L @NU,,<N$"+YC"A\><^7X:B%HJ4W' )'".B1R%<
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M./BS';79@-N#LI=&V,,76ZL-Z8IM]WIOX>S =2Q:21?'\1/64\GB4;TS-I^
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M%P*<&&3_\?\!4$L! A0#%     @ *H"F4@,:!XM%_   XU$. !$
M     ( !     &UE:7 M,C R,3 S,S$N>&UL4$L! A0#%     @ *H"F4BG0
M]B0U$0  VZ@  !$              ( !=/P  &UE:7 M,C R,3 S,S$N>'-D
M4$L! A0#%     @ *H"F4L'@JN;K"0  (8,  !4              ( !V T!
M &UE:7 M,C R,3 S,S%?8V%L+GAM;%!+ 0(4 Q0    ( "J IE+O17Q]3T$
M .DB!  5              "  ?87 0!M96EP+3(P,C$P,S,Q7V1E9BYX;6Q0
M2P$"% ,4    "  J@*92!-C8NI=A  "2AP4 %0              @ %X60$
M;65I<"TR,#(Q,#,S,5]L86(N>&UL4$L! A0#%     @ *H"F4O@)PSA22
MB<P$ !4              ( !0KL! &UE:7 M,C R,3 S,S%?<')E+GAM;%!+
4!08     !@ & (H!  #' P(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
